Peptides derived from Campylobacter jejuni and their use in vaccination

Abstract

Disclosed are polypeptides for Campylobacter jejuni that are useful as immunogenic agents for vaccine use. Also disclosed are nucleic acid fragments encoding the polypeptides as well as compositions, methods and molecular biology tools derived from or related to the proteins.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] In accordance with 37 C.F.R. 1.76, a claim of priority is included in an Application Data Sheet filed concurrently herewith. Accordingly, the present invention claims priority as a continuation of U.S. patent application Ser. No. 14/351,423 entitled "PEPTIDES DERIVED FROM CAMPYLOBACTER JEJUNI AND THEIR USE IN VACCINATION", filed Apr. 11, 2014, which is a national stage filing in accordance with 35 U.S.C. .sctn.371 of PCT/EP2012/070282, filed Oct. 12, 2012, which claims the benefit of the priority of Denmark Patent Application No. PA 2011 00789, filed Oct. 12, 2011, and U.S. Provisional Patent Application No. 61/550,494, filed Oct. 24, 2011, the contents of each are incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of antimicrobial prophylaxis and therapy. In particular the present invention relates to novel proteins and polynucleotides derived from Campylobacter jejuni. The invention further relates to vectors comprising the polynucleotides, transformed host organisms expressing the polynucleotides, antibodies (mono- or polyclonal) specific for the polypeptides as well as diagnostic, prophylactic and therapeutic uses and methods. Finally, also methods of preparation are part of the invention.

BACKGROUND OF THE INVENTION

[0003] C. jejuni is a bacterium commonly associated with poultry, since it naturally colonises the digestive tract of many bird species. Contaminated drinking water and unpasteurized milk provide an efficient means for distribution in human populations. Contaminated food is a major source of isolated C. jejuni infections, with incorrectly prepared meat and poultry normally being the source of the bacteria.

[0004] Infection with C. jejuni usually results in enteritis, which is characterised by abdominal pain, diarrhea, fever, and malaise. The symptoms usually persist for between 24 hours and a week, but may be longer. Diarrhea can vary in severity from loose stools to bloody stools. The disease is usually self-limiting. However, it does respond to antibiotics. Severe (accompanying fevers, blood in stools) or prolonged cases may require ciprofloxacin, erythromycin, azithromycin or norfloxacin. The drug of choice is usually erythromycin. About 90% of cases respond to ciprofloxacin treatment. Fluid and electrolyte replacement may be required for serious cases.

[0005] The first full-genome sequence of C. jejuni was performed in 2000 (strain NCTC11168) with a circular chromosome of 1,641,481 base pairs.

[0006] As mentioned, C. jejuni infections may successfully be treated by administration of antibiotics to patients in need thereof, but that would not prevent acute illness. Further, due to careless or thoughtless use of powerful antibiotics, many pathological germs, including C. jejuni become resistant against antibiotics over time. In particular in hospitals, treatment with antibiotics can prove inadequate: not only will a C. jejuni infection be life-threatening for patients that already suffer from other health problems meaning that treatment with antibiotics may simply be non-effective within the relevant time-span, but in addition antibiotic-resistant C. jejuni strains will also withstand treatment with those antibiotics used as the initial choice in treatment. There is thus a need to provide alternatives to current treatment regimens. Also, infection with C. jejuni is associated with reactive arthritis and Guillain-Barre Syndrome.

[0007] Vaccination is considered to be a very effective method of preventing infectious diseases in human and veterinary health care. Vaccination is the administration of immunogenically effective amounts of antigenic material (the vaccine) to produce immunity to a disease/disease-causing pathogenic agent. Vaccines have contributed to the eradication of smallpox, the near eradication of polio, and the control of a variety of diseases, including rubella, measles, mumps, chickenpox, typhoid fever.

[0008] Before "the genomic era", vaccines were based on killed or live attenuated, microorganisms, or parts purified from them. Subunit vaccines are considered as a modern upgrade of these types of vaccine, as the subunit vaccines contain one or more protective antigens, which are more or less the weak spot of the pathogen. Hence, in order to develop subunit vaccines, it is critical to identify the proteins, which are important for inducing protection and to eliminate others.

[0009] An antigen is said to be protective if it is able to induce protection from subsequent challenge by a disease-causing infectious agent in an appropriate animal model following immunization.

[0010] The empirical approach to subunit vaccine development, which includes several steps, begins with pathogen cultivation, followed by purification into components, and then testing of antigens for protection. Apart from being time and labour consuming, this approach has several limitations that can lead to failure. It is not possible to develop vaccines using this approach for microorganisms, which cannot easily be cultured and only allows for the identification of the antigens, which can be obtained in sufficient quantities. The empirical approach has a tendency to focus on the most abundant proteins, which in some cases are not immuno-protective. In other cases, the antigen expressed during in vivo infection is not expressed during in vitro cultivation. Furthermore, antigen discovery by use of the empirical approach demands an extreme amount of proteins in order to discover the protective antigens, which are like finding needles in the haystack. This renders it a very expensive approach, and it limits the vaccine development around diseases, which is caused by pathogens with a large genome or disease areas, which perform badly in a cost-effective perspective.

OBJECT OF THE INVENTION

[0011] It is an object of embodiments of the invention to provide C. jejuni derived antigenic polypeptides that may serve as constituents in vaccines against C. jejuni infections and in diagnosis of C. jejuni infections. It is also an object to provide nucleic acids, vectors, transformed cells, vaccine compositions, and other useful means for molecular cloning as well as for therapy and diagnosis with relevance for C. jejuni.

SUMMARY OF THE INVENTION

[0012] It has been found by the present inventor(s) that C. jejuni, in particular drug resistant C. jejuni, expresses a number of hitherto unknown putatively surface exposed proteins which are candidates as vaccine targets as well as candidates as immunizing agents for preparation of antibodies that target C. jejuni. One of these putatively surface exposed antigens (cj0404; SEQ ID NO: 13) has now been tested for suitability as a vaccine agent and has as the only candidate among 25 randomly isolated C. jejuni proteins been found to be a capable of providing protection against challenge infection. The remaining 29 variants are currently being investigated in a similar setup.

[0013] So, in a first aspect the present invention relates to a polypeptide comprising a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, orb) an amino acid sequence consisting of at least 5 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, orc) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of a), d) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of b), ore) an assembly of amino acids derived from any one of SEQ ID NOs: 1-30 which has essentially the same 3D conformation as in the protein from which said assembly is derived so as to constitute a B-cell epitope, said polypeptide being antigenic in a mammal.

[0014] In another aspect, the invention relates to an isolated nucleic acid fragment, which comprises i) a nucleotide sequence encoding a polypeptide of the invention, or ii) a nucleotide sequence consisting of any one of SEQ ID NOs: 31-90. iii) a nucleotide sequence consisting of at least 10 consecutive nucleotides in any one of SEQ ID NOs: 31-90, iv) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in i) or ii), v) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in iii), vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

[0015] In a third aspect, the invention relates to a vector comprising the nucleic acid of the invention, such as a cloning vector or an expression vector.

[0016] In fourth aspect, the invention relates to a cell which is transformed so as to carry the vector of the invention.

[0017] In a fifth aspect, the invention relates to a pharmaceutical composition comprising a polypeptide of the invention, a nucleic acid fragment of the invention, a vector of the invention, or a transformed cell of the invention, and a pharmaceutically acceptable carrier, vehicle or diluent.

[0018] In a sixth aspect, the invention relates to a method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a polypeptide of the invention, a nucleic acid fragment of the invention, a vector of the invention, a transformed cell of the invention, or a pharmaceutical composition of the fifth aspect of the invention so as to induce adaptive immunity against C. jejuni in the animal.

[0019] In a seventh and eighth aspect, the invention relates to 1) a polyclonal antibody in which the antibodies specifically bind to at least one polypeptide of the invention, and which is essentially free from antibodies binding specifically to other C. jejuni polypeptides, and to 2) an isolated monoclonal antibody or antibody analogue which binds specifically to a polypeptide of the invention. In a related ninth aspect, the invention relates to a pharmaceutical composition comprising such a polyclonal or monoclona antibody and a pharmaceutically acceptable carrier, vehicle or diluent.

[0020] In a 10.sup.th aspect, the invention relates to a method for prophylaxis, treatment or amelioration of infection with C. jejuni, in particular infection with multi-resistant C. jejuni, comprising administering a therapeutically effective amount of an antibody of the 7.sup.th or 8.sup.th aspect of the invention or a pharmaceutical composition of the eighth aspect to an individual in need thereof.

[0021] In an 11.sup.th aspect, the invention relates to a method for determining, quantitatively or qualitatively, the presence of C. jejuni, in particular the presence of multi-resistant C. jejuni, in a sample, the method comprising contacting the sample with an antibody of aspects 8 or 9 of the invention and detecting the presence of antibody bound to material in the sample.

[0022] In an 12.sup.th aspect of the invention is provided a method for determining, quantitatively or qualitatively, the presence of antibodies specific for C. jejuni, in particular the presence of antibodies specific for multi-resistant C. jejuni, in a sample, the method comprising contacting the sample with a polypeptide of the invention and detecting the presence of antibody that specifically bind said polypeptide.

[0023] In a 13.sup.th aspect, the invention relates to a method for determining, quantitatively or qualitatively, the presence of a nucleic acid characteristic of C. jejuni, in particular the presence of a nucleic acid characteristic of multi-resistant C. jejuni, in a sample, the method comprising contacting the sample with a nucleic acid fragment of the invention and detecting the presence of nucleic acid in the sample that hybridizes to said nucleic acid fragment.

[0024] In a 14.sup.th aspect, the invention relates to a method for the preparation of the polypeptide of the invention, comprising--culturing a transformed cell of the present invention, which is capable of expressing the nucleic acid of the invention, under conditions that facilitate that the transformed cell expresses the nucleic acid fragment of the invention, which encodes a polypeptide of the invention, and subsequently recovering said polypeptide, or--preparing said polypeptide by means of solid or liquid phase peptide synthesis.

[0025] In a 15.sup.th aspect, the invention relates to a method for determining whether a substance, such as an antibody, is potentially useful for treating infection with C. jejuni, the method comprising contacting the polypeptide of the invention with the substance and subsequently establishing whether the substance has at least one of the following characteristics: 1) the ability to bind specifically to said polypeptide, 2) the ability to compeed with said polypeptide for specific binding to a ligand/receptor, and 3) the ability to specifically inactivate said polypeptide.

[0026] Finally, in a 16.sup.th aspect, the invention relates to a method for determining whether a substance, such as a nucleic acid, is potentially useful for treating infection with C. jejuni, the method comprising contacting the substance with the nucleic acid fragment of claim of the invention and subsequently establishing whether the substance has either the ability to 1) bind specifically to the nucleic acid fragment, or 2) bind specifically to a nucleic acid that hybridizes specifically with the nucleic acid fragment.

LEGENDS TO THE FIGURE

[0027] FIG. 1: Gels showing the expression of 14 proteins of C. jejuni genes cloned in E. coli BL21.X: presence of expression product in BL21 after induction. O: No induction of protein expression.

[0028] FIG. 2: C. jejuni transformed clones were tested for antibody recognition in a dot blot assay. Four clones were tested for expression and antigenicity. The dot blots are showing reactivity of 4 C. jejuni antigens with antiserea from rabbits immunized with five different C. jejuni strains from five different isolates. All clones reacted to all sera.

[0029] FIG. 3: Dot blots showing reactivity of 7 C. jejuni antigens against human sera.

DETAILED DISCLOSURE OF THE INVENTION

Definitions

[0030] The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, i.e. functional biomolecules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide (s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

[0031] The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleotides, derived directly from a naturally occurring amino acid sequence or nucleic acid sequence, respectively

[0032] The term "amino acid sequence" s the order in which amino acid residues, connected by peptide bonds, lie in the chain in peptides and proteins.

[0033] The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting a specific immune response against the immunogen of the vaccine, but which is 2) nevertheless capable of enhancing the immune response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the combined vaccination with immunogen and adjuvant induces an immune response against the immunogen which is stronger than that induced by the immunogen alone.

[0034] "Sequence identity" is in the context of the present invention determined by comparing 2 optimally aligned sequences of equal length (e.g. DNA, RNA or amino acid) according to the following formula: (N.sub.ref-N.sub.dif)100/N.sub.ref, wherein N.sub.ref is the number of residues in one of the 2 sequences and N.sub.dif is the number of residues which are non-identical in the two sequences when they are aligned over their entire lengths and in the same direction. So, two sequences 5'-ATTCGGAAC-3' and 5'-ATACGGGAC-3' will provide the sequence identity 77,78% (N.sub.ref=9 and N.sub.dif=2).

[0035] An "assembly of amino acids" means two or more amino acids bound together by physical or chemical means.

[0036] The "3D conformation" is the 3 dimensional structure of a biomolecule such as a protein. In monomeric polypeptides/proteins, the 3D conformation is also termed "the tertiary structure" and denotes the relative locations in 3 dimensional space of the amino acid residues forming the polypeptide.

[0037] "An immunogenic carrier" is a molecule or moiety to which an immunogen or a hapten can be coupled in order to enhance or enable the elicitation of an immune response against the immunogen/hapten. Immunogenic carriers are in classical cases relatively large molecules (such as tetanus toxoid, KLH, diphtheria toxoid etc.) which can be fused or conjugated to an immunogen/hapten, which is not sufficiently immunogenic in its own right--typically, the immunogenic carrier is capable of eliciting a strong T-helper lymphocyte response against the combined substance constituted by the immunogen and the immunogenic carrier, and this in turn provides for improved responses against the immunogen by B-lymphocytes and cytotoxic lymphocytes. More recently, the large carrier molecules have to a certain extent been substituted by so-called promiscuous T-helper epitopes, i.e. shorter peptides that are recognized by a large fraction of HLA haplotypes in a population, and which elicit T-helper lymphocyte responses.

[0038] A "T-helper lymphocyte response" is an immune response elicited on the basis of a peptide, which is able to bind to an MHC class II molecule (e.g. an HLA class II molecule) in an antigen-presenting cell and which stimulates T-helper lymphocytes in an animal species as a consequence of T-cell receptor recognition of the complex between the peptide and the MHC Class II molecule prese

[0039] An "immunogen" is a substance of matter which is capable of inducing an adaptive immune response in a host, whose immune system is confronted with the immunogen. As such, immunogens are a subset of the larger genus "antigens", which are substances that can be recognized specifically by the immune system (e.g. when bound by antibodies or, alternatively, when fragments of the are antigens bound to MHC molecules are being recognized by T-cell receptors) but which are not necessarily capable of inducing immunity--an antigen is, however, always capable of eliciting immunity, meaning that a host that has an established memory immunity against the antigen will mount a specific immune response against the antigen.

[0040] A "hapten" is a small molecule, which can neither induce or elicit an immune response, but if conjugated to an immunogenic carrier, antibodies or TCRs that recognize the hapten can be induced upon confrontation of the immune system with the hapten carrier conjugate.

[0041] An "adaptive immune response" is an immune response in response to confrontation with an antigen or immunogen, where the immune response is specific for antigenic determinants of the antigen/immunogen--examples of adaptive immune responses are induction of antigen specific antibody production or antigen specific induction/activation of T helper lymphocytes or cytotoxic lymphocytes.

[0042] A "protective, adaptive immune response" is an antigen-specific immune response induced in a subject as a reaction to immunization (artificial or natural) with an antigen, where the immune response is capable of protecting the subject against subsequent challenges with the antigen or a pathology-related agent that includes the antigen. Typically, prophylactic vaccination aims at establishing a protective adaptive immune response against one or several pathogens.

[0043] "Stimulation of the immune system" means that a substance or composition of matter exhibits a general, non-specific immunostimulatory effect. A number of adjuvants and putative adjuvants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimulating agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune response compared to isolated use of the immunogen.

[0044] Hybridization under "stringent conditions" is herein defined as hybridization performed under conditions by which a probe will hybridize to its target sequence, to a detectably greater degree than to other sequences. Stringent conditions are target-sequence-dependent and will differ depending on the structure of the polynucleotide. By controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are 100% complementary to a probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. Generally, stringent wash temperature conditions are selected to be about 5.degree. C. to about 2.degree. C. lower than the melting point (Tm) for the specific sequence at a defined ionic strength and pH. The melting point, or denaturation, of DNA occurs over a narrow temperature range and represents the disruption of the double helix into its complementary single strands. The process is described by the temperature of the midpoint of transition, Tm, which is also called the melting temperature. Formulas are available in the art for the determination of melting temperatures.

[0045] The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as Homo sapiens, Canis domesticus, etc. and not just one single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention substantially all will mount an immune response against the immunogen of the present invention.

[0046] As used herein, the term "antibody" refers to a polypeptide or group of polypeptides composed of at least one antibody combining site. An "antibody combining site" is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. "Antibody" includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, altered antibodies, univalent antibodies, Fab proteins, and single domain antibodies.

[0047] "Specific binding" denotes binding between two substances which goes beyond binding of either substance to randomly chosen substances and also goes beyond simple association between substances that tend to aggregate because they share the same overall hydrophobicity or hydrophilicity. As such, specific binding usually involves a combination of electrostatic and other interactions between two conformationally complementary areas on the two substances, meaning that the substances can "recognize" each other in a complex mixture.

[0048] The term "vector" is used to refer to a carrier nucleic acid molecule into which a heterologous nucleic acid sequence can be inserted for introduction into a cell where it can be replicated and expressed. The term further denotes certain biological vehicles useful for the same purpose, e.g. viral vectors and phage--both these infectious agents are capable of introducing a heterologous nucleic acid sequence

[0049] The term "expression vector" refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, when the transcription product is an mRNA molecule, this is in turn translated into a protein, polypeptide, or peptide.

Specific Embodiments of the Invention

The Polypeptides of the Invention

[0050] In some embodiments the at least 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention constitute at least 6, such as at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27 at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, and at least 51 contiguous amino acid residues.

[0051] The number may, where applicable, be higher, such as at least 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, at least 124, and at least 125 contiguous amino acid residues. Another way to phrase this is that for each of SEQ ID NOs: 1-30, the number of the contiguous amino acid residues is at least N-n, where N is the length of the sequence ID in question and n is any integer between 6 and N-1; that is, the at least 5 contiguous amino acids can be at least any number between 5 and the length of the reference sequence minus one, in increments of one.

[0052] In some embodiments, the polypeptide of the invention also has a sequence identity with the amino acid sequence of a) defined above of at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%. Similarly, the polypeptide of the invention in some embodiments also has a sequence identity with the amino acid sequence of b) defined above of at least 60%, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

[0053] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47 in any one of SEQ ID NOs: 1-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0054] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, and 61 in any on of SEQ ID NOs: 2-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0055] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, and 112 in any one of SEQ ID NOs: 3-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0056] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, and 134 in any one of SEQ ID NOs: 4-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0057] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 135, 136, and 137 in any one of SEQ ID NOs: 5-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0058] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 138, 139, and 140 in any one of SEQ ID NOs: 6-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0059] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, and 170 in any one of SEQ ID NOs: 7-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0060] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, and 197 in any one of SEQ ID NOs: 8-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0061] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 198, 199, 200, 201, 202, 203, 204, 205, and 206 in any one of SEQ ID NOs: 9-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0062] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, and 240 in any one of SEQ ID NOs: 10-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0063] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, and 255 in any one of SEQ ID NOs: 11-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0064] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, and 269 in any one of SEQ ID NOs: 12-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0065] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 270, 271, 272, 273, and 274 in any one of SEQ ID NOs: 13-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0066] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, and 386 in any one of SEQ ID NOs: 14-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0067] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, and 538 in any one of SEQ ID NOs: 15-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0068] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, and 606 in any one of SEQ ID NOs: 16-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0069] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655 in any one of SEQ ID NOs: 17-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0070] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 656, 657, 658, 659, 660, 661 in any one of SEQ ID NOs: 18-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0071] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, and 746 in any one of SEQ ID NOs: 19-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0072] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, and 861 in any one of SEQ ID NOs: 20-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0073] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 862, 863, 864, 865, 866, and 867 in any one of SEQ ID NOs: 21-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0074] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, and 942 in any one of SEQ ID NOs: 22-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0075] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, and 1037 in any one of SEQ ID NOs: 23-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0076] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, and 1085 in any one of SEQ ID NOs: 24-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0077] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, and 1116 in any one of SEQ ID NOs: 25-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0078] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, and 1140 in any one of SEQ ID NOs: 26-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0079] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, and 1182 in any one of SEQ ID NOs: 27-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0080] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, and 1374 in any one of SEQ ID NOs: 28-30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0081] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, and 1492 in SEQ ID NO: 29 or 30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0082] In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1493, 1494, 1495, 1496, 1497, 1498, 1499, 1500, 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513 in SEQ ID NO: 30, if the length of the at least 5 amino acid residues so permit--if the length of the at least 5 amino acids are higher than 5, the N-terminal first residue will not be higher numbered than N-L+1, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b.

[0083] The polypeptide of the invention is in certain embodiments also fused or conjugated to an immunogenic carrier molecule; or, phrased otherwise, the polypeptide of the invention also includes such an immunogenic carrier molecule in addition to the material derived from SEQ ID NOs. 1-30. The immunogenic carrier molecule is a typically polypeptide that induces T-helper lymphocyte responses in a majority of humans, such as immunogenic carrier proteins selected from the group consisting of keyhole limpet hemocyanino or a fragment thereof, tetanus toxoid or a fragment thereof, diphtheria toxoid or a fragment thereof. Other suitable carrier molecules are discussed infra.

[0084] In preferred embodiments, the polypeptide of the invention detailed above is capable of inducing an adaptive immune response against the polypeptide in a mammal, in particular in a human being. Preferably, the adaptive immune response is a protective adaptive immune response against infection with C. jejuni, in particular multi-resistant C. jejuni. The polypeptide may in these cases induce a humeral and/or a cellular immune response.

Epitopes

[0085] SEQ ID NOs: 1-30 include antigenic determinants (epitopes) that are as such recognized by antibodies and/or when bound to MHC molecules by T-cell receptors. For the purposes of the present invention, B-cell epitopes (i.e. antibody binding epitopes) are of particular relevance.

[0086] It is relatively uncomplicated to identify linear B-cell epitopes--one very simple approach entails that antibodies raised agains C. jejuni or C. jejuni derived proteins disclosed herein are tested for binding to overlapping oligomeric peptides derived from any one of SEQ ID NO: 1-30. Thereby, the regions of the C. jejuni polypeptide which are responsible for or contribute to binding to the antibodies can be identified.

[0087] Alternatively, or additionally, one can produce mutated versions of the polypeptides of the invention, e.g. version where each single non-alanine residue in SEQ ID NOs.: 1-30 are point mutated to alanine--this method also assists in identifying complex assembled B-cell epitopes; this is the case when binding of the same antibody is modified by exchanging amino acids in different areas of the full-length polypeptide.

[0088] Also, in silico methods for B-cell epitope prediction can be employed: useful state-of-the-art systems for .beta.-turn prediction is provided in Petersen B et al. (November 2010), Plos One 5(11): e15079; prediction of linear B-cell epitopes, cf: Larsen J E P et al. (April 2006), Immunome Research, 2:2; prediction of solvent exposed amino acids: Petersen B et al (July 2009), BMC Structural Biology, 9:51.

The Nucleic Acid Fragments of the Invention

[0089] The nucleic acid fragment of the invention referred to above is preferably is a DNA fragment (such as SEQ ID NOs: 31-60) or an RNA fragment (such as SEQ ID NOs 61-90).

[0090] The nucleic acid fragment of the invention typically consists of at least 11, such as at least 12, at least 13, at least 14, at least 15, at least 16, at least 17 at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, at least 100, at least 101, at least 102, at least 103, at least 104, at least 105, at least 106, at least 107, at least 108, at least 109, at least 110, at least 111, at least 112, at least 113, at least 114, at least 115, at least 116, at least 117, at least 118, at least 119, at least 120, at least 121, at least 122, at least 123, at least 124, at least 125, at least 126, at least 127, at least 128, at least 129, at least 130, at least 131, at least 132, at least 133, at least 134, at least 135, at least 136, at least 137, at least 138, at least 139, at least 140, at least 141, at least 142, at least 143, at least 144, at least 145, at least 146, at least 147, at least 148, at least 149, at least 150, at least 151, at least 152, and at least 153 consecutive nucleotides in any one of SEQ ID NOs: 31-90. Longer fragments are contemplated, i.e. fragments having at least 200, at least 300 at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 3500, and at least 4000 nucleotides from those of SEQ ID NOs: 31-90 that encompass fragments of such lengths.

[0091] The nucleic acid fragment of the invention discussed above typically has a sequence identity with the nucleotide sequence defined for i) or ii) above, which is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

[0092] The nucleic acid fragment of the invention discussed above may also have a sequence identity with the nucleotide sequence defined for iii) above, which is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

The Vectors of the Invention

[0093] Vectors of the invention fall into several categories discussed infra. One preferred vector of the invention comprises in operable linkage and in the 5'-3' direction, an expression control region comprising an enhancer/promoter for driving expression of the nucleic acid fragment defined for option i) above, optionally a signal peptide coding sequence, a nucleotide sequence defined for option i), and optionally a terminator. Hence, such a vector constitutes an expression vector useful for effecting production in cells of the polypeptide of the invention. Since the polypeptides of the invention are bacterial of origin, recombinant production is conveniently effected in bacterial host cells, so here it is preferred that the expression control region drives expression in prokaryotic cell such as a bacterium, e.g. in E coli. However, if the vector is to drive expression in mammalian cell (as would be the case for a DNA vaccine vector), the expression control region should be adapted to this particular use.

[0094] At any rate, certain vectors of the invention are capable of autonomous replication.

[0095] Also, the vector of the invention may be one that is capable of being integrated into the genome of a host cell--this is particularly useful if the vector is use in the production of stably transformed cells, where the progeny will also include the genetic information introduced via the vector. Alternatively, vectors incapable of being integrated into the genome of a mammalian host cell are useful in e.g. DNA vaccination.

[0096] Typically, the vector of the invention is selected from the group consisting of a virus, such as a attenuated virus (which may in itself be useful as a vaccine agent), a bacteriophage, a plasmid, a minichromosome, and a cosmid.

[0097] A more detailed discussion of vectors of the invention is provided in the following:

Polypeptides of the invention may be encoded by a nucleic acid molecule comprised in a vector. A nucleic acid sequence can be "heterologous," which means that it is in a context foreign to the cell in which the vector is being introduced, which includes a sequence homologous to a sequence in the cell but in a position within the host cell where it is ordinarily not found. Vectors include naked DNAs, RNAs, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (for example Sambrook et al, 2001; Ausubel et al, 1996, both incorporated herein by reference). In addition to encoding the polypeptides of this invention, a vector of the present invention may encode polypeptide sequences such as a tag or immunogenicity enhancing peptide (e.g. an immunogenic carrier or a fusion partner that stimulates the immune system, such as a cytokine or active fragment thereof). Useful vectors encoding such fusion proteins include pIN vectors (Inouye et al, 1985), vectors encoding a stretch of histidines, and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage.

[0098] Vectors of the invention may be used in a host cell to produce a polypeptide of the invention that may subsequently be purified for administration to a subject or the vector may be purified for direct administration to a subject for expression of the protein in the subject (as is the case when administering a nucleic acid vaccine).

[0099] Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described infra.

1. Promoters and Enhancers

[0100] A "promoter" is a control sequence. The promoter is typically a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases "operatively positioned," "operatively linked," "under control," and "under transcriptional control" mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and expression of that sequence. A promoter may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

[0101] A promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon. Such a promoter can be referred to as "endogenous." Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural state. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and promoters or enhancers not "naturally occurring," i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR.TM., in connection with the compositions disclosed herein (see U.S. Pat. No. 4,683,202, U.S. Pat. No. 5,928,906, each incorporated herein by reference).

[0102] Naturally, it may be important to employ a promoter and/or enhancer that effectively direct(s) the expression of the DNA segment in the cell type or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression (see Sambrook et al, 2001, incorporated herein by reference). The promoters employed may be constitutive, tissue-specific, or inducible and in certain embodiments may direct high level expression of the introduced DNA segment under specified conditions, such as large-scale production of recombinant proteins or peptides.

[0103] Examples of inducible elements, which are regions of a nucleic acid sequence that can be activated in response to a specific stimulus, include but are not limited to Immunoglobulin Heavy Chain (Banerji et al, 1983; Gilles et al, 1983; Grosschedl et al, 1985; Atchinson et al, 1986, 1987; toiler et al, 1987; Weinberger et al, 1984; Kiledjian et al, 1988; Porton et al; 1990), Immunoglobulin Light Chain (Queen et al, 1983; Picard et al, 1984), T Cell Receptor (Luria et al, 1987; Winoto et al, 1989; Redondo et al; 1990), HLA DQa and/or DQp (Sullivan et al, 1987), .beta.-Interferon (Goodbourn et al, 1986; Fujita et al, 1987; Goodbourn et al, 1988), Interleukin-2 (Greene et al, 1989), Interleukin-2 Receptor (Greene et al, 1989; Lin et al, 1990), MHC Class II 5 (Koch et al, 1989), MHC Class II HLA-DRa (Sherman et al, 1989), .beta.-Actin (Kawamoto et al, 1988; Ng et al; 1989), Muscle Creatine Kinase (MCK) (Jaynes et al, 1988; Horlick et al, 1989; Johnson et al, 1989), Prealbumin (Transthyretin) (Costa et al, 1988), Elastase I (Omitz et al, 1987), Metallothionein (MTII) (Karin et al, 1987; Culotta et al, 1989), Collagenase (Pinkert et al, 1987; Angel et al, 1987), Albumin (Pinkert et al, 1987; Tranche et al, 1989, 1990), .alpha.-Fetoprotein (Godbout et al, 1988; Campere et al, 1989), .gamma.-Globin (Bodine et al, 1987; Perez-Stable et al, 1990), .beta.-Globin (Trudel et al, 1987), c-fos (Cohen et al, 1987), c-HA-ras (Triesman, 1986; Deschamps et al, 1985), Insulin (Edlund et al, 1985), Neural Cell Adhesion Molecule (NCAM) (Hirsh et al, 1990), al-Antitrypain (Larimer et al, 1990), H2B (TH2B) Histone (Hwang et al, 1990), Mouse and/or Type I Collagen (Ripe et al, 1989), Glucose-Regulated Proteins (GRP94 and GRP78) (Chang et al, 1989), Rat Growth Hormone (Larsen et al, 1986), Human Serum Amyloid A (SAA) (Edbrooke et al, 1989), Troponin I (TN I) (Yutzey et al, 1989), Platelet-Derived Growth Factor (PDGF) (Peck et al, 1989), Duchenne Muscular Dystrophy (Klamut et al, 1990), SV40 (Banerji et al, 1981; Moreau et al, 1981; Sleigh et al, 1985; Firak et al, 1986; Herr et al, 1986; Imbra et al, 1986; Kadesch et al, 1986; Wang et al, 1986; Ondek et al, 1987; Kuhl et al, 1987; Schaffner et al, 1988), Polyoma (Swartzendruber et al, 1975; Vasseur at al, 1980; Katinka et al, 1980, 1981; Tyndell et al, 1981; Dandolo et al, 1983; de Villiers et al, 1984; Hen et al, 1986; Satake et al, 1988; Campbell et al, 1988), Retroviruses (Kriegler et al, 1982, 1983; Levinson et al, 1982; Kriegler et al, 1983, 1984a, b, 1988; Bosze et al, 1986; Miksicek et al, 1986; Celander et al, 1987; Thiesen et al, 1988; Celander et al, 1988; Choi et al, 1988; Reisman et al, 1989), Papilloma Virus (Campo et al, 1983; Lusky et al, 1983; Spandidos and Wilkie, 1983; Spalholz et al, 1985; Lusky et al, 1986; Cripe et al, 1987; Gloss et al, 1987; Hirochika et al, 1987; Stephens et al, 1987), Hepatitis B Virus (Bulla et al, 1986; Jameel et al, 1986; Shaul et al, 1987; Spandau et al, 1988; Vannice et al, 1988), Human Immunodeficiency Virus (Muesing et al, 1987; Hauber et al, 1988; Jakobovits et al, 1988; Feng et al, 1988; Takebe et al, 1988; Rosen et al, 1988; Berkhout et al, 1989; Laspia et al, 1989; Sharp et al, 1989; Braddock et al, 1989), Cytomegalovirus (CMV) IE (Weber et al, 1984; Boshart et al, 1985; Foecking et al, 1986), Gibbon Ape Leukemia Virus (Holbrook et al, 1987; Quinn et al, 1989).

[0104] Inducible Elements include, but are not limited to MT II-Phorbol Ester (TFA)/Heavy metals (Palmiter et al, 1982; Haslinger et al, 1985; Searle et al, 1985; Stuart et al, 1985; Imagawa et al, 1987, Karin et al, 1987; Angel et al, 1987b; McNeall et al, 1989); MMTV (mouse mammary tumor virus)-Glucocorticoids (Huang et al, 1981; Lee et al, 1981; Majors et al, 1983; Chandler et al, 1983; Lee et al, 1984; Ponta et al, 1985; Sakai et al, 1988); .beta.-Interferon-poly(rl).times./poly(rc) (Tavernier et al, 1983); Adenovirus 5 E2-E1A (Imperiale et al, 1984); Collagenase-Phorbol Ester (TPA) (Angel et al, 1987a); Stromelysin-Phorbol Ester (TPA) (Angel et al, 1987b); SV40-Phorbol Ester (TPA) (Angel et al, 1987b); Murine MX Gene-Interferon, Newcastle Disease Virus (Hug et al, 1988); GRP78 Gene-A23187 (Resendez et al, 1988); .alpha.-2-Macroglobulin-IL-6 (Kunz et al, 1989); Vimentin-Serum (Rittling et al, 1989); MHC Class I Gene H-2.kappa.b-Interferon (Blanar et al, 1989); HSP70-E1A/SV40 Large T Antigen (Taylor et al, 1989, 1990a, 1990b); Proliferin-Phorbol Ester/TPA (Mordacq et al, 1989); Tumor Necrosis Factor-PMA (Hensel et al, 1989); and Thyroid Stimulating Hormone.alpha. Gene-Thyroid Hormone (Chatterjee et al, 1989).

[0105] Also contemplated as useful in the present invention are the dectin-1 and dectin-2 promoters. Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of structural genes encoding oligosaccharide processing enzymes, protein folding accessory proteins, selectable marker proteins or a heterologous protein of interest.

[0106] The particular promoter that is employed to control the expression of peptide or protein encoding polynucleotide of the invention is not believed to be critical, so long as it is capable of expressing the polynucleotide in a targeted cell, preferably a bacterial cell. Where a human cell is targeted, it is preferable to position the polynucleotide coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a bacterial, human or viral promoter.

[0107] In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, and the Rous sarcoma virus long terminal repeat can be used to obtain high level expression of a related polynucleotide to this invention. The use of other viral or mammalian cellular or bacterial phage promoters, which are well known in the art, to achieve expression of polynucleotides is contemplated as well.

[0108] In embodiments in which a vector is administered to a subject for expression of the protein, it is contemplated that a desirable promoter for use with the vector is one that is not down-regulated by cytokines or one that is strong enough that even if down-regulated, it produces an effective amount of the protein/polypeptide of the current invention in a subject to elicit an immune response. Non-limiting examples of these are CMV IE and RSV LTR. In other embodiments, a promoter that is up-regulated in the presence of cytokines is employed. The MHC I promoter increases expression in the presence of IFN-.gamma..

[0109] Tissue specific promoters can be used, particularly if expression is in cells in which expression of an antigen is desirable, such as dendritic cells or macrophages. The mammalian MHC I and MHC II promoters are examples of such tissue-specific promoters. 2. Initiation Signals and Internal Ribosome Binding Sites (IRES)

[0110] A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic and may be operable in bacteria or mammalian cells. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

[0111] In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Pat. Nos. 5,925,565 and 5,935,819, herein incorporated by reference).

2. Multiple Cloning Sites

[0112] Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector. (See Carbonelli et al, 1999, Levenson et al, 1998, and Cocea, 1997, incorporated herein by reference.) Frequently, a vector is linearized or fragmented using a restriction enzyme that cuts within the MCS to enable exogenous sequences to be ligated to the vector. Techniques involving restriction enzymes and ligation reactions are well known to those of skill in the art of recombinant technology.

3. Splicing Sites

[0113] Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. If relevant in the context of vectors of the present invention, vectors containing genomic eukaryotic sequences may require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression. (See Chandler et al, 1997, incorporated herein by reference.)

4. Termination Signals

[0114] The vectors or constructs of the present invention will generally comprise at least one termination signal. A "termination signal" or "terminator" is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary in vivo to achieve desirable message levels.

[0115] In eukaryotic systems, the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site. This signals a specialized endogenous polymerase to add a stretch of about 200 A residues (poly A) to the 3' end of the transcript. RNA molecules modified with this polyA tail appear to more stable and are translated more efficiently. Thus, in other embodiments involving eukaryotes, it is preferred that that terminator comprises a signal for the cleavage of the RNA, and it is more preferred that the terminator signal promotes polyadenylation of the message.

[0116] Terminators contemplated for use in the invention include any known terminator of transcription described herein or known to one of ordinary skill in the art, including but not limited to, for example, the bovine growth hormone terminator or viral termination sequences, such as the SV40 terminator. In certain embodiments, the termination signal may be a lack of transcribable or translatable sequence, such as due to a sequence truncation.

5. Polyadenylation Signals

[0117] In expression, particularly eukaryotic expression (as is relevant in nucleic acid vaccination), one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and/or any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation signal and/or the bovine growth hormone polyadenylation signal, convenient and/or known to function well in various target cells. Polyadenylation may increase the stability of the transcript or may facilitate cytoplasmic transport.

6. Origins of Replication

[0118] In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed "on"), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be employed if the host cell is yeast.

7. Selectable and Screenable Markers

[0119] In certain embodiments of the invention, cells containing a nucleic acid construct of the present invention may be identified in vitro or in vivo by encoding a screenable or selectable marker in the expression vector. When transcribed and translated, a marker confers an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

[0120] Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, markers that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin or histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP for colorimetric analysis. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers that can be used in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a protein of the invention. Further examples of selectable and screenable markers are well known to one of skill in the art.

The Transformed Cells of the Invention

[0121] Transformed cells of the invention are useful as organisms for producing the polypeptide of the invention, but also as simple "containers" of nucleic acids and vectors of the invention.

[0122] Certain transformed cells of the invention are capable of replicating the nucleic acid fragment defined for option i) of the second aspect of the invention. Preferred transformed cells of the invention are capable of expressing the nucleic acid fragment defined for option i).

[0123] For recombinant production it is convenient, but not a prerequisite that the transformed cell according is prokaryotic, such as a bacterium, but generally both prokaryotic cells and eukaryotic cells may be used.

[0124] Suitable prokaryotic cells are bacterial cells selected from the group consisting of Escherichia (such as E. coli.), Bacillus, (e.g. Bacillus subtilis) Salmonella, and Mycobacterium [preferably non-pathogenic, (e.g. M. bovis BCG)].

[0125] Eukaryotic cells can be in the form of yeasts (such as Saccharomyces cerevisiae) and protozoans. Alternatively, the transformed eukaryotic cells are derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell.

[0126] For production purposes, it is advantageous that the transformed cell of the invention is is stably transformed by having the nucleic acid defined above for option i) stably integrated into its genome, and in certain embodiments it is also preferred that the transformed cell secretes or carries on its surface the polypeptide of the invention, since this facilitates recovery of the polypeptides produced. A particular version of this embodiment is one where the transformed cell is a bacterium and secretion of the polypeptide of the invention is into the periplasmic space.

[0127] As noted above, stably transformed cells are preferred--these inter alia allows that cell lines comprised of transformed cells as defined herein may be established--such cell lines are particularly preferred aspects of the invention.

[0128] Further details on cells and cell lines are presented in the following:

[0129] Suitable cells for recombinant nucleic acid expression of the nucleic acid fragments of the present invention are prokaryotes and eukaryotes. Examples of prokaryotic cells include E. coli; members of the Staphylococcus genus, such as S. epidermidis; members of the Lactobacillus genus, such as L. plantarum; members of the Lactococcus genus, such as L. lactis; members of the Bacillus genus, such as B. subtilis; members of the Corynebacterium genus such as C. glutamicum; and members of the Pseudomonas genus such as Ps. fluorescens. Examples of eukaryotic cells include mammalian cells; insect cells; yeast cells such as members of the Saccharomyces genus (e.g. S. cerevisiae), members of the Pichia genus (e.g. P. pastoris), members of the Hansenula genus (e.g. H. polymorpha), members of the Kluyveromyces genus (e.g. K. lactis or K. fragilis) and members of the Schizosaccharomyces genus (e.g. S. pombe).

[0130] Techniques for recombinant gene production, introduction into a cell, and recombinant gene expression are well known in the art. Examples of such techniques are provided in references such as Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, and Sambrook et al., Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Laboratory Press, 1989.

[0131] As used herein, the terms "cell," "cell line," and "cell culture" may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. In the context of expressing a heterologous nucleic acid sequence, "host cell" refers to a prokaryotic or eukaryotic cell, and it includes any transformable organism that is capable of replicating a vector or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors or viruses. A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid, such as a recombinant protein-encoding sequence, is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny.

[0132] Host cells may be derived from prokaryotes or eukaryotes, including bacteria, yeast cells, insect cells, and mammalian cells for replication of the vector or expression of part or all of the nucleic acid sequence(s). Numerous cell lines and cultures are available for use as a host cell, and they can be obtained through the American Type Culture Collection (ATCC), which is an organization that serves as an archive for living cultures and genetic materials or from other depository institutions such as Deutsche Sammlung vor Micrroorganismen and Zellkulturen (DSM). An appropriate host can be determined by one of skill in the art based on the vector backbone and the desired result. A plasmid or cosmid, for example, can be introduced into a prokaryote host cell for replication of many vectors or expression of encoded proteins. Bacterial cells used as host cells for vector replication and/or expression include Staphylococcus strains, DH5.alpha., JMl 09, and KC8, as well as a number of commercially available bacterial hosts such as SURE.RTM. Competent Cells and SOLOP ACK.TM. Gold Cells (STRATAGENE.RTM., La Jolla, Calif.). Alternatively, bacterial cells such as (E. coli LE392) could be used as host cells for phage viruses. Appropriate yeast cells include Saccharomyces cerevisiae, Saccharomyces pombe, and Pichia pastoris.

[0133] Examples of eukaryotic host cells for replication and/or expression of a vector include HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector may be used in conjunction with either a eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector.

[0134] Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further understand the conditions under which to incubate all of the above described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.

Expression Systems

[0135] Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

[0136] The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Pat. Nos. 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBACC.RTM. 2.0 from INVITROGEN.RTM. and BACPACK.TM. Baculovirus expression system from CLONTECH.RTM..

[0137] In addition to the disclosed expression systems of the invention, other examples of expression systems include STRATAGENE.RTM.'s COMPLETE CONTROL.TM. Inducible Mammalian Expression System, which involves a synthetic ecdysone-inducible receptor, or its pET Expression System, an E. coli expression system. Another example of an inducible expression system is available from INVITROGEN.RTM., which carries the T-REX.TM. (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. INVITROGEN.RTM. also provides a yeast expression system called the Pichia methanolica Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast (Pichia methanolica). One of skill in the art would know how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

Amplification of Nucleic Acids

[0138] Nucleic acids used as a template for amplification may be isolated from cells, tissues or other samples according to standard methodologies (Sambrook et al, 2001). In certain embodiments, analysis is performed on whole cell or tissue homogenates or biological fluid samples without substantial purification of the template nucleic acid. The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to first convert the RNA to a complementary DNA.

[0139] The term "primer," as used herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process. Typically, primers are oligonucleotides from ten to twenty and/or thirty base pairs in length, but longer sequences can be employed. Primers may be provided in double-stranded and/or single-stranded form, although the single-stranded form is preferred.

[0140] Pairs of primers designed to selectively hybridize to nucleic acids corresponding to sequences of genes identified herein are contacted with the template nucleic acid under conditions that permit selective hybridization. Depending upon the desired application, high stringency hybridization conditions may be selected that will only allow hybridization to sequences that are completely complementary to the primers. In other embodiments, hybridization may occur under reduced stringency to allow for amplification of nucleic acids containing one or more mismatches with the primer sequences. Once hybridized, the template-primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

[0141] The amplification product may be detected or quantified. In certain applications, the detection may be performed by visual means. Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical and/or thermal impulse signals (Bellus, 1994).

[0142] A number of template dependent processes are available to amplify the oligonucleotide sequences present in a given template sample. One of the best known amplification methods is the polymerase chain reaction (referred to as PCR.TM.) which is described in detail in U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,800,159, and in Innis et al., 1988, each of which is incorporated herein by reference in their entirety.

[0143] Alternative methods for amplification of target nucleic acid sequences that may be used in the practice of the present invention are disclosed in U.S. Pat. Nos. 5,843,650, 5,846,709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 5,858,652, 5,866,366, 5,916,776, 5,922,574, 5,928,905, 5,928,906, 5,932,451, 5,935,825, 5,939,291 and 5,942,391, GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety.

Methods of Gene Transfer

[0144] Suitable methods for nucleic acid delivery to effect expression of compositions of the present invention are believed to include virtually any method by which a nucleic acid (e.g., DNA, including viral and nonviral vectors) can be introduced into a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by injection (U.S. Pat. Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; U.S. Pat. No. 5,789,215, incorporated herein by reference); by electroporation (U.S. Pat. No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990); by using DEAE dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer et al, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley et al, 1979; Nicolau et al, 1987; Wong et al, 1980; Kaneda et al, 1989; Kato et al, 1991); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Pat. Nos. 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein by reference); by agitation with silicon carbide fibers (Kaeppler et al, 1990; U.S. Pat. Nos. 5,302,523 and 5,464,765, each incorporated herein by reference); by Agrobacterium mediated transformation (U.S. Pat. Nos. 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG mediated transformation of protoplasts (Omirulleh et al, 1993; U.S. Pat. Nos. 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition mediated DNA uptake (Potrykus et al, 1985). Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

The Antibodies of the Invention--and their Production/Isolation

[0145] Antibodies directed against the proteins of the invention are useful for affinity chromatography, immunoassays, and for distinguishing/identifying staphylococcus proteins as well as for passive immunisation and therapy.

[0146] Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 .mu.g/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by in vitro immunization using methods known in the art, which for the purposes of this invention is considered equivalent to in vivo immunization. Polyclonal antiserum is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25 C for one hour, followed by incubating at 4 C for 2-18 hours. The serum is recovered by centrifugation (eg. 1,000 g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.

[0147] Monoclonal antibodies are prepared using the standard method of Kohler & Milstein [Nature (1975) 256: 495-96], or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum, the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective 1 aedium (elg. hypexanthine, aminopterin, thymidine medium,"HAT"). The resulting hybridomas are plated by limiting dilution, and are assayed for production of antibodies, which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either in vitro (eg. in tissue culture bottles or hollow fiber reactors), or in vivo (as ascites in mice).

[0148] If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly 32p and 125I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3', 5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. "Specific binding partner" refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, 1151 may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with, 125I, or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

[0149] According to the invention, the isolated monoclonal antibody or antibody analogue is preferably a monoclonal antibody selected from a multi-domain antibody such as a murine antibody, a chimeric antibody such as a humanized antibody, a fully human antibody, and single-domain antibody of a llama or a camel, or which is an antibody analogue selected from a fragment of an antibody such as an Fab or an F(ab').sub.2, an scFV; cf. also the definition of the term "antibody" presented above.

Compositions of the Invention; Vaccines

[0150] Pharmaceutical compositions, in particular vaccines, according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie, to treat disease after infection).

[0151] Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid(s), usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles.

[0152] Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogen, cf. the description of immunogenic carriers supra.

[0153] The pharmaceutical compositions of the invention thus typically contain an immunological adjuvant, which is commonly an aluminium based adjuvant or one of the other adjuvants described in the following:

[0154] Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detox.TM.); (3) saponin adjuvants such as Stimulon.TM. (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (eg. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59.TM. adjuvants are preferred.

[0155] As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2''-2'-dipalmitoyl-sn-- glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

[0156] The immunogenic compositions (eg. the immunising antigen or immunogen or polypeptide or protein or nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

[0157] Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

[0158] Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (eg. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies or generally mount an immune response, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. However, for the purposes of protein vaccination, the amount administered per immunization is typically in the range between 0.5 .mu.g and 500 mg (however, often not higher than 5,000 .mu.g), and very often in the range between 10 and 200 .mu.g.

[0159] The immunogenic compositions are conventionally administered parenterally, eg, by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (eg. WO98/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. In the case of nucleic acid vaccination, also the intravenous or intraarterial routes may be applicable.

[0160] Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

[0161] As an alternative to protein-based vaccines, DNA vaccination (also termed nucleic acid vaccination or gene vaccination) may be used [eg. Robinson & Torres (1997) Seminars in Immunol 9: 271-283; Donnelly et al. (1997) Annu Rev Immunol 15: 617-648; later herein].

Treatment Methods of the Invention

[0162] The method of the sixth aspect of the invention generally relates to induction of immunity and as such also entails method that relate to treatment, prophylaxis and amelioration of disease.

[0163] When immunization methods entail that a polypeptide of the invention or a composition comprising such a polypeptide is administered the animal (e.g. the human) typically receives between 0.5 and 5,000 .mu.g of the polypeptide of the invention per administration.

[0164] In preferred embodiments of the sixth aspect, the immunization scheme includes that the animal (e.g. the human) receives a priming administration and one or more booster administrations.

[0165] Preferred embodiments of the 6.sup.th aspect of the invention comprise that the administration is for the purpose of inducing protective immunity against C. jejuni. In this embodiment it is particularly preferred that the protective immunity is effective in reducing the risk of attracting infection with C. jejuni or is effective in treating or ameliorating infection with C. jejuni.

[0166] As mentioned herein, the preferred vaccines of the invention induce humoral immunity, so it is preferred that the administration is for the purpose of inducing antibodies specific for C. jejuni and wherein said antibodies or B-lymphocytes producing said antibodies are subsequently recovered from the animal.

[0167] But, as also mentioned the method of the 6.sup.th aspect may also be useful in antibody production, so in other embodiments the administration is for the purpose of inducing antibodies specific for C. jejuni and wherein B-lymphocytes producing said antibodies are subsequently recovered from the animal and used for preparation of monoclonal antibodies.

[0168] Pharmaceutical compositions can as mentioned above comprise polypeptides, antibodies, or nucleic acids of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount thereof.

[0169] The term "therapeutically effective amount" or "prophylactically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. Reference is however made to the ranges for dosages of immunologically effective amounts of polypeptides, cf. above.

[0170] However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.

[0171] For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

[0172] A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

[0173] Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J. 1991).

[0174] Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

[0175] As is apparent from the claim, the invention also relates to related embodiments to the treatment and prophylaxis disclosed herein: the invention also includes embodiments where

[0176] the polypeptide of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with C. jejuni;

[0177] the nucleic acid fragment of the invention or the vector of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with C. jejuni;

[0178] the transformed cell of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with C. jejuni.

[0179] the antibody, antibody fragment or antibody analogue of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with C. jejuni.

EXAMPLES

Material and Methods

Bacterial Strains and Plasmid

[0180] The bacterial strains used in this study included E. coli SURE (Stratagene) and E. coli BL21 (DE3) (Stratagene) and the plasmid was pTLJ03. Strains and plasmid originates from a NCTC 11168 C. jejuni ORF library (Parrish et al., 2004) available from Geneservice. The expression clone set comprises >1,600 C. jejuni ORF's and the expression vector pTLJ03 generates N-terminal GST-His-tagged fusion proteins.

[0181] Strains were grown in LB media or the expression media MagicMedia (Invitrogen) at 37.degree. C. pTLJ03 containing strains were grown in media containing 50 .mu.g/mL ampicillin unless otherwise specified. C. jejuni 11168H is a stable motile variant of the reference strain C. jejuni NCTC 11168; its preparation is described infra in the section headed "recombinant DNA techniques". C. jejuni strains (NCTC 11168 and 11168H) were grown at 37.degree. C. microaerophilic on blood plates (BaseII and 5% blood) in BHI broth or biphasic (blood plates and BHI broth) with antibiotic when needed (30 .mu.g/mL kanamycin or/and 50 .mu.g/mL streptomycin).

Expression Library

[0182] The library was originally created in E. coli SURE for optimal storage. This strain does not contain the T7 polymerase and for that reason the library was transformed to the E. coli BL21 (DE3) expression strain. The clones were grown separately overnight in microtiter plates in 200 .mu.l LB media containing ampicillin and subsequently the plasmids were purified as a pool and transformed to the chemocompetent E. coli BL21 (DE3) strain. This revealed an expression library consisting of 2304 clones (24 microtiter plates).

Immunoblot Assay

[0183] Individual clones were grown 16-20 hrs in microtiter plates in MagicMedia for optimal expression. 2 .mu.l of the culture was spotted on nitrocellulose membranes. The membranes were blocked in blocking buffer 30 min., washed in PBS Tween and then incubated in primary antibody (1:1000) at 4.degree. C. for 16-20 hrs. The membranes were then washed in PBS Tween and incubated in secondary antibody (Polyclonal goat anti-rabbit immunoglobulins/HRP, Dako) for 1 hr. The reaction was visualised by chemoluminescence (chemoluminescent substrate, Invitrogen). The primary antibody was raised in rabbit immunised with a boiled-treated (100.degree. C. for 1 h) C. jejuni Penner serotype 2 originally isolated from a human patient. Rabbit serum from immunisations with the Penner serotype 2 was chosen since it corresponds to the serotype used for creating the commercial library (NCTC 11168). The serum was preincubated with E. coli BL21 (DE3) before use to minimise background reaction. To verify that the antigens also reacted against human serum, a dot blot with 10 selected clones expressing antigens and serum isolated from a patient infected with C. jejuni Penner serotype 2 (Strid M A et al. 2001, "Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients", Clin. Diag. Lab. Immunol. 183:2553-9.) was carried out as described above.

Clone Sequencing

[0184] Plasmid DNA was isolated from 100 ml E. coli BL21 (DE3) cultures using MidiPrep (Qiagen). Sequencing was conducted by Macrogen Inc. and the primer 5' GCT ATC CCA CAA ATT GAT AA 3' (SEQ ID NO: 91).

Recombinant DNA Techniques

[0185] C. jejuni 11168H knock-out mutants were kindly provided by Brendan Wren from the London School of Hygiene and Tropical Medicine, University of London. Mutants were constructed via insertion of the Km cassette into unique sites present in pUC18-based recombinant plasmids containing random 1-kb fragments from the C. jejuni NCTC 11168 genome library (Garenaux A et al. 2008, "Role of the Cj1371 periplasmic protein and the Cj0355c two-component regulator in the Campylobacter jejuni NCTC 11168 response to oxidative stress caused by paraquat", Res Microbiol. 159: 718-26 and Parkhill J et al. 2000, "The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences", Nature 10; 403(6770):665-8). The 11168H knock out mutant provided for this study is: Cj0034c. Subsequently the gene knock-outs were transferred from the C. jejuni 11168H strain to the C. jejuni 11168 strain to restore motility and spiral morfology. Natural transformation was performed as described previously (Wang Y and Taylor D E 1990, "Natural transformation in Campylobacter species", J Bacteriol. 172: 949-55) with some modifications. C. jejuni cultures grown overnight on BHI agar plates were collected and resuspended in 12 ml BHI broth to OD.sub.600 of 0.001. Bacterial suspensions in three dilutions were transferred to sterilized Petri dishes, incubated at 37.degree. C. with no shaking under micro aerobic conditions over night. 200 .mu.g cultures with OD.sub.600 0.2-0.3 were transferred to sterilized tube with 1 ml BHI and incubated at 37.degree. C. with shaking under micro aerobic conditions 2 h. Then 10 ng of genomic DNA, purified with Qiagen blood and tissue kit, of the mutants, was added each tube. After additional incubation for 3 h, bacterial cultures were serially diluted and plated on BaseII agar plates with antibiotics (50 mg/l kanamycin). The agar plates were incubated at 37.degree. C. under microaerobic conditions 3 days. The mutants were checked for curved shape and motility before tested in assays.

INT407 Adhesion Assay

[0186] INT407 cells (representing intestinal cell line) were grown in MEM (+glutamax) media (Invitrogen) added 25 .mu.g/ml gentamycin and 10% heat inactivated fetal bovine serum in 5% CO.sub.2. Cells were seeded at 2.5.times.10.sup.5pr well in 24 well plates, incubated overnight and checked for 100% confluent monolayer. The E. coli clones were grown overnight in MagicMedia broth at 37.degree. C. and C. jejuni on blood agar plates microaerophilic at 37.degree. C. Immediately before assay, the OD.sub.600 of the bacteria was adjusted to 1 in PBS and 1 ml bacteria culture was added the INT407 cells and cells were incubated with bacteria for 2 hours at 37.degree. C., then resuspended and diluted in PBS and spotted on agar plates with appropriate antibiotics.

Electron Microscopy

[0187] To investigate, whether the C. jejuni mutant strain differed morphologically from the wild type strain, a transmission electron microscopy analysis was conducted. Initially, the bacterial cultures were fixated in 1% glutaraldehyde (EMS, Hatfield, USA) for 30 minutes. To improve the adhesion of the bacteria, formvar coated 400-mesh copper grids were treated for 5 minutes with alcian blue (Sigma-Aldrich). The alcian blue treated grids were placed on top of cultures of C. jejuni NCTC11168 and C. jejuni NCTC11168L0034 (Cj0034c), respectively, and after 5 minutes of incubation, most of the suspensions were removed from the grids with filter paper and the grids were stained for 30 seconds with phosphotungstic acid (BDH Chemicals). The grids were allowed to air-dry, and then they were viewed in a Morgagni 268D transmission electron microscope, and pictures were taken using a Mega-view III digital camera.

Motility Assay

[0188] A motility assay was carried out to ensure no altered motility for the 11168L0034 mutant. 0.25% soft agar plates were supplied with 1 .mu.l bacterial culture (OD.sub.600 adjusted to 0.1) in the middle of the plate and diameter was measured over a time period.

Serum Resistance Assay

[0189] Serum sensitivity assays were performed by modification of the method of Blaser at al (Blaser M J et al. 1985, "Susceptibility of Campylobacter isolates to the bactericidal activity of human serum", J Infect Dis. 151: 227-235.) C. jejuni strains were grown overnight in Brucella biphasic cultures at 37.degree. C., washed in PBS, pH 7.4, and adjusted to a concentration of 10.sup.3 CFU/ml. C. jejuni cells (10-.mu.l aliquots) were incubated in 240-.mu.l pools of whole human blood (venous blood), human serum (whole blood incubated at 25.degree. C. 30 min, centrifuged 1000.times.g 10 min at 4.degree. C. and supernatant isolated) and heat inactivated human serum (56.degree. C. for 30 min) respectively for 30, 60, 90 and 120 min. Following the incubation period, CFU was enumerated on BHI agar.

Biofilm and Autoagglutination

[0190] Cell-to-cell autoagglutination was assayed in PBS as described by Misawa and Blaser (Misawa N and Blaser M J 2000, "Detection and characterization of autoagglutination activity by Campylobacter jejuni", Infect. Immun. 68: 6168-6175.)

[0191] Biofilm assay was made in 50 ml centrifuge tubes containing 25 ml inoculated Brucella broth with NCTC 11168 and the knock out mutants in Cj0034c. A glass slide was added each tube and incubated micro aerobic for 48 h. Then the slides were stained with crystal violet and biofilm formation visualised.

Predictions of Protein Localization

[0192] Prediction of protein localization and amount of transmembrane helixes was made by TMHMM 2.0 server (Moller S et al. 2001, "Evaluation of methods for the prediction of membrane spanning regions", Bioinformatics, 17: 646-653).

[0193] The SignalP 3.0 server predicts the presence and location of signal peptide cleavage sites in amino acid sequences. The method incorporates a prediction of cleavage sites and a signal peptide/non-signal peptide prediction based on a combination of several artificial neural networks and hidden Markov models. The LipoP 1.0 server produces predictions of lipoproteins and discriminates between lipoprotein signal peptides, other signal peptides and N-terminal membrane helices in Gram-negative bacteria (Juncker A S et al. 2003, "Prediction of lipoprotein signal peptides in Gram-negative bacteria", Protein Sci. 12:1652-62).

Protein Purification

[0194] His-tag purification was made with the already GST-His-tagged constructed vector from Geneservice. An overnight pre-culture of E. coli BL21(DE3) containing the vectors was 50-fold diluted to inoculate 1000 ml LB medium containing appropriate antibiotics. The cultures were incubated with shaking at 37.degree. C. to an OD.sub.600 of 0.5, then induced with 10 mM IPTG and incubated with shaking for 16 hours at 30.degree. C. After induction, cells were lysed on ice in 20 ml lysis buffer (50 mM NaH.sub.2PO.sub.4, 300 mM NaCl, 10 mM imidazole 10% glycerol) by addition of 1 mg/ml lysozyme followed by sonication. Lysates were cleared by centrifugation at 15,000.times.g for 30 min. Proteins were purified by nickel affinity chromatography using the Ni-NTA resin (Qiagen) equilibrated with lysis buffer and eluted with 250 mM imidazole. Eluted proteins were concentrated and dialyzed against 25 mM HEPES pH 7.5, 50 mMNaCl, 10% glycerol.

Mouse Vaccination and Challenge Studies

[0195] To study ability of the proteins to protection against infection, immunization of mice were carried out. Cj0404 (SEQ ID NO: 13) was tested together with other putative vaccine candidates for its ability to protect against C. jejuni infection. Mice (10 in each group) were immunized with 5 .mu.g/dose, except one with 1.6 .mu.g/dose (Cj1371c), along with adjuvant (GNE, Intervet, NL). Four weeks later, the mice (Balb/c for colonization and CH3/HeN for invasion) were treated for three days with streptomycin (5 g/l in drinking water) and challenged orally one day later with C. jejuni 81116 (6.times.10.sup.5 CFU, colonization study) and 72Dz/92 (5.times.10.sup.7 CFU, invasion study) respectively. Balb/c mice 6-8 weeks (female) were used in groups of three. One fresh faecal dropping was collected and weighted from each animal and dilutions were made in order to determine CFU/gram faeces. Faecal samples were collected from the Balb/c mice regularly in 23 days. Necropsy was prepared one week after challenge of the CH3/HeN mice, spleen and liver were collected and CFU/organ were detected.

Results

[0196] Identification of C. jejuni Antigens

[0197] With the aim of identifying immuno-reactive C. jejuni proteins plasmid DNA was isolated from a pooled mixture of commercial library clones established by Parrish et al (Parrish J R et al. 2004, "High-throughput cloning of Campylobacter jejuni ORfs by in vivo recombination in Escherichia coli", J Proteome Res. 3: 582-6.) with C. jejuni NCTC11168 ORFs in the plasmid pTLJO3 (Parrish J R et al. 2004). Plasmid DNA was transformed into E. coli BL21 to allow expression from the T7 promoter. The resulting transformants were individually spotted on a nitrocellulose membrane and reacted with serum isolated from a rabbit infected with a C. jejuni human clinical isolate (serotype 2). The screening revealed several immunogenic E. coli clones that selectively reacted with the serum. Inserts in plasmids isolated from the transformants that repeatedly proved as most immunogenic were selected for sequencing and from a total of 2304 clones, 52 inserts were sequenced representing 25 genes encoding potential antigens. The identified C. jejuni genes were classified according to their predicted function.

[0198] To confirm that the identified antigens also are functional in humans we reacted 10 of the 25 clones (Cj0034, Cj0203, Cj0404 (SEQ ID NO: 13), Cj0525c, Cj0645, Cj0917c, Cj1094c, Cj1371, Cj1382c, Cj1632c) with human antiserum obtained from a patient infected with a C. jejuni Penner serotype 2 and found in all cases a positive reaction. This result supports that the antigens reacting with the mouse antiserum also are antigens in humans.

Prediction of Protein Localization

[0199] Prediction of localization of the proteins and amount of transmembrane helixes was made: 14 out of 25 proteins are predicted to contain one or more membrane helixes, two of them further with a signal peptide. Other ten of the proteins are predicted to be located externally, where three of them harbor a signal peptide. None of the proteins were predicted to contain a lipoprotein signal peptidase.

Several Antigens Support Host Cell Adhesion

[0200] Adhesion of C. jejuni to host cells forms the first important step in the infection process. With the aim of addressing whether the identified antigens contribute to host cell invasion a selection of 10 E. coli clones expressing C. jejuni antigens were investigated for their ability to adhere to the intestinal epithelial cell line, INT407. Interestingly, expression of three of the C. jejuni antigens enhanced the ability of E. coli BL21 to adhere to INT407 cells, Cj0034c, Cj0404 (SEQ ID NO: 13) and Cj1371. Subsequently, gene-specific C. jejuni mutations were constructed in the corresponding genes, and the resulting mutants were examined in the same cell adhesion assay. While the absence of Cj0404 and Cj1371 did not affect the ability of C. jejuni to adhere to INT407 cells, inactivation of Cj0034 dramatically reduced adhesion suggesting that Cj0034 may contribute to establishment of C. jejuni in host organisms.

[0201] Further characterization of the Cj0034 mutant C. jejuni strain revealed, that the mutation does not result in major structural changes of the bacterial cell morphology as visualized by electron microscopy. Also, the inactivation of Cj0034 did not influence serum resistance, motility, autoagglutination and biofilm formation, when compared to wild type strain.

Antigens as Vaccine Candidates

[0202] Five identified antigens were selected to test as vaccine candidates in two Campylobacter oral challenge mouse models; one in C3H/HeN mice in which invasion in liver and spleen was measured and the other in Balb/c mice in which shedding faecal was determined. The challenge study showed a reduced invasion into spleen and liver for at least two of the proteins; Cj0525c and Cj0404 (SEQ ID NO: 13). No decreased colonization for any of the proteins was observed.

Further Examples

C. jejuni Antigen Expression

[0203] 30 genes encoding potentially antigenic C. jejuni proteins were identified and checked in NCBI and presence in the clone library. Of the 30 suggested gene sequences, 19 were commercially available and purchased from Life Sciences. All 19 were used for cloning in expression plasmid (with his-tag) and transformation into the expression strain E. coli BL21. Two of the constructs were not transferred to E. coli BL21 and after several attempts we did not proceed, which left 17 successful transformants.

[0204] We also separately PCR-cloned from Campylobacter jejuni 11168. Thus Cj0404, Cj0788, Cj0892 and Cj0424 were cloned into plasmid with his-tag and transformed into E. coli BL21. Previous work suggested that Cj0404 was antigenic (Clin Vaccine Immunol. 2012 February; 19(2):113-9) whereas Cj0424 was identified by us.

[0205] Preliminary tests were performed with the 4 C. jejuni genes transformed in BL21.

[0206] Further, several inductions were made with the 17 C. jejuni genes transformed in E. coli BL21. Media and induction protocols were tested. "Magic media" was seen to induce relevant sized proteins as can be seen from the SDS gels shown in FIG. 1. It was demonstrated that 7 C. jejuni clones were induced (circle markings). Overnight cultures were run on the 12% SDS gel. All experiments were performed at least twice with essentially the same results.

Protein Purification and Verification of Immunogenicity

[0207] The C. jejuni transformed clones were tested for antibody recognition in a dot blot assay.

[0208] The four selected clones produced from PCR cloning were tested for expression and antibody antigenicity in a dot blot assay against human sera (dot blot 1 shown in FIG. 2).

[0209] The 7 E. coli clones that could be induced to produce C. jejuni proteins were tested for reaction with antisera from rabbits immunised with five different Campylobacter strains of five different isolates. All clones reacted to all sera.

[0210] All experiments were performed at least twice with essentially the same results.

[0211] Since all antigens were recognised by rabbit antisera, they were subsequently tested with sera from patients that were shown to have antibodies against Campylobacter jejuni tested in the diagnostic test that runs at the Danish State Serum Institute (Strid et al. Clin Diagn Lab Immunol. 2001 March; 8(2):314-9).

[0212] The sera were randomly picked but all exhibited antibodies against Campylobacter jejuni. Patients with no antibodies to C. jejuni by ELISA are not expected to react in the dot blot assay (data not shown). Examples of the dot blots are seen in FIG. 2.

[0213] From the dot blots it is seen that all patients found to have antibodies against C. jejuni by a diagnostic ELISA react also react with colonies of E. coli BL21 that express C. jejuni antigens. In many cases the negative control being an E. coli BL21 without a plasmid is seen to also react with the sera This is expected since humans have encountered E. coli infections and are colonised in the gut.

IN CONCLUSION

[0214] We have identified 30 C. jejuni genes that are be potentially antigenic and recognised by antibodies against Campylobacter. We have been able to show that 7 of these are indeed able to be recognised by antibodies raised in humans after a natural infection with Campylobacter jejuni (diarrea).

Sequences of Proteins of the Invention:

[0215] The protein sequences of the invention mentioned in the above examples are related to the sequences in the sequence listing as follows:

TABLE-US-00001 Aa sequence Designation SEQ ID NO: 1: Cj0251c SEQ ID NO: 2: Cj1464 SEQ ID NO: 3: Cj1406c SEQ ID NO: 4: Cj0579c SEQ ID NO: 5: Cj0158c SEQ ID NO: 6: Cj0592c SEQ ID NO: 7: Cj0783 SEQ ID NO: 8: Cj0371 SEQ ID NO: 9: Cj0424 SEQ ID NO: 10: Cj0944c SEQ ID NO: 11: Cj0111 SEQ ID NO: 12: Cj0596 SEQ ID NO: 13: Cj0404 SEQ ID NO: 14: Cj0606 SEQ ID NO: 15: Cj1178c SEQ ID NO: 16: Cj1357c SEQ ID NO: 17: Cj0144 SEQ ID NO: 18: Cj0262c SEQ ID NO: 19: Cj0887c SEQ ID NO: 20: Cj1729c SEQ ID NO: 21: Cj0136 SEQ ID NO: 22: Cj0886c SEQ ID NO: 23: Cj1365c SEQ ID NO: 24: Cj0279 SEQ ID NO: 25: Cj1677 SEQ ID NO: 26: Cj0628 SEQ ID NO: 27: Cj1476c SEQ ID NO: 28: Cj0478 SEQ ID NO: 29: Cj0007 SEQ ID NO: 30: Cj0479

[0216] For easy reference, the protein sequences of the invention are set forth in one-letter amino acid code in the following:

TABLE-US-00002 SEQ ID NO: 1 MAYEDEEDLN YDDYENEDEE YPQNHHKNYN YDDDDYEYDD DNNDDDFYEM D 51 SEQ ID NO: 2 MINPIQQSYV ANTALNTNRI DKETKTNDTQ KTENDKASKI AEQIKNGTYK IDTKATAAAI 60 ADSLI 65 SEQ ID NO: 3 MKKILILLTL CAFAFGASEC DRKIDRINKE ISFSKAHNDT ARTLSLELAL KQVQNDCAKD 60 PMFYDKKLEA KKLKEQEVEK IEKELDALKE QKDYMSKAEY KAKKEALKEQ KEKIKK 116 SEQ ID NO: 4 MSFGEIIVIL VVAILVLGPD KLPEAIVQIA KILKAVKRNI DDAKSSIEKE IRINDLKEEA 60 KKYKDEFSST NENIRKKLSF EEFDDLKRDI LDKTKVDLTF DSRDDKVKNN LSGQNLNTEE 120 KPNLSKLETQ DKNGKINV 138 SEQ ID NO: 5 MQKAKILIAL SFFLLVLSAC SNDEKNISKT QNTDQEVVQI EQNDEKTELS DSNLPLPVDD 60 EAQSSNDEHE VNPSIINSLY KQKCATCHGE KGELKPKNST AIKTLSNKIF IQKIKTIKDK 120 NHSFLSDEQI QNLADFINKG K 141 SEQ ID NO: 6 MRRLSILLAI LIVINITACD SKTENYYKNL PSEAKEKAKE CKESGTLSED CINALKVGVK 60 PTNEEGKYSP NTPKKSDNQI LEALKQNDLK KEKTTKDINQ SSENNESIII PPIAETPSEI 120 YPSKTTENNQ SSIFSDDVNM TQEK 144 SEQ ID NO: 7 MMKKKLVLLG SAAVVFFAAC AMNSGVSSEQ IGLRKASLEN ENKVNLVEAN FTTLQPGEST 60 RFERSYENAP PLIPHAIEDL LPITKDNNMC LSCHDKAIAA DAGATPLPAS HYYDFRHNKT 120 TGDMISDSRF NCTQCHVPQS DAKPLVGNSF KPEFKNEQLK SRSNLIDVIN EGVK 174 SEQ ID NO: 8 MKKIKKIIQI GMIGGLAAVA GGALAGCGSN NDNADTLNQA ANAQGAFVII EETAPGQYKI 60 KDQYPSDETR VVLKDLNGTE RILSKEEMDA LIKEEAAKID NGTSNLTKDN GQISSGGLSL 120 GETLLASAAG AILGSWIGSK LFNNQNFANQ QRGAFSNQSA YQRSVNSFNK AGTTSSASSA 180 KKSGFFGGGS KATSSSSSFG S 201 SEQ ID NO: 9 MTKFLSICSL IAMLLSGCGS DFPGQPSDVA RVQQNKYPNG NLKKEIPYNK DSRIHGLKRA 60 FYDNGQLRAE ENYKNGKKDG ISREYSRNGQ LLEEVHFKDN RGYGDFASYY ENGNMRAKGK 120 LLGYNEDGMP EFEGNYKEYY ENGTLMCDYN FDNKGKFDGV QKRYDENGAL EDEENYKNGL 180 KNGVFREYKK GEIVREEEYK NGILVAKPKN 210 SEQ ID NO: 10 MKKIFLSVFL VLSLNAQNLE IDKIRTDLYS KSGANVLKKV EISLEFDGNN LKENENKLID 60 AVNTVISGFF YEDIFTEIGK NNFKKTLEKF LDKKYKIKLD DIYIISLSGV EKFDLEEFKR 120 FLESTEAKEK GMGSEVKKAL ENLEVPKTQV PSVEKIPTPS VPNLEVKQVE QLFKDPDEEN 180 KNDNGEINID NLNTPKMTPD IEEKIKRDLI ANPPQIFKEN NASKPYHLPQ TGYDIKLDEN 240 STQN 244 SEQ ID NO: 11 MKNYGLSNLN SFLLALAIYI SIVILVFFRL VSEVEPAIQY TDIKDSFVDI ELAEPSKQVI 60 TQSNTPKEIQ KPTEQIDIEK LFAQTTNKTV KTEDIDQKAS NFNELFGNIK EIQEEKTTKI 120 QSSAKSGISS APKPQASELV KQLNDSLLQE ESSTQGESTK AQKIGIYDEF LGKVVRIITQ 180 RWTQYYPNSE KISVKVKIFI DENGKFGYTS VEKSGNPLYD AKVAEFLESQ KGKFITYPPQ 240 NKNISITMNL RDEVKVKND 259 SEQ ID NO: 12 MKKFSLVAAT LIAGVVLNVN AATVATVNGK SISDTEVSEF FAPMLRGQDF KTLPDNQKKA 60 LIQQYIMQDL ILQDAKKQNL EKDPLYTKEL DRAKDAILVN VYQEKILNTI KIDAAKVKAF 120 YDQNKDKYVK PARVQAKHIL VATEKEAKDI INELKGLKGK ELDAKFSELA KEKSIDPGSK 180 NQGGELGWFD QSTMVKPFTD AAFALKNGTI TTTPVKTNFG YHVILKENSQ AKGQIKFDEV 240 KQGIENGLKF EEFKKVINQK GQDLLNSAKV EYK 273 SEQ ID NO: 13 MENQKNEFDD IILEKSNKSE KVKKILLRVI ALVILFLAIM IVMKLINGSG DENTQNQSVL 60 PSEPIATQDN NNDTSFESMP ITDNTSAEDQ FEALRKQFQD EQNTTQNTTT SSSNNNDTTN 120 FAMPDQEVPA EPTATTSANT TPQASTPKQE VTQTAKSKEE AKKQTAVKKE KESAKQTPKK 180 EQNANDLFKN VDAKPVHPSG LASGIYVQIF SVSNLDQKSK ELASVKQKGY DYKLYKTTVG 240 SKEITKVLIG PFEKADIAAE LAKIRKDIAK DAFSFTLK 278 SEQ ID NO: 14 MKKKIVLIIL IAILGSVGAY FIFFNNDEKI SYLTQKIQKK DISQTIEAVG KVYAKDQVDV 60 GAQVSGQIIK LYVDVGTHVK QGDLIAQIDK DKQQNDLDIT KAQLESAKAN LESKKVALEI 120 ANKQYQREQK LYAAKASSLE NLETQKNNYY TLKANVAELN AQVVQLEITL KNAQKDLGYT 180 TITAPMDGVV INVAVDEGQT VNANQNTPTI VRIANLDEME VRMEIAEADV SKIKVGTELD 240 FSLLNDPQKT YHAKIASIDP ADTEVSDSST SSSSSSSSSS SSSSSNAIYY YAKFYVANKD 300 DFLRIGMSIQ NEIVVASAKA VLAVPTYAIK SDPKGYYVEI LENQKAVKKY VKLGIKDSIN 360 TQILEGVNED EELIVSSSAD GLAPKMKLRF 390 SEQ ID NO: 15 MKILLLNENP VVSRLVSLSA KKMSYDFEEL NAYSENLGNY DVIVVDSDTP APLKILKEKC 60 DRLIFLAPRN QNVEDIDAQI LQKPFLPTDF LNLLNNKDAN KHTSIDLPML SNDENPYADI 120 SLDLDNLNLD DLPDENSLDI NSEGMEDLSF DDDAQDDNAN KTLETQNLEH ETIKEQTQED 180 TQIDLDLTLE DGESEKEDLS QEHTALDTEP SLDELDDKND EDLEIKEDDK NEEIEKQELL 240 DDSKTNTLEM QEELSESQDD NSNKTLETQN LEHDNLEQET IKEQTQEDTQ IDLDLTLEDG 300 ESEKEDLSQE HTALDTEPSL DELDDKNDED LEDNKELQAN ISDFDDLPEV EEQEKEMDFD 360 DLPEDAEFLG QAKYNEESEE NLEEFAPVVE EDIQDEIDDF ASNLSTQDQI KEELAQLDEL 420 DYGIDSDNSS KVLEDFKDEP ILDDKELGTN EEEVVVPNLN ISDFDTLKES DIQEALGEEI 480 LEKNEEPIVS DVTKDDNSEE IVNELSQSIA GAITSSIKDD TLKAALKGMN MNININISFK 540 ED 542 SEQ ID NO: 16 MKKNILRLGI VVLVLLIAGV LWLNNDINQK KEDEANKNAI AANADFSLLS DDDPNFEKWG 60 KVFPEQLKMY LTVEKEEPKA TEFGGNLAYS KLIRFPQLTI LWAGYPFSLD FNEERGHFWV 120 QVDQMKTARN NKDFLNAHGL AAFKGQPAAC MNCHSGWTPW LIKNVAKGDF TAFNSTNYWT 180 MIKNIPAVDG IVENSPEHAG PHGGKRMGVT CADCHNPNDM SLRLTRPAAI NALVSRGYEK 240 DPVQGVKATR EEMRTLVCSQ CHVEYYFKPT GEKVKVMGET IVDDSSKKWW NGTQKNYDEY 300 EFWRDGNKVK EIETDGIVLT FPWSEWKKGQ PFRIEMLDDY YDKVRGVFGA DFTHKLTGAQ 360 IIKIQHPESE LYSGGVHAAN GVSCVDCHMP YVREGAKKVT QHNITSPLRD INSACKSCHK 420 QSEDYLKAQV LDIQNSVAHD QRTAEYAIVS LIMDTKKLRD ELGNMEKFQS DGKADAKKIS 480 EELKEVLELH RKAQMRADFV NAENSTGFHN PREASRMLLQ AVDMARMGQT KLVEIAAANG 540 IKDFKTSNLG FEDIQKFNPG ELYYKVDVNN HKAGERYYAD EKDVNGNPPK ELLEHDKELA 600 PYNYQVIDKK 610 SEQ ID NO: 17 MKSVKLKVSL IANLIAVVCL IILGVVTFIF VKQAIFHEVV NAEINYVKTA KNSIESFKAR 60 NSLALESLAK SILKHPIEQL DSQDALMHYV GKDLKNFRDA GRFLAVYIAQ PNGELVVSDP 120 DSDAKNLDFG TYGKADNYDA RTREYYIEAV KTNKLYITPS YIDVTTNLPC FTYSIPLYKD 180 GKFIGVLAVD ILAADLQAEF ENLPGRTFVF DEENKVFVST DKALLQKGYD ISAIANLAKT 240 KEDLEPFEYT RPKDGNERFA VCTKVSGIYT ACVGEPIEQI EAPVYKIAFI QTAIVIFTSI 300 ISVILLYFIV SKYLSPLAAI QTGLTSFFDF INYKTKNVST IEVKSNDEFG QISNAINENI 360 LATKRGLEQD NQAVKESVQT VSVVEGGNLT ARITANPRNP QLIELKNVLN KLLDVLQARV 420 GSDMNAIHKI FEEYKSLDFR NKLENASGSV ELTTNALGDE IVKMLKQSSD FANALANESG 480 KLQTAVQSLT TSSNSQAQSL EETAAALEEI TSSMQNVSVK TSDVITQSEE IKNVTGIIGD 540 IADQINLLAL NAAIEAARAG EHGRGFAVVA DEVRKLAERT QKSLSEIEAN TNLLVQSIND 600 MAESIKEQTA GITQINDSVA QIDQTTKDNV EIANESAIIS STVSDIANNI LEDVKKKRF 659 SEQ ID NO: 18 MQSINSGKSV GISAKLTLWV GILVVLILAI TSAISYFDSR NNTYELLKDT QLKTMQDVDA 60 FFKSYAMSKR NGIQILANEL TNRPDMSDEE LINLIKVIKK VNDYDLVYVG FDNTGKNYQS 120 DDQILDLSKG YDTKNRPWYK AAKEAKKLIV TEPYKSAASG EVGLTYAAPF YDRNGNFRGV 180 VGGDYDLANF STNVLTVGKS DNTFTEVLDS EGTILFNDEV AKILTKTELS INIANAIKAN 240 PALIDPRNQD TLFTAKDHQG VDYAIMCNSA FNPLFRICTI TENKVYTEAV NSILMKQVIV 300 GIIAIIIALI LIRFLISRSL SPLAAIQTGL TSFFDFINYK TKNVSTIEVK SNDEFGQISN 360 AINENILATK RGLEQDNQAV KESVQTVSVV EGGNLTARIT ANPRNPQLIE LKNVLNKLLD 420 VLQARVGSDM NAIHKIFEEY KSLDFRNKLE NASGSVELTT NALGDEIVKM LKQSSDFANA 480 LANESGKLQT AVQSLTTSSN SQAQSLEETA AALEEITSSM QNVSVKTSDV ITQSEEIKNV 540 TGIIGDIADQ INLLALNAAI EAARAGEHGR GFAVVADEVR KLAERTQKSL SEIEANTNLL 600 VQSINDMAES IKEQTAGITQ INDSVAQIDQ TTKDNVEIAN ESAIISSTVS DIANNILEDV 660 KKKRF 665 SEQ ID NO: 19 MRITNKLNFT NSVNNSMGGQ SALYQISQQL ASGLKIQNSY EDASTYIDNT RLEYEIKTLE 60 QVKESTSRAQ EMTQNSMKAL QDMVKLLEDF KVKVTQAASD SNSQTSREAI AKELERIKES 120 IVQLANTSVN GQYLFAGSQV ANKPFDSNGN YYGDKNNINV VTGAGTESPY NIPGWDLFFK 180 ADGDYKKQIS TNVSFTDNRW DLNKDPDKTK YLTGDSKWQQ LIGQSYVKDN SLDADKDFEY 240 DDSKLDFPPT TLYVQGTRPD GTSFKSAVLV KPEDTLEDVM ENIGALYGNT PNNKVVEVSM 300 NDSGQIQITD LKQGNNKLDF HAVAFTPQAD DKTELNNIIQ AAQDEGITME DVTNRVMTAA 360 LGNPNNGDIT NLNNPVTIQI NGQNFEIDLK QTDFIKSKMT DTDGNAANGA DYDNVYFEKN 420 GNTVYGNVSQ VIKGSNAYAT DSTKLSEVMA GDSLNGTTLN LKVNSKGGNS YDVTINLQTS 480 TVSYPDPNNP GQTISFPIMH TNPATGNSGV VTGSNDITYG QINDIIGMFA ADKIPTTTIQ 540 ANNGQINNAD YTQIQQLMKD SQATVDVSMD YKGRISVTDK LSSGTNIEIS LSDSQSGQFP 600 APPFTTTSTV QNGPNFSFSA NNSLTIDEPN VDIIKDLDSM IDAVLKGNMR ADSESENPRN 660 TGMQGALERL DHLADHVSKL NTTMGAYHNT IEGVNTRTSF LSVNVQSIKS NVIDVDYGEA 720 MMNLMQVQLA YQASLKASTT ISQLSLLNYM 750 SEQ ID NO: 20 MMRSLWSGVS GLQAHQVAMD VEGNNISNVN TTGFKYSRAD FGTMFSQTVK IATAPTDGRG 60 GSNPLQIGLG VSVSSTTRIH SQGSVQTTDK NTDVAINGDG FFMVSDDGGL TNYLTRSGDF 120 KLDAYGNFVN NAGFVVQGWN INWDDQTIDS SRTPQNIFID PGMHIPAAKS TEVAIKANLN 180 SGLNIGTSSR NLYALDSVHG WNTKTQRAED ENDTGTTQFY TTSKNSVEVT EKGVDAGSLF 240 NAKGQGLNLR DGQGIWVSYA DATYSTNKVG VNAFDPNLQQ NQTAAFWGTA NQKVNLDITL 300 NGVRIQNADI QSIDDAIAYI NTFTAPTDTR DGTGVKAVKN KDGSGIDFVN DNADGTTDNM 360

KNINLVVANT NTAGELWNAV WNNNNQTFTF NNNGNGQAGT PTINKNGSSL WTATNITFTP 420 QPPQAATNVQ LTGGLNAQII TAHKYIYSSN PVDIGPMYNP DGGPAFQPGA NATTRPTEPG 480 SAAYWDAVNG GLLNTNVRTF RTTEDLRELL QRDARYGVDY DGSGTFAAAD INQNIKVVVT 540 ADGHFAISNA NEQSTVPPNA INGVGNATTT DPKNMSFNIT AYSNKQGTVS TNDAFTAIFK 600 AFDGPLVIGN QIKESEQLKL SAFSAGLEIY DSLGSKHTLE VQFVKQSTTQ DGGNEWQMII 660 RVPEPAEINT TGEGPNNIIV GTARFNNDGS LASYTPRTIN FSPNNGAAPN QQIKLSFGTS 720 GSNDGLVSSN SASTLTGQAT DGYTSGNLKP DAIRVDDKGN ILGEFTNGKT FAVAKIAMAS 780 VANNSGLEEI GGNLFKVTAN SGNIVVGEAG TGGRGEMKTS ALEMSNVDLS RSLTELIIIQ 840 RGYQANSKTI STSDQMLQTL IQLKQ 865 SEQ ID NO: 21 MAKIRIHEIA KELGYDSKEI IEKANELGLG IKTASNAVEP EIAAAIYEYI QTREIPEAFK 60 KNIKTPTAKK PKKENIKEQE KLNESEKKEP KKEEKLKQEV KKEELKIEKE NAKEEEKQEI 120 IDAHKPQSLA SATLAKRRGL VIVKKKKDEE EIQVKKEEVK NSNDISINNE ERLSLKTMFS 180 NADESLKKKK KEKKSFVASK KESTEKMNFL DEHDFGDISL DDEDEVVLPD FSVKEQEKPQ 240 NINKKQPNFI RQAVGNSAGF GFEGGIQRRS RKKPSKKIEK KEVEEVGSVA ISKEIRVYEF 300 ADKIGKSTSE VISKLFMLGM MTTKNDFLDE DAIEILAAEF GIEINIINEA DEFDYVKDYE 360 EETDEKDLVT RAPVITIMGH VDHGKTSLLD YIRKSRVASG EAGGITQHVG AYMVEKNGRK 420 ITFIDTPGHE AFTAMRARGA SITDIVIIVV AADDGVKPQT KEAINHAKAA GVPIIIAINK 480 MDKEAANPDM VKTQLAEMEI MPVEWGGSYE FVGVSAKTGM GIEDLLEIVL LQADILELKA 540 NPKSFAKASI IESSVQKGRG AVATVIVQNG TLTVGSTVVA GEAYGKVRAM SDDQGKALKE 600 IKPGECGVIV GLSEVADAGE ILIAVKTDKE AREYANKRHE YNRQKELSKS TKVSIDELGA 660 KIKEGNLKAL PVILKADVQG SLEALKASLE KLRNDEIKVN IIHSGVGGIT QSDIELASAS 720 ENSIVLGFNI RPTGEVKERA KDKGVEIKTY NVIYNLLDDV KALLGGMMSP IISEEQLGQA 780 EIRQVINVPK IGQIAGCMVT EGVINRGAKI RLIRDGVVVY EGNVSSLKRF KDDAKEVAKG 840 YECGVGIEGC DDMRVGDYIE SYKEVEEQAS L 871 SEQ ID NO: 22 MLAPGMGEWV YKANLFLFGE FAYYYPFFLF ILNYVYYKRN YKLANFTRRE LFGIGFAFFS 60 SLLLFAVFYP NSGYILELAY AIFSTILGHT GSGIFALLLL LFSLVLLFPK FAKEILKIEL 120 DFTYLLKVEQ AFKSLLMRVF GGENEKEDVG KSEPIVPKLN ILQDSIYGNL QINKKGETNN 180 LEQIIKDSNI NASKNSITTA KENFEKLKNQ ILDETIEIDK QSLKESRSFV HEHSQQVRNF 240 AQKASKMSIS LDEDFNFISE EEVDMIPERF LKPKKLEDIK QIDTNKNLDE PSYKRKNIEI 300 PVSNQEVKPK IFTKELELRE NLIKKEKLEQ EYKAYQNEIL ENKVKQEIKK LEEYDAINSS 360 DIIEGNKYSF NSPKTIKTET EESDKINENK NLDKADNIFE FAPIVEELNH PYIEPTPIKN 420 INEIVIEEKN TLDFIQNTET KIDNEKTNDQ EIKLQKAVLA KEIAINQALL REIEQGEIEK 480 PKDFTLPPLD FLANPKEHKQ EINESEIDKK IYNLLEKLRR FKIGGDVIST YVGPVVTTFE 540 FRPSADVKVS RILNLQDDLT MALMAKSIRI QAPIPGKDVV GIEVPNDEIQ TIYLREILQS 600 EVFKNAKSPL TIALGKDIVG NAFVTDLKKL PHLLIAGTTG SGKSVGINSM LLSLLYRNSP 660 KTLRLMMIDP KMLEFSIYND IPHLLTPVIT DPKKAVNALS NMVAEMERRY RLMADAKTKN 720 IENYNEKMKE LGGEKLPFIV VIIDELADLM MTAGKDVEFY IGRLAQMARA SGIHLIVATQ 780 RPSVDVVTGL IKANLPSRIS YKVGQKIDSK VILDAMGAES LLGRGDCLFT PPGTSSIVRL 840 HAPFASEFEI EKIVDFLKDQ QSVEYDESFL KDQQSVGVTT NESFDGEADE LYEEAKRVIL 900 EDGKTSISYL QRRLKIGYNR SANIIEQLTQ NGILSEPDAK GQREIL 946 SEQ ID NO: 23 MKKFFCLTLV CKLFALSEFE LHHIDKVHKL GYSGDTIIIG VADDAFNQDH ISLKDKILKS 60 TYPTDTAGKQ LIPDLKKSTH GSHVAGIAVG AKIGDSKPYG VAYGAKFYGA GVFPNGSYTQ 120 IPDIYNFFKD VSIINNSWGI NFYPYFNLKA SNSGLVDCTQ TNQGTSYNIC NTPLEYVMKA 180 DKVANDMMRL SKDKGVLNVF AAGNEGILSP ALHAILPSYD ESLRAWLAVG ALDANEITLE 240 SDGTLIIKSQ GLADFSNGFK GATNFSLVAA GVNINNVDSS TNDKFTKKSG TSMAAPMVSG 300 TAALVKQNFP FLDGKQIADI LLSTANKNYK APKFTVKQVT DGTNQPKFLI VYISQDPPGI 360 EDEIKRDLKQ LYNGIQVQVN GQWIDYSDYI WDNRDSAQSQ KLNTSTISSI NGVVRVEKEE 420 LFGQGILDAQ KALKGLSILD ANRLSDQDVL KYEQEPNTAY YTINTAGYDA EFSNDISQRK 480 WDESTHLSSA INKPTHLANL NIGLSKEGEG ILIISGQNTY EGATLIKQGE LKLKGKVKNN 540 AYVEQKAILS GNGIVGQNLN NKGIVRPGNE DLNDLTVQGT YTQEGVDSKL QLDFGNYKNS 600 KLIAKTYDIK SGNLEYIPLP KYYILNKPVK INLGDLEKSL SSFNHVLIQN TYALNFDFVL 660 SDDLVSINKT LIKPNLKPNA YEIPNTSLGN ALRQLRSRAD LSQTYQEFFA SLDNGIDVKT 720 KLNRIEGSGY LSTFSNHNQS NLMQNNMLFT LHPLNINNFA QNNNILLAST YLPRIFSNEE 780 YFWHLTPSYK YYKDKDFSGQ KTGANISLGE NFSSGFLAYA LSLSSAKFNF NNGSDLKSYN 840 MDLLLNYNHD LDFIKILSGL GIGVGFNTLN RFVVEQPIEG KYKTLQTSAQ LGVTKDIILG 900 QDFIFNPLMY FTHSFFYQED FKENKSPFAK NYESLKHHSI NANLGFNLAK NIEQDDYQAS 960 FSTFVIFEKR IYGRTLENKA SFVDFPIAFI QKYKLKDNIL SQGFNSEFLY KNNVFWQFML 1020 MNRFSHNAYE LHLMSSVGKR F 1041 SEQ ID NO: 24 MPKRTDIKSI LLIGSGPIVI GQACEFDYSG TQAAKTLKEL GYRVVLINSN PATIMTDPEF 60 ADATYIEPIT KESILSIIKK EKIDAILPTM GGQVALNVAM EVYESGLLGD VKFLGANPEA 120 IKKGEDRQVF KECMKKIGMD LPKSMYAYNY DEALKAVDEI DFPLMIRASY TLGGAGSGVV 180 YNMDEFKELT NTALALSPIH EILIEESLLG WKEYEMEVIR DRADNCIIVC SIENIDPMGV 240 HTGDSITIAP ALTLTDKEYQ VMRNASFAIL REIGVDTGGS NVQFAINPKN GRMIVIEMNP 300 RVSRSSALAS KATGYPIAKV ATLLAVGFSL DEIKNDITGT PASFEPVIDY IVTKIPRFTF 360 EKFPGANTTL GTAMKSVGEV MAIGRTFKES IQKALCSLER SLSGFDRVKF EDRNDLVFKI 420 RNANEKRLLY VAQAFREGFS VEELYELCKI DPWFLTQIKE IVDFEEQIDM DILNNKALLR 480 KAKTMGFSDK MIALLVNLKD NLELSQNDIY YVRMKQKIIA EFSEVDTCAG EFEALTPYLY 540 SSINVSELTQ SKNDAKDKKE KKVMIIGGGP NRIGQGIEFD YACVHASFAL KDMGIKTIMY 600 NCNPETVSTD YDTSDILYFE PIDFEHLRAV IEREKPDGVI VHFGGQTPLK FAKRLSAFGA 660 KIIGTSARVI DMAEDRKKFA EFITKLGINQ PKNSTATSVE EAVLKASDIG YPVLVRPSYV 720 LGGRAMRVVN DEAELRLYMQ EAVDVSDKSP VLIDQFLDNA TEIDVDAICD GKDVYVAGIM 780 EHIEEAGIHS GDSACSLPPC NIDEKMQEFI AQKTADIALN LGVVGLLNIQ FALHNNELYM 840 IEVNPRASRT IPFVSKATGI PLAKVATRVM WQGNLKEALK FYDTFKVVNF DTKILRPKTP 900 KYMSVKEAVF PFAKLSGSDL ELGPEMRSTG EVMGISKDFA NSYAKSQIAS FNHLPEQGVV 960 FISLKDKDKK YTKKIAAEYV KLGFKLMATG GTCKEILESG FECELVHKIS EGRPNVEDKL 1020 KNGEIHLVIN TSDSHSFKGD TKKIRENIIR FKIPYFTNLR SALAGAKSIK AIQSKSCLDV 1080 KSLQEWLKS 1089 SEQ ID NO: 25 MKNITLTKIP IGEGKEPCLN SKKIVLSLAT ISFLASCANA KLNSEIKTYD EVNKNVKTRS 60 ASVYSPQAKI NTTINSLHNQ QVTITGNGTS NSLTIGSSGT LGSIGNTGKI IYAHANGSNT 120 LTLANLTNNR TINGKIGIEN NGNFTGTIAV NTFENTGQIN GQIYMGIWGN NSGTLNIDKF 180 DNSGTIIDNN KGVFEGKNTN IQTFNNSGFI SANKGVDIGN IGTIKNFNNN GTIQGSEVGV 240 AINTKIDTFT NNGFINSPGS GQWNNGIWIS SNATIEKLVN NGTIKGGHSA IMVTSQHIKT 300 VENTGIIHAE GEWGSSILLE YGGFIEHIIN TGTISNNNVG IGSAYGVFGT LTIKDGGMVY 360 GKYSAIGVGR SQTLGDLYID GRSNNGTVSG IYSEEHGILL ENNSRTQKIE LKNGGIIKGN 420 IDGIRLINSA SLSGEMILSG EGSRVEGGRG VGILNRSGKI EGSIKVEDGA TVTATSNRAI 480 ANSGSGSITG GITVSGKNTK LEGNIINTGN ASIGSDIKIE GGAKVEGGLV NQGNGSISGS 540 VQVSGGSSID SITNEGNGAI SGSITVYKDS KLDSITNTST SSTGISGSIT NNSDNKLEIS 600 NSGNIGGKIE STGSADMVIS NSNGGTISGG ISSSGSGSTS ISNSQGSTIN NGITVSGSAQ 660 VEISNQGSVG KDENGNTVTN NGSGSVGIKD WLVSTDKNTG KLNTVVIGGS RAFNVKVENI 720 TVDQSNVDLE ELNDINNIIS GVNQNNIGNI GTNGSGEISL SFDPITGKLT TDFNLNASIS 780 GATFRSLIST TSRRSTFIDN VMGNSMQSFA LASSSKSQSI AMSEKGNLYA DASDYIKSDL 840 NNGSYGSNKE HSLFILPYTS SQNVELSLNE ESKGHTKGTI IGYSTLKDSG IYGVYAGYED 900 TKMGSTYFDI NNRTYYAGLK YFNTLFTTEK GQEVYIKAQG KAALIKNDLT EKIGNNEAKA 960 EPNSYAYGVN TALGMNFISN KDIFSPEIGL AYEGGYTEAF SMKDTIGQAT VKGGERTYAN 1020 YLNLFSTKTS LTWFRDWLPN LKTSVELGAK FNINPKVEAE ARFGNIKVSD EFDLPRVQKF 1080 VSTSFIVPVN EAFYFSLNYN GMFDKDGNTH TGFAQFNYLW 1120 SEQ ID NO: 26 MNKTALTKTY TKDIQNSCLN SKKIVLSLAT ISFLASCTHA TLTPEIKTYE ETNRHAKARS 60 GLQSRNSNNE TINNLQTLTK TISDTGNTLV IESSGTITIS NDGQQAVNFQ PNSSTSTFLN 120 KGTLIGGNNT ASVQLGAANG NNGVSIETFN NQGIIGNGSS KFGVTVFGGG SKDNPKSIIN 180 NFSNSGTIHS NTGESIYFGN AKISSFVNSG TIKSKQGAGV NISQGTSIEN FNNTGTGIIE 240 GKRMGVNVRS TINTFVNDGL IAATNDGIQI NANVKTLINK GTIKGDAISI RSLGGTIETL 300 TNEGIMYGKS AGIYMNRSLV KTLTNSGTIN QNNSATWSAG IKLENGSIIE NIINTGSIRS 360 NAFGISVTGG KFGTLTIKDG GMVYGKYSAI GVGRSQTLGD LYIDGRSNNG TVSGIYSEEH 420 GILLENNSRT QKIELKNGGI IKGNIDGIRL INSASLSGEM ILSGEGSRVE GGRGVGILNR 480 SGKIEGSIKV EDGATVTATS NRAIANSGSG SITGGITVSG KNTKLEGNII NTGNASIGSD 540 IKIEGGAKVE GGLVNQGNGS ISGSVQVSGG SSIDSITNEG NGAISGSITV YKDSKLDSIT 600 NTSTSSTGIS GSITNNSDNK LEISNSGNIG GKIESTGSAD MVISNSNGGT ISGGISSSGS 660 GSTSISNSQG STINNGITVS GSAQVEISNQ GSVGKDENGN TVTNNGSGSV GIKDWLVSTD 720 KNTGKLNTVV IGGSRAFNVK VENITVDQSN VDLEELNDIN NIISGVNQNN IGNIGTNGSG 780 EISLSFDPIT GKLTTDFNLN ASISGATFRS LISTTSRRST FIDNVMGNSM QSFALASSSK 840 SQSIAMSEKG NLYADASDYI KSDLNNGSYG SNKEHSLFIL PYTSSQNVEL SLNEESKGHT 900 KGTIIGYSTL KDSGIYGVYA GYEDTKMGST YFDINNRTYY AGLKYFNTLF TTEKGQEVYI 960 KAQGKAALIK NDLTEKIGNN EAKAEPNSYA YGVNTALGMN FISNKDIFSP EIGLAYEGGY 1020 TEAFSMKDTI GQATVKGGER TYANYLNLFS TKTSLTWFRD WLPNLKTSVE LGAKFNINPK 1080 VEAEARFGNI KVSDEFDLPR VQKFVSTSFI VPVNEAFYFS LNYNGMFDKD GNTHTGFAQF 1140 NYLW 1144 SEQ ID NO: 27 MGKIMKTMDG NEAAAYAAYA FTEVAGIYPI TPSSPMADYT DMWAAAGKKN LFGVPVKIVE 60 MQSEAGAAGS VHGSLQAGAL TTTYTASQGL LLKIPNMYKI AGQLLPCVIH VAARSLAAQA 120 LSIFGDHQDI YAARQIGFAM LCSHSVQETM DLAGVAHLAA IKGRVPFLHF FDGFRTSHEI 180 QKVEVMDYAH FDRLLDREAL LEFRNNALNP ENPKTRGTAQ NDDIYFQTRE VSNRFYDALP 240 DVVNEYMQEI SKITGREYKP FTYYGHKEPE CVIVAMGSVT QALEEVVDYL NAKGEKVGIL 300 KVYLYRPFSL KYFFDVMPKS VKKIAVLDRT KEPGSLGEPL YLDVKSAFYG RENAPVIVGG 360

RYGLSSKDVD PAQMIAVFEN LKLDNPKDGF TVGIIDDVTH TSLSTGEKIS LGDESTIECL 420 FYGLGADGTV GANKNSIKII GDKTDFYAQA YFAYDSKKSG GYTRSHLRFS KKPIRSTYLV 480 STPHFIACSV AAYLEIYDVL AGIRKGGTFL LNSIWNAEET IRQLPDAVKK TLAEKEVNFY 540 IINATKLARD IGLGNRTNTI MQSAFFKLAK IIPYEDAQKY MKELAYKSYS KKGDAIVEMN 600 YKAIDVGADG LVKVEVDPNW KNLELKEKEQ TNAYKGTEFV EKIVKPMNAA KGDDLPVSAF 660 LGYEDGSFEH GTTEYEKRGV GVMVPRWIEA NCIQCNQCAS VCPHAVIRPF LINDEEMANA 720 PRGVKDHALE AKGTKGEKLS FKIQVSPLDC TGCELCVHEC PTKEKSLVMV PLQEEMDFGE 780 QENADYLFKE ITYKDDILNK ETTKGAQFAQ PLFEFHGACP GCGETPYITL ITRLFGERMI 840 VANATGCSSI YGGSAPSTPY RKSVKNGHGP AWGNSLFEDN AEFGLGMKIA TENTRHRIEH 900 IMNESMQEVP NALSALFKDW IANKDNGAMS VEIKDKMIPI LEQNKNIKAV QDILELKQYL 960 SKKSHWIFGG DGWAYDIGYG GLDHVLASGE NVNILVLDTE VYSNTGGQSS KSSRTGAVAQ 1020 FAAAGKPIQK KDLGQIAMTY GYIFVAQVNS TANYTHLIKA ITAAEAYDGP SLVICYSPCI 1080 AHGIKGGLGY SGEQGELATK CGYWPLYTFD PRLEEQGKNP LTLTGKEPDW DLYEQFLMNE 1140 VRYNSLKKAN PEHAAELFER NKKDAQRRYR QLKRIAMADY SNEVES 1186 SEQ ID NO: 28 MCDMLDNKLG NRLRVDFSNI SKQIEIPNLL QLQKKSFDYF LNLDNGESGI EKVFKSIFPI 60 HDPQNRLSLE YVSSEIGKPK YTIRECMERG LTYSVNLKMK IRLTLHEKDE KTGEKVGVKD 120 IKEQEIYIRE IPLMTDRVSF IINGVERVVV NQLHRSPGVI FKEEESSTVA NKLVYTAQII 180 PDRGSWLYFE YDAKDVLYVR INKRRKVPVT MLFRALGYKK QDIIKLFYPI QTIHVKKDKF 240 LTEFNPNDFM DRIEYDIKDE KGKIVHQAGK RLTKKKAEQL IKDGLKWIEY PVEILLNRYL 300 ANPIIDKESG EVLFDSLTLL DESKLAKIKE QKSFDIANDL ANGVDAAIIN SFAQDGETLK 360 LLKQSENIDD ENDLAAIRIY KVMRPGEPVV KDAAKAFVND LFFNPERYDL TKVGRMKMNH 420 KLGLEVPEYV TVLTNEDIIK TAKYLIKVKN GKGHIDDRDH LGNRRIRSIG ELLANELHLG 480 LAKMQKAIRD KFTSLNADLD KVMPYDLINP KMITTTIIEF FTGGQLSQFM DQTNPLSEVT 540 HKRRLSALGE GGLVKERAGF EVRDVHATHY GRICPVETPE GQNIGLINTL STYAKVNELG 600 FVEAPYRKVV NGKVTNEVVY LTATQEEGLF IAPASTKVDA KGNIVEEFVE ARQDGETILA 660 RREEVQLIDL CSGMVVGVAA SLIPFLEHDD ANRALMGSNM QRQAVPLLTA SAPIVGTGME 720 QIIARDAWEA VKAKRGGVVE KVDNKSIFIL GEDDKGPFID HYTMEKNLRT NQNTNYIQHP 780 IVKKGDIVKA GQIIADGPSM DQGELAIGKN ALIAFMPWNG YNYEDAIVVS ERIIREDTFT 840 SVHIYEKEIE ARELKDGIEE ITKDIPNVKE EDVAHLDESG IAKIGTHIKP GMILVGKVSP 900 KGEVKPTPEE RLLRAIFGEK AGHVVNKSLY ATASLEGVVV DVKIFTKKGY EKDDRAIKSY 960 DKEKMALEKE HHDRLLMMDR EEMLRVCALL SKASLNSDQK IGDKNYKKGQ TADISELEKI 1020 NRFTLTTLIK AYSKEIQKEY DDLKNHFQNE KKKLKAEHDE KLEILEKDDI LPSGVIKLVK 1080 VYIATKRKLK VGDKMAGRHG NKGIVSTIVP EVDMPYLPNG KSVDIALNPL GVPSRMNIGQ 1140 ILESHLGLVG LRLGDQIQEI FDRKQKDFLK ELRAKILEIC SIPRLANEKE FIKSLSDEEL 1200 LNYARDWSKG VKFSTPVFEG VNIEEFSKLF KMAKIDMDGK TELYDGRTGE KIAERVHVGC 1260 MYMLKLHHLV DEKVHARSTG PYSLVTQQPV GGKALFGGQR FGEMEVWALE AYGAAHTLRE 1320 MLTIKSDDVE GRFSAYKALT KGENVPATGI PETFFVLTNE LKSLALDVEI FDKDEDNE 1378 SEQ ID NO: 29 MDLENILENN QSIGLYHPKN EHDACGIAAV ANIRGIASYK VICDALEILM NLEHRGGTGA 60 EENSGDGAGI LIQIPHDFFK TQELGFELPK KGDYAVAQMF LSPNTDAKEE AKEIFLQGLK 120 DKKLEFLGFR EVPFNPSDIG ASALKAMPYF LQAFVKKPSK ISAGLEFERV LYSTRRLIEK 180 RAINVPKFYF SSFSSRTIVY KGMLLSTQLS DFYLDFKDVN MKSAIALVHS RFSTNTFPSW 240 ERAHPNRYMV HNGEINTIRG NVDSIRAREG LMQSEYFENL DEIFPIIAKL SSDSAMFDNT 300 LEFLALNGRT LEEAFMMMVP EPWHKNENME SKKRAFYEYH SLLMEPWDGP AAIVFTDGVI 360 MGASLDRNGF RPSRYYLTKD DMLILSSETG ALKLDEKNIK AKKRLEPGKL LLVDTARGRV 420 IADNEIKEHY ANAKPYKKWL KNLVELEKQK SGVYKHQFLK EDEVLKLQKA FGWSYDELKM 480 SVAAMAQNGK EAIAAMGVDT PLAILSKTYQ PLYNYFKQLF AQVTNPPLDA IREEIVTSTR 540 IYLGSEGNLL KPDENNAKRV KIALPVISNE ELFEVKALNK FQVKEFSILY DYSKKTLEKA 600 LDELCVKIED EVKKGVSIII LSDKGVDEKN AYIPALLAVS GVHNHLVRKN LRTHTSLIIE 660 SGEPREIHHF ACLLGYGATV INPYLVYESI QKLIANKDLN LSYEKAVENF IKASSSGIVK 720 IASKMGVSTL QSYNGSALFE CLGLSSKVID KYFTSTTSRI EGMDLEDFEK ELIALHKHAF 780 NDTHKALDSK GIHGFRSAKE EHLIDPLVIF NLQQACRNKD YKSFKKYSAL VDEKQVNLRS 840 LMEFDFSEAI SIDKVESVES IVKRFRTGAM SYGSISKEAH ECLAQAMNKI GAKSNSGEGG 900 EDEERYEIKE GVDKNSAIKQ VASGRFGVDL NYLSHAKEIQ IKVAQGAKPG EGGQLMGFKV 960 YPWIAKARHS TAGVTLISPP PHHDIYSIED LAQLIYDLKH ANKDAKISVK LVSENGIGTV 1020 AAGVAKAGAN LILVSGYDGG TGASPRTSIP HAGIPWELGL AETHQTLILN KLRDRVRLET 1080 DGKLMNGRDL AIAALLGAEE FGFATAPLIV LGCTMMRVCH LNTCPFGIAT QDTELRDRFK 1140 GKVDDVINFM YFIAEELREY MARLGFERLD DMIGRVDKLR QKSVQGKAGK LNLDKILKSL 1200 PTYNRTAVHF KDYKDNKLEK TIDYRILLPL CKNAVEKKEP IKLSLEVGNQ SRTFATMLSS 1260 EILKTYGKDA LDEDSIHIKA IGNAGNSFGA FLLKGIKLEI IGDSNDYLGK GLSGGKIIAK 1320 ISNEATFSPE ENIIAGNACL YGATKGEVYL DGIAGERFCV RNSGALAVVL GTGVHGCEYM 1380 TGGQVVVLGD VGANFAAGMS GGVVYIFGRH NEAHVNTELV DIKDLNAKDE KELKAVIEKH 1440 ITYTDSKKAK DILEKFDKKD FFKVMPRDYE KMLKMLDLCK NEKDPNLAAF LKITQK 1496 SEQ ID NO: 30 MSKFKVIEIK EDARPRDFEA FQLRLASPEK IKSWSYGEVK KPETINYRTL KPERDGLFCA 60 KIFGPIRDYE CLCGKYKKMR FKGVKCEKCG VEVANSKVRR SRMGHIELVT PVAHIWYVNS 120 LPSRIGTLLG VKMKDLERVL YYEAYIVENP GDAFYDNEST KKVEYCDVLN EEQYQNLMQR 180 YENSGFKARM GGEVVRDLLA NLDLVALLNQ LKEEMGATNS EAKKKTIIKR LKVVENFLNS 240 NLNANTDSDE AVPNRPEWMM ITNLPVLPPD LRPLVALDGG KFAVSDVNDL YRRVINRNTR 300 LKKLMELDAP EIIIRNEKRM LQEAVDALFD NGRRANAVKG ANKRPLKSLS EIIKGKQGRF 360 RQNLLGKRVD FSGRSVIVVG PKLRMDQCGL PKKMALELFK PHLLAKLEEK GYATTVKQAK 420 KMIENKTNEV WECLEEVVKG HPVMLNRAPT LHKLSIQAFH PVLVEGKAIQ LHPLVCAAFN 480 ADFDGDQMAV HVPLSQEAIA ECKVLMLSSM NILLPASGKS VTVPSQDMVL GIYYLSLEKA 540 GAKGSHKICT GIDEVMMALE SKCLDIHASI QTMVDGRKIT TTAGRLIVKS ILPDFVPENS 600 WNKVLKKKDI AALVDYVYKQ GGLEITASFL DRLKNLGFEY ATKAGISISI ADIIVPNDKQ 660 KAIDEAKKQV REIQNSYNLG LITSGERYNK IIDIWKSTNN VLSKEMMKLV EKDKEGFNSI 720 YMMADSGARG SAAQISQLAA MRGLMTKPDG SIIETPIISN FREGLNVLEY FISTHGARKG 780 LADTALKTAN AGYLTRKLID VAQNVKITIE DCGTHEGVEI NEITADSSII ETLEERILGR 840 VLAEDVIDPI TNSVLFAEGT LMDEEKAKIL GESGIKSVNI RTPITCKAKK GICAKCYGIN 900 LGEGKLVKPG EAVGIISAQS IGEPGTQLTL RTFHSGGTAS TDLQDRQVSA QKEGFIRFYN 960 LKTYKNKEGK NIVANRRNAA VLLVEPKIKT PFKGVINIEN IHEDVIVSIK DKKQEVKYIL 1020 RKYDLAKPNE LAGVSGSIDG KLYLPYQSGM QVEENESIVE VIKEGWNVPN RIPFASEILV 1080 EDGEPVVQNI KAGEKGTLKF YILKGDGLDR VKNVKKGDIV KEKGFFVVIA DENDREAKRH 1140 YIPRESKIEF NDSEKIDDAN TIIASAPKKE RKVIAEWDAY NNTIIAEIDG VVSFEDIEAG 1200 YSADEQIDEA TGKRSLVINE YLPSGVRPTL VIAGKGDKAV RYHLEPKTVI FVHDGDKIAQ 1260 ADILAKTPKA AAKSKDITGG LPRVSELFEA RKPKNAAVIA EIDGVVRFDK PLRSKERIII 1320 QAEDGTSAEY LIDKSKHIQV RDGEFIHAGE KLTDGVVSSH DVLKILGEKA LHYYLISEIQ 1380 QVYRGQGVVI SDKHIEVIVS QMLRQVKVVD SGHTKFIEGD LVSRRKFREE NERIIRMGGE 1440 PAIAEPVLLG VTRAAIGSDS VISAASFQET TKVLTEASIA GKFDYLEDLK ENVILGRMIP 1500 VGTGLYGEQN LKLKEQE 1517

LIST OF REFERENCES CITED IN APPLICATION

[0217] Angel et al., Cell, 49:729, 1987b. [0218] Angel et al., Mol. Cell. Biol., 7:2256, 1987a. [0219] Arap et al., Cancer Res., 55:1351-1354, 1995. [0220] Atchison and Perry, Cell, 46:253, 1986. [0221] Atchison and Perry, Cell, 48:121, 1987. [0222] Ausubel, ed., Current protocols in molecular biology, New York, John Wiley & Sons, 1996. [0223] Banerji et al., Cell, 27:299, 1981. [0224] Banerji et al., Cell, 35:729, 1983. [0225] Berkhout et al., Cell, 59:273, 1989. [0226] Blanar et al, EMBO J, 8:1139, 1989. [0227] Bodine and Ley, EMBO J, 6:2997, 1987. [0228] Boshart et al., Cell, 41:521, 1985. [0229] Bosze et al., EMBO J, 5:1615, 1986. [0230] Braddock et al., Cell, 58:269, 1989. [0231] Bulla et al., J. Virol., 62:1437, 1986. [0232] Campbell et al., Mol. Cell. Biol., 8:1993, 1988. [0233] Campo et al., Nature, 303:77, 1983. [0234] Carbonelli et al. FEMS Microbiol Lett. 177(1):75-82, 1999. [0235] Celander and Haseltine, J. Virology, 61:269, 1987. [0236] Celander et al., J Virology, 62:1314, 1988. [0237] Chandler et al., Cell, 33:489, 1983. [0238] Chang et al., Mol. Cell. Biol., 9:2153, 1989. [0239] Chatterjee et al, Proc. Nat'l Acad. Sci. USA., 86:9114, 1989. [0240] Chen and Okayama, Mol. Cell. Biol., 7:2745-2752, 1987. [0241] Choi et al., Cell, 53:519, 1988. [0242] Cohen et al, J. Cell. Physiol, 5:75, 1987. [0243] Costa et al, Mol. Cell. Biol., 8:81, 1988. [0244] Cripe et al., EMBO J, 6:3745, 1987. [0245] Culotta and Hamer, Mol. Cell. Biol., 9:1376, 1989. [0246] Dandolo et al., J. Virology, 47:55, 1983. [0247] De Villiers et al., Nature, 312:242, 1984. [0248] Deschamps et al., Science, 230:1174, 1985. [0249] Edbrooke et al., Mol. Cell. Biol., 9:1908, 1989. [0250] Edlund et al., Science, 230:912, 1985. [0251] Feng et al., Nature, 334:6178, 1988. [0252] Firak and Subramanian, Mol. Cell. Biol., 6:3667, 1986. [0253] Foecking and Hofstetter, Gene, 45(1):101-5, 1986. [0254] Fraley et al., Proc. Nat'l Acad. Sci. USA, 76:3348-3352, 1979. [0255] Fujita et al., Cell, 49:357, 1987. [0256] Gilles et al., Cell, 33:717, 1983. [0257] Gloss et al., EMBO J, 6:3735, 1987. [0258] Godbout et al., Mol. Cell. Biol., 8:1169, 1988. [0259] Goodbourn et al., Proc. Nat'l Acad. Sci. USA, 85:1447, 1988. [0260] Goodbourn et al., Cell, 45:601, 1986. [0261] Greene et al., Immunology Today, 10:272, 1989. [0262] Grosschedl et al., Cell, 41:885, 1985. [0263] Haslinger and Karin, Proc. Nat'l Acad. Sci. USA., 82:8572, 1985. [0264] Hauber and Cullen, J. Virology, 62:673, 1988. [0265] Hen et al., Nature, 321:249, 1986. [0266] Hensel et al., Lymphokine Res., 8:347, 1989. [0267] Herr et al., Cell, 45:461, 1986. [0268] Hirochika et al., J. Virol., 61:2599, 1987. [0269] Hirsch et al., Mol. Cell. Biol., 10: 1959, 1990. [0270] Holbrook et al., Virology, 157:211, 1987. [0271] Horlick and Benfield, Mol. Cell. Biol., 9:2396, 1989. [0272] Huang et al., Cell, 27:245, 1981. [0273] Hug et al., Mol Cell Biol., 8:3065, 1988. [0274] Hwang et al., Mol. Cell. Biol., 10:585, 1990. [0275] Imagawa et al., Cell, 51:251, 1987. [0276] Imbra and Karin, Nature, 323:555, 1986. [0277] Imperiale and Nevins, Mol. Cell. Biol., 4:875, 1984. [0278] Innis et al., Proc Natl Acad Sci USA. 85(24):9436-9440, 1988. [0279] Inouye et al., Nucleic Acids Res., 13:3101-3109, 1985. [0280] Jakobovits et al., Mol. Cell. Biol., 8:2555, 1988. [0281] Jameel and Siddiqui, Mol. Cell. Biol., 6:710, 1986. [0282] Jaynes et al, Mol. Cell. Biol., 8:62, 1988. [0283] Johnson et al., Mol. Cell. Biol., 9:3393, 1989. [0284] Kadesch et al., Mol. Cell. Biol., 6:2593, 1986. [0285] Kaeppler et al., Plant Cell Reports 9: 415-418, 1990. [0286] Kaneda et al., Science, 243:375-378, 1989. [0287] Karin et al., Mol. Cell. Biol., 7:606, 1987. [0288] Katinka et al., Cell, 20:393, 1980. [0289] Katinka et al., Nature, 290:720, 1981. [0290] Kato et al, J. Biol. Chem., 266:3361-3364, 1991. [0291] Kawamoto et al., Mol. Cell. Biol., 8:267, 1988. [0292] Kiledjian et al., Mol. Cell. Biol., 8:145, 1988. [0293] Klamut et al., Mol. Cell. Biol., 10:193, 1990. [0294] Koch et al., Mol. Cell. Biol., 9:303, 1989. [0295] Kriegler et al, In: Eukaryotic Viral Vectors, Y. Gluzman, ed., Cold Spring Harbor: Cold Spring Harbor Laboratory, N Y, 1982. [0296] Kriegler and Botchan, Mol. Cell. Biol., 3:325, 1983. [0297] Kriegler et al., Cell, 38:483, 1984a. Kriegler et al., [0298] Cell, 53:45, 1988. [0299] Kriegler et al., In: Cancer Cells 2/Oncogenes and Viral Genes, Van de Woude et al. eds, Cold Spring Harbor, Cold Spring Harbor Laboratory, 1984b. [0300] Kriegler et al., In: Gene Expression, D. Hamer and M. [0301] Rosenberg, eds., New York: Alan R. Liss, 1983. [0302] Kuhl et al., Cell, 50:1057, 1987. [0303] Kunz et al., Nucl. Acids Res., 17:1121, 1989. [0304] Larsen et al., Proc. Nat'l Acad. Sci. USA., 83:8283, 1986. [0305] Latimer et al., Mol. Cell. Biol., 10:760, 1990. [0306] Lee et al., Nature, 294:228, 1981. [0307] Lee et al., Nucleic Acids Res., 12:4191-206, 1984. [0308] Levenson et al., Hum Gene Ther. 20; 9(8):1233-1236, 1998. [0309] Levinson et al., Nature, 295:79, 1982. [0310] Lin et al., Mol. Cell. Biol., 10:850, 1990. [0311] Luria et al, EMBO J., 6:3307, 1987. [0312] Lusky et al., Proc. Nat'l Acad. Sci. USA., 83:3609, 1986. [0313] Lusky et al., Mol. Cell. Biol., 3:1108, 1983. [0314] Majors and Vannus, Proc. Nat'l Acad. Sci. USA., 80:5866, 1983. [0315] McNeall et al., Gene, 76:81, 1989. [0316] Miksicek et al., Cell, 46:203, 1986. [0317] Mordacq and Linzer, Genes and Dev., 3:760, 1989. [0318] Moreau et al., Nucl. Acids Res., 9:6047, 1981. [0319] Muesing et al., Cell, 48:691, 1987. [0320] Ng et al, Nuc. Acids Res., 17:601, 1989. [0321] Nicolau et al., Methods Enzymol., 149:157-176, 1987. [0322] Omirulleh et al., Plant Mol. Biol., 21:415-28, 1993. [0323] Ondek et al., EMBO J., 6:1017, 1987 [0324] Ornitz et al., Mol. Cell. Biol., 7:3466, 1987. [0325] Palmiter et al., Nature, 300:611, 1982. [0326] Pech et al., Mol. Cell. Biol., 9:396, 1989. [0327] Perez-Stable and Constantini, Mol. Cell. Biol., 10:1116, 1990. [0328] Picard and Schaffner, Nature, 307:83, 1984. [0329] Pietras et al., Oncogene, 17(17):2235-49, 1998. [0330] Pinkert et al., Genes and Dev., 1:268, 1987. [0331] Ponta et al., Proc. Nat'l Acad. Sci. USA., 82:1020, 1985. [0332] Porton et al., Mol. Cell. Biol., 10:1076, 1990. [0333] Potrykus et al., Mol. Gen. Genet., 199:183-188, 1985. [0334] Queen et al., Cell, 35:741, 1983. [0335] Quinn et al., Mol. Cell. Biol., 9:4713, 1989. [0336] Redondo et al., Science, 247:1225, 1990. [0337] Reisman and Rotter, Mol. Cell. Biol., 9:3571, 1989. [0338] Resendez Jr. et al., Mol. Cell. Biol., 8:4579, 1988. [0339] Ripe et al., Mol. Cell. Biol., 9:2224, 1989. [0340] Rippe et al., Mol. Cell. Biol., 10:689-695, 1990. [0341] Rittling et al., Nucl. Acids Res., 17:1619, 1989. [0342] Roselli et al., In Vivo 1993; 7:615-21, 1993. [0343] Rosen et al., Cell, 41:813, 1988. [0344] Sakai et al., Genes and Dev., 2:1144, 1988. [0345] Sambrook et al., In: Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, N. Y., 1989. [0346] Satake et al., J. Virology, 62:970, 1988. [0347] Schaffner et al., J. Mol. Biol., 201:81, 1988. [0348] Searle et al, Mol. Cell. Biol., 5:1480, 1985. [0349] Sharp et al., Cell, 59:229, 1989. [0350] Shaul et al, EMBO J, 6:1913, 1987. [0351] Sherman et al., Mol. Cell. Biol., 9:50, 1989. [0352] Sleigh et al., J. EMBO, 4:3831, 1985. [0353] Spalholz et al., Cell, 42:183, 1985. [0354] Spandau and Lee, J. Virology, 62:427, 1988. [0355] Spandidos and Wilkie, EMBO J., 2:1193, 1983. [0356] Stephens et al, Biochem. J, 248:1, 1987. [0357] Stuart et al., Nature, 317:828, 1985. [0358] Sullivan and Peterlin, Mol. Cell. Biol., 7:3315, 1987. [0359] Swartzendruber and Lehman, J. Cell. Physiology, 85:179, 1975. [0360] Takebe et al., Mol. Cell. Biol., 8:466, 1988. [0361] Tavernier et al., Nature, 301:634, 1983. [0362] Taylor et al., Mol. Cell. Biol., 10:165, 1990a. [0363] Taylor et al., Mol. Cell. Biol., 10:176, 1990b. [0364] Taylor et al., J. Biol. Chem., 264:15160, 1989. [0365] Thiesen et al., J. Virology, 62:614, 1988. [0366] Triesman, Cell, 46:567-74, 1986. [0367] Toiler et al., Mol. Cell. Biol., 7:2558, 1987. [0368] Tranche et al., Mol. Biol. Med., 7:173, 1990. [0369] Tranche et al., Mol. Cell. Biol., 9:4759, 1989. [0370] Tyndell et al., Nuc. Acids. Res., 9:6231, 1981. [0371] Vannice and Levinson, J. Virology, 62:1305, 1988. [0372] Vasseur et al., Proc. Nat'l Acad. Sci. USA., 77:1068, 1980. [0373] Wang and Calame, Cell, 47:241, 1986. [0374] Weber et al., Cell, 36:983, 1984. [0375] Weinberger et al. Mol. Cell. Biol., 8:988, 1984. [0376] Winoto and Baltimore, Cell, 59:649, 1989. [0377] Wong et al., Gene, 10:87-94, 1980. [0378] Yutzey et al. Mol. Cell. Biol., 9:1397, 1989.

Sequence CWU 1

1

91151PRTCampylobacter jejuni 1Met Ala Tyr Glu Asp Glu Glu Asp Leu Asn Tyr Asp Asp Tyr Glu Asn 1 5 10 15 Glu Asp Glu Glu Tyr Pro Gln Asn His His Lys Asn Tyr Asn Tyr Asp 20 25 30 Asp Asp Asp Tyr Glu Tyr Asp Asp Asp Asn Asn Asp Asp Asp Phe Tyr 35 40 45 Glu Met Asp 50 265PRTCampylobacter jejuni 2Met Ile Asn Pro Ile Gln Gln Ser Tyr Val Ala Asn Thr Ala Leu Asn 1 5 10 15 Thr Asn Arg Ile Asp Lys Glu Thr Lys Thr Asn Asp Thr Gln Lys Thr 20 25 30 Glu Asn Asp Lys Ala Ser Lys Ile Ala Glu Gln Ile Lys Asn Gly Thr 35 40 45 Tyr Lys Ile Asp Thr Lys Ala Thr Ala Ala Ala Ile Ala Asp Ser Leu 50 55 60 Ile 65 3116PRTCampylobacter jejuni 3Met Lys Lys Ile Leu Ile Leu Leu Thr Leu Cys Ala Phe Ala Phe Gly 1 5 10 15 Ala Ser Glu Cys Asp Arg Lys Ile Asp Arg Ile Asn Lys Glu Ile Ser 20 25 30 Phe Ser Lys Ala His Asn Asp Thr Ala Arg Thr Leu Ser Leu Glu Leu 35 40 45 Ala Leu Lys Gln Val Gln Asn Asp Cys Ala Lys Asp Pro Met Phe Tyr 50 55 60 Asp Lys Lys Leu Glu Ala Lys Lys Leu Lys Glu Gln Glu Val Glu Lys 65 70 75 80 Ile Glu Lys Glu Leu Asp Ala Leu Lys Glu Gln Lys Asp Tyr Met Ser 85 90 95 Lys Ala Glu Tyr Lys Ala Lys Lys Glu Ala Leu Lys Glu Gln Lys Glu 100 105 110 Lys Ile Lys Lys 115 4138PRTCampylobacter jejuni 4Met Ser Phe Gly Glu Ile Ile Val Ile Leu Val Val Ala Ile Leu Val 1 5 10 15 Leu Gly Pro Asp Lys Leu Pro Glu Ala Ile Val Gln Ile Ala Lys Ile 20 25 30 Leu Lys Ala Val Lys Arg Asn Ile Asp Asp Ala Lys Ser Ser Ile Glu 35 40 45 Lys Glu Ile Arg Ile Asn Asp Leu Lys Glu Glu Ala Lys Lys Tyr Lys 50 55 60 Asp Glu Phe Ser Ser Thr Asn Glu Asn Ile Arg Lys Lys Leu Ser Phe 65 70 75 80 Glu Glu Phe Asp Asp Leu Lys Arg Asp Ile Leu Asp Lys Thr Lys Val 85 90 95 Asp Leu Thr Phe Asp Ser Arg Asp Asp Lys Val Lys Asn Asn Leu Ser 100 105 110 Gly Gln Asn Leu Asn Thr Glu Glu Lys Pro Asn Leu Ser Lys Leu Glu 115 120 125 Thr Gln Asp Lys Asn Gly Lys Ile Asn Val 130 135 5141PRTCampylobacter jejuni 5Met Gln Lys Ala Lys Ile Leu Ile Ala Leu Ser Phe Phe Leu Leu Val 1 5 10 15 Leu Ser Ala Cys Ser Asn Asp Glu Lys Asn Ile Ser Lys Thr Gln Asn 20 25 30 Thr Asp Gln Glu Val Val Gln Ile Glu Gln Asn Asp Glu Lys Thr Glu 35 40 45 Leu Ser Asp Ser Asn Leu Pro Leu Pro Val Asp Asp Glu Ala Gln Ser 50 55 60 Ser Asn Asp Glu His Glu Val Asn Pro Ser Ile Ile Asn Ser Leu Tyr 65 70 75 80 Lys Gln Lys Cys Ala Thr Cys His Gly Glu Lys Gly Glu Leu Lys Pro 85 90 95 Lys Asn Ser Thr Ala Ile Lys Thr Leu Ser Asn Lys Ile Phe Ile Gln 100 105 110 Lys Ile Lys Thr Ile Lys Asp Lys Asn His Ser Phe Leu Ser Asp Glu 115 120 125 Gln Ile Gln Asn Leu Ala Asp Phe Ile Asn Lys Gly Lys 130 135 140 6144PRTCampylobacter jejuni 6Met Arg Arg Leu Ser Ile Leu Leu Ala Ile Leu Ile Val Ile Asn Ile 1 5 10 15 Thr Ala Cys Asp Ser Lys Thr Glu Asn Tyr Tyr Lys Asn Leu Pro Ser 20 25 30 Glu Ala Lys Glu Lys Ala Lys Glu Cys Lys Glu Ser Gly Thr Leu Ser 35 40 45 Glu Asp Cys Ile Asn Ala Leu Lys Val Gly Val Lys Pro Thr Asn Glu 50 55 60 Glu Gly Lys Tyr Ser Pro Asn Thr Pro Lys Lys Ser Asp Asn Gln Ile 65 70 75 80 Leu Glu Ala Leu Lys Gln Asn Asp Leu Lys Lys Glu Lys Thr Thr Lys 85 90 95 Asp Ile Asn Gln Ser Ser Glu Asn Asn Glu Ser Ile Ile Ile Pro Pro 100 105 110 Ile Ala Glu Thr Pro Ser Glu Ile Tyr Pro Ser Lys Thr Thr Glu Asn 115 120 125 Asn Gln Ser Ser Ile Phe Ser Asp Asp Val Asn Met Thr Gln Glu Lys 130 135 140 7174PRTCampylobacter jejuni 7Met Met Lys Lys Lys Leu Val Leu Leu Gly Ser Ala Ala Val Val Phe 1 5 10 15 Phe Ala Ala Cys Ala Met Asn Ser Gly Val Ser Ser Glu Gln Ile Gly 20 25 30 Leu Arg Lys Ala Ser Leu Glu Asn Glu Asn Lys Val Asn Leu Val Glu 35 40 45 Ala Asn Phe Thr Thr Leu Gln Pro Gly Glu Ser Thr Arg Phe Glu Arg 50 55 60 Ser Tyr Glu Asn Ala Pro Pro Leu Ile Pro His Ala Ile Glu Asp Leu 65 70 75 80 Leu Pro Ile Thr Lys Asp Asn Asn Met Cys Leu Ser Cys His Asp Lys 85 90 95 Ala Ile Ala Ala Asp Ala Gly Ala Thr Pro Leu Pro Ala Ser His Tyr 100 105 110 Tyr Asp Phe Arg His Asn Lys Thr Thr Gly Asp Met Ile Ser Asp Ser 115 120 125 Arg Phe Asn Cys Thr Gln Cys His Val Pro Gln Ser Asp Ala Lys Pro 130 135 140 Leu Val Gly Asn Ser Phe Lys Pro Glu Phe Lys Asn Glu Gln Leu Lys 145 150 155 160 Ser Arg Ser Asn Leu Ile Asp Val Ile Asn Glu Gly Val Lys 165 170 8201PRTCampylobacter jejuni 8Met Lys Lys Ile Lys Lys Ile Ile Gln Ile Gly Met Ile Gly Gly Leu 1 5 10 15 Ala Ala Val Ala Gly Gly Ala Leu Ala Gly Cys Gly Ser Asn Asn Asp 20 25 30 Asn Ala Asp Thr Leu Asn Gln Ala Ala Asn Ala Gln Gly Ala Phe Val 35 40 45 Ile Ile Glu Glu Thr Ala Pro Gly Gln Tyr Lys Ile Lys Asp Gln Tyr 50 55 60 Pro Ser Asp Glu Thr Arg Val Val Leu Lys Asp Leu Asn Gly Thr Glu 65 70 75 80 Arg Ile Leu Ser Lys Glu Glu Met Asp Ala Leu Ile Lys Glu Glu Ala 85 90 95 Ala Lys Ile Asp Asn Gly Thr Ser Asn Leu Thr Lys Asp Asn Gly Gln 100 105 110 Ile Ser Ser Gly Gly Leu Ser Leu Gly Glu Thr Leu Leu Ala Ser Ala 115 120 125 Ala Gly Ala Ile Leu Gly Ser Trp Ile Gly Ser Lys Leu Phe Asn Asn 130 135 140 Gln Asn Phe Ala Asn Gln Gln Arg Gly Ala Phe Ser Asn Gln Ser Ala 145 150 155 160 Tyr Gln Arg Ser Val Asn Ser Phe Asn Lys Ala Gly Thr Thr Ser Ser 165 170 175 Ala Ser Ser Ala Lys Lys Ser Gly Phe Phe Gly Gly Gly Ser Lys Ala 180 185 190 Thr Ser Ser Ser Ser Ser Phe Gly Ser 195 200 9210PRTCampylobacter jejuni 9Met Thr Lys Phe Leu Ser Ile Cys Ser Leu Ile Ala Met Leu Leu Ser 1 5 10 15 Gly Cys Gly Ser Asp Phe Pro Gly Gln Pro Ser Asp Val Ala Arg Val 20 25 30 Gln Gln Asn Lys Tyr Pro Asn Gly Asn Leu Lys Lys Glu Ile Pro Tyr 35 40 45 Asn Lys Asp Ser Arg Ile His Gly Leu Lys Arg Ala Phe Tyr Asp Asn 50 55 60 Gly Gln Leu Arg Ala Glu Glu Asn Tyr Lys Asn Gly Lys Lys Asp Gly 65 70 75 80 Ile Ser Arg Glu Tyr Ser Arg Asn Gly Gln Leu Leu Glu Glu Val His 85 90 95 Phe Lys Asp Asn Arg Gly Tyr Gly Asp Phe Ala Ser Tyr Tyr Glu Asn 100 105 110 Gly Asn Met Arg Ala Lys Gly Lys Leu Leu Gly Tyr Asn Glu Asp Gly 115 120 125 Met Pro Glu Phe Glu Gly Asn Tyr Lys Glu Tyr Tyr Glu Asn Gly Thr 130 135 140 Leu Met Cys Asp Tyr Asn Phe Asp Asn Lys Gly Lys Phe Asp Gly Val 145 150 155 160 Gln Lys Arg Tyr Asp Glu Asn Gly Ala Leu Glu Asp Glu Glu Asn Tyr 165 170 175 Lys Asn Gly Leu Lys Asn Gly Val Phe Arg Glu Tyr Lys Lys Gly Glu 180 185 190 Ile Val Arg Glu Glu Glu Tyr Lys Asn Gly Ile Leu Val Ala Lys Pro 195 200 205 Lys Asn 210 10244PRTCampylobacter jejuni 10Met Lys Lys Ile Phe Leu Ser Val Phe Leu Val Leu Ser Leu Asn Ala 1 5 10 15 Gln Asn Leu Glu Ile Asp Lys Ile Arg Thr Asp Leu Tyr Ser Lys Ser 20 25 30 Gly Ala Asn Val Leu Lys Lys Val Glu Ile Ser Leu Glu Phe Asp Gly 35 40 45 Asn Asn Leu Lys Glu Asn Glu Asn Lys Leu Ile Asp Ala Val Asn Thr 50 55 60 Val Ile Ser Gly Phe Phe Tyr Glu Asp Ile Phe Thr Glu Ile Gly Lys 65 70 75 80 Asn Asn Phe Lys Lys Thr Leu Glu Lys Phe Leu Asp Lys Lys Tyr Lys 85 90 95 Ile Lys Leu Asp Asp Ile Tyr Ile Ile Ser Leu Ser Gly Val Glu Lys 100 105 110 Phe Asp Leu Glu Glu Phe Lys Arg Phe Leu Glu Ser Thr Glu Ala Lys 115 120 125 Glu Lys Gly Met Gly Ser Glu Val Lys Lys Ala Leu Glu Asn Leu Glu 130 135 140 Val Pro Lys Thr Gln Val Pro Ser Val Glu Lys Ile Pro Thr Pro Ser 145 150 155 160 Val Pro Asn Leu Glu Val Lys Gln Val Glu Gln Leu Phe Lys Asp Pro 165 170 175 Asp Glu Glu Asn Lys Asn Asp Asn Gly Glu Ile Asn Ile Asp Asn Leu 180 185 190 Asn Thr Pro Lys Met Thr Pro Asp Ile Glu Glu Lys Ile Lys Arg Asp 195 200 205 Leu Ile Ala Asn Pro Pro Gln Ile Phe Lys Glu Asn Asn Ala Ser Lys 210 215 220 Pro Tyr His Leu Pro Gln Thr Gly Tyr Asp Ile Lys Leu Asp Glu Asn 225 230 235 240 Ser Thr Gln Asn 11259PRTCampylobacter jejuni 11Met Lys Asn Tyr Gly Leu Ser Asn Leu Asn Ser Phe Leu Leu Ala Leu 1 5 10 15 Ala Ile Tyr Ile Ser Ile Val Ile Leu Val Phe Phe Arg Leu Val Ser 20 25 30 Glu Val Glu Pro Ala Ile Gln Tyr Thr Asp Ile Lys Asp Ser Phe Val 35 40 45 Asp Ile Glu Leu Ala Glu Pro Ser Lys Gln Val Ile Thr Gln Ser Asn 50 55 60 Thr Pro Lys Glu Ile Gln Lys Pro Thr Glu Gln Ile Asp Ile Glu Lys 65 70 75 80 Leu Phe Ala Gln Thr Thr Asn Lys Thr Val Lys Thr Glu Asp Ile Asp 85 90 95 Gln Lys Ala Ser Asn Phe Asn Glu Leu Phe Gly Asn Ile Lys Glu Ile 100 105 110 Gln Glu Glu Lys Thr Thr Lys Ile Gln Ser Ser Ala Lys Ser Gly Ile 115 120 125 Ser Ser Ala Pro Lys Pro Gln Ala Ser Glu Leu Val Lys Gln Leu Asn 130 135 140 Asp Ser Leu Leu Gln Glu Glu Ser Ser Thr Gln Gly Glu Ser Thr Lys 145 150 155 160 Ala Gln Lys Ile Gly Ile Tyr Asp Glu Phe Leu Gly Lys Val Val Arg 165 170 175 Ile Ile Thr Gln Arg Trp Thr Gln Tyr Tyr Pro Asn Ser Glu Lys Ile 180 185 190 Ser Val Lys Val Lys Ile Phe Ile Asp Glu Asn Gly Lys Phe Gly Tyr 195 200 205 Thr Ser Val Glu Lys Ser Gly Asn Pro Leu Tyr Asp Ala Lys Val Ala 210 215 220 Glu Phe Leu Glu Ser Gln Lys Gly Lys Phe Ile Thr Tyr Pro Pro Gln 225 230 235 240 Asn Lys Asn Ile Ser Ile Thr Met Asn Leu Arg Asp Glu Val Lys Val 245 250 255 Lys Asn Asp 12273PRTCampylobacter jejuni 12Met Lys Lys Phe Ser Leu Val Ala Ala Thr Leu Ile Ala Gly Val Val 1 5 10 15 Leu Asn Val Asn Ala Ala Thr Val Ala Thr Val Asn Gly Lys Ser Ile 20 25 30 Ser Asp Thr Glu Val Ser Glu Phe Phe Ala Pro Met Leu Arg Gly Gln 35 40 45 Asp Phe Lys Thr Leu Pro Asp Asn Gln Lys Lys Ala Leu Ile Gln Gln 50 55 60 Tyr Ile Met Gln Asp Leu Ile Leu Gln Asp Ala Lys Lys Gln Asn Leu 65 70 75 80 Glu Lys Asp Pro Leu Tyr Thr Lys Glu Leu Asp Arg Ala Lys Asp Ala 85 90 95 Ile Leu Val Asn Val Tyr Gln Glu Lys Ile Leu Asn Thr Ile Lys Ile 100 105 110 Asp Ala Ala Lys Val Lys Ala Phe Tyr Asp Gln Asn Lys Asp Lys Tyr 115 120 125 Val Lys Pro Ala Arg Val Gln Ala Lys His Ile Leu Val Ala Thr Glu 130 135 140 Lys Glu Ala Lys Asp Ile Ile Asn Glu Leu Lys Gly Leu Lys Gly Lys 145 150 155 160 Glu Leu Asp Ala Lys Phe Ser Glu Leu Ala Lys Glu Lys Ser Ile Asp 165 170 175 Pro Gly Ser Lys Asn Gln Gly Gly Glu Leu Gly Trp Phe Asp Gln Ser 180 185 190 Thr Met Val Lys Pro Phe Thr Asp Ala Ala Phe Ala Leu Lys Asn Gly 195 200 205 Thr Ile Thr Thr Thr Pro Val Lys Thr Asn Phe Gly Tyr His Val Ile 210 215 220 Leu Lys Glu Asn Ser Gln Ala Lys Gly Gln Ile Lys Phe Asp Glu Val 225 230 235 240 Lys Gln Gly Ile Glu Asn Gly Leu Lys Phe Glu Glu Phe Lys Lys Val 245 250 255 Ile Asn Gln Lys Gly Gln Asp Leu Leu Asn Ser Ala Lys Val Glu Tyr 260 265 270 Lys 13278PRTCampylobacter jejuni 13Met Glu Asn Gln Lys Asn Glu Phe Asp Asp Ile Ile Leu Glu Lys Ser 1 5 10 15 Asn Lys Ser Glu Lys Val Lys Lys Ile Leu Leu Arg Val Ile Ala Leu 20 25 30 Val Ile Leu Phe Leu Ala Ile Met Ile Val Met Lys Leu Ile Asn Gly 35 40 45 Ser Gly Asp Glu Asn Thr Gln Asn Gln Ser Val Leu Pro Ser Glu Pro 50 55 60 Ile Ala Thr Gln Asp Asn Asn Asn Asp Thr Ser Phe Glu Ser Met Pro 65 70 75 80 Ile Thr Asp Asn Thr Ser Ala Glu Asp Gln Phe Glu Ala Leu Arg Lys 85 90 95 Gln Phe Gln Asp Glu Gln Asn Thr Thr Gln Asn Thr Thr Thr Ser Ser 100 105 110 Ser Asn Asn Asn Asp Thr Thr Asn Phe Ala Met Pro Asp Gln Glu Val 115 120 125 Pro Ala Glu Pro Thr Ala Thr Thr Ser Ala Asn Thr Thr Pro Gln Ala 130 135 140 Ser Thr Pro Lys Gln Glu Val Thr Gln Thr Ala Lys Ser Lys Glu Glu 145 150 155 160 Ala Lys Lys Gln Thr Ala Val Lys Lys Glu Lys Glu Ser Ala Lys Gln 165 170 175 Thr Pro Lys Lys Glu Gln Asn Ala Asn Asp Leu Phe Lys Asn Val Asp 180 185 190 Ala Lys Pro Val His Pro Ser Gly Leu Ala Ser Gly Ile Tyr Val Gln 195 200 205 Ile Phe Ser Val Ser Asn Leu Asp Gln Lys Ser Lys Glu Leu Ala Ser 210 215 220 Val Lys Gln Lys Gly Tyr Asp Tyr Lys Leu Tyr Lys Thr Thr Val Gly 225 230 235

240 Ser Lys Glu Ile Thr Lys Val Leu Ile Gly Pro Phe Glu Lys Ala Asp 245 250 255 Ile Ala Ala Glu Leu Ala Lys Ile Arg Lys Asp Ile Ala Lys Asp Ala 260 265 270 Phe Ser Phe Thr Leu Lys 275 14390PRTCampylobacter jejuni 14Met Lys Lys Lys Ile Val Leu Ile Ile Leu Ile Ala Ile Leu Gly Ser 1 5 10 15 Val Gly Ala Tyr Phe Ile Phe Phe Asn Asn Asp Glu Lys Ile Ser Tyr 20 25 30 Leu Thr Gln Lys Ile Gln Lys Lys Asp Ile Ser Gln Thr Ile Glu Ala 35 40 45 Val Gly Lys Val Tyr Ala Lys Asp Gln Val Asp Val Gly Ala Gln Val 50 55 60 Ser Gly Gln Ile Ile Lys Leu Tyr Val Asp Val Gly Thr His Val Lys 65 70 75 80 Gln Gly Asp Leu Ile Ala Gln Ile Asp Lys Asp Lys Gln Gln Asn Asp 85 90 95 Leu Asp Ile Thr Lys Ala Gln Leu Glu Ser Ala Lys Ala Asn Leu Glu 100 105 110 Ser Lys Lys Val Ala Leu Glu Ile Ala Asn Lys Gln Tyr Gln Arg Glu 115 120 125 Gln Lys Leu Tyr Ala Ala Lys Ala Ser Ser Leu Glu Asn Leu Glu Thr 130 135 140 Gln Lys Asn Asn Tyr Tyr Thr Leu Lys Ala Asn Val Ala Glu Leu Asn 145 150 155 160 Ala Gln Val Val Gln Leu Glu Ile Thr Leu Lys Asn Ala Gln Lys Asp 165 170 175 Leu Gly Tyr Thr Thr Ile Thr Ala Pro Met Asp Gly Val Val Ile Asn 180 185 190 Val Ala Val Asp Glu Gly Gln Thr Val Asn Ala Asn Gln Asn Thr Pro 195 200 205 Thr Ile Val Arg Ile Ala Asn Leu Asp Glu Met Glu Val Arg Met Glu 210 215 220 Ile Ala Glu Ala Asp Val Ser Lys Ile Lys Val Gly Thr Glu Leu Asp 225 230 235 240 Phe Ser Leu Leu Asn Asp Pro Gln Lys Thr Tyr His Ala Lys Ile Ala 245 250 255 Ser Ile Asp Pro Ala Asp Thr Glu Val Ser Asp Ser Ser Thr Ser Ser 260 265 270 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Asn Ala Ile 275 280 285 Tyr Tyr Tyr Ala Lys Phe Tyr Val Ala Asn Lys Asp Asp Phe Leu Arg 290 295 300 Ile Gly Met Ser Ile Gln Asn Glu Ile Val Val Ala Ser Ala Lys Ala 305 310 315 320 Val Leu Ala Val Pro Thr Tyr Ala Ile Lys Ser Asp Pro Lys Gly Tyr 325 330 335 Tyr Val Glu Ile Leu Glu Asn Gln Lys Ala Val Lys Lys Tyr Val Lys 340 345 350 Leu Gly Ile Lys Asp Ser Ile Asn Thr Gln Ile Leu Glu Gly Val Asn 355 360 365 Glu Asp Glu Glu Leu Ile Val Ser Ser Ser Ala Asp Gly Leu Ala Pro 370 375 380 Lys Met Lys Leu Arg Phe 385 390 15542PRTCampylobacter jejuni 15Met Lys Ile Leu Leu Leu Asn Glu Asn Pro Val Val Ser Arg Leu Val 1 5 10 15 Ser Leu Ser Ala Lys Lys Met Ser Tyr Asp Phe Glu Glu Leu Asn Ala 20 25 30 Tyr Ser Glu Asn Leu Gly Asn Tyr Asp Val Ile Val Val Asp Ser Asp 35 40 45 Thr Pro Ala Pro Leu Lys Ile Leu Lys Glu Lys Cys Asp Arg Leu Ile 50 55 60 Phe Leu Ala Pro Arg Asn Gln Asn Val Glu Asp Ile Asp Ala Gln Ile 65 70 75 80 Leu Gln Lys Pro Phe Leu Pro Thr Asp Phe Leu Asn Leu Leu Asn Asn 85 90 95 Lys Asp Ala Asn Lys His Thr Ser Ile Asp Leu Pro Met Leu Ser Asn 100 105 110 Asp Glu Asn Pro Tyr Ala Asp Ile Ser Leu Asp Leu Asp Asn Leu Asn 115 120 125 Leu Asp Asp Leu Pro Asp Glu Asn Ser Leu Asp Ile Asn Ser Glu Gly 130 135 140 Met Glu Asp Leu Ser Phe Asp Asp Asp Ala Gln Asp Asp Asn Ala Asn 145 150 155 160 Lys Thr Leu Glu Thr Gln Asn Leu Glu His Glu Thr Ile Lys Glu Gln 165 170 175 Thr Gln Glu Asp Thr Gln Ile Asp Leu Asp Leu Thr Leu Glu Asp Gly 180 185 190 Glu Ser Glu Lys Glu Asp Leu Ser Gln Glu His Thr Ala Leu Asp Thr 195 200 205 Glu Pro Ser Leu Asp Glu Leu Asp Asp Lys Asn Asp Glu Asp Leu Glu 210 215 220 Ile Lys Glu Asp Asp Lys Asn Glu Glu Ile Glu Lys Gln Glu Leu Leu 225 230 235 240 Asp Asp Ser Lys Thr Asn Thr Leu Glu Met Gln Glu Glu Leu Ser Glu 245 250 255 Ser Gln Asp Asp Asn Ser Asn Lys Thr Leu Glu Thr Gln Asn Leu Glu 260 265 270 His Asp Asn Leu Glu Gln Glu Thr Ile Lys Glu Gln Thr Gln Glu Asp 275 280 285 Thr Gln Ile Asp Leu Asp Leu Thr Leu Glu Asp Gly Glu Ser Glu Lys 290 295 300 Glu Asp Leu Ser Gln Glu His Thr Ala Leu Asp Thr Glu Pro Ser Leu 305 310 315 320 Asp Glu Leu Asp Asp Lys Asn Asp Glu Asp Leu Glu Asp Asn Lys Glu 325 330 335 Leu Gln Ala Asn Ile Ser Asp Phe Asp Asp Leu Pro Glu Val Glu Glu 340 345 350 Gln Glu Lys Glu Met Asp Phe Asp Asp Leu Pro Glu Asp Ala Glu Phe 355 360 365 Leu Gly Gln Ala Lys Tyr Asn Glu Glu Ser Glu Glu Asn Leu Glu Glu 370 375 380 Phe Ala Pro Val Val Glu Glu Asp Ile Gln Asp Glu Ile Asp Asp Phe 385 390 395 400 Ala Ser Asn Leu Ser Thr Gln Asp Gln Ile Lys Glu Glu Leu Ala Gln 405 410 415 Leu Asp Glu Leu Asp Tyr Gly Ile Asp Ser Asp Asn Ser Ser Lys Val 420 425 430 Leu Glu Asp Phe Lys Asp Glu Pro Ile Leu Asp Asp Lys Glu Leu Gly 435 440 445 Thr Asn Glu Glu Glu Val Val Val Pro Asn Leu Asn Ile Ser Asp Phe 450 455 460 Asp Thr Leu Lys Glu Ser Asp Ile Gln Glu Ala Leu Gly Glu Glu Ile 465 470 475 480 Leu Glu Lys Asn Glu Glu Pro Ile Val Ser Asp Val Thr Lys Asp Asp 485 490 495 Asn Ser Glu Glu Ile Val Asn Glu Leu Ser Gln Ser Ile Ala Gly Ala 500 505 510 Ile Thr Ser Ser Ile Lys Asp Asp Thr Leu Lys Ala Ala Leu Lys Gly 515 520 525 Met Asn Met Asn Ile Asn Ile Asn Ile Ser Phe Lys Glu Asp 530 535 540 16610PRTCampylobacter jejuni 16Met Lys Lys Asn Ile Leu Arg Leu Gly Ile Val Val Leu Val Leu Leu 1 5 10 15 Ile Ala Gly Val Leu Trp Leu Asn Asn Asp Ile Asn Gln Lys Lys Glu 20 25 30 Asp Glu Ala Asn Lys Asn Ala Ile Ala Ala Asn Ala Asp Phe Ser Leu 35 40 45 Leu Ser Asp Asp Asp Pro Asn Phe Glu Lys Trp Gly Lys Val Phe Pro 50 55 60 Glu Gln Leu Lys Met Tyr Leu Thr Val Glu Lys Glu Glu Pro Lys Ala 65 70 75 80 Thr Glu Phe Gly Gly Asn Leu Ala Tyr Ser Lys Leu Ile Arg Phe Pro 85 90 95 Gln Leu Thr Ile Leu Trp Ala Gly Tyr Pro Phe Ser Leu Asp Phe Asn 100 105 110 Glu Glu Arg Gly His Phe Trp Val Gln Val Asp Gln Met Lys Thr Ala 115 120 125 Arg Asn Asn Lys Asp Phe Leu Asn Ala His Gly Leu Ala Ala Phe Lys 130 135 140 Gly Gln Pro Ala Ala Cys Met Asn Cys His Ser Gly Trp Thr Pro Trp 145 150 155 160 Leu Ile Lys Asn Val Ala Lys Gly Asp Phe Thr Ala Phe Asn Ser Thr 165 170 175 Asn Tyr Trp Thr Met Ile Lys Asn Ile Pro Ala Val Asp Gly Ile Val 180 185 190 Glu Asn Ser Pro Glu His Ala Gly Pro His Gly Gly Lys Arg Met Gly 195 200 205 Val Thr Cys Ala Asp Cys His Asn Pro Asn Asp Met Ser Leu Arg Leu 210 215 220 Thr Arg Pro Ala Ala Ile Asn Ala Leu Val Ser Arg Gly Tyr Glu Lys 225 230 235 240 Asp Pro Val Gln Gly Val Lys Ala Thr Arg Glu Glu Met Arg Thr Leu 245 250 255 Val Cys Ser Gln Cys His Val Glu Tyr Tyr Phe Lys Pro Thr Gly Glu 260 265 270 Lys Val Lys Val Met Gly Glu Thr Ile Val Asp Asp Ser Ser Lys Lys 275 280 285 Trp Trp Asn Gly Thr Gln Lys Asn Tyr Asp Glu Tyr Glu Phe Trp Arg 290 295 300 Asp Gly Asn Lys Val Lys Glu Ile Glu Thr Asp Gly Ile Val Leu Thr 305 310 315 320 Phe Pro Trp Ser Glu Trp Lys Lys Gly Gln Pro Phe Arg Ile Glu Met 325 330 335 Leu Asp Asp Tyr Tyr Asp Lys Val Arg Gly Val Phe Gly Ala Asp Phe 340 345 350 Thr His Lys Leu Thr Gly Ala Gln Ile Ile Lys Ile Gln His Pro Glu 355 360 365 Ser Glu Leu Tyr Ser Gly Gly Val His Ala Ala Asn Gly Val Ser Cys 370 375 380 Val Asp Cys His Met Pro Tyr Val Arg Glu Gly Ala Lys Lys Val Thr 385 390 395 400 Gln His Asn Ile Thr Ser Pro Leu Arg Asp Ile Asn Ser Ala Cys Lys 405 410 415 Ser Cys His Lys Gln Ser Glu Asp Tyr Leu Lys Ala Gln Val Leu Asp 420 425 430 Ile Gln Asn Ser Val Ala His Asp Gln Arg Thr Ala Glu Tyr Ala Ile 435 440 445 Val Ser Leu Ile Met Asp Thr Lys Lys Leu Arg Asp Glu Leu Gly Asn 450 455 460 Met Glu Lys Phe Gln Ser Asp Gly Lys Ala Asp Ala Lys Lys Ile Ser 465 470 475 480 Glu Glu Leu Lys Glu Val Leu Glu Leu His Arg Lys Ala Gln Met Arg 485 490 495 Ala Asp Phe Val Asn Ala Glu Asn Ser Thr Gly Phe His Asn Pro Arg 500 505 510 Glu Ala Ser Arg Met Leu Leu Gln Ala Val Asp Met Ala Arg Met Gly 515 520 525 Gln Thr Lys Leu Val Glu Ile Ala Ala Ala Asn Gly Ile Lys Asp Phe 530 535 540 Lys Thr Ser Asn Leu Gly Phe Glu Asp Ile Gln Lys Phe Asn Pro Gly 545 550 555 560 Glu Leu Tyr Tyr Lys Val Asp Val Asn Asn His Lys Ala Gly Glu Arg 565 570 575 Tyr Tyr Ala Asp Glu Lys Asp Val Asn Gly Asn Pro Pro Lys Glu Leu 580 585 590 Leu Glu His Asp Lys Glu Leu Ala Pro Tyr Asn Tyr Gln Val Ile Asp 595 600 605 Lys Lys 610 17659PRTCampylobacter jejuni 17Met Lys Ser Val Lys Leu Lys Val Ser Leu Ile Ala Asn Leu Ile Ala 1 5 10 15 Val Val Cys Leu Ile Ile Leu Gly Val Val Thr Phe Ile Phe Val Lys 20 25 30 Gln Ala Ile Phe His Glu Val Val Asn Ala Glu Ile Asn Tyr Val Lys 35 40 45 Thr Ala Lys Asn Ser Ile Glu Ser Phe Lys Ala Arg Asn Ser Leu Ala 50 55 60 Leu Glu Ser Leu Ala Lys Ser Ile Leu Lys His Pro Ile Glu Gln Leu 65 70 75 80 Asp Ser Gln Asp Ala Leu Met His Tyr Val Gly Lys Asp Leu Lys Asn 85 90 95 Phe Arg Asp Ala Gly Arg Phe Leu Ala Val Tyr Ile Ala Gln Pro Asn 100 105 110 Gly Glu Leu Val Val Ser Asp Pro Asp Ser Asp Ala Lys Asn Leu Asp 115 120 125 Phe Gly Thr Tyr Gly Lys Ala Asp Asn Tyr Asp Ala Arg Thr Arg Glu 130 135 140 Tyr Tyr Ile Glu Ala Val Lys Thr Asn Lys Leu Tyr Ile Thr Pro Ser 145 150 155 160 Tyr Ile Asp Val Thr Thr Asn Leu Pro Cys Phe Thr Tyr Ser Ile Pro 165 170 175 Leu Tyr Lys Asp Gly Lys Phe Ile Gly Val Leu Ala Val Asp Ile Leu 180 185 190 Ala Ala Asp Leu Gln Ala Glu Phe Glu Asn Leu Pro Gly Arg Thr Phe 195 200 205 Val Phe Asp Glu Glu Asn Lys Val Phe Val Ser Thr Asp Lys Ala Leu 210 215 220 Leu Gln Lys Gly Tyr Asp Ile Ser Ala Ile Ala Asn Leu Ala Lys Thr 225 230 235 240 Lys Glu Asp Leu Glu Pro Phe Glu Tyr Thr Arg Pro Lys Asp Gly Asn 245 250 255 Glu Arg Phe Ala Val Cys Thr Lys Val Ser Gly Ile Tyr Thr Ala Cys 260 265 270 Val Gly Glu Pro Ile Glu Gln Ile Glu Ala Pro Val Tyr Lys Ile Ala 275 280 285 Phe Ile Gln Thr Ala Ile Val Ile Phe Thr Ser Ile Ile Ser Val Ile 290 295 300 Leu Leu Tyr Phe Ile Val Ser Lys Tyr Leu Ser Pro Leu Ala Ala Ile 305 310 315 320 Gln Thr Gly Leu Thr Ser Phe Phe Asp Phe Ile Asn Tyr Lys Thr Lys 325 330 335 Asn Val Ser Thr Ile Glu Val Lys Ser Asn Asp Glu Phe Gly Gln Ile 340 345 350 Ser Asn Ala Ile Asn Glu Asn Ile Leu Ala Thr Lys Arg Gly Leu Glu 355 360 365 Gln Asp Asn Gln Ala Val Lys Glu Ser Val Gln Thr Val Ser Val Val 370 375 380 Glu Gly Gly Asn Leu Thr Ala Arg Ile Thr Ala Asn Pro Arg Asn Pro 385 390 395 400 Gln Leu Ile Glu Leu Lys Asn Val Leu Asn Lys Leu Leu Asp Val Leu 405 410 415 Gln Ala Arg Val Gly Ser Asp Met Asn Ala Ile His Lys Ile Phe Glu 420 425 430 Glu Tyr Lys Ser Leu Asp Phe Arg Asn Lys Leu Glu Asn Ala Ser Gly 435 440 445 Ser Val Glu Leu Thr Thr Asn Ala Leu Gly Asp Glu Ile Val Lys Met 450 455 460 Leu Lys Gln Ser Ser Asp Phe Ala Asn Ala Leu Ala Asn Glu Ser Gly 465 470 475 480 Lys Leu Gln Thr Ala Val Gln Ser Leu Thr Thr Ser Ser Asn Ser Gln 485 490 495 Ala Gln Ser Leu Glu Glu Thr Ala Ala Ala Leu Glu Glu Ile Thr Ser 500 505 510 Ser Met Gln Asn Val Ser Val Lys Thr Ser Asp Val Ile Thr Gln Ser 515 520 525 Glu Glu Ile Lys Asn Val Thr Gly Ile Ile Gly Asp Ile Ala Asp Gln 530 535 540 Ile Asn Leu Leu Ala Leu Asn Ala Ala Ile Glu Ala Ala Arg Ala Gly 545 550 555 560 Glu His Gly Arg Gly Phe Ala Val Val Ala Asp Glu Val Arg Lys Leu 565 570 575 Ala Glu Arg Thr Gln Lys Ser Leu Ser Glu Ile Glu Ala Asn Thr Asn 580 585 590 Leu Leu Val Gln Ser Ile Asn Asp Met Ala Glu Ser Ile Lys Glu Gln 595 600 605 Thr Ala Gly Ile Thr Gln Ile Asn Asp Ser Val Ala Gln Ile Asp Gln 610 615 620 Thr Thr Lys Asp Asn Val Glu Ile Ala Asn Glu Ser Ala Ile Ile Ser 625 630 635 640 Ser Thr Val Ser Asp Ile Ala Asn Asn Ile Leu Glu Asp Val Lys Lys 645 650 655 Lys Arg Phe 18665PRTCampylobacter jejuni 18Met Gln Ser Ile Asn Ser Gly Lys Ser Val Gly Ile Ser Ala Lys Leu 1 5 10 15 Thr Leu Trp Val Gly Ile Leu Val Val Leu Ile Leu Ala Ile Thr Ser 20 25 30 Ala Ile Ser Tyr Phe Asp Ser Arg Asn Asn Thr Tyr Glu Leu Leu Lys 35 40 45 Asp

Thr Gln Leu Lys Thr Met Gln Asp Val Asp Ala Phe Phe Lys Ser 50 55 60 Tyr Ala Met Ser Lys Arg Asn Gly Ile Gln Ile Leu Ala Asn Glu Leu 65 70 75 80 Thr Asn Arg Pro Asp Met Ser Asp Glu Glu Leu Ile Asn Leu Ile Lys 85 90 95 Val Ile Lys Lys Val Asn Asp Tyr Asp Leu Val Tyr Val Gly Phe Asp 100 105 110 Asn Thr Gly Lys Asn Tyr Gln Ser Asp Asp Gln Ile Leu Asp Leu Ser 115 120 125 Lys Gly Tyr Asp Thr Lys Asn Arg Pro Trp Tyr Lys Ala Ala Lys Glu 130 135 140 Ala Lys Lys Leu Ile Val Thr Glu Pro Tyr Lys Ser Ala Ala Ser Gly 145 150 155 160 Glu Val Gly Leu Thr Tyr Ala Ala Pro Phe Tyr Asp Arg Asn Gly Asn 165 170 175 Phe Arg Gly Val Val Gly Gly Asp Tyr Asp Leu Ala Asn Phe Ser Thr 180 185 190 Asn Val Leu Thr Val Gly Lys Ser Asp Asn Thr Phe Thr Glu Val Leu 195 200 205 Asp Ser Glu Gly Thr Ile Leu Phe Asn Asp Glu Val Ala Lys Ile Leu 210 215 220 Thr Lys Thr Glu Leu Ser Ile Asn Ile Ala Asn Ala Ile Lys Ala Asn 225 230 235 240 Pro Ala Leu Ile Asp Pro Arg Asn Gln Asp Thr Leu Phe Thr Ala Lys 245 250 255 Asp His Gln Gly Val Asp Tyr Ala Ile Met Cys Asn Ser Ala Phe Asn 260 265 270 Pro Leu Phe Arg Ile Cys Thr Ile Thr Glu Asn Lys Val Tyr Thr Glu 275 280 285 Ala Val Asn Ser Ile Leu Met Lys Gln Val Ile Val Gly Ile Ile Ala 290 295 300 Ile Ile Ile Ala Leu Ile Leu Ile Arg Phe Leu Ile Ser Arg Ser Leu 305 310 315 320 Ser Pro Leu Ala Ala Ile Gln Thr Gly Leu Thr Ser Phe Phe Asp Phe 325 330 335 Ile Asn Tyr Lys Thr Lys Asn Val Ser Thr Ile Glu Val Lys Ser Asn 340 345 350 Asp Glu Phe Gly Gln Ile Ser Asn Ala Ile Asn Glu Asn Ile Leu Ala 355 360 365 Thr Lys Arg Gly Leu Glu Gln Asp Asn Gln Ala Val Lys Glu Ser Val 370 375 380 Gln Thr Val Ser Val Val Glu Gly Gly Asn Leu Thr Ala Arg Ile Thr 385 390 395 400 Ala Asn Pro Arg Asn Pro Gln Leu Ile Glu Leu Lys Asn Val Leu Asn 405 410 415 Lys Leu Leu Asp Val Leu Gln Ala Arg Val Gly Ser Asp Met Asn Ala 420 425 430 Ile His Lys Ile Phe Glu Glu Tyr Lys Ser Leu Asp Phe Arg Asn Lys 435 440 445 Leu Glu Asn Ala Ser Gly Ser Val Glu Leu Thr Thr Asn Ala Leu Gly 450 455 460 Asp Glu Ile Val Lys Met Leu Lys Gln Ser Ser Asp Phe Ala Asn Ala 465 470 475 480 Leu Ala Asn Glu Ser Gly Lys Leu Gln Thr Ala Val Gln Ser Leu Thr 485 490 495 Thr Ser Ser Asn Ser Gln Ala Gln Ser Leu Glu Glu Thr Ala Ala Ala 500 505 510 Leu Glu Glu Ile Thr Ser Ser Met Gln Asn Val Ser Val Lys Thr Ser 515 520 525 Asp Val Ile Thr Gln Ser Glu Glu Ile Lys Asn Val Thr Gly Ile Ile 530 535 540 Gly Asp Ile Ala Asp Gln Ile Asn Leu Leu Ala Leu Asn Ala Ala Ile 545 550 555 560 Glu Ala Ala Arg Ala Gly Glu His Gly Arg Gly Phe Ala Val Val Ala 565 570 575 Asp Glu Val Arg Lys Leu Ala Glu Arg Thr Gln Lys Ser Leu Ser Glu 580 585 590 Ile Glu Ala Asn Thr Asn Leu Leu Val Gln Ser Ile Asn Asp Met Ala 595 600 605 Glu Ser Ile Lys Glu Gln Thr Ala Gly Ile Thr Gln Ile Asn Asp Ser 610 615 620 Val Ala Gln Ile Asp Gln Thr Thr Lys Asp Asn Val Glu Ile Ala Asn 625 630 635 640 Glu Ser Ala Ile Ile Ser Ser Thr Val Ser Asp Ile Ala Asn Asn Ile 645 650 655 Leu Glu Asp Val Lys Lys Lys Arg Phe 660 665 19750PRTCampylobacter jejuni 19Met Arg Ile Thr Asn Lys Leu Asn Phe Thr Asn Ser Val Asn Asn Ser 1 5 10 15 Met Gly Gly Gln Ser Ala Leu Tyr Gln Ile Ser Gln Gln Leu Ala Ser 20 25 30 Gly Leu Lys Ile Gln Asn Ser Tyr Glu Asp Ala Ser Thr Tyr Ile Asp 35 40 45 Asn Thr Arg Leu Glu Tyr Glu Ile Lys Thr Leu Glu Gln Val Lys Glu 50 55 60 Ser Thr Ser Arg Ala Gln Glu Met Thr Gln Asn Ser Met Lys Ala Leu 65 70 75 80 Gln Asp Met Val Lys Leu Leu Glu Asp Phe Lys Val Lys Val Thr Gln 85 90 95 Ala Ala Ser Asp Ser Asn Ser Gln Thr Ser Arg Glu Ala Ile Ala Lys 100 105 110 Glu Leu Glu Arg Ile Lys Glu Ser Ile Val Gln Leu Ala Asn Thr Ser 115 120 125 Val Asn Gly Gln Tyr Leu Phe Ala Gly Ser Gln Val Ala Asn Lys Pro 130 135 140 Phe Asp Ser Asn Gly Asn Tyr Tyr Gly Asp Lys Asn Asn Ile Asn Val 145 150 155 160 Val Thr Gly Ala Gly Thr Glu Ser Pro Tyr Asn Ile Pro Gly Trp Asp 165 170 175 Leu Phe Phe Lys Ala Asp Gly Asp Tyr Lys Lys Gln Ile Ser Thr Asn 180 185 190 Val Ser Phe Thr Asp Asn Arg Trp Asp Leu Asn Lys Asp Pro Asp Lys 195 200 205 Thr Lys Tyr Leu Thr Gly Asp Ser Lys Trp Gln Gln Leu Ile Gly Gln 210 215 220 Ser Tyr Val Lys Asp Asn Ser Leu Asp Ala Asp Lys Asp Phe Glu Tyr 225 230 235 240 Asp Asp Ser Lys Leu Asp Phe Pro Pro Thr Thr Leu Tyr Val Gln Gly 245 250 255 Thr Arg Pro Asp Gly Thr Ser Phe Lys Ser Ala Val Leu Val Lys Pro 260 265 270 Glu Asp Thr Leu Glu Asp Val Met Glu Asn Ile Gly Ala Leu Tyr Gly 275 280 285 Asn Thr Pro Asn Asn Lys Val Val Glu Val Ser Met Asn Asp Ser Gly 290 295 300 Gln Ile Gln Ile Thr Asp Leu Lys Gln Gly Asn Asn Lys Leu Asp Phe 305 310 315 320 His Ala Val Ala Phe Thr Pro Gln Ala Asp Asp Lys Thr Glu Leu Asn 325 330 335 Asn Ile Ile Gln Ala Ala Gln Asp Glu Gly Ile Thr Met Glu Asp Val 340 345 350 Thr Asn Arg Val Met Thr Ala Ala Leu Gly Asn Pro Asn Asn Gly Asp 355 360 365 Ile Thr Asn Leu Asn Asn Pro Val Thr Ile Gln Ile Asn Gly Gln Asn 370 375 380 Phe Glu Ile Asp Leu Lys Gln Thr Asp Phe Ile Lys Ser Lys Met Thr 385 390 395 400 Asp Thr Asp Gly Asn Ala Ala Asn Gly Ala Asp Tyr Asp Asn Val Tyr 405 410 415 Phe Glu Lys Asn Gly Asn Thr Val Tyr Gly Asn Val Ser Gln Val Ile 420 425 430 Lys Gly Ser Asn Ala Tyr Ala Thr Asp Ser Thr Lys Leu Ser Glu Val 435 440 445 Met Ala Gly Asp Ser Leu Asn Gly Thr Thr Leu Asn Leu Lys Val Asn 450 455 460 Ser Lys Gly Gly Asn Ser Tyr Asp Val Thr Ile Asn Leu Gln Thr Ser 465 470 475 480 Thr Val Ser Tyr Pro Asp Pro Asn Asn Pro Gly Gln Thr Ile Ser Phe 485 490 495 Pro Ile Met His Thr Asn Pro Ala Thr Gly Asn Ser Gly Val Val Thr 500 505 510 Gly Ser Asn Asp Ile Thr Tyr Gly Gln Ile Asn Asp Ile Ile Gly Met 515 520 525 Phe Ala Ala Asp Lys Ile Pro Thr Thr Thr Ile Gln Ala Asn Asn Gly 530 535 540 Gln Ile Asn Asn Ala Asp Tyr Thr Gln Ile Gln Gln Leu Met Lys Asp 545 550 555 560 Ser Gln Ala Thr Val Asp Val Ser Met Asp Tyr Lys Gly Arg Ile Ser 565 570 575 Val Thr Asp Lys Leu Ser Ser Gly Thr Asn Ile Glu Ile Ser Leu Ser 580 585 590 Asp Ser Gln Ser Gly Gln Phe Pro Ala Pro Pro Phe Thr Thr Thr Ser 595 600 605 Thr Val Gln Asn Gly Pro Asn Phe Ser Phe Ser Ala Asn Asn Ser Leu 610 615 620 Thr Ile Asp Glu Pro Asn Val Asp Ile Ile Lys Asp Leu Asp Ser Met 625 630 635 640 Ile Asp Ala Val Leu Lys Gly Asn Met Arg Ala Asp Ser Glu Ser Glu 645 650 655 Asn Pro Arg Asn Thr Gly Met Gln Gly Ala Leu Glu Arg Leu Asp His 660 665 670 Leu Ala Asp His Val Ser Lys Leu Asn Thr Thr Met Gly Ala Tyr His 675 680 685 Asn Thr Ile Glu Gly Val Asn Thr Arg Thr Ser Phe Leu Ser Val Asn 690 695 700 Val Gln Ser Ile Lys Ser Asn Val Ile Asp Val Asp Tyr Gly Glu Ala 705 710 715 720 Met Met Asn Leu Met Gln Val Gln Leu Ala Tyr Gln Ala Ser Leu Lys 725 730 735 Ala Ser Thr Thr Ile Ser Gln Leu Ser Leu Leu Asn Tyr Met 740 745 750 20865PRTCampylobacter jejuni 20Met Met Arg Ser Leu Trp Ser Gly Val Ser Gly Leu Gln Ala His Gln 1 5 10 15 Val Ala Met Asp Val Glu Gly Asn Asn Ile Ser Asn Val Asn Thr Thr 20 25 30 Gly Phe Lys Tyr Ser Arg Ala Asp Phe Gly Thr Met Phe Ser Gln Thr 35 40 45 Val Lys Ile Ala Thr Ala Pro Thr Asp Gly Arg Gly Gly Ser Asn Pro 50 55 60 Leu Gln Ile Gly Leu Gly Val Ser Val Ser Ser Thr Thr Arg Ile His 65 70 75 80 Ser Gln Gly Ser Val Gln Thr Thr Asp Lys Asn Thr Asp Val Ala Ile 85 90 95 Asn Gly Asp Gly Phe Phe Met Val Ser Asp Asp Gly Gly Leu Thr Asn 100 105 110 Tyr Leu Thr Arg Ser Gly Asp Phe Lys Leu Asp Ala Tyr Gly Asn Phe 115 120 125 Val Asn Asn Ala Gly Phe Val Val Gln Gly Trp Asn Ile Asn Trp Asp 130 135 140 Asp Gln Thr Ile Asp Ser Ser Arg Thr Pro Gln Asn Ile Phe Ile Asp 145 150 155 160 Pro Gly Met His Ile Pro Ala Ala Lys Ser Thr Glu Val Ala Ile Lys 165 170 175 Ala Asn Leu Asn Ser Gly Leu Asn Ile Gly Thr Ser Ser Arg Asn Leu 180 185 190 Tyr Ala Leu Asp Ser Val His Gly Trp Asn Thr Lys Thr Gln Arg Ala 195 200 205 Glu Asp Glu Asn Asp Thr Gly Thr Thr Gln Phe Tyr Thr Thr Ser Lys 210 215 220 Asn Ser Val Glu Val Thr Glu Lys Gly Val Asp Ala Gly Ser Leu Phe 225 230 235 240 Asn Ala Lys Gly Gln Gly Leu Asn Leu Arg Asp Gly Gln Gly Ile Trp 245 250 255 Val Ser Tyr Ala Asp Ala Thr Tyr Ser Thr Asn Lys Val Gly Val Asn 260 265 270 Ala Phe Asp Pro Asn Leu Gln Gln Asn Gln Thr Ala Ala Phe Trp Gly 275 280 285 Thr Ala Asn Gln Lys Val Asn Leu Asp Ile Thr Leu Asn Gly Val Arg 290 295 300 Ile Gln Asn Ala Asp Ile Gln Ser Ile Asp Asp Ala Ile Ala Tyr Ile 305 310 315 320 Asn Thr Phe Thr Ala Pro Thr Asp Thr Arg Asp Gly Thr Gly Val Lys 325 330 335 Ala Val Lys Asn Lys Asp Gly Ser Gly Ile Asp Phe Val Asn Asp Asn 340 345 350 Ala Asp Gly Thr Thr Asp Asn Met Lys Asn Ile Asn Leu Val Val Ala 355 360 365 Asn Thr Asn Thr Ala Gly Glu Leu Trp Asn Ala Val Trp Asn Asn Asn 370 375 380 Asn Gln Thr Phe Thr Phe Asn Asn Asn Gly Asn Gly Gln Ala Gly Thr 385 390 395 400 Pro Thr Ile Asn Lys Asn Gly Ser Ser Leu Trp Thr Ala Thr Asn Ile 405 410 415 Thr Phe Thr Pro Gln Pro Pro Gln Ala Ala Thr Asn Val Gln Leu Thr 420 425 430 Gly Gly Leu Asn Ala Gln Ile Ile Thr Ala His Lys Tyr Ile Tyr Ser 435 440 445 Ser Asn Pro Val Asp Ile Gly Pro Met Tyr Asn Pro Asp Gly Gly Pro 450 455 460 Ala Phe Gln Pro Gly Ala Asn Ala Thr Thr Arg Pro Thr Glu Pro Gly 465 470 475 480 Ser Ala Ala Tyr Trp Asp Ala Val Asn Gly Gly Leu Leu Asn Thr Asn 485 490 495 Val Arg Thr Phe Arg Thr Thr Glu Asp Leu Arg Glu Leu Leu Gln Arg 500 505 510 Asp Ala Arg Tyr Gly Val Asp Tyr Asp Gly Ser Gly Thr Phe Ala Ala 515 520 525 Ala Asp Ile Asn Gln Asn Ile Lys Val Val Val Thr Ala Asp Gly His 530 535 540 Phe Ala Ile Ser Asn Ala Asn Glu Gln Ser Thr Val Pro Pro Asn Ala 545 550 555 560 Ile Asn Gly Val Gly Asn Ala Thr Thr Thr Asp Pro Lys Asn Met Ser 565 570 575 Phe Asn Ile Thr Ala Tyr Ser Asn Lys Gln Gly Thr Val Ser Thr Asn 580 585 590 Asp Ala Phe Thr Ala Ile Phe Lys Ala Phe Asp Gly Pro Leu Val Ile 595 600 605 Gly Asn Gln Ile Lys Glu Ser Glu Gln Leu Lys Leu Ser Ala Phe Ser 610 615 620 Ala Gly Leu Glu Ile Tyr Asp Ser Leu Gly Ser Lys His Thr Leu Glu 625 630 635 640 Val Gln Phe Val Lys Gln Ser Thr Thr Gln Asp Gly Gly Asn Glu Trp 645 650 655 Gln Met Ile Ile Arg Val Pro Glu Pro Ala Glu Ile Asn Thr Thr Gly 660 665 670 Glu Gly Pro Asn Asn Ile Ile Val Gly Thr Ala Arg Phe Asn Asn Asp 675 680 685 Gly Ser Leu Ala Ser Tyr Thr Pro Arg Thr Ile Asn Phe Ser Pro Asn 690 695 700 Asn Gly Ala Ala Pro Asn Gln Gln Ile Lys Leu Ser Phe Gly Thr Ser 705 710 715 720 Gly Ser Asn Asp Gly Leu Val Ser Ser Asn Ser Ala Ser Thr Leu Thr 725 730 735 Gly Gln Ala Thr Asp Gly Tyr Thr Ser Gly Asn Leu Lys Pro Asp Ala 740 745 750 Ile Arg Val Asp Asp Lys Gly Asn Ile Leu Gly Glu Phe Thr Asn Gly 755 760 765 Lys Thr Phe Ala Val Ala Lys Ile Ala Met Ala Ser Val Ala Asn Asn 770 775 780 Ser Gly Leu Glu Glu Ile Gly Gly Asn Leu Phe Lys Val Thr Ala Asn 785 790 795 800 Ser Gly Asn Ile Val Val Gly Glu Ala Gly Thr Gly Gly Arg Gly Glu 805 810 815 Met Lys Thr Ser Ala Leu Glu Met Ser Asn Val Asp Leu Ser Arg Ser 820 825 830 Leu Thr Glu Leu Ile Ile Ile Gln Arg Gly Tyr Gln Ala Asn Ser Lys 835 840 845 Thr Ile Ser Thr Ser Asp Gln Met Leu Gln Thr Leu Ile Gln Leu Lys 850 855 860 Gln 865 21871PRTCampylobacter jejuni 21Met Ala Lys Ile Arg Ile His Glu Ile Ala Lys Glu Leu Gly Tyr Asp 1 5 10 15 Ser Lys Glu Ile Ile Glu Lys Ala Asn Glu Leu Gly Leu Gly Ile Lys 20 25 30 Thr Ala Ser Asn Ala Val Glu Pro Glu Ile Ala Ala Ala Ile Tyr Glu 35 40 45 Tyr Ile Gln Thr Arg Glu Ile Pro Glu Ala Phe Lys Lys Asn Ile Lys 50 55 60

Thr Pro Thr Ala Lys Lys Pro Lys Lys Glu Asn Ile Lys Glu Gln Glu 65 70 75 80 Lys Leu Asn Glu Ser Glu Lys Lys Glu Pro Lys Lys Glu Glu Lys Leu 85 90 95 Lys Gln Glu Val Lys Lys Glu Glu Leu Lys Ile Glu Lys Glu Asn Ala 100 105 110 Lys Glu Glu Glu Lys Gln Glu Ile Ile Asp Ala His Lys Pro Gln Ser 115 120 125 Leu Ala Ser Ala Thr Leu Ala Lys Arg Arg Gly Leu Val Ile Val Lys 130 135 140 Lys Lys Lys Asp Glu Glu Glu Ile Gln Val Lys Lys Glu Glu Val Lys 145 150 155 160 Asn Ser Asn Asp Ile Ser Ile Asn Asn Glu Glu Arg Leu Ser Leu Lys 165 170 175 Thr Met Phe Ser Asn Ala Asp Glu Ser Leu Lys Lys Lys Lys Lys Glu 180 185 190 Lys Lys Ser Phe Val Ala Ser Lys Lys Glu Ser Thr Glu Lys Met Asn 195 200 205 Phe Leu Asp Glu His Asp Phe Gly Asp Ile Ser Leu Asp Asp Glu Asp 210 215 220 Glu Val Val Leu Pro Asp Phe Ser Val Lys Glu Gln Glu Lys Pro Gln 225 230 235 240 Asn Ile Asn Lys Lys Gln Pro Asn Phe Ile Arg Gln Ala Val Gly Asn 245 250 255 Ser Ala Gly Phe Gly Phe Glu Gly Gly Ile Gln Arg Arg Ser Arg Lys 260 265 270 Lys Pro Ser Lys Lys Ile Glu Lys Lys Glu Val Glu Glu Val Gly Ser 275 280 285 Val Ala Ile Ser Lys Glu Ile Arg Val Tyr Glu Phe Ala Asp Lys Ile 290 295 300 Gly Lys Ser Thr Ser Glu Val Ile Ser Lys Leu Phe Met Leu Gly Met 305 310 315 320 Met Thr Thr Lys Asn Asp Phe Leu Asp Glu Asp Ala Ile Glu Ile Leu 325 330 335 Ala Ala Glu Phe Gly Ile Glu Ile Asn Ile Ile Asn Glu Ala Asp Glu 340 345 350 Phe Asp Tyr Val Lys Asp Tyr Glu Glu Glu Thr Asp Glu Lys Asp Leu 355 360 365 Val Thr Arg Ala Pro Val Ile Thr Ile Met Gly His Val Asp His Gly 370 375 380 Lys Thr Ser Leu Leu Asp Tyr Ile Arg Lys Ser Arg Val Ala Ser Gly 385 390 395 400 Glu Ala Gly Gly Ile Thr Gln His Val Gly Ala Tyr Met Val Glu Lys 405 410 415 Asn Gly Arg Lys Ile Thr Phe Ile Asp Thr Pro Gly His Glu Ala Phe 420 425 430 Thr Ala Met Arg Ala Arg Gly Ala Ser Ile Thr Asp Ile Val Ile Ile 435 440 445 Val Val Ala Ala Asp Asp Gly Val Lys Pro Gln Thr Lys Glu Ala Ile 450 455 460 Asn His Ala Lys Ala Ala Gly Val Pro Ile Ile Ile Ala Ile Asn Lys 465 470 475 480 Met Asp Lys Glu Ala Ala Asn Pro Asp Met Val Lys Thr Gln Leu Ala 485 490 495 Glu Met Glu Ile Met Pro Val Glu Trp Gly Gly Ser Tyr Glu Phe Val 500 505 510 Gly Val Ser Ala Lys Thr Gly Met Gly Ile Glu Asp Leu Leu Glu Ile 515 520 525 Val Leu Leu Gln Ala Asp Ile Leu Glu Leu Lys Ala Asn Pro Lys Ser 530 535 540 Phe Ala Lys Ala Ser Ile Ile Glu Ser Ser Val Gln Lys Gly Arg Gly 545 550 555 560 Ala Val Ala Thr Val Ile Val Gln Asn Gly Thr Leu Thr Val Gly Ser 565 570 575 Thr Val Val Ala Gly Glu Ala Tyr Gly Lys Val Arg Ala Met Ser Asp 580 585 590 Asp Gln Gly Lys Ala Leu Lys Glu Ile Lys Pro Gly Glu Cys Gly Val 595 600 605 Ile Val Gly Leu Ser Glu Val Ala Asp Ala Gly Glu Ile Leu Ile Ala 610 615 620 Val Lys Thr Asp Lys Glu Ala Arg Glu Tyr Ala Asn Lys Arg His Glu 625 630 635 640 Tyr Asn Arg Gln Lys Glu Leu Ser Lys Ser Thr Lys Val Ser Ile Asp 645 650 655 Glu Leu Gly Ala Lys Ile Lys Glu Gly Asn Leu Lys Ala Leu Pro Val 660 665 670 Ile Leu Lys Ala Asp Val Gln Gly Ser Leu Glu Ala Leu Lys Ala Ser 675 680 685 Leu Glu Lys Leu Arg Asn Asp Glu Ile Lys Val Asn Ile Ile His Ser 690 695 700 Gly Val Gly Gly Ile Thr Gln Ser Asp Ile Glu Leu Ala Ser Ala Ser 705 710 715 720 Glu Asn Ser Ile Val Leu Gly Phe Asn Ile Arg Pro Thr Gly Glu Val 725 730 735 Lys Glu Arg Ala Lys Asp Lys Gly Val Glu Ile Lys Thr Tyr Asn Val 740 745 750 Ile Tyr Asn Leu Leu Asp Asp Val Lys Ala Leu Leu Gly Gly Met Met 755 760 765 Ser Pro Ile Ile Ser Glu Glu Gln Leu Gly Gln Ala Glu Ile Arg Gln 770 775 780 Val Ile Asn Val Pro Lys Ile Gly Gln Ile Ala Gly Cys Met Val Thr 785 790 795 800 Glu Gly Val Ile Asn Arg Gly Ala Lys Ile Arg Leu Ile Arg Asp Gly 805 810 815 Val Val Val Tyr Glu Gly Asn Val Ser Ser Leu Lys Arg Phe Lys Asp 820 825 830 Asp Ala Lys Glu Val Ala Lys Gly Tyr Glu Cys Gly Val Gly Ile Glu 835 840 845 Gly Cys Asp Asp Met Arg Val Gly Asp Tyr Ile Glu Ser Tyr Lys Glu 850 855 860 Val Glu Glu Gln Ala Ser Leu 865 870 22946PRTCampylobacter jejuni 22Met Leu Ala Pro Gly Met Gly Glu Trp Val Tyr Lys Ala Asn Leu Phe 1 5 10 15 Leu Phe Gly Glu Phe Ala Tyr Tyr Tyr Pro Phe Phe Leu Phe Ile Leu 20 25 30 Asn Tyr Val Tyr Tyr Lys Arg Asn Tyr Lys Leu Ala Asn Phe Thr Arg 35 40 45 Arg Glu Leu Phe Gly Ile Gly Phe Ala Phe Phe Ser Ser Leu Leu Leu 50 55 60 Phe Ala Val Phe Tyr Pro Asn Ser Gly Tyr Ile Leu Glu Leu Ala Tyr 65 70 75 80 Ala Ile Phe Ser Thr Ile Leu Gly His Thr Gly Ser Gly Ile Phe Ala 85 90 95 Leu Leu Leu Leu Leu Phe Ser Leu Val Leu Leu Phe Pro Lys Phe Ala 100 105 110 Lys Glu Ile Leu Lys Ile Glu Leu Asp Phe Thr Tyr Leu Leu Lys Val 115 120 125 Glu Gln Ala Phe Lys Ser Leu Leu Met Arg Val Phe Gly Gly Glu Asn 130 135 140 Glu Lys Glu Asp Val Gly Lys Ser Glu Pro Ile Val Pro Lys Leu Asn 145 150 155 160 Ile Leu Gln Asp Ser Ile Tyr Gly Asn Leu Gln Ile Asn Lys Lys Gly 165 170 175 Glu Thr Asn Asn Leu Glu Gln Ile Ile Lys Asp Ser Asn Ile Asn Ala 180 185 190 Ser Lys Asn Ser Ile Thr Thr Ala Lys Glu Asn Phe Glu Lys Leu Lys 195 200 205 Asn Gln Ile Leu Asp Glu Thr Ile Glu Ile Asp Lys Gln Ser Leu Lys 210 215 220 Glu Ser Arg Ser Phe Val His Glu His Ser Gln Gln Val Arg Asn Phe 225 230 235 240 Ala Gln Lys Ala Ser Lys Met Ser Ile Ser Leu Asp Glu Asp Phe Asn 245 250 255 Phe Ile Ser Glu Glu Glu Val Asp Met Ile Pro Glu Arg Phe Leu Lys 260 265 270 Pro Lys Lys Leu Glu Asp Ile Lys Gln Ile Asp Thr Asn Lys Asn Leu 275 280 285 Asp Glu Pro Ser Tyr Lys Arg Lys Asn Ile Glu Ile Pro Val Ser Asn 290 295 300 Gln Glu Val Lys Pro Lys Ile Phe Thr Lys Glu Leu Glu Leu Arg Glu 305 310 315 320 Asn Leu Ile Lys Lys Glu Lys Leu Glu Gln Glu Tyr Lys Ala Tyr Gln 325 330 335 Asn Glu Ile Leu Glu Asn Lys Val Lys Gln Glu Ile Lys Lys Leu Glu 340 345 350 Glu Tyr Asp Ala Ile Asn Ser Ser Asp Ile Ile Glu Gly Asn Lys Tyr 355 360 365 Ser Phe Asn Ser Pro Lys Thr Ile Lys Thr Glu Thr Glu Glu Ser Asp 370 375 380 Lys Ile Asn Glu Asn Lys Asn Leu Asp Lys Ala Asp Asn Ile Phe Glu 385 390 395 400 Phe Ala Pro Ile Val Glu Glu Leu Asn His Pro Tyr Ile Glu Pro Thr 405 410 415 Pro Ile Lys Asn Ile Asn Glu Ile Val Ile Glu Glu Lys Asn Thr Leu 420 425 430 Asp Phe Ile Gln Asn Thr Glu Thr Lys Ile Asp Asn Glu Lys Thr Asn 435 440 445 Asp Gln Glu Ile Lys Leu Gln Lys Ala Val Leu Ala Lys Glu Ile Ala 450 455 460 Ile Asn Gln Ala Leu Leu Arg Glu Ile Glu Gln Gly Glu Ile Glu Lys 465 470 475 480 Pro Lys Asp Phe Thr Leu Pro Pro Leu Asp Phe Leu Ala Asn Pro Lys 485 490 495 Glu His Lys Gln Glu Ile Asn Glu Ser Glu Ile Asp Lys Lys Ile Tyr 500 505 510 Asn Leu Leu Glu Lys Leu Arg Arg Phe Lys Ile Gly Gly Asp Val Ile 515 520 525 Ser Thr Tyr Val Gly Pro Val Val Thr Thr Phe Glu Phe Arg Pro Ser 530 535 540 Ala Asp Val Lys Val Ser Arg Ile Leu Asn Leu Gln Asp Asp Leu Thr 545 550 555 560 Met Ala Leu Met Ala Lys Ser Ile Arg Ile Gln Ala Pro Ile Pro Gly 565 570 575 Lys Asp Val Val Gly Ile Glu Val Pro Asn Asp Glu Ile Gln Thr Ile 580 585 590 Tyr Leu Arg Glu Ile Leu Gln Ser Glu Val Phe Lys Asn Ala Lys Ser 595 600 605 Pro Leu Thr Ile Ala Leu Gly Lys Asp Ile Val Gly Asn Ala Phe Val 610 615 620 Thr Asp Leu Lys Lys Leu Pro His Leu Leu Ile Ala Gly Thr Thr Gly 625 630 635 640 Ser Gly Lys Ser Val Gly Ile Asn Ser Met Leu Leu Ser Leu Leu Tyr 645 650 655 Arg Asn Ser Pro Lys Thr Leu Arg Leu Met Met Ile Asp Pro Lys Met 660 665 670 Leu Glu Phe Ser Ile Tyr Asn Asp Ile Pro His Leu Leu Thr Pro Val 675 680 685 Ile Thr Asp Pro Lys Lys Ala Val Asn Ala Leu Ser Asn Met Val Ala 690 695 700 Glu Met Glu Arg Arg Tyr Arg Leu Met Ala Asp Ala Lys Thr Lys Asn 705 710 715 720 Ile Glu Asn Tyr Asn Glu Lys Met Lys Glu Leu Gly Gly Glu Lys Leu 725 730 735 Pro Phe Ile Val Val Ile Ile Asp Glu Leu Ala Asp Leu Met Met Thr 740 745 750 Ala Gly Lys Asp Val Glu Phe Tyr Ile Gly Arg Leu Ala Gln Met Ala 755 760 765 Arg Ala Ser Gly Ile His Leu Ile Val Ala Thr Gln Arg Pro Ser Val 770 775 780 Asp Val Val Thr Gly Leu Ile Lys Ala Asn Leu Pro Ser Arg Ile Ser 785 790 795 800 Tyr Lys Val Gly Gln Lys Ile Asp Ser Lys Val Ile Leu Asp Ala Met 805 810 815 Gly Ala Glu Ser Leu Leu Gly Arg Gly Asp Cys Leu Phe Thr Pro Pro 820 825 830 Gly Thr Ser Ser Ile Val Arg Leu His Ala Pro Phe Ala Ser Glu Phe 835 840 845 Glu Ile Glu Lys Ile Val Asp Phe Leu Lys Asp Gln Gln Ser Val Glu 850 855 860 Tyr Asp Glu Ser Phe Leu Lys Asp Gln Gln Ser Val Gly Val Thr Thr 865 870 875 880 Asn Glu Ser Phe Asp Gly Glu Ala Asp Glu Leu Tyr Glu Glu Ala Lys 885 890 895 Arg Val Ile Leu Glu Asp Gly Lys Thr Ser Ile Ser Tyr Leu Gln Arg 900 905 910 Arg Leu Lys Ile Gly Tyr Asn Arg Ser Ala Asn Ile Ile Glu Gln Leu 915 920 925 Thr Gln Asn Gly Ile Leu Ser Glu Pro Asp Ala Lys Gly Gln Arg Glu 930 935 940 Ile Leu 945 231041PRTCampylobacter jejuni 23Met Lys Lys Phe Phe Cys Leu Thr Leu Val Cys Lys Leu Phe Ala Leu 1 5 10 15 Ser Glu Phe Glu Leu His His Ile Asp Lys Val His Lys Leu Gly Tyr 20 25 30 Ser Gly Asp Thr Ile Ile Ile Gly Val Ala Asp Asp Ala Phe Asn Gln 35 40 45 Asp His Ile Ser Leu Lys Asp Lys Ile Leu Lys Ser Thr Tyr Pro Thr 50 55 60 Asp Thr Ala Gly Lys Gln Leu Ile Pro Asp Leu Lys Lys Ser Thr His 65 70 75 80 Gly Ser His Val Ala Gly Ile Ala Val Gly Ala Lys Ile Gly Asp Ser 85 90 95 Lys Pro Tyr Gly Val Ala Tyr Gly Ala Lys Phe Tyr Gly Ala Gly Val 100 105 110 Phe Pro Asn Gly Ser Tyr Thr Gln Ile Pro Asp Ile Tyr Asn Phe Phe 115 120 125 Lys Asp Val Ser Ile Ile Asn Asn Ser Trp Gly Ile Asn Phe Tyr Pro 130 135 140 Tyr Phe Asn Leu Lys Ala Ser Asn Ser Gly Leu Val Asp Cys Thr Gln 145 150 155 160 Thr Asn Gln Gly Thr Ser Tyr Asn Ile Cys Asn Thr Pro Leu Glu Tyr 165 170 175 Val Met Lys Ala Asp Lys Val Ala Asn Asp Met Met Arg Leu Ser Lys 180 185 190 Asp Lys Gly Val Leu Asn Val Phe Ala Ala Gly Asn Glu Gly Ile Leu 195 200 205 Ser Pro Ala Leu His Ala Ile Leu Pro Ser Tyr Asp Glu Ser Leu Arg 210 215 220 Ala Trp Leu Ala Val Gly Ala Leu Asp Ala Asn Glu Ile Thr Leu Glu 225 230 235 240 Ser Asp Gly Thr Leu Ile Ile Lys Ser Gln Gly Leu Ala Asp Phe Ser 245 250 255 Asn Gly Phe Lys Gly Ala Thr Asn Phe Ser Leu Val Ala Ala Gly Val 260 265 270 Asn Ile Asn Asn Val Asp Ser Ser Thr Asn Asp Lys Phe Thr Lys Lys 275 280 285 Ser Gly Thr Ser Met Ala Ala Pro Met Val Ser Gly Thr Ala Ala Leu 290 295 300 Val Lys Gln Asn Phe Pro Phe Leu Asp Gly Lys Gln Ile Ala Asp Ile 305 310 315 320 Leu Leu Ser Thr Ala Asn Lys Asn Tyr Lys Ala Pro Lys Phe Thr Val 325 330 335 Lys Gln Val Thr Asp Gly Thr Asn Gln Pro Lys Phe Leu Ile Val Tyr 340 345 350 Ile Ser Gln Asp Pro Pro Gly Ile Glu Asp Glu Ile Lys Arg Asp Leu 355 360 365 Lys Gln Leu Tyr Asn Gly Ile Gln Val Gln Val Asn Gly Gln Trp Ile 370 375 380 Asp Tyr Ser Asp Tyr Ile Trp Asp Asn Arg Asp Ser Ala Gln Ser Gln 385 390 395 400 Lys Leu Asn Thr Ser Thr Ile Ser Ser Ile Asn Gly Val Val Arg Val 405 410 415 Glu Lys Glu Glu Leu Phe Gly Gln Gly Ile Leu Asp Ala Gln Lys Ala 420 425 430 Leu Lys Gly Leu Ser Ile Leu Asp Ala Asn Arg Leu Ser Asp Gln Asp 435 440 445 Val Leu Lys Tyr Glu Gln Glu Pro Asn Thr Ala Tyr Tyr Thr Ile Asn 450 455 460 Thr Ala Gly Tyr Asp Ala Glu Phe Ser Asn Asp Ile Ser Gln Arg Lys 465 470 475 480 Trp Asp Glu Ser Thr His Leu Ser Ser Ala Ile Asn Lys Pro Thr His 485 490 495 Leu Ala Asn Leu Asn Ile Gly Leu Ser Lys Glu Gly Glu Gly Ile Leu 500 505 510 Ile Ile Ser Gly Gln Asn Thr Tyr Glu Gly Ala Thr Leu Ile Lys Gln 515 520 525 Gly Glu Leu Lys Leu Lys Gly Lys Val Lys Asn Asn Ala Tyr Val Glu 530 535 540 Gln Lys Ala Ile

Leu Ser Gly Asn Gly Ile Val Gly Gln Asn Leu Asn 545 550 555 560 Asn Lys Gly Ile Val Arg Pro Gly Asn Glu Asp Leu Asn Asp Leu Thr 565 570 575 Val Gln Gly Thr Tyr Thr Gln Glu Gly Val Asp Ser Lys Leu Gln Leu 580 585 590 Asp Phe Gly Asn Tyr Lys Asn Ser Lys Leu Ile Ala Lys Thr Tyr Asp 595 600 605 Ile Lys Ser Gly Asn Leu Glu Tyr Ile Pro Leu Pro Lys Tyr Tyr Ile 610 615 620 Leu Asn Lys Pro Val Lys Ile Asn Leu Gly Asp Leu Glu Lys Ser Leu 625 630 635 640 Ser Ser Phe Asn His Val Leu Ile Gln Asn Thr Tyr Ala Leu Asn Phe 645 650 655 Asp Phe Val Leu Ser Asp Asp Leu Val Ser Ile Asn Lys Thr Leu Ile 660 665 670 Lys Pro Asn Leu Lys Pro Asn Ala Tyr Glu Ile Pro Asn Thr Ser Leu 675 680 685 Gly Asn Ala Leu Arg Gln Leu Arg Ser Arg Ala Asp Leu Ser Gln Thr 690 695 700 Tyr Gln Glu Phe Phe Ala Ser Leu Asp Asn Gly Ile Asp Val Lys Thr 705 710 715 720 Lys Leu Asn Arg Ile Glu Gly Ser Gly Tyr Leu Ser Thr Phe Ser Asn 725 730 735 His Asn Gln Ser Asn Leu Met Gln Asn Asn Met Leu Phe Thr Leu His 740 745 750 Pro Leu Asn Ile Asn Asn Phe Ala Gln Asn Asn Asn Ile Leu Leu Ala 755 760 765 Ser Thr Tyr Leu Pro Arg Ile Phe Ser Asn Glu Glu Tyr Phe Trp His 770 775 780 Leu Thr Pro Ser Tyr Lys Tyr Tyr Lys Asp Lys Asp Phe Ser Gly Gln 785 790 795 800 Lys Thr Gly Ala Asn Ile Ser Leu Gly Glu Asn Phe Ser Ser Gly Phe 805 810 815 Leu Ala Tyr Ala Leu Ser Leu Ser Ser Ala Lys Phe Asn Phe Asn Asn 820 825 830 Gly Ser Asp Leu Lys Ser Tyr Asn Met Asp Leu Leu Leu Asn Tyr Asn 835 840 845 His Asp Leu Asp Phe Ile Lys Ile Leu Ser Gly Leu Gly Ile Gly Val 850 855 860 Gly Phe Asn Thr Leu Asn Arg Phe Val Val Glu Gln Pro Ile Glu Gly 865 870 875 880 Lys Tyr Lys Thr Leu Gln Thr Ser Ala Gln Leu Gly Val Thr Lys Asp 885 890 895 Ile Ile Leu Gly Gln Asp Phe Ile Phe Asn Pro Leu Met Tyr Phe Thr 900 905 910 His Ser Phe Phe Tyr Gln Glu Asp Phe Lys Glu Asn Lys Ser Pro Phe 915 920 925 Ala Lys Asn Tyr Glu Ser Leu Lys His His Ser Ile Asn Ala Asn Leu 930 935 940 Gly Phe Asn Leu Ala Lys Asn Ile Glu Gln Asp Asp Tyr Gln Ala Ser 945 950 955 960 Phe Ser Thr Phe Val Ile Phe Glu Lys Arg Ile Tyr Gly Arg Thr Leu 965 970 975 Glu Asn Lys Ala Ser Phe Val Asp Phe Pro Ile Ala Phe Ile Gln Lys 980 985 990 Tyr Lys Leu Lys Asp Asn Ile Leu Ser Gln Gly Phe Asn Ser Glu Phe 995 1000 1005 Leu Tyr Lys Asn Asn Val Phe Trp Gln Phe Met Leu Met Asn Arg 1010 1015 1020 Phe Ser His Asn Ala Tyr Glu Leu His Leu Met Ser Ser Val Gly 1025 1030 1035 Lys Arg Phe 1040 241089PRTCampylobacter jejuni 24Met Pro Lys Arg Thr Asp Ile Lys Ser Ile Leu Leu Ile Gly Ser Gly 1 5 10 15 Pro Ile Val Ile Gly Gln Ala Cys Glu Phe Asp Tyr Ser Gly Thr Gln 20 25 30 Ala Ala Lys Thr Leu Lys Glu Leu Gly Tyr Arg Val Val Leu Ile Asn 35 40 45 Ser Asn Pro Ala Thr Ile Met Thr Asp Pro Glu Phe Ala Asp Ala Thr 50 55 60 Tyr Ile Glu Pro Ile Thr Lys Glu Ser Ile Leu Ser Ile Ile Lys Lys 65 70 75 80 Glu Lys Ile Asp Ala Ile Leu Pro Thr Met Gly Gly Gln Val Ala Leu 85 90 95 Asn Val Ala Met Glu Val Tyr Glu Ser Gly Leu Leu Gly Asp Val Lys 100 105 110 Phe Leu Gly Ala Asn Pro Glu Ala Ile Lys Lys Gly Glu Asp Arg Gln 115 120 125 Val Phe Lys Glu Cys Met Lys Lys Ile Gly Met Asp Leu Pro Lys Ser 130 135 140 Met Tyr Ala Tyr Asn Tyr Asp Glu Ala Leu Lys Ala Val Asp Glu Ile 145 150 155 160 Asp Phe Pro Leu Met Ile Arg Ala Ser Tyr Thr Leu Gly Gly Ala Gly 165 170 175 Ser Gly Val Val Tyr Asn Met Asp Glu Phe Lys Glu Leu Thr Asn Thr 180 185 190 Ala Leu Ala Leu Ser Pro Ile His Glu Ile Leu Ile Glu Glu Ser Leu 195 200 205 Leu Gly Trp Lys Glu Tyr Glu Met Glu Val Ile Arg Asp Arg Ala Asp 210 215 220 Asn Cys Ile Ile Val Cys Ser Ile Glu Asn Ile Asp Pro Met Gly Val 225 230 235 240 His Thr Gly Asp Ser Ile Thr Ile Ala Pro Ala Leu Thr Leu Thr Asp 245 250 255 Lys Glu Tyr Gln Val Met Arg Asn Ala Ser Phe Ala Ile Leu Arg Glu 260 265 270 Ile Gly Val Asp Thr Gly Gly Ser Asn Val Gln Phe Ala Ile Asn Pro 275 280 285 Lys Asn Gly Arg Met Ile Val Ile Glu Met Asn Pro Arg Val Ser Arg 290 295 300 Ser Ser Ala Leu Ala Ser Lys Ala Thr Gly Tyr Pro Ile Ala Lys Val 305 310 315 320 Ala Thr Leu Leu Ala Val Gly Phe Ser Leu Asp Glu Ile Lys Asn Asp 325 330 335 Ile Thr Gly Thr Pro Ala Ser Phe Glu Pro Val Ile Asp Tyr Ile Val 340 345 350 Thr Lys Ile Pro Arg Phe Thr Phe Glu Lys Phe Pro Gly Ala Asn Thr 355 360 365 Thr Leu Gly Thr Ala Met Lys Ser Val Gly Glu Val Met Ala Ile Gly 370 375 380 Arg Thr Phe Lys Glu Ser Ile Gln Lys Ala Leu Cys Ser Leu Glu Arg 385 390 395 400 Ser Leu Ser Gly Phe Asp Arg Val Lys Phe Glu Asp Arg Asn Asp Leu 405 410 415 Val Phe Lys Ile Arg Asn Ala Asn Glu Lys Arg Leu Leu Tyr Val Ala 420 425 430 Gln Ala Phe Arg Glu Gly Phe Ser Val Glu Glu Leu Tyr Glu Leu Cys 435 440 445 Lys Ile Asp Pro Trp Phe Leu Thr Gln Ile Lys Glu Ile Val Asp Phe 450 455 460 Glu Glu Gln Ile Asp Met Asp Ile Leu Asn Asn Lys Ala Leu Leu Arg 465 470 475 480 Lys Ala Lys Thr Met Gly Phe Ser Asp Lys Met Ile Ala Leu Leu Val 485 490 495 Asn Leu Lys Asp Asn Leu Glu Leu Ser Gln Asn Asp Ile Tyr Tyr Val 500 505 510 Arg Met Lys Gln Lys Ile Ile Ala Glu Phe Ser Glu Val Asp Thr Cys 515 520 525 Ala Gly Glu Phe Glu Ala Leu Thr Pro Tyr Leu Tyr Ser Ser Ile Asn 530 535 540 Val Ser Glu Leu Thr Gln Ser Lys Asn Asp Ala Lys Asp Lys Lys Glu 545 550 555 560 Lys Lys Val Met Ile Ile Gly Gly Gly Pro Asn Arg Ile Gly Gln Gly 565 570 575 Ile Glu Phe Asp Tyr Ala Cys Val His Ala Ser Phe Ala Leu Lys Asp 580 585 590 Met Gly Ile Lys Thr Ile Met Tyr Asn Cys Asn Pro Glu Thr Val Ser 595 600 605 Thr Asp Tyr Asp Thr Ser Asp Ile Leu Tyr Phe Glu Pro Ile Asp Phe 610 615 620 Glu His Leu Arg Ala Val Ile Glu Arg Glu Lys Pro Asp Gly Val Ile 625 630 635 640 Val His Phe Gly Gly Gln Thr Pro Leu Lys Phe Ala Lys Arg Leu Ser 645 650 655 Ala Phe Gly Ala Lys Ile Ile Gly Thr Ser Ala Arg Val Ile Asp Met 660 665 670 Ala Glu Asp Arg Lys Lys Phe Ala Glu Phe Ile Thr Lys Leu Gly Ile 675 680 685 Asn Gln Pro Lys Asn Ser Thr Ala Thr Ser Val Glu Glu Ala Val Leu 690 695 700 Lys Ala Ser Asp Ile Gly Tyr Pro Val Leu Val Arg Pro Ser Tyr Val 705 710 715 720 Leu Gly Gly Arg Ala Met Arg Val Val Asn Asp Glu Ala Glu Leu Arg 725 730 735 Leu Tyr Met Gln Glu Ala Val Asp Val Ser Asp Lys Ser Pro Val Leu 740 745 750 Ile Asp Gln Phe Leu Asp Asn Ala Thr Glu Ile Asp Val Asp Ala Ile 755 760 765 Cys Asp Gly Lys Asp Val Tyr Val Ala Gly Ile Met Glu His Ile Glu 770 775 780 Glu Ala Gly Ile His Ser Gly Asp Ser Ala Cys Ser Leu Pro Pro Cys 785 790 795 800 Asn Ile Asp Glu Lys Met Gln Glu Phe Ile Ala Gln Lys Thr Ala Asp 805 810 815 Ile Ala Leu Asn Leu Gly Val Val Gly Leu Leu Asn Ile Gln Phe Ala 820 825 830 Leu His Asn Asn Glu Leu Tyr Met Ile Glu Val Asn Pro Arg Ala Ser 835 840 845 Arg Thr Ile Pro Phe Val Ser Lys Ala Thr Gly Ile Pro Leu Ala Lys 850 855 860 Val Ala Thr Arg Val Met Trp Gln Gly Asn Leu Lys Glu Ala Leu Lys 865 870 875 880 Phe Tyr Asp Thr Phe Lys Val Val Asn Phe Asp Thr Lys Ile Leu Arg 885 890 895 Pro Lys Thr Pro Lys Tyr Met Ser Val Lys Glu Ala Val Phe Pro Phe 900 905 910 Ala Lys Leu Ser Gly Ser Asp Leu Glu Leu Gly Pro Glu Met Arg Ser 915 920 925 Thr Gly Glu Val Met Gly Ile Ser Lys Asp Phe Ala Asn Ser Tyr Ala 930 935 940 Lys Ser Gln Ile Ala Ser Phe Asn His Leu Pro Glu Gln Gly Val Val 945 950 955 960 Phe Ile Ser Leu Lys Asp Lys Asp Lys Lys Tyr Thr Lys Lys Ile Ala 965 970 975 Ala Glu Tyr Val Lys Leu Gly Phe Lys Leu Met Ala Thr Gly Gly Thr 980 985 990 Cys Lys Glu Ile Leu Glu Ser Gly Phe Glu Cys Glu Leu Val His Lys 995 1000 1005 Ile Ser Glu Gly Arg Pro Asn Val Glu Asp Lys Leu Lys Asn Gly 1010 1015 1020 Glu Ile His Leu Val Ile Asn Thr Ser Asp Ser His Ser Phe Lys 1025 1030 1035 Gly Asp Thr Lys Lys Ile Arg Glu Asn Ile Ile Arg Phe Lys Ile 1040 1045 1050 Pro Tyr Phe Thr Asn Leu Arg Ser Ala Leu Ala Gly Ala Lys Ser 1055 1060 1065 Ile Lys Ala Ile Gln Ser Lys Ser Cys Leu Asp Val Lys Ser Leu 1070 1075 1080 Gln Glu Trp Leu Lys Ser 1085 251120PRTCampylobacter jejuni 25Met Lys Asn Ile Thr Leu Thr Lys Ile Pro Ile Gly Glu Gly Lys Glu 1 5 10 15 Pro Cys Leu Asn Ser Lys Lys Ile Val Leu Ser Leu Ala Thr Ile Ser 20 25 30 Phe Leu Ala Ser Cys Ala Asn Ala Lys Leu Asn Ser Glu Ile Lys Thr 35 40 45 Tyr Asp Glu Val Asn Lys Asn Val Lys Thr Arg Ser Ala Ser Val Tyr 50 55 60 Ser Pro Gln Ala Lys Ile Asn Thr Thr Ile Asn Ser Leu His Asn Gln 65 70 75 80 Gln Val Thr Ile Thr Gly Asn Gly Thr Ser Asn Ser Leu Thr Ile Gly 85 90 95 Ser Ser Gly Thr Leu Gly Ser Ile Gly Asn Thr Gly Lys Ile Ile Tyr 100 105 110 Ala His Ala Asn Gly Ser Asn Thr Leu Thr Leu Ala Asn Leu Thr Asn 115 120 125 Asn Arg Thr Ile Asn Gly Lys Ile Gly Ile Glu Asn Asn Gly Asn Phe 130 135 140 Thr Gly Thr Ile Ala Val Asn Thr Phe Glu Asn Thr Gly Gln Ile Asn 145 150 155 160 Gly Gln Ile Tyr Met Gly Ile Trp Gly Asn Asn Ser Gly Thr Leu Asn 165 170 175 Ile Asp Lys Phe Asp Asn Ser Gly Thr Ile Ile Asp Asn Asn Lys Gly 180 185 190 Val Phe Glu Gly Lys Asn Thr Asn Ile Gln Thr Phe Asn Asn Ser Gly 195 200 205 Phe Ile Ser Ala Asn Lys Gly Val Asp Ile Gly Asn Ile Gly Thr Ile 210 215 220 Lys Asn Phe Asn Asn Asn Gly Thr Ile Gln Gly Ser Glu Val Gly Val 225 230 235 240 Ala Ile Asn Thr Lys Ile Asp Thr Phe Thr Asn Asn Gly Phe Ile Asn 245 250 255 Ser Pro Gly Ser Gly Gln Trp Asn Asn Gly Ile Trp Ile Ser Ser Asn 260 265 270 Ala Thr Ile Glu Lys Leu Val Asn Asn Gly Thr Ile Lys Gly Gly His 275 280 285 Ser Ala Ile Met Val Thr Ser Gln His Ile Lys Thr Val Glu Asn Thr 290 295 300 Gly Ile Ile His Ala Glu Gly Glu Trp Gly Ser Ser Ile Leu Leu Glu 305 310 315 320 Tyr Gly Gly Phe Ile Glu His Ile Ile Asn Thr Gly Thr Ile Ser Asn 325 330 335 Asn Asn Val Gly Ile Gly Ser Ala Tyr Gly Val Phe Gly Thr Leu Thr 340 345 350 Ile Lys Asp Gly Gly Met Val Tyr Gly Lys Tyr Ser Ala Ile Gly Val 355 360 365 Gly Arg Ser Gln Thr Leu Gly Asp Leu Tyr Ile Asp Gly Arg Ser Asn 370 375 380 Asn Gly Thr Val Ser Gly Ile Tyr Ser Glu Glu His Gly Ile Leu Leu 385 390 395 400 Glu Asn Asn Ser Arg Thr Gln Lys Ile Glu Leu Lys Asn Gly Gly Ile 405 410 415 Ile Lys Gly Asn Ile Asp Gly Ile Arg Leu Ile Asn Ser Ala Ser Leu 420 425 430 Ser Gly Glu Met Ile Leu Ser Gly Glu Gly Ser Arg Val Glu Gly Gly 435 440 445 Arg Gly Val Gly Ile Leu Asn Arg Ser Gly Lys Ile Glu Gly Ser Ile 450 455 460 Lys Val Glu Asp Gly Ala Thr Val Thr Ala Thr Ser Asn Arg Ala Ile 465 470 475 480 Ala Asn Ser Gly Ser Gly Ser Ile Thr Gly Gly Ile Thr Val Ser Gly 485 490 495 Lys Asn Thr Lys Leu Glu Gly Asn Ile Ile Asn Thr Gly Asn Ala Ser 500 505 510 Ile Gly Ser Asp Ile Lys Ile Glu Gly Gly Ala Lys Val Glu Gly Gly 515 520 525 Leu Val Asn Gln Gly Asn Gly Ser Ile Ser Gly Ser Val Gln Val Ser 530 535 540 Gly Gly Ser Ser Ile Asp Ser Ile Thr Asn Glu Gly Asn Gly Ala Ile 545 550 555 560 Ser Gly Ser Ile Thr Val Tyr Lys Asp Ser Lys Leu Asp Ser Ile Thr 565 570 575 Asn Thr Ser Thr Ser Ser Thr Gly Ile Ser Gly Ser Ile Thr Asn Asn 580 585 590 Ser Asp Asn Lys Leu Glu Ile Ser Asn Ser Gly Asn Ile Gly Gly Lys 595 600 605 Ile Glu Ser Thr Gly Ser Ala Asp Met Val Ile Ser Asn Ser Asn Gly 610 615 620 Gly Thr Ile Ser Gly Gly Ile Ser Ser Ser Gly Ser Gly Ser Thr Ser 625 630 635 640 Ile Ser Asn Ser Gln Gly Ser Thr Ile Asn Asn Gly Ile Thr Val Ser 645 650 655 Gly Ser Ala Gln Val Glu Ile Ser Asn Gln Gly Ser Val Gly Lys Asp 660 665 670 Glu Asn Gly Asn Thr Val Thr Asn Asn Gly Ser Gly Ser Val Gly Ile 675 680 685 Lys Asp Trp Leu Val Ser Thr Asp Lys Asn Thr Gly Lys Leu Asn Thr 690 695 700 Val Val Ile Gly Gly

Ser Arg Ala Phe Asn Val Lys Val Glu Asn Ile 705 710 715 720 Thr Val Asp Gln Ser Asn Val Asp Leu Glu Glu Leu Asn Asp Ile Asn 725 730 735 Asn Ile Ile Ser Gly Val Asn Gln Asn Asn Ile Gly Asn Ile Gly Thr 740 745 750 Asn Gly Ser Gly Glu Ile Ser Leu Ser Phe Asp Pro Ile Thr Gly Lys 755 760 765 Leu Thr Thr Asp Phe Asn Leu Asn Ala Ser Ile Ser Gly Ala Thr Phe 770 775 780 Arg Ser Leu Ile Ser Thr Thr Ser Arg Arg Ser Thr Phe Ile Asp Asn 785 790 795 800 Val Met Gly Asn Ser Met Gln Ser Phe Ala Leu Ala Ser Ser Ser Lys 805 810 815 Ser Gln Ser Ile Ala Met Ser Glu Lys Gly Asn Leu Tyr Ala Asp Ala 820 825 830 Ser Asp Tyr Ile Lys Ser Asp Leu Asn Asn Gly Ser Tyr Gly Ser Asn 835 840 845 Lys Glu His Ser Leu Phe Ile Leu Pro Tyr Thr Ser Ser Gln Asn Val 850 855 860 Glu Leu Ser Leu Asn Glu Glu Ser Lys Gly His Thr Lys Gly Thr Ile 865 870 875 880 Ile Gly Tyr Ser Thr Leu Lys Asp Ser Gly Ile Tyr Gly Val Tyr Ala 885 890 895 Gly Tyr Glu Asp Thr Lys Met Gly Ser Thr Tyr Phe Asp Ile Asn Asn 900 905 910 Arg Thr Tyr Tyr Ala Gly Leu Lys Tyr Phe Asn Thr Leu Phe Thr Thr 915 920 925 Glu Lys Gly Gln Glu Val Tyr Ile Lys Ala Gln Gly Lys Ala Ala Leu 930 935 940 Ile Lys Asn Asp Leu Thr Glu Lys Ile Gly Asn Asn Glu Ala Lys Ala 945 950 955 960 Glu Pro Asn Ser Tyr Ala Tyr Gly Val Asn Thr Ala Leu Gly Met Asn 965 970 975 Phe Ile Ser Asn Lys Asp Ile Phe Ser Pro Glu Ile Gly Leu Ala Tyr 980 985 990 Glu Gly Gly Tyr Thr Glu Ala Phe Ser Met Lys Asp Thr Ile Gly Gln 995 1000 1005 Ala Thr Val Lys Gly Gly Glu Arg Thr Tyr Ala Asn Tyr Leu Asn 1010 1015 1020 Leu Phe Ser Thr Lys Thr Ser Leu Thr Trp Phe Arg Asp Trp Leu 1025 1030 1035 Pro Asn Leu Lys Thr Ser Val Glu Leu Gly Ala Lys Phe Asn Ile 1040 1045 1050 Asn Pro Lys Val Glu Ala Glu Ala Arg Phe Gly Asn Ile Lys Val 1055 1060 1065 Ser Asp Glu Phe Asp Leu Pro Arg Val Gln Lys Phe Val Ser Thr 1070 1075 1080 Ser Phe Ile Val Pro Val Asn Glu Ala Phe Tyr Phe Ser Leu Asn 1085 1090 1095 Tyr Asn Gly Met Phe Asp Lys Asp Gly Asn Thr His Thr Gly Phe 1100 1105 1110 Ala Gln Phe Asn Tyr Leu Trp 1115 1120 261144PRTCampylobacter jejuni 26Met Asn Lys Thr Ala Leu Thr Lys Thr Tyr Thr Lys Asp Ile Gln Asn 1 5 10 15 Ser Cys Leu Asn Ser Lys Lys Ile Val Leu Ser Leu Ala Thr Ile Ser 20 25 30 Phe Leu Ala Ser Cys Thr His Ala Thr Leu Thr Pro Glu Ile Lys Thr 35 40 45 Tyr Glu Glu Thr Asn Arg His Ala Lys Ala Arg Ser Gly Leu Gln Ser 50 55 60 Arg Asn Ser Asn Asn Glu Thr Ile Asn Asn Leu Gln Thr Leu Thr Lys 65 70 75 80 Thr Ile Ser Asp Thr Gly Asn Thr Leu Val Ile Glu Ser Ser Gly Thr 85 90 95 Ile Thr Ile Ser Asn Asp Gly Gln Gln Ala Val Asn Phe Gln Pro Asn 100 105 110 Ser Ser Thr Ser Thr Phe Leu Asn Lys Gly Thr Leu Ile Gly Gly Asn 115 120 125 Asn Thr Ala Ser Val Gln Leu Gly Ala Ala Asn Gly Asn Asn Gly Val 130 135 140 Ser Ile Glu Thr Phe Asn Asn Gln Gly Ile Ile Gly Asn Gly Ser Ser 145 150 155 160 Lys Phe Gly Val Thr Val Phe Gly Gly Gly Ser Lys Asp Asn Pro Lys 165 170 175 Ser Ile Ile Asn Asn Phe Ser Asn Ser Gly Thr Ile His Ser Asn Thr 180 185 190 Gly Glu Ser Ile Tyr Phe Gly Asn Ala Lys Ile Ser Ser Phe Val Asn 195 200 205 Ser Gly Thr Ile Lys Ser Lys Gln Gly Ala Gly Val Asn Ile Ser Gln 210 215 220 Gly Thr Ser Ile Glu Asn Phe Asn Asn Thr Gly Thr Gly Ile Ile Glu 225 230 235 240 Gly Lys Arg Met Gly Val Asn Val Arg Ser Thr Ile Asn Thr Phe Val 245 250 255 Asn Asp Gly Leu Ile Ala Ala Thr Asn Asp Gly Ile Gln Ile Asn Ala 260 265 270 Asn Val Lys Thr Leu Ile Asn Lys Gly Thr Ile Lys Gly Asp Ala Ile 275 280 285 Ser Ile Arg Ser Leu Gly Gly Thr Ile Glu Thr Leu Thr Asn Glu Gly 290 295 300 Ile Met Tyr Gly Lys Ser Ala Gly Ile Tyr Met Asn Arg Ser Leu Val 305 310 315 320 Lys Thr Leu Thr Asn Ser Gly Thr Ile Asn Gln Asn Asn Ser Ala Thr 325 330 335 Trp Ser Ala Gly Ile Lys Leu Glu Asn Gly Ser Ile Ile Glu Asn Ile 340 345 350 Ile Asn Thr Gly Ser Ile Arg Ser Asn Ala Phe Gly Ile Ser Val Thr 355 360 365 Gly Gly Lys Phe Gly Thr Leu Thr Ile Lys Asp Gly Gly Met Val Tyr 370 375 380 Gly Lys Tyr Ser Ala Ile Gly Val Gly Arg Ser Gln Thr Leu Gly Asp 385 390 395 400 Leu Tyr Ile Asp Gly Arg Ser Asn Asn Gly Thr Val Ser Gly Ile Tyr 405 410 415 Ser Glu Glu His Gly Ile Leu Leu Glu Asn Asn Ser Arg Thr Gln Lys 420 425 430 Ile Glu Leu Lys Asn Gly Gly Ile Ile Lys Gly Asn Ile Asp Gly Ile 435 440 445 Arg Leu Ile Asn Ser Ala Ser Leu Ser Gly Glu Met Ile Leu Ser Gly 450 455 460 Glu Gly Ser Arg Val Glu Gly Gly Arg Gly Val Gly Ile Leu Asn Arg 465 470 475 480 Ser Gly Lys Ile Glu Gly Ser Ile Lys Val Glu Asp Gly Ala Thr Val 485 490 495 Thr Ala Thr Ser Asn Arg Ala Ile Ala Asn Ser Gly Ser Gly Ser Ile 500 505 510 Thr Gly Gly Ile Thr Val Ser Gly Lys Asn Thr Lys Leu Glu Gly Asn 515 520 525 Ile Ile Asn Thr Gly Asn Ala Ser Ile Gly Ser Asp Ile Lys Ile Glu 530 535 540 Gly Gly Ala Lys Val Glu Gly Gly Leu Val Asn Gln Gly Asn Gly Ser 545 550 555 560 Ile Ser Gly Ser Val Gln Val Ser Gly Gly Ser Ser Ile Asp Ser Ile 565 570 575 Thr Asn Glu Gly Asn Gly Ala Ile Ser Gly Ser Ile Thr Val Tyr Lys 580 585 590 Asp Ser Lys Leu Asp Ser Ile Thr Asn Thr Ser Thr Ser Ser Thr Gly 595 600 605 Ile Ser Gly Ser Ile Thr Asn Asn Ser Asp Asn Lys Leu Glu Ile Ser 610 615 620 Asn Ser Gly Asn Ile Gly Gly Lys Ile Glu Ser Thr Gly Ser Ala Asp 625 630 635 640 Met Val Ile Ser Asn Ser Asn Gly Gly Thr Ile Ser Gly Gly Ile Ser 645 650 655 Ser Ser Gly Ser Gly Ser Thr Ser Ile Ser Asn Ser Gln Gly Ser Thr 660 665 670 Ile Asn Asn Gly Ile Thr Val Ser Gly Ser Ala Gln Val Glu Ile Ser 675 680 685 Asn Gln Gly Ser Val Gly Lys Asp Glu Asn Gly Asn Thr Val Thr Asn 690 695 700 Asn Gly Ser Gly Ser Val Gly Ile Lys Asp Trp Leu Val Ser Thr Asp 705 710 715 720 Lys Asn Thr Gly Lys Leu Asn Thr Val Val Ile Gly Gly Ser Arg Ala 725 730 735 Phe Asn Val Lys Val Glu Asn Ile Thr Val Asp Gln Ser Asn Val Asp 740 745 750 Leu Glu Glu Leu Asn Asp Ile Asn Asn Ile Ile Ser Gly Val Asn Gln 755 760 765 Asn Asn Ile Gly Asn Ile Gly Thr Asn Gly Ser Gly Glu Ile Ser Leu 770 775 780 Ser Phe Asp Pro Ile Thr Gly Lys Leu Thr Thr Asp Phe Asn Leu Asn 785 790 795 800 Ala Ser Ile Ser Gly Ala Thr Phe Arg Ser Leu Ile Ser Thr Thr Ser 805 810 815 Arg Arg Ser Thr Phe Ile Asp Asn Val Met Gly Asn Ser Met Gln Ser 820 825 830 Phe Ala Leu Ala Ser Ser Ser Lys Ser Gln Ser Ile Ala Met Ser Glu 835 840 845 Lys Gly Asn Leu Tyr Ala Asp Ala Ser Asp Tyr Ile Lys Ser Asp Leu 850 855 860 Asn Asn Gly Ser Tyr Gly Ser Asn Lys Glu His Ser Leu Phe Ile Leu 865 870 875 880 Pro Tyr Thr Ser Ser Gln Asn Val Glu Leu Ser Leu Asn Glu Glu Ser 885 890 895 Lys Gly His Thr Lys Gly Thr Ile Ile Gly Tyr Ser Thr Leu Lys Asp 900 905 910 Ser Gly Ile Tyr Gly Val Tyr Ala Gly Tyr Glu Asp Thr Lys Met Gly 915 920 925 Ser Thr Tyr Phe Asp Ile Asn Asn Arg Thr Tyr Tyr Ala Gly Leu Lys 930 935 940 Tyr Phe Asn Thr Leu Phe Thr Thr Glu Lys Gly Gln Glu Val Tyr Ile 945 950 955 960 Lys Ala Gln Gly Lys Ala Ala Leu Ile Lys Asn Asp Leu Thr Glu Lys 965 970 975 Ile Gly Asn Asn Glu Ala Lys Ala Glu Pro Asn Ser Tyr Ala Tyr Gly 980 985 990 Val Asn Thr Ala Leu Gly Met Asn Phe Ile Ser Asn Lys Asp Ile Phe 995 1000 1005 Ser Pro Glu Ile Gly Leu Ala Tyr Glu Gly Gly Tyr Thr Glu Ala 1010 1015 1020 Phe Ser Met Lys Asp Thr Ile Gly Gln Ala Thr Val Lys Gly Gly 1025 1030 1035 Glu Arg Thr Tyr Ala Asn Tyr Leu Asn Leu Phe Ser Thr Lys Thr 1040 1045 1050 Ser Leu Thr Trp Phe Arg Asp Trp Leu Pro Asn Leu Lys Thr Ser 1055 1060 1065 Val Glu Leu Gly Ala Lys Phe Asn Ile Asn Pro Lys Val Glu Ala 1070 1075 1080 Glu Ala Arg Phe Gly Asn Ile Lys Val Ser Asp Glu Phe Asp Leu 1085 1090 1095 Pro Arg Val Gln Lys Phe Val Ser Thr Ser Phe Ile Val Pro Val 1100 1105 1110 Asn Glu Ala Phe Tyr Phe Ser Leu Asn Tyr Asn Gly Met Phe Asp 1115 1120 1125 Lys Asp Gly Asn Thr His Thr Gly Phe Ala Gln Phe Asn Tyr Leu 1130 1135 1140 Trp 271186PRTCampylobacter jejuni 27Met Gly Lys Ile Met Lys Thr Met Asp Gly Asn Glu Ala Ala Ala Tyr 1 5 10 15 Ala Ala Tyr Ala Phe Thr Glu Val Ala Gly Ile Tyr Pro Ile Thr Pro 20 25 30 Ser Ser Pro Met Ala Asp Tyr Thr Asp Met Trp Ala Ala Ala Gly Lys 35 40 45 Lys Asn Leu Phe Gly Val Pro Val Lys Ile Val Glu Met Gln Ser Glu 50 55 60 Ala Gly Ala Ala Gly Ser Val His Gly Ser Leu Gln Ala Gly Ala Leu 65 70 75 80 Thr Thr Thr Tyr Thr Ala Ser Gln Gly Leu Leu Leu Lys Ile Pro Asn 85 90 95 Met Tyr Lys Ile Ala Gly Gln Leu Leu Pro Cys Val Ile His Val Ala 100 105 110 Ala Arg Ser Leu Ala Ala Gln Ala Leu Ser Ile Phe Gly Asp His Gln 115 120 125 Asp Ile Tyr Ala Ala Arg Gln Ile Gly Phe Ala Met Leu Cys Ser His 130 135 140 Ser Val Gln Glu Thr Met Asp Leu Ala Gly Val Ala His Leu Ala Ala 145 150 155 160 Ile Lys Gly Arg Val Pro Phe Leu His Phe Phe Asp Gly Phe Arg Thr 165 170 175 Ser His Glu Ile Gln Lys Val Glu Val Met Asp Tyr Ala His Phe Asp 180 185 190 Arg Leu Leu Asp Arg Glu Ala Leu Leu Glu Phe Arg Asn Asn Ala Leu 195 200 205 Asn Pro Glu Asn Pro Lys Thr Arg Gly Thr Ala Gln Asn Asp Asp Ile 210 215 220 Tyr Phe Gln Thr Arg Glu Val Ser Asn Arg Phe Tyr Asp Ala Leu Pro 225 230 235 240 Asp Val Val Asn Glu Tyr Met Gln Glu Ile Ser Lys Ile Thr Gly Arg 245 250 255 Glu Tyr Lys Pro Phe Thr Tyr Tyr Gly His Lys Glu Pro Glu Cys Val 260 265 270 Ile Val Ala Met Gly Ser Val Thr Gln Ala Leu Glu Glu Val Val Asp 275 280 285 Tyr Leu Asn Ala Lys Gly Glu Lys Val Gly Ile Leu Lys Val Tyr Leu 290 295 300 Tyr Arg Pro Phe Ser Leu Lys Tyr Phe Phe Asp Val Met Pro Lys Ser 305 310 315 320 Val Lys Lys Ile Ala Val Leu Asp Arg Thr Lys Glu Pro Gly Ser Leu 325 330 335 Gly Glu Pro Leu Tyr Leu Asp Val Lys Ser Ala Phe Tyr Gly Arg Glu 340 345 350 Asn Ala Pro Val Ile Val Gly Gly Arg Tyr Gly Leu Ser Ser Lys Asp 355 360 365 Val Asp Pro Ala Gln Met Ile Ala Val Phe Glu Asn Leu Lys Leu Asp 370 375 380 Asn Pro Lys Asp Gly Phe Thr Val Gly Ile Ile Asp Asp Val Thr His 385 390 395 400 Thr Ser Leu Ser Thr Gly Glu Lys Ile Ser Leu Gly Asp Glu Ser Thr 405 410 415 Ile Glu Cys Leu Phe Tyr Gly Leu Gly Ala Asp Gly Thr Val Gly Ala 420 425 430 Asn Lys Asn Ser Ile Lys Ile Ile Gly Asp Lys Thr Asp Phe Tyr Ala 435 440 445 Gln Ala Tyr Phe Ala Tyr Asp Ser Lys Lys Ser Gly Gly Tyr Thr Arg 450 455 460 Ser His Leu Arg Phe Ser Lys Lys Pro Ile Arg Ser Thr Tyr Leu Val 465 470 475 480 Ser Thr Pro His Phe Ile Ala Cys Ser Val Ala Ala Tyr Leu Glu Ile 485 490 495 Tyr Asp Val Leu Ala Gly Ile Arg Lys Gly Gly Thr Phe Leu Leu Asn 500 505 510 Ser Ile Trp Asn Ala Glu Glu Thr Ile Arg Gln Leu Pro Asp Ala Val 515 520 525 Lys Lys Thr Leu Ala Glu Lys Glu Val Asn Phe Tyr Ile Ile Asn Ala 530 535 540 Thr Lys Leu Ala Arg Asp Ile Gly Leu Gly Asn Arg Thr Asn Thr Ile 545 550 555 560 Met Gln Ser Ala Phe Phe Lys Leu Ala Lys Ile Ile Pro Tyr Glu Asp 565 570 575 Ala Gln Lys Tyr Met Lys Glu Leu Ala Tyr Lys Ser Tyr Ser Lys Lys 580 585 590 Gly Asp Ala Ile Val Glu Met Asn Tyr Lys Ala Ile Asp Val Gly Ala 595 600 605 Asp Gly Leu Val Lys Val Glu Val Asp Pro Asn Trp Lys Asn Leu Glu 610 615 620 Leu Lys Glu Lys Glu Gln Thr Asn Ala Tyr Lys Gly Thr Glu Phe Val 625 630 635 640 Glu Lys Ile Val Lys Pro Met Asn Ala Ala Lys Gly Asp Asp Leu Pro 645 650 655 Val Ser Ala Phe Leu Gly Tyr Glu Asp Gly Ser Phe Glu His Gly Thr 660 665 670 Thr Glu Tyr Glu Lys Arg Gly Val Gly Val Met Val Pro Arg Trp Ile 675 680 685 Glu Ala Asn Cys Ile Gln Cys Asn Gln Cys Ala Ser Val Cys Pro His 690 695 700 Ala Val Ile Arg Pro Phe Leu Ile Asn Asp Glu Glu Met Ala Asn Ala 705 710 715 720 Pro Arg Gly Val Lys Asp His Ala Leu Glu Ala Lys Gly Thr Lys Gly

725 730 735 Glu Lys Leu Ser Phe Lys Ile Gln Val Ser Pro Leu Asp Cys Thr Gly 740 745 750 Cys Glu Leu Cys Val His Glu Cys Pro Thr Lys Glu Lys Ser Leu Val 755 760 765 Met Val Pro Leu Gln Glu Glu Met Asp Phe Gly Glu Gln Glu Asn Ala 770 775 780 Asp Tyr Leu Phe Lys Glu Ile Thr Tyr Lys Asp Asp Ile Leu Asn Lys 785 790 795 800 Glu Thr Thr Lys Gly Ala Gln Phe Ala Gln Pro Leu Phe Glu Phe His 805 810 815 Gly Ala Cys Pro Gly Cys Gly Glu Thr Pro Tyr Ile Thr Leu Ile Thr 820 825 830 Arg Leu Phe Gly Glu Arg Met Ile Val Ala Asn Ala Thr Gly Cys Ser 835 840 845 Ser Ile Tyr Gly Gly Ser Ala Pro Ser Thr Pro Tyr Arg Lys Ser Val 850 855 860 Lys Asn Gly His Gly Pro Ala Trp Gly Asn Ser Leu Phe Glu Asp Asn 865 870 875 880 Ala Glu Phe Gly Leu Gly Met Lys Ile Ala Thr Glu Asn Thr Arg His 885 890 895 Arg Ile Glu His Ile Met Asn Glu Ser Met Gln Glu Val Pro Asn Ala 900 905 910 Leu Ser Ala Leu Phe Lys Asp Trp Ile Ala Asn Lys Asp Asn Gly Ala 915 920 925 Met Ser Val Glu Ile Lys Asp Lys Met Ile Pro Ile Leu Glu Gln Asn 930 935 940 Lys Asn Ile Lys Ala Val Gln Asp Ile Leu Glu Leu Lys Gln Tyr Leu 945 950 955 960 Ser Lys Lys Ser His Trp Ile Phe Gly Gly Asp Gly Trp Ala Tyr Asp 965 970 975 Ile Gly Tyr Gly Gly Leu Asp His Val Leu Ala Ser Gly Glu Asn Val 980 985 990 Asn Ile Leu Val Leu Asp Thr Glu Val Tyr Ser Asn Thr Gly Gly Gln 995 1000 1005 Ser Ser Lys Ser Ser Arg Thr Gly Ala Val Ala Gln Phe Ala Ala 1010 1015 1020 Ala Gly Lys Pro Ile Gln Lys Lys Asp Leu Gly Gln Ile Ala Met 1025 1030 1035 Thr Tyr Gly Tyr Ile Phe Val Ala Gln Val Asn Ser Thr Ala Asn 1040 1045 1050 Tyr Thr His Leu Ile Lys Ala Ile Thr Ala Ala Glu Ala Tyr Asp 1055 1060 1065 Gly Pro Ser Leu Val Ile Cys Tyr Ser Pro Cys Ile Ala His Gly 1070 1075 1080 Ile Lys Gly Gly Leu Gly Tyr Ser Gly Glu Gln Gly Glu Leu Ala 1085 1090 1095 Thr Lys Cys Gly Tyr Trp Pro Leu Tyr Thr Phe Asp Pro Arg Leu 1100 1105 1110 Glu Glu Gln Gly Lys Asn Pro Leu Thr Leu Thr Gly Lys Glu Pro 1115 1120 1125 Asp Trp Asp Leu Tyr Glu Gln Phe Leu Met Asn Glu Val Arg Tyr 1130 1135 1140 Asn Ser Leu Lys Lys Ala Asn Pro Glu His Ala Ala Glu Leu Phe 1145 1150 1155 Glu Arg Asn Lys Lys Asp Ala Gln Arg Arg Tyr Arg Gln Leu Lys 1160 1165 1170 Arg Ile Ala Met Ala Asp Tyr Ser Asn Glu Val Glu Ser 1175 1180 1185 281378PRTCampylobacter jejuni 28Met Cys Asp Met Leu Asp Asn Lys Leu Gly Asn Arg Leu Arg Val Asp 1 5 10 15 Phe Ser Asn Ile Ser Lys Gln Ile Glu Ile Pro Asn Leu Leu Gln Leu 20 25 30 Gln Lys Lys Ser Phe Asp Tyr Phe Leu Asn Leu Asp Asn Gly Glu Ser 35 40 45 Gly Ile Glu Lys Val Phe Lys Ser Ile Phe Pro Ile His Asp Pro Gln 50 55 60 Asn Arg Leu Ser Leu Glu Tyr Val Ser Ser Glu Ile Gly Lys Pro Lys 65 70 75 80 Tyr Thr Ile Arg Glu Cys Met Glu Arg Gly Leu Thr Tyr Ser Val Asn 85 90 95 Leu Lys Met Lys Ile Arg Leu Thr Leu His Glu Lys Asp Glu Lys Thr 100 105 110 Gly Glu Lys Val Gly Val Lys Asp Ile Lys Glu Gln Glu Ile Tyr Ile 115 120 125 Arg Glu Ile Pro Leu Met Thr Asp Arg Val Ser Phe Ile Ile Asn Gly 130 135 140 Val Glu Arg Val Val Val Asn Gln Leu His Arg Ser Pro Gly Val Ile 145 150 155 160 Phe Lys Glu Glu Glu Ser Ser Thr Val Ala Asn Lys Leu Val Tyr Thr 165 170 175 Ala Gln Ile Ile Pro Asp Arg Gly Ser Trp Leu Tyr Phe Glu Tyr Asp 180 185 190 Ala Lys Asp Val Leu Tyr Val Arg Ile Asn Lys Arg Arg Lys Val Pro 195 200 205 Val Thr Met Leu Phe Arg Ala Leu Gly Tyr Lys Lys Gln Asp Ile Ile 210 215 220 Lys Leu Phe Tyr Pro Ile Gln Thr Ile His Val Lys Lys Asp Lys Phe 225 230 235 240 Leu Thr Glu Phe Asn Pro Asn Asp Phe Met Asp Arg Ile Glu Tyr Asp 245 250 255 Ile Lys Asp Glu Lys Gly Lys Ile Val His Gln Ala Gly Lys Arg Leu 260 265 270 Thr Lys Lys Lys Ala Glu Gln Leu Ile Lys Asp Gly Leu Lys Trp Ile 275 280 285 Glu Tyr Pro Val Glu Ile Leu Leu Asn Arg Tyr Leu Ala Asn Pro Ile 290 295 300 Ile Asp Lys Glu Ser Gly Glu Val Leu Phe Asp Ser Leu Thr Leu Leu 305 310 315 320 Asp Glu Ser Lys Leu Ala Lys Ile Lys Glu Gln Lys Ser Phe Asp Ile 325 330 335 Ala Asn Asp Leu Ala Asn Gly Val Asp Ala Ala Ile Ile Asn Ser Phe 340 345 350 Ala Gln Asp Gly Glu Thr Leu Lys Leu Leu Lys Gln Ser Glu Asn Ile 355 360 365 Asp Asp Glu Asn Asp Leu Ala Ala Ile Arg Ile Tyr Lys Val Met Arg 370 375 380 Pro Gly Glu Pro Val Val Lys Asp Ala Ala Lys Ala Phe Val Asn Asp 385 390 395 400 Leu Phe Phe Asn Pro Glu Arg Tyr Asp Leu Thr Lys Val Gly Arg Met 405 410 415 Lys Met Asn His Lys Leu Gly Leu Glu Val Pro Glu Tyr Val Thr Val 420 425 430 Leu Thr Asn Glu Asp Ile Ile Lys Thr Ala Lys Tyr Leu Ile Lys Val 435 440 445 Lys Asn Gly Lys Gly His Ile Asp Asp Arg Asp His Leu Gly Asn Arg 450 455 460 Arg Ile Arg Ser Ile Gly Glu Leu Leu Ala Asn Glu Leu His Leu Gly 465 470 475 480 Leu Ala Lys Met Gln Lys Ala Ile Arg Asp Lys Phe Thr Ser Leu Asn 485 490 495 Ala Asp Leu Asp Lys Val Met Pro Tyr Asp Leu Ile Asn Pro Lys Met 500 505 510 Ile Thr Thr Thr Ile Ile Glu Phe Phe Thr Gly Gly Gln Leu Ser Gln 515 520 525 Phe Met Asp Gln Thr Asn Pro Leu Ser Glu Val Thr His Lys Arg Arg 530 535 540 Leu Ser Ala Leu Gly Glu Gly Gly Leu Val Lys Glu Arg Ala Gly Phe 545 550 555 560 Glu Val Arg Asp Val His Ala Thr His Tyr Gly Arg Ile Cys Pro Val 565 570 575 Glu Thr Pro Glu Gly Gln Asn Ile Gly Leu Ile Asn Thr Leu Ser Thr 580 585 590 Tyr Ala Lys Val Asn Glu Leu Gly Phe Val Glu Ala Pro Tyr Arg Lys 595 600 605 Val Val Asn Gly Lys Val Thr Asn Glu Val Val Tyr Leu Thr Ala Thr 610 615 620 Gln Glu Glu Gly Leu Phe Ile Ala Pro Ala Ser Thr Lys Val Asp Ala 625 630 635 640 Lys Gly Asn Ile Val Glu Glu Phe Val Glu Ala Arg Gln Asp Gly Glu 645 650 655 Thr Ile Leu Ala Arg Arg Glu Glu Val Gln Leu Ile Asp Leu Cys Ser 660 665 670 Gly Met Val Val Gly Val Ala Ala Ser Leu Ile Pro Phe Leu Glu His 675 680 685 Asp Asp Ala Asn Arg Ala Leu Met Gly Ser Asn Met Gln Arg Gln Ala 690 695 700 Val Pro Leu Leu Thr Ala Ser Ala Pro Ile Val Gly Thr Gly Met Glu 705 710 715 720 Gln Ile Ile Ala Arg Asp Ala Trp Glu Ala Val Lys Ala Lys Arg Gly 725 730 735 Gly Val Val Glu Lys Val Asp Asn Lys Ser Ile Phe Ile Leu Gly Glu 740 745 750 Asp Asp Lys Gly Pro Phe Ile Asp His Tyr Thr Met Glu Lys Asn Leu 755 760 765 Arg Thr Asn Gln Asn Thr Asn Tyr Ile Gln His Pro Ile Val Lys Lys 770 775 780 Gly Asp Ile Val Lys Ala Gly Gln Ile Ile Ala Asp Gly Pro Ser Met 785 790 795 800 Asp Gln Gly Glu Leu Ala Ile Gly Lys Asn Ala Leu Ile Ala Phe Met 805 810 815 Pro Trp Asn Gly Tyr Asn Tyr Glu Asp Ala Ile Val Val Ser Glu Arg 820 825 830 Ile Ile Arg Glu Asp Thr Phe Thr Ser Val His Ile Tyr Glu Lys Glu 835 840 845 Ile Glu Ala Arg Glu Leu Lys Asp Gly Ile Glu Glu Ile Thr Lys Asp 850 855 860 Ile Pro Asn Val Lys Glu Glu Asp Val Ala His Leu Asp Glu Ser Gly 865 870 875 880 Ile Ala Lys Ile Gly Thr His Ile Lys Pro Gly Met Ile Leu Val Gly 885 890 895 Lys Val Ser Pro Lys Gly Glu Val Lys Pro Thr Pro Glu Glu Arg Leu 900 905 910 Leu Arg Ala Ile Phe Gly Glu Lys Ala Gly His Val Val Asn Lys Ser 915 920 925 Leu Tyr Ala Thr Ala Ser Leu Glu Gly Val Val Val Asp Val Lys Ile 930 935 940 Phe Thr Lys Lys Gly Tyr Glu Lys Asp Asp Arg Ala Ile Lys Ser Tyr 945 950 955 960 Asp Lys Glu Lys Met Ala Leu Glu Lys Glu His His Asp Arg Leu Leu 965 970 975 Met Met Asp Arg Glu Glu Met Leu Arg Val Cys Ala Leu Leu Ser Lys 980 985 990 Ala Ser Leu Asn Ser Asp Gln Lys Ile Gly Asp Lys Asn Tyr Lys Lys 995 1000 1005 Gly Gln Thr Ala Asp Ile Ser Glu Leu Glu Lys Ile Asn Arg Phe 1010 1015 1020 Thr Leu Thr Thr Leu Ile Lys Ala Tyr Ser Lys Glu Ile Gln Lys 1025 1030 1035 Glu Tyr Asp Asp Leu Lys Asn His Phe Gln Asn Glu Lys Lys Lys 1040 1045 1050 Leu Lys Ala Glu His Asp Glu Lys Leu Glu Ile Leu Glu Lys Asp 1055 1060 1065 Asp Ile Leu Pro Ser Gly Val Ile Lys Leu Val Lys Val Tyr Ile 1070 1075 1080 Ala Thr Lys Arg Lys Leu Lys Val Gly Asp Lys Met Ala Gly Arg 1085 1090 1095 His Gly Asn Lys Gly Ile Val Ser Thr Ile Val Pro Glu Val Asp 1100 1105 1110 Met Pro Tyr Leu Pro Asn Gly Lys Ser Val Asp Ile Ala Leu Asn 1115 1120 1125 Pro Leu Gly Val Pro Ser Arg Met Asn Ile Gly Gln Ile Leu Glu 1130 1135 1140 Ser His Leu Gly Leu Val Gly Leu Arg Leu Gly Asp Gln Ile Gln 1145 1150 1155 Glu Ile Phe Asp Arg Lys Gln Lys Asp Phe Leu Lys Glu Leu Arg 1160 1165 1170 Ala Lys Ile Leu Glu Ile Cys Ser Ile Pro Arg Leu Ala Asn Glu 1175 1180 1185 Lys Glu Phe Ile Lys Ser Leu Ser Asp Glu Glu Leu Leu Asn Tyr 1190 1195 1200 Ala Arg Asp Trp Ser Lys Gly Val Lys Phe Ser Thr Pro Val Phe 1205 1210 1215 Glu Gly Val Asn Ile Glu Glu Phe Ser Lys Leu Phe Lys Met Ala 1220 1225 1230 Lys Ile Asp Met Asp Gly Lys Thr Glu Leu Tyr Asp Gly Arg Thr 1235 1240 1245 Gly Glu Lys Ile Ala Glu Arg Val His Val Gly Cys Met Tyr Met 1250 1255 1260 Leu Lys Leu His His Leu Val Asp Glu Lys Val His Ala Arg Ser 1265 1270 1275 Thr Gly Pro Tyr Ser Leu Val Thr Gln Gln Pro Val Gly Gly Lys 1280 1285 1290 Ala Leu Phe Gly Gly Gln Arg Phe Gly Glu Met Glu Val Trp Ala 1295 1300 1305 Leu Glu Ala Tyr Gly Ala Ala His Thr Leu Arg Glu Met Leu Thr 1310 1315 1320 Ile Lys Ser Asp Asp Val Glu Gly Arg Phe Ser Ala Tyr Lys Ala 1325 1330 1335 Leu Thr Lys Gly Glu Asn Val Pro Ala Thr Gly Ile Pro Glu Thr 1340 1345 1350 Phe Phe Val Leu Thr Asn Glu Leu Lys Ser Leu Ala Leu Asp Val 1355 1360 1365 Glu Ile Phe Asp Lys Asp Glu Asp Asn Glu 1370 1375 291496PRTCampylobacter jejuni 29Met Asp Leu Glu Asn Ile Leu Glu Asn Asn Gln Ser Ile Gly Leu Tyr 1 5 10 15 His Pro Lys Asn Glu His Asp Ala Cys Gly Ile Ala Ala Val Ala Asn 20 25 30 Ile Arg Gly Ile Ala Ser Tyr Lys Val Ile Cys Asp Ala Leu Glu Ile 35 40 45 Leu Met Asn Leu Glu His Arg Gly Gly Thr Gly Ala Glu Glu Asn Ser 50 55 60 Gly Asp Gly Ala Gly Ile Leu Ile Gln Ile Pro His Asp Phe Phe Lys 65 70 75 80 Thr Gln Glu Leu Gly Phe Glu Leu Pro Lys Lys Gly Asp Tyr Ala Val 85 90 95 Ala Gln Met Phe Leu Ser Pro Asn Thr Asp Ala Lys Glu Glu Ala Lys 100 105 110 Glu Ile Phe Leu Gln Gly Leu Lys Asp Lys Lys Leu Glu Phe Leu Gly 115 120 125 Phe Arg Glu Val Pro Phe Asn Pro Ser Asp Ile Gly Ala Ser Ala Leu 130 135 140 Lys Ala Met Pro Tyr Phe Leu Gln Ala Phe Val Lys Lys Pro Ser Lys 145 150 155 160 Ile Ser Ala Gly Leu Glu Phe Glu Arg Val Leu Tyr Ser Thr Arg Arg 165 170 175 Leu Ile Glu Lys Arg Ala Ile Asn Val Pro Lys Phe Tyr Phe Ser Ser 180 185 190 Phe Ser Ser Arg Thr Ile Val Tyr Lys Gly Met Leu Leu Ser Thr Gln 195 200 205 Leu Ser Asp Phe Tyr Leu Asp Phe Lys Asp Val Asn Met Lys Ser Ala 210 215 220 Ile Ala Leu Val His Ser Arg Phe Ser Thr Asn Thr Phe Pro Ser Trp 225 230 235 240 Glu Arg Ala His Pro Asn Arg Tyr Met Val His Asn Gly Glu Ile Asn 245 250 255 Thr Ile Arg Gly Asn Val Asp Ser Ile Arg Ala Arg Glu Gly Leu Met 260 265 270 Gln Ser Glu Tyr Phe Glu Asn Leu Asp Glu Ile Phe Pro Ile Ile Ala 275 280 285 Lys Leu Ser Ser Asp Ser Ala Met Phe Asp Asn Thr Leu Glu Phe Leu 290 295 300 Ala Leu Asn Gly Arg Thr Leu Glu Glu Ala Phe Met Met Met Val Pro 305 310 315 320 Glu Pro Trp His Lys Asn Glu Asn Met Glu Ser Lys Lys Arg Ala Phe 325 330 335 Tyr Glu Tyr His Ser Leu Leu Met Glu Pro Trp Asp Gly Pro Ala Ala 340 345 350 Ile Val Phe Thr Asp Gly Val Ile Met Gly Ala Ser Leu Asp Arg Asn 355 360 365 Gly Phe Arg Pro Ser Arg Tyr Tyr Leu Thr Lys Asp Asp Met Leu Ile 370 375 380 Leu Ser Ser Glu Thr Gly Ala Leu Lys Leu Asp Glu Lys Asn Ile Lys 385 390 395 400 Ala Lys Lys Arg Leu Glu Pro Gly Lys Leu Leu Leu Val Asp Thr Ala 405 410 415 Arg Gly Arg Val Ile Ala Asp Asn Glu Ile Lys Glu His Tyr Ala Asn 420 425 430 Ala

Lys Pro Tyr Lys Lys Trp Leu Lys Asn Leu Val Glu Leu Glu Lys 435 440 445 Gln Lys Ser Gly Val Tyr Lys His Gln Phe Leu Lys Glu Asp Glu Val 450 455 460 Leu Lys Leu Gln Lys Ala Phe Gly Trp Ser Tyr Asp Glu Leu Lys Met 465 470 475 480 Ser Val Ala Ala Met Ala Gln Asn Gly Lys Glu Ala Ile Ala Ala Met 485 490 495 Gly Val Asp Thr Pro Leu Ala Ile Leu Ser Lys Thr Tyr Gln Pro Leu 500 505 510 Tyr Asn Tyr Phe Lys Gln Leu Phe Ala Gln Val Thr Asn Pro Pro Leu 515 520 525 Asp Ala Ile Arg Glu Glu Ile Val Thr Ser Thr Arg Ile Tyr Leu Gly 530 535 540 Ser Glu Gly Asn Leu Leu Lys Pro Asp Glu Asn Asn Ala Lys Arg Val 545 550 555 560 Lys Ile Ala Leu Pro Val Ile Ser Asn Glu Glu Leu Phe Glu Val Lys 565 570 575 Ala Leu Asn Lys Phe Gln Val Lys Glu Phe Ser Ile Leu Tyr Asp Tyr 580 585 590 Ser Lys Lys Thr Leu Glu Lys Ala Leu Asp Glu Leu Cys Val Lys Ile 595 600 605 Glu Asp Glu Val Lys Lys Gly Val Ser Ile Ile Ile Leu Ser Asp Lys 610 615 620 Gly Val Asp Glu Lys Asn Ala Tyr Ile Pro Ala Leu Leu Ala Val Ser 625 630 635 640 Gly Val His Asn His Leu Val Arg Lys Asn Leu Arg Thr His Thr Ser 645 650 655 Leu Ile Ile Glu Ser Gly Glu Pro Arg Glu Ile His His Phe Ala Cys 660 665 670 Leu Leu Gly Tyr Gly Ala Thr Val Ile Asn Pro Tyr Leu Val Tyr Glu 675 680 685 Ser Ile Gln Lys Leu Ile Ala Asn Lys Asp Leu Asn Leu Ser Tyr Glu 690 695 700 Lys Ala Val Glu Asn Phe Ile Lys Ala Ser Ser Ser Gly Ile Val Lys 705 710 715 720 Ile Ala Ser Lys Met Gly Val Ser Thr Leu Gln Ser Tyr Asn Gly Ser 725 730 735 Ala Leu Phe Glu Cys Leu Gly Leu Ser Ser Lys Val Ile Asp Lys Tyr 740 745 750 Phe Thr Ser Thr Thr Ser Arg Ile Glu Gly Met Asp Leu Glu Asp Phe 755 760 765 Glu Lys Glu Leu Ile Ala Leu His Lys His Ala Phe Asn Asp Thr His 770 775 780 Lys Ala Leu Asp Ser Lys Gly Ile His Gly Phe Arg Ser Ala Lys Glu 785 790 795 800 Glu His Leu Ile Asp Pro Leu Val Ile Phe Asn Leu Gln Gln Ala Cys 805 810 815 Arg Asn Lys Asp Tyr Lys Ser Phe Lys Lys Tyr Ser Ala Leu Val Asp 820 825 830 Glu Lys Gln Val Asn Leu Arg Ser Leu Met Glu Phe Asp Phe Ser Glu 835 840 845 Ala Ile Ser Ile Asp Lys Val Glu Ser Val Glu Ser Ile Val Lys Arg 850 855 860 Phe Arg Thr Gly Ala Met Ser Tyr Gly Ser Ile Ser Lys Glu Ala His 865 870 875 880 Glu Cys Leu Ala Gln Ala Met Asn Lys Ile Gly Ala Lys Ser Asn Ser 885 890 895 Gly Glu Gly Gly Glu Asp Glu Glu Arg Tyr Glu Ile Lys Glu Gly Val 900 905 910 Asp Lys Asn Ser Ala Ile Lys Gln Val Ala Ser Gly Arg Phe Gly Val 915 920 925 Asp Leu Asn Tyr Leu Ser His Ala Lys Glu Ile Gln Ile Lys Val Ala 930 935 940 Gln Gly Ala Lys Pro Gly Glu Gly Gly Gln Leu Met Gly Phe Lys Val 945 950 955 960 Tyr Pro Trp Ile Ala Lys Ala Arg His Ser Thr Ala Gly Val Thr Leu 965 970 975 Ile Ser Pro Pro Pro His His Asp Ile Tyr Ser Ile Glu Asp Leu Ala 980 985 990 Gln Leu Ile Tyr Asp Leu Lys His Ala Asn Lys Asp Ala Lys Ile Ser 995 1000 1005 Val Lys Leu Val Ser Glu Asn Gly Ile Gly Thr Val Ala Ala Gly 1010 1015 1020 Val Ala Lys Ala Gly Ala Asn Leu Ile Leu Val Ser Gly Tyr Asp 1025 1030 1035 Gly Gly Thr Gly Ala Ser Pro Arg Thr Ser Ile Pro His Ala Gly 1040 1045 1050 Ile Pro Trp Glu Leu Gly Leu Ala Glu Thr His Gln Thr Leu Ile 1055 1060 1065 Leu Asn Lys Leu Arg Asp Arg Val Arg Leu Glu Thr Asp Gly Lys 1070 1075 1080 Leu Met Asn Gly Arg Asp Leu Ala Ile Ala Ala Leu Leu Gly Ala 1085 1090 1095 Glu Glu Phe Gly Phe Ala Thr Ala Pro Leu Ile Val Leu Gly Cys 1100 1105 1110 Thr Met Met Arg Val Cys His Leu Asn Thr Cys Pro Phe Gly Ile 1115 1120 1125 Ala Thr Gln Asp Thr Glu Leu Arg Asp Arg Phe Lys Gly Lys Val 1130 1135 1140 Asp Asp Val Ile Asn Phe Met Tyr Phe Ile Ala Glu Glu Leu Arg 1145 1150 1155 Glu Tyr Met Ala Arg Leu Gly Phe Glu Arg Leu Asp Asp Met Ile 1160 1165 1170 Gly Arg Val Asp Lys Leu Arg Gln Lys Ser Val Gln Gly Lys Ala 1175 1180 1185 Gly Lys Leu Asn Leu Asp Lys Ile Leu Lys Ser Leu Pro Thr Tyr 1190 1195 1200 Asn Arg Thr Ala Val His Phe Lys Asp Tyr Lys Asp Asn Lys Leu 1205 1210 1215 Glu Lys Thr Ile Asp Tyr Arg Ile Leu Leu Pro Leu Cys Lys Asn 1220 1225 1230 Ala Val Glu Lys Lys Glu Pro Ile Lys Leu Ser Leu Glu Val Gly 1235 1240 1245 Asn Gln Ser Arg Thr Phe Ala Thr Met Leu Ser Ser Glu Ile Leu 1250 1255 1260 Lys Thr Tyr Gly Lys Asp Ala Leu Asp Glu Asp Ser Ile His Ile 1265 1270 1275 Lys Ala Ile Gly Asn Ala Gly Asn Ser Phe Gly Ala Phe Leu Leu 1280 1285 1290 Lys Gly Ile Lys Leu Glu Ile Ile Gly Asp Ser Asn Asp Tyr Leu 1295 1300 1305 Gly Lys Gly Leu Ser Gly Gly Lys Ile Ile Ala Lys Ile Ser Asn 1310 1315 1320 Glu Ala Thr Phe Ser Pro Glu Glu Asn Ile Ile Ala Gly Asn Ala 1325 1330 1335 Cys Leu Tyr Gly Ala Thr Lys Gly Glu Val Tyr Leu Asp Gly Ile 1340 1345 1350 Ala Gly Glu Arg Phe Cys Val Arg Asn Ser Gly Ala Leu Ala Val 1355 1360 1365 Val Leu Gly Thr Gly Val His Gly Cys Glu Tyr Met Thr Gly Gly 1370 1375 1380 Gln Val Val Val Leu Gly Asp Val Gly Ala Asn Phe Ala Ala Gly 1385 1390 1395 Met Ser Gly Gly Val Val Tyr Ile Phe Gly Arg His Asn Glu Ala 1400 1405 1410 His Val Asn Thr Glu Leu Val Asp Ile Lys Asp Leu Asn Ala Lys 1415 1420 1425 Asp Glu Lys Glu Leu Lys Ala Val Ile Glu Lys His Ile Thr Tyr 1430 1435 1440 Thr Asp Ser Lys Lys Ala Lys Asp Ile Leu Glu Lys Phe Asp Lys 1445 1450 1455 Lys Asp Phe Phe Lys Val Met Pro Arg Asp Tyr Glu Lys Met Leu 1460 1465 1470 Lys Met Leu Asp Leu Cys Lys Asn Glu Lys Asp Pro Asn Leu Ala 1475 1480 1485 Ala Phe Leu Lys Ile Thr Gln Lys 1490 1495 301517PRTCampylobacter jejuni 30Met Ser Lys Phe Lys Val Ile Glu Ile Lys Glu Asp Ala Arg Pro Arg 1 5 10 15 Asp Phe Glu Ala Phe Gln Leu Arg Leu Ala Ser Pro Glu Lys Ile Lys 20 25 30 Ser Trp Ser Tyr Gly Glu Val Lys Lys Pro Glu Thr Ile Asn Tyr Arg 35 40 45 Thr Leu Lys Pro Glu Arg Asp Gly Leu Phe Cys Ala Lys Ile Phe Gly 50 55 60 Pro Ile Arg Asp Tyr Glu Cys Leu Cys Gly Lys Tyr Lys Lys Met Arg 65 70 75 80 Phe Lys Gly Val Lys Cys Glu Lys Cys Gly Val Glu Val Ala Asn Ser 85 90 95 Lys Val Arg Arg Ser Arg Met Gly His Ile Glu Leu Val Thr Pro Val 100 105 110 Ala His Ile Trp Tyr Val Asn Ser Leu Pro Ser Arg Ile Gly Thr Leu 115 120 125 Leu Gly Val Lys Met Lys Asp Leu Glu Arg Val Leu Tyr Tyr Glu Ala 130 135 140 Tyr Ile Val Glu Asn Pro Gly Asp Ala Phe Tyr Asp Asn Glu Ser Thr 145 150 155 160 Lys Lys Val Glu Tyr Cys Asp Val Leu Asn Glu Glu Gln Tyr Gln Asn 165 170 175 Leu Met Gln Arg Tyr Glu Asn Ser Gly Phe Lys Ala Arg Met Gly Gly 180 185 190 Glu Val Val Arg Asp Leu Leu Ala Asn Leu Asp Leu Val Ala Leu Leu 195 200 205 Asn Gln Leu Lys Glu Glu Met Gly Ala Thr Asn Ser Glu Ala Lys Lys 210 215 220 Lys Thr Ile Ile Lys Arg Leu Lys Val Val Glu Asn Phe Leu Asn Ser 225 230 235 240 Asn Leu Asn Ala Asn Thr Asp Ser Asp Glu Ala Val Pro Asn Arg Pro 245 250 255 Glu Trp Met Met Ile Thr Asn Leu Pro Val Leu Pro Pro Asp Leu Arg 260 265 270 Pro Leu Val Ala Leu Asp Gly Gly Lys Phe Ala Val Ser Asp Val Asn 275 280 285 Asp Leu Tyr Arg Arg Val Ile Asn Arg Asn Thr Arg Leu Lys Lys Leu 290 295 300 Met Glu Leu Asp Ala Pro Glu Ile Ile Ile Arg Asn Glu Lys Arg Met 305 310 315 320 Leu Gln Glu Ala Val Asp Ala Leu Phe Asp Asn Gly Arg Arg Ala Asn 325 330 335 Ala Val Lys Gly Ala Asn Lys Arg Pro Leu Lys Ser Leu Ser Glu Ile 340 345 350 Ile Lys Gly Lys Gln Gly Arg Phe Arg Gln Asn Leu Leu Gly Lys Arg 355 360 365 Val Asp Phe Ser Gly Arg Ser Val Ile Val Val Gly Pro Lys Leu Arg 370 375 380 Met Asp Gln Cys Gly Leu Pro Lys Lys Met Ala Leu Glu Leu Phe Lys 385 390 395 400 Pro His Leu Leu Ala Lys Leu Glu Glu Lys Gly Tyr Ala Thr Thr Val 405 410 415 Lys Gln Ala Lys Lys Met Ile Glu Asn Lys Thr Asn Glu Val Trp Glu 420 425 430 Cys Leu Glu Glu Val Val Lys Gly His Pro Val Met Leu Asn Arg Ala 435 440 445 Pro Thr Leu His Lys Leu Ser Ile Gln Ala Phe His Pro Val Leu Val 450 455 460 Glu Gly Lys Ala Ile Gln Leu His Pro Leu Val Cys Ala Ala Phe Asn 465 470 475 480 Ala Asp Phe Asp Gly Asp Gln Met Ala Val His Val Pro Leu Ser Gln 485 490 495 Glu Ala Ile Ala Glu Cys Lys Val Leu Met Leu Ser Ser Met Asn Ile 500 505 510 Leu Leu Pro Ala Ser Gly Lys Ser Val Thr Val Pro Ser Gln Asp Met 515 520 525 Val Leu Gly Ile Tyr Tyr Leu Ser Leu Glu Lys Ala Gly Ala Lys Gly 530 535 540 Ser His Lys Ile Cys Thr Gly Ile Asp Glu Val Met Met Ala Leu Glu 545 550 555 560 Ser Lys Cys Leu Asp Ile His Ala Ser Ile Gln Thr Met Val Asp Gly 565 570 575 Arg Lys Ile Thr Thr Thr Ala Gly Arg Leu Ile Val Lys Ser Ile Leu 580 585 590 Pro Asp Phe Val Pro Glu Asn Ser Trp Asn Lys Val Leu Lys Lys Lys 595 600 605 Asp Ile Ala Ala Leu Val Asp Tyr Val Tyr Lys Gln Gly Gly Leu Glu 610 615 620 Ile Thr Ala Ser Phe Leu Asp Arg Leu Lys Asn Leu Gly Phe Glu Tyr 625 630 635 640 Ala Thr Lys Ala Gly Ile Ser Ile Ser Ile Ala Asp Ile Ile Val Pro 645 650 655 Asn Asp Lys Gln Lys Ala Ile Asp Glu Ala Lys Lys Gln Val Arg Glu 660 665 670 Ile Gln Asn Ser Tyr Asn Leu Gly Leu Ile Thr Ser Gly Glu Arg Tyr 675 680 685 Asn Lys Ile Ile Asp Ile Trp Lys Ser Thr Asn Asn Val Leu Ser Lys 690 695 700 Glu Met Met Lys Leu Val Glu Lys Asp Lys Glu Gly Phe Asn Ser Ile 705 710 715 720 Tyr Met Met Ala Asp Ser Gly Ala Arg Gly Ser Ala Ala Gln Ile Ser 725 730 735 Gln Leu Ala Ala Met Arg Gly Leu Met Thr Lys Pro Asp Gly Ser Ile 740 745 750 Ile Glu Thr Pro Ile Ile Ser Asn Phe Arg Glu Gly Leu Asn Val Leu 755 760 765 Glu Tyr Phe Ile Ser Thr His Gly Ala Arg Lys Gly Leu Ala Asp Thr 770 775 780 Ala Leu Lys Thr Ala Asn Ala Gly Tyr Leu Thr Arg Lys Leu Ile Asp 785 790 795 800 Val Ala Gln Asn Val Lys Ile Thr Ile Glu Asp Cys Gly Thr His Glu 805 810 815 Gly Val Glu Ile Asn Glu Ile Thr Ala Asp Ser Ser Ile Ile Glu Thr 820 825 830 Leu Glu Glu Arg Ile Leu Gly Arg Val Leu Ala Glu Asp Val Ile Asp 835 840 845 Pro Ile Thr Asn Ser Val Leu Phe Ala Glu Gly Thr Leu Met Asp Glu 850 855 860 Glu Lys Ala Lys Ile Leu Gly Glu Ser Gly Ile Lys Ser Val Asn Ile 865 870 875 880 Arg Thr Pro Ile Thr Cys Lys Ala Lys Lys Gly Ile Cys Ala Lys Cys 885 890 895 Tyr Gly Ile Asn Leu Gly Glu Gly Lys Leu Val Lys Pro Gly Glu Ala 900 905 910 Val Gly Ile Ile Ser Ala Gln Ser Ile Gly Glu Pro Gly Thr Gln Leu 915 920 925 Thr Leu Arg Thr Phe His Ser Gly Gly Thr Ala Ser Thr Asp Leu Gln 930 935 940 Asp Arg Gln Val Ser Ala Gln Lys Glu Gly Phe Ile Arg Phe Tyr Asn 945 950 955 960 Leu Lys Thr Tyr Lys Asn Lys Glu Gly Lys Asn Ile Val Ala Asn Arg 965 970 975 Arg Asn Ala Ala Val Leu Leu Val Glu Pro Lys Ile Lys Thr Pro Phe 980 985 990 Lys Gly Val Ile Asn Ile Glu Asn Ile His Glu Asp Val Ile Val Ser 995 1000 1005 Ile Lys Asp Lys Lys Gln Glu Val Lys Tyr Ile Leu Arg Lys Tyr 1010 1015 1020 Asp Leu Ala Lys Pro Asn Glu Leu Ala Gly Val Ser Gly Ser Ile 1025 1030 1035 Asp Gly Lys Leu Tyr Leu Pro Tyr Gln Ser Gly Met Gln Val Glu 1040 1045 1050 Glu Asn Glu Ser Ile Val Glu Val Ile Lys Glu Gly Trp Asn Val 1055 1060 1065 Pro Asn Arg Ile Pro Phe Ala Ser Glu Ile Leu Val Glu Asp Gly 1070 1075 1080 Glu Pro Val Val Gln Asn Ile Lys Ala Gly Glu Lys Gly Thr Leu 1085 1090 1095 Lys Phe Tyr Ile Leu Lys Gly Asp Gly Leu Asp Arg Val Lys Asn 1100 1105 1110 Val Lys Lys Gly Asp Ile Val Lys Glu Lys Gly Phe Phe Val Val 1115 1120 1125 Ile Ala Asp Glu Asn Asp Arg Glu Ala Lys Arg His Tyr Ile Pro 1130 1135 1140 Arg Glu Ser Lys Ile Glu Phe Asn Asp Ser Glu Lys Ile Asp Asp 1145 1150 1155 Ala Asn Thr Ile Ile Ala Ser Ala Pro Lys Lys Glu Arg Lys Val 1160 1165 1170 Ile Ala Glu Trp Asp Ala Tyr Asn Asn Thr Ile Ile Ala Glu Ile 1175 1180 1185 Asp Gly Val Val Ser Phe Glu Asp Ile Glu Ala Gly Tyr Ser Ala 1190 1195 1200

Asp Glu Gln Ile Asp Glu Ala Thr Gly Lys Arg Ser Leu Val Ile 1205 1210 1215 Asn Glu Tyr Leu Pro Ser Gly Val Arg Pro Thr Leu Val Ile Ala 1220 1225 1230 Gly Lys Gly Asp Lys Ala Val Arg Tyr His Leu Glu Pro Lys Thr 1235 1240 1245 Val Ile Phe Val His Asp Gly Asp Lys Ile Ala Gln Ala Asp Ile 1250 1255 1260 Leu Ala Lys Thr Pro Lys Ala Ala Ala Lys Ser Lys Asp Ile Thr 1265 1270 1275 Gly Gly Leu Pro Arg Val Ser Glu Leu Phe Glu Ala Arg Lys Pro 1280 1285 1290 Lys Asn Ala Ala Val Ile Ala Glu Ile Asp Gly Val Val Arg Phe 1295 1300 1305 Asp Lys Pro Leu Arg Ser Lys Glu Arg Ile Ile Ile Gln Ala Glu 1310 1315 1320 Asp Gly Thr Ser Ala Glu Tyr Leu Ile Asp Lys Ser Lys His Ile 1325 1330 1335 Gln Val Arg Asp Gly Glu Phe Ile His Ala Gly Glu Lys Leu Thr 1340 1345 1350 Asp Gly Val Val Ser Ser His Asp Val Leu Lys Ile Leu Gly Glu 1355 1360 1365 Lys Ala Leu His Tyr Tyr Leu Ile Ser Glu Ile Gln Gln Val Tyr 1370 1375 1380 Arg Gly Gln Gly Val Val Ile Ser Asp Lys His Ile Glu Val Ile 1385 1390 1395 Val Ser Gln Met Leu Arg Gln Val Lys Val Val Asp Ser Gly His 1400 1405 1410 Thr Lys Phe Ile Glu Gly Asp Leu Val Ser Arg Arg Lys Phe Arg 1415 1420 1425 Glu Glu Asn Glu Arg Ile Ile Arg Met Gly Gly Glu Pro Ala Ile 1430 1435 1440 Ala Glu Pro Val Leu Leu Gly Val Thr Arg Ala Ala Ile Gly Ser 1445 1450 1455 Asp Ser Val Ile Ser Ala Ala Ser Phe Gln Glu Thr Thr Lys Val 1460 1465 1470 Leu Thr Glu Ala Ser Ile Ala Gly Lys Phe Asp Tyr Leu Glu Asp 1475 1480 1485 Leu Lys Glu Asn Val Ile Leu Gly Arg Met Ile Pro Val Gly Thr 1490 1495 1500 Gly Leu Tyr Gly Glu Gln Asn Leu Lys Leu Lys Glu Gln Glu 1505 1510 1515 31156DNACampylobacter jejuni 31atggcttatg aagatgaaga agatttaaat tacgatgatt atgaaaacga agatgaagaa 60tatccacaaa atcaccataa aaattataat tacgatgatg atgattatga atacgatgat 120gataacaatg atgatgattt ttatgagatg gattaa 15632198DNACampylobacter jejuni 32atgatcaatc ctatacaaca aagttatgtg gcaaataccg cattaaatac aaatagaata 60gataaagaaa ctaaaacaaa cgatactcaa aaaacggaaa atgataaagc gagtaaaatc 120gcagagcaga ttaaaaacgg tacttataaa atcgatacaa aagctacagc tgctgcgatt 180gctgactctt taatctaa 19833351DNACampylobacter jejuni 33atgaaaaaaa tacttattct acttacacta tgtgcttttg cttttggtgc aagtgaatgt 60gatagaaaaa tcgatcgtat caataaagaa atcagttttt ctaaagcgca taatgataca 120gctagaactt taagcttaga gcttgcttta aaacaagtac aaaatgattg tgctaaagat 180cctatgtttt atgataaaaa gttagaagct aaaaaactta aagaacaaga agtggaaaaa 240atcgaaaaag aacttgatgc tttaaaagaa caaaaagatt atatgagcaa ggctgagtat 300aaagctaaaa aagaagcttt aaaagaacaa aaagagaaaa tcaaaaaata a 35134417DNACampylobacter jejuni 34atgagttttg gtgaaattat agttatttta gttgtagcga ttttagtctt aggacctgat 60aaacttccag aagctatagt acaaatagca aaaattctaa aggctgtaaa acgcaacata 120gatgatgcaa aatcaagcat agaaaaagaa atacgcatca atgacttaaa agaagaagct 180aagaaataca aagatgaatt ttcaagcact aatgaaaata tacgcaaaaa actcagcttt 240gaagaatttg atgaccttaa gagagatatt ttagataaaa caaaggtaga tttaaccttt 300gatagcagag atgataaagt aaaaaataac cttagcggac aaaatttaaa tacagaagaa 360aaaccaaatc ttagcaaatt agaaacacaa gataaaaacg gaaaaataaa tgtttga 41735426DNACampylobacter jejuni 35atgcaaaaag ctaaaatttt aattgcctta agtttttttt tattagtttt atctgcctgt 60tctaatgatg aaaaaaatat ttccaagact caaaatacag atcaagaagt agtccaaata 120gaacaaaacg atgaaaaaac agaattaagt gactccaacc tgcctttacc tgtagatgat 180gaagcacaaa gttcaaatga tgaacatgaa gtcaatccta gtattatcaa ctctttatat 240aaacaaaaat gcgccacttg tcatggagaa aaaggggaat taaaacctaa aaacagcacg 300gccattaaaa ccttgagcaa taaaattttt atacaaaaaa taaaaacgat aaaagataaa 360aaccatagtt ttttaagtga tgaacaaatt caaaatttag ctgattttat aaacaaagga 420aaataa 42636435DNACampylobacter jejuni 36atgcgaagac taagtatttt acttgcaatt ttaatagtta ttaatataac agcttgtgat 60agtaaaacag aaaattacta caaaaatctt cctagcgaag caaaagaaaa agcgaaagaa 120tgcaaagaaa gcggaactct tagcgaagat tgtattaatg cattaaaagt tggtgttaaa 180ccaacaaatg aagagggtaa atacagtcca aacacaccga aaaaatctga taatcaaata 240ttagaagctt taaaacaaaa tgatttaaaa aaagaaaaaa ccacaaaaga tattaaccaa 300agttcagaaa ataatgaaag tattataata ccacctatag cagaaacacc ttctgaaatt 360tatccttcca aaacaacaga aaacaatcaa agttctatct ttagcgatga tgttaatatg 420acacaggaaa aatga 43537525DNACampylobacter jejuni 37atgatgaaga agaaattggt tttattagga agtgctgcag tggtattttt tgccgcttgt 60gcaatgaata gtggggtaag ttcagaacaa attggactta gaaaagcaag tttagaaaat 120gaaaataaag taaatttagt ggaggcaaat ttcacaactt tacagcctgg ggaatctact 180cgttttgagc gttcttatga aaatgcacca ccattaattc cgcatgctat tgaagatttg 240ttacctataa ctaaagataa caatatgtgc ttaagctgcc atgataaggc tatagcagca 300gatgctggtg caactccact tcctgctagt cattattatg attttagaca caataaaacc 360acaggagata tgattagcga tagtcgtttt aattgcactc agtgtcatgt tccacaaagt 420gatgcaaaac ctttagtggg aaatagcttt aaacctgaat ttaaaaatga acaattaaaa 480agtcgttcaa atttaattga tgtgattaat gagggtgtaa agtaa 52538606DNACampylobacter jejuni 38atgaaaaaaa tcaaaaaaat cattcaaatt ggtatgatag gtggtttagc agctgttgct 60ggaggtgctt tagcaggttg tggaagtaat aatgacaatg cagatacttt aaatcaagcg 120gctaatgctc aaggagcttt tgtaattatc gaagaaacag ctccagggca gtataaaatc 180aaagatcaat atccaagtga tgaaacaagg gtagttttaa aagatcttaa tggtacagaa 240agaattttat ccaaagaaga aatggatgct ttgattaaag aagaagcagc taaaattgat 300aatggaactt caaatttaac taaagacaat ggacaaatca gtagtggggg attgagttta 360ggggaaactt tactcgcaag tgctgcaggt gctattttag gaagttggat aggttcaaaa 420cttttcaata atcaaaattt tgccaaccaa caacgcggtg ctttttcaaa tcaaagtgct 480tatcaaagga gtgttaatag ttttaataaa gcaggcacaa caagctctgc ttcaagtgct 540aaaaaatcag gtttttttgg tggaggctct aaagccacaa gttctagttc ttcttttggc 600tcttaa 60639633DNACampylobacter jejuni 39atgacaaaat ttttaagcat ttgtagttta attgcgatgt tgttaagtgg ttgtggaagt 60gattttcctg gacaacctag cgatgtggct agagttcagc aaaacaaata tccaaatgga 120aatttaaaaa aagaaattcc ctataataaa gattcaagaa tacatgggtt aaaaagagct 180ttttatgaca atggtcagct aagagctgaa gaaaattata aaaatggaaa aaaagatgga 240attagcaggg aatattctag aaatgggcaa ttacttgagg aggtgcattt taaagataat 300cgcggatatg gtgattttgc aagctattat gagaatggaa atatgagagc aaagggaaaa 360ctacttggct ataatgaaga tggtatgcca gaatttgaag gtaattacaa ggaatattat 420gaaaatggaa ctttaatgtg tgattataat tttgataata aaggtaaatt tgatggagta 480caaaagcgtt atgatgaaaa tggcgcctta gaagacgaag aaaattataa aaatggactt 540aaaaatggag tctttagaga atataaaaaa ggggagattg taagagaaga agaatataaa 600aatggtattt tagtagcaaa acctaaaaat tag 63340735DNACampylobacter jejuni 40atgaaaaaaa tatttttaag tgtttttttg gttttgagtt taaatgctca aaatcttgaa 60atagataaaa taagaacaga tttgtattct aaaagtggag caaatgttct taaaaaagtt 120gaaatttctt tggaatttga tgggaataat ttaaaagaaa atgaaaataa gttaattgat 180gctgtaaata cagtaatttc agggtttttt tatgaagata tttttacaga aattggaaaa 240aataatttta aaaaaacttt agaaaaattt ttagataaga aatataagat taaactagat 300gatatatata tcatatcttt aagtggagtg gaaaaatttg atttagagga gtttaaacgc 360tttttagaaa gtactgaggc taaagagaag ggtatgggta gcgaggtaaa aaaagcactt 420gaaaacttag aagttcctaa aactcaagtt cctagtgttg aaaagatccc aactcctagt 480gttccaaatt tagaagtcaa gcaagttgaa cagcttttca aagatccaga tgaagaaaat 540aaaaatgaca atggagaaat caatatagat aatttaaata cacctaaaat gactccagat 600atagaagaaa aaattaaaag agatttaatc gccaatcctc cacaaatatt caaagaaaat 660aacgcaagca agccttatca tttgccacaa acaggctatg atataaagct tgatgagaat 720tcaacgcaaa attag 73541780DNACampylobacter jejuni 41atgaaaaatt atggtttgag taatttaaat tcgtttttac ttgctttagc aatatatatt 60agtatagtaa ttcttgtttt ttttagactt gtaagcgagg ttgaacctgc tatacaatat 120actgatataa aagatagttt tgtagatatt gaacttgctg aaccatcaaa acaagttatt 180actcaaagca acactcctaa agaaatacaa aaaccaacag agcaaattga tatagaaaag 240ctttttgctc agactacaaa taaaacagtt aaaactgaag atattgacca aaaggcaagt 300aattttaatg agctttttgg aaatattaaa gaaatacaag aagaaaagac tacaaaaatt 360caatcaagtg ctaaatcagg aatttctagt gccccaaaac ctcaagcttc tgaacttgta 420aaacaactta atgatagttt acttcaagaa gaaagttcaa cgcaaggcga aagcacaaag 480gcgcaaaaga ttggaattta tgatgaattt ttagggaaag ttgtgcgtat tatcactcaa 540agatggactc agtattatcc aaatagtgaa aaaatttctg ttaaggtaaa aatttttatt 600gatgaaaatg gaaaatttgg ctatacttca gttgaaaaaa gtgggaatcc tttatatgat 660gctaaagtgg ctgaattttt agaaagtcaa aaaggtaaat ttattactta tcctccgcaa 720aataaaaata taagcattac catgaattta agagatgaag taaaagttaa aaatgattag 78042822DNACampylobacter jejuni 42atgaaaaaat tttctttagt cgcagcaact ttgattgcag gtgtagtttt aaatgtaaat 60gcagctacag tagctactgt taatggcaag agcattagcg atacagaagt aagtgaattt 120tttgccccta tgcttagagg acaggatttt aaaactttgc cagataatca aaaaaaagct 180cttattcagc aatatattat gcaagattta attttgcaag atgctaaaaa acaaaattta 240gaaaaagacc ctttatacac aaaagaactt gatcgtgcaa aagatgcaat acttgttaat 300gtttatcaag agaaaatttt aaatactatt aaaattgatg cggctaaagt taaagctttt 360tatgatcaaa ataaagacaa atatgtaaaa cctgcaagag tgcaagcaaa acatatctta 420gtagcgacag aaaaagaagc taaggatatt attaacgaac ttaaaggttt aaaaggtaaa 480gaactagatg ctaaatttag cgagcttgct aaagagaaat caattgatcc aggttcaaaa 540aaccaaggtg gtgagcttgg ttggtttgat caatcaacta tggtaaagcc ttttacagat 600gctgctttcg cgcttaaaaa tggtactatt actacaactc cggtaaaaac gaattttggt 660tatcatgtaa tcttaaaaga aaattcgcaa gctaaaggtc aaatcaaatt tgatgaagta 720aaacaaggta ttgaaaacgg acttaaattt gaagaattta aaaaagttat caatcaaaaa 780ggccaagatc tcttaaatag tgctaaagtg gaatataaat aa 82243837DNACampylobacter jejuni 43atggaaaatc aaaaaaatga atttgatgat attattttag aaaaaagtaa taaaagtgaa 60aaagtaaaaa aaattctttt acgagttatt gctttagtta ttttgttttt agctatcatg 120atagttatga agcttattaa tggtagtggt gatgaaaata cgcaaaatca aagtgtattg 180ccaagtgaac ctatagcaac tcaagacaat aacaatgata cttcttttga aagtatgcca 240attacagata atacttcagc agaagatcaa tttgaggcat taagaaaaca atttcaagat 300gaacaaaata caactcaaaa tacaacaacc tctagttcaa ataacaatga tactacaaat 360tttgctatgc ctgatcaaga agttccagca gaaccaacag caactacttc agcaaatacc 420actccacaag caagtactcc taaacaagaa gtaacacaaa ctgcaaaatc taaagaagaa 480gcaaaaaaac aaacagctgt aaaaaaagaa aaagaaagtg caaaacaaac ccctaaaaaa 540gaacaaaatg caaatgattt atttaaaaat gttgatgcta aacctgtaca tccaagtggt 600ttagcatcgg gtatttatgt gcaaattttc tcagtaagta atttggatca aaaatcaaaa 660gaacttgctt ctgtaaagca aaaaggttat gattataaac tttataaaac tacagttgga 720agtaaagaaa ttaccaaggt tttaatagga ccatttgaaa aggcagatat tgcagcagaa 780cttgctaaaa tccgtaagga tattgcaaaa gatgcttttt cttttacttt aaaatga 837441173DNACampylobacter jejuni 44atgaaaaaga agattgtttt aatcatttta attgcaatac ttggaagtgt tggggcttat 60tttatttttt ttaataatga tgaaaaaatc agctatttaa ctcaaaaaat acaaaaaaaa 120gatatatctc aaaccataga ggcagtagga aaggtatatg ccaaagatca agtcgatgtg 180ggtgctcaag ttagtggaca aattataaaa ctttatgttg atgtgggaac tcatgtaaag 240caaggtgatt tgatcgctca aattgataaa gataaacaac aaaacgattt agatattaca 300aaagctcagc ttgaaagtgc taaggctaat ttagagagta aaaaagttgc ccttgagatt 360gcgaataagc aatatcaaag agagcaaaaa ctttatgcag ctaaagcaag ttctcttgaa 420aatttagaaa ctcaaaaaaa taattattat actttaaaag ccaatgttgc agagcttaat 480gctcaagtag ttcagcttga aatcactctt aaaaatgcac aaaaagattt aggttataca 540accattactg ctcctatgga tggtgttgtg attaatgtag ctgtagatga aggacaaaca 600gttaatgcta atcaaaacac tcctactata gtccgtatag ctaatttaga cgaaatggaa 660gtaagaatgg aaatagcaga ggctgatgtg agtaagataa aagtaggaac agagcttgat 720ttttctttgc ttaatgatcc tcaaaaaact tatcatgcta agattgcaag tatagatcca 780gctgatactg aagtgagtga ttctagtaca agctcaagct catcaagttc gagttcttca 840agctcaagct catcaaatgc tatttattat tacgcaaaat tttatgtagc caataaagat 900gattttttgc gtattggtat gagtatacaa aatgaaattg tcgtagcaag tgcaaaggct 960gttttagcag tgccaactta tgcaattaaa agcgatccaa aaggctatta tgttgaaatt 1020ttggaaaatc aaaaagctgt taaaaaatat gtcaaacttg gcattaaaga ttctatcaat 1080actcaaattt tagaaggtgt aaatgaagat gaagaattga tagtaagctc aagtgctgat 1140ggtttagctc ctaaaatgaa gttgagattt taa 1173451629DNACampylobacter jejuni 45atgaaaattt tacttttaaa tgaaaaccct gtagtttcaa gacttgtaag ccttagtgct 60aaaaaaatgt cttatgattt tgaagaactt aatgcttata gtgaaaattt gggtaattat 120gatgtgattg ttgtagatag tgatactcca gcacctttaa aaattcttaa agaaaaatgc 180gataggttga tttttttagc cccgcgaaat caaaatgtag aagatataga tgcgcaaatt 240ttacaaaaac cttttttacc tacagatttt ttaaatttac ttaataataa agatgcgaac 300aagcatacat ctattgattt gccaatgtta agcaatgatg aaaatcctta tgctgatata 360agcttggatt tagataattt aaatttagat gatttgcctg atgaaaattc tttagatata 420aattcagagg gaatggaaga tttgagtttt gatgatgatg ctcaagatga taatgcaaac 480aaaactttag aaactcaaaa tttagaacat gaaacaatta aagaacagac tcaagaagac 540actcaaattg atttagattt aactttagaa gatggcgaaa gtgaaaaaga agacttaagc 600caagaacata cagctttgga tactgagcct agtttagatg agctagatga taaaaatgat 660gaagatttag aaatcaaaga agatgataaa aatgaagaaa tagaaaagca agaattatta 720gacgattcta aaacaaatac attagaaatg caagaagagc ttagcgaatc tcaagatgat 780aattcaaaca aaactttaga aactcaaaat ttagaacatg acaatttaga acaagaaaca 840attaaagaac agactcaaga agacactcaa attgatttag atttaacttt agaagatggc 900gaaagtgaaa aagaagactt aagccaagaa catacagctt tggatactga gcctagttta 960gatgagctag atgataaaaa tgatgaagat ttagaagata ataaagaatt acaagctaat 1020ataagcgatt ttgatgatct tcctgaggtt gaagagcaag aaaaagaaat ggattttgat 1080gatcttcctg aggatgctga atttttaggt caagcaaaat ataatgaaga atcagaggaa 1140aatttagagg agtttgctcc tgttgtggaa gaagatattc aagatgaaat agatgatttt 1200gcttcaaatt tgagtactca agatcaaatc aaagaagaac tagctcaact tgatgagctt 1260gattatggta ttgatagtga caatagtagc aaggtcttag aagattttaa agatgaacca 1320attttagacg ataaagaatt aggaacaaat gaagaggaag tggttgtgcc aaatttaaat 1380ataagtgatt ttgatacatt gaaagaaagt gatatacaag aagctcttgg agaggaaatc 1440ttagaaaaaa atgaagagcc tatagtaagt gatgtaacta aagatgataa tagcgaagag 1500atagttaatg agcttagcca aagcatagca ggagcgatca cttcaagtat taaagatgat 1560accttaaaag ctgctcttaa gggtatgaat atgaatataa atataaacat tagttttaaa 1620gaggattga 1629461833DNACampylobacter jejuni 46atgaaaaaaa atattttacg cttaggtatt gtcgttttgg ttttacttat agcgggagtt 60ttatggctaa ataatgatat caatcaaaaa aaagaagatg aagcaaataa aaatgccatt 120gcagcaaatg ctgatttttc tttgcttagc gatgatgatc caaattttga aaaatggggt 180aaggtttttc cagagcaact aaaaatgtat ttaacggttg aaaaagaaga gcctaaggct 240actgaatttg gtggtaattt agcttattca aaattaattc gctttcctca attaaccata 300ctttgggcag gatatccttt tagtcttgat ttcaatgaag aaagagggca tttttgggtt 360caagtagatc aaatgaaaac agcaagaaac aacaaagatt ttcttaatgc ccatggactt 420gctgctttta aaggtcaacc tgcagcttgt atgaattgtc atagtggatg gactccatgg 480cttataaaaa atgttgctaa aggagatttt actgctttta actctacaaa ttattggact 540atgattaaaa atatcccagc tgttgatggt atagtagaaa attcacctga acatgcaggc 600ccacatggtg gtaaaagaat gggtgtaact tgtgcagatt gtcacaatcc aaatgatatg 660agtttaagac ttactcgtcc agcagctatt aatgctttag tttctagagg atatgaaaaa 720gatccagtac aaggcgtaaa agctacaaga gaagaaatga gaactttagt ttgctctcaa 780tgtcatgttg aatactattt taaaccaaca ggggaaaaag taaaagtaat gggtgaaact 840attgtagatg atagttctaa aaaatggtgg aatggaactc agaaaaatta tgatgagtat 900gagttttgga gagatggcaa taaagttaaa gagattgaaa ccgatggtat agttttaact 960tttccttgga gtgagtggaa aaaaggacaa ccatttagaa ttgaaatgct agatgattat 1020tatgataaag ttcgtggagt atttggagct gattttactc ataaattaac aggagcgcaa 1080attattaaaa ttcaacatcc agaaagtgaa ctttatagtg gcggtgtgca tgctgcaaat 1140ggagtaagtt gcgtggattg tcatatgcct tatgttagag aaggagctaa aaaggttact 1200caacacaata tcacttctcc tttaagagat attaactctg cttgtaagtc ttgtcataaa 1260caaagtgaag attatttaaa agctcaagtg cttgacatac aaaacagcgt tgcacatgat 1320caaagaactg cagagtatgc aattgttagt ttgattatgg atactaaaaa attacgcgat 1380gaactaggca atatggaaaa attccaaagc gatggaaaag ctgatgcgaa aaaaattagc 1440gaagagctaa aagaagtttt agaacttcat cgtaaagctc aaatgagagc ggattttgtt 1500aatgctgaaa actcaactgg tttccataat cctcgcgaag cttcaagaat gttattgcaa 1560gctgttgata tggcaagaat gggacaaact aaacttgtag aaattgcagc ggcaaatgga 1620attaaagatt ttaaaacttc aaatttaggt tttgaagata ttcaaaaatt taatccagga 1680gagctttatt ataaagtaga tgttaataat cataaagctg gagagcgtta ctatgcagat 1740gaaaaagatg ttaatggcaa tcctccaaaa gaacttttag agcatgataa agagcttgct 1800ccttataatt atcaagtgat tgataaaaaa taa 1833471980DNACampylobacter jejuni 47atgaaaagcg taaaattgaa ggtttcgctg attgcaaatt taatcgcagt agtgtgtttg 60ataattttag gtgttgtaac atttatattt gtaaagcaag caatttttca tgaagttgtg 120aatgctgaaa taaattatgt taaaacggct aaaaattcta tagagtcttt taaggcaaga 180aattctttag ctcttgaaag tttagctaaa agtattttaa agcatcctat agaacagtta 240gatagtcaag atgctttaat gcattatgtt ggaaaagatt taaagaattt tagagatgct 300ggaagattct tagcagttta tattgctcaa ccaaatggcg aacttgttgt aagcgatcca 360gactctgatg ctaaaaattt agattttgga

acttatggaa aagctgataa ttatgatgct 420agaacaagag agtattatat agaagcagtt aaaacaaata aactttatat taccccatct 480tatattgatg taactacaaa tttaccttgc tttacatatt ctattccgct ttataaagat 540ggtaaattta taggggtttt ggctgtagat attcttgcgg cagatttgca agctgaattt 600gaaaatttac caggtagaac ttttgtattt gatgaagaaa ataaagtatt tgtttctaca 660gacaaagctc ttttacaaaa aggttatgat attagtgcaa ttgcaaatct tgctaaaact 720aaagaggatc ttgaaccttt tgagtatact agaccaaaag atggtaatga aagatttgct 780gtatgcacaa aggtttctgg aatttatact gcttgcgttg gagagccaat agaacaaata 840gaagctccag tttataaaat tgcatttata caaactgcga ttgttatttt tacaagtatt 900attagcgtca tcctccttta tttcatcgta tcaaaatacc tctccccact tgcagctatc 960caaacaggtt taacttcatt ctttgatttt atcaactata aaacaaaaaa tgtttccact 1020atagaagtaa aaagcaatga tgaatttgga caaatctcaa atgctatcaa tgaaaacatt 1080cttgctacta aaagaggctt agaacaagac aatcaagccg ttaaagaatc agttcaaacc 1140gtatcagttg tagaaggtgg taatttaaca gcaagaatta ctgctaatcc aagaaaccca 1200cagcttattg aacttaaaaa tgttctaaat aaacttcttg atgttttaca agctagagta 1260ggttctgata tgaatgctat tcataaaatt tttgaagaat acaaaagctt agactttaga 1320aataaattag aaaatgctag cggtagtgta gaattaacta ctaatgcttt aggtgatgaa 1380atagttaaaa tgctaaaaca aagttcagac tttgctaatg ctttagctaa tgaaagtgga 1440aaattacaaa ctgctgttca aagcttaacc acttcttcaa attctcaagc tcaatcttta 1500gaagaaactg cagcagcttt agaagagatc acttcttcta tgcaaaatgt ttcagttaaa 1560actagtgatg ttatcactca atctgaagag attaaaaatg ttacaggtat tataggtgat 1620attgcagatc aaatcaatct tttagcttta aatgcagcta ttgaagcagc tcgtgctgga 1680gaacatggta gaggctttgc agtggtagct gatgaagtta gaaagttagc tgaaagaact 1740caaaagtctt tatcagaaat tgaagctaat actaatttac ttgttcaatc tatcaatgat 1800atggcagaaa gtattaaaga acaaactgca ggtatcactc aaatcaatga tagcgtagct 1860caaattgatc aaactactaa agataatgtt gaaattgcta atgaatcagc tattatttct 1920agtacagtaa gtgatatagc taataatatc ttagaagatg ttaagaagaa gaggttttaa 1980481998DNACampylobacter jejuni 48atgcaatcaa taaattcagg caaatccgtt ggaatttcag ctaagcttac gctatgggtt 60ggaattttag ttgtattaat tttagcaatc acaagtgcta ttagttactt tgattcgaga 120aacaatacat atgaattgct aaaagacact cagttaaaaa ctatgcaaga tgtggatgct 180ttctttaaaa gctatgctat gtcaaaaaga aatggtattc aaatactagc caatgagcta 240acaaatcgtc ctgatatgag cgatgaagag ctaatcaatc ttatcaaagt aattaaaaaa 300gttaatgact acgatctagt ttatgtagga tttgataata caggaaaaaa ttatcaatct 360gatgatcaaa ttttagatct atcaaaaggt tatgatacta aaaatcgtcc ttggtataaa 420gctgccaaag aagcaaaaaa gcttatagta acagaacctt ataaatccgc cgctagcgga 480gaggttggtt taacttacgc tgctccattt tatgatagaa atggaaattt tagaggtgtt 540gtaggtggag attatgatct agcaaatttt tcaaccaatg ttttaactgt aggaaaatca 600gacaatacct ttactgaagt acttgattca gaaggaacaa tactttttaa tgatgaagtt 660gctaaaatac taacaaaaac agaattaagt atcaatatcg ccaatgcaat caaagcaaat 720cctgctctta ttgatccaag aaaccaagat actttattta ccgctaaaga tcaccaaggc 780gtagattatg cgattatgtg taattctgct tttaatcctt tatttagaat ttgtacaata 840acagaaaaca aagtttatac cgaagctgtt aattctattt taatgaaaca agttatagtt 900ggtattatag ctataatcat agctttaatc ttgattagat ttttaatcag cagaagtctc 960tccccacttg cagctatcca aacaggttta acttcattct ttgattttat caactataaa 1020acaaaaaatg tttccactat agaagtaaaa agcaatgatg aatttggaca aatctcaaat 1080gctatcaatg aaaacattct tgctactaaa agaggcttag aacaagacaa tcaagccgtt 1140aaagaatcag ttcaaaccgt atcagttgta gaaggtggta atttaacagc aagaattact 1200gctaatccaa gaaacccaca gcttattgaa cttaaaaatg ttctaaataa acttcttgat 1260gttttacaag ctagagtagg ttctgatatg aatgctattc ataaaatttt tgaagaatac 1320aaaagcttag actttagaaa taaattagaa aatgctagcg gtagtgtaga attaactact 1380aatgctttag gtgatgaaat agttaaaatg ctaaaacaaa gttcagactt tgctaatgct 1440ttagctaatg aaagtggaaa attacaaact gctgttcaaa gcttaaccac ttcttcaaat 1500tctcaagctc aatctttaga agaaactgca gcagctttag aagagatcac ttcttctatg 1560caaaatgttt cagttaaaac tagtgatgtt atcactcaat ctgaagagat taaaaatgtt 1620acaggtatta taggtgatat tgcagatcaa atcaatcttt tagctttaaa tgcagctatt 1680gaagcagctc gtgctggaga acatggtaga ggctttgcag tggtagctga tgaagttaga 1740aagttagctg aaagaactca aaagtcttta tcagaaattg aagctaatac taatttactt 1800gttcaatcta tcaatgatat ggcagaaagt attaaagaac aaactgcagg tatcactcaa 1860atcaatgata gcgtagctca aattgatcaa actactaaag ataatgttga aattgctaat 1920gaatcagcta ttatttctag tacagtaagt gatatagcta ataatatctt agaagatgtt 1980aagaagaaga ggttttaa 1998492253DNACampylobacter jejuni 49atgagaatta caaataaact taacttcaca aatagtgtga ataattctat gggcggtcaa 60agtgctttat atcagatatc tcaacaactt gcttcaggtt tgaaaataca aaattcatat 120gaagatgcaa gcacttatat agataatacg cgtcttgaat atgaaattaa aacgttagaa 180caagtaaaag aatcaacaag tagagctcaa gaaatgactc aaaatagtat gaaagcttta 240caagatatgg ttaaacttct tgaagatttt aaagttaaag taacccaagc tgcaagcgat 300agcaattctc aaacctcaag agaagctata gcaaaagaac tagaacgtat aaaagaaagc 360atagttcagc ttgcaaatac cagtgttaat ggtcagtatc tttttgcggg ttctcaagtt 420gcaaacaaac cttttgattc taatggaaat tattatggag ataaaaataa tattaatgta 480gtaactggag ctggaactga aagcccatac aatataccag gttgggattt attttttaaa 540gcagatggag actataaaaa acaaataagc actaatgtta gttttacaga taatcgttgg 600gatttaaata aagaccctga taaaactaaa tatctcacag gagattctaa atggcaacaa 660cttatcggac aaagttatgt aaaagataat agcttagatg ctgacaaaga ctttgagtat 720gatgatagca aactagattt tcctccaaca actctttatg ttcaaggtac aagacccgat 780ggaacaagtt ttaaaagtgc tgtactcgtc aaacccgaag atactttaga agatgtaatg 840gaaaatattg gagctcttta tggtaatact ccaaataata aagtagtaga agtaagtatg 900aatgatagtg gtcaaattca aattacagat ctaaagcaag gtaataataa actcgatttt 960catgctgtag ctttcacacc acaagctgat gataaaactg aattaaataa tattatccaa 1020gcagcacagg atgaaggcat tacaatggaa gatgttacaa acagggttat gactgctgca 1080ctaggaaatc ccaataatgg agatattaca aatttaaata atcctgtaac cattcaaatt 1140aacggacaaa actttgaaat tgatttaaaa caaactgatt ttatcaaaag taaaatgaca 1200gatacagatg gaaatgctgc taatggagct gattacgata atgtgtattt tgaaaaaaat 1260ggcaatactg tttatggtaa tgtttctcaa gttatcaaag gaagcaatgc ttatgccact 1320gattcaacca aacttagcga ggtaatggca ggagatagcc taaatggtac tactttaaat 1380ttaaaagtca attccaaagg tggaaattct tacgatgtta ctataaattt acaaacttca 1440actgtaagct atcctgatcc taataatcca ggtcaaacca taagctttcc tattatgcat 1500actaatcctg caactggaaa tagtggggtt gttacaggat caaatgatat tacttatggt 1560caaattaatg atattatagg tatgtttgct gcagataaaa ttcctacaac aaccatacaa 1620gccaataatg gtcaaattaa taatgcagat tatacccaaa tacaacaact catgaaagat 1680tcacaagcta ctgttgatgt aagtatggat tataaaggtc gtattagtgt tactgataaa 1740ctttcatcag gaaccaatat agaaatttct cttagtgatt ctcaaagtgg ccaatttcca 1800gcacctcctt ttaccacaac ttctactgta caaaatggtc caaattttag ttttagcgcg 1860aataattctt taactataga tgagccaaat gtggatatta ttaaagattt agattcaatg 1920attgatgctg ttttaaaagg caatatgaga gcagactccg aaagtgaaaa ccctagaaat 1980acaggtatgc aaggagcttt agaaagactt gatcatttag cagatcatgt tagcaagctt 2040aatacaacta tgggagcata tcataatact atcgaaggtg ttaatacacg cacatcattt 2100ttaagcgtta atgtccaaag tataaaatca aatgtgattg atgtagatta tggtgaggca 2160atgatgaatt taatgcaagt tcaacttgca tatcaagctt ctcttaaagc tagtacaaca 2220atttctcaac ttagcttatt aaattatatg taa 2253502598DNACampylobacter jejuni 50atgatgagat cactttggtc tggcgtaagc ggactacaag cacatcaagt tgcgatggat 60gttgaaggta ataacatttc aaatgttaat accactggtt ttaaatattc tcgtgcagat 120tttgggacta tgtttagcca aactgtgaaa atcgctacag ctccaactga tggaagaggc 180ggatctaatc cacttcaaat cggtcttggc gtttcagtaa gttctacaac tagaattcat 240tctcaaggtt cagttcaaac cacagataaa aacactgacg ttgctataaa tggcgatggt 300ttttttatgg taagcgatga tggtggtctt acaaactatc ttacaaggag cggggatttt 360aaactagatg cttatggaaa ttttgttaat aatgcaggtt ttgttgtcca agggtggaat 420atcaactggg atgatcaaac tatagatagt tcaagaactc cacaaaatat ttttatcgat 480ccaggtatgc atatccctgc agcaaaatct actgaagttg ctatcaaagc gaatttaaat 540agtggtttaa atataggaac ttcaagtaga aatctttatg cacttgattc tgttcatgga 600tggaatacta aaacccaaag agcagaagat gaaaatgata caggaactac tcagttttat 660acgacttcta agaattctgt agaagtgaca gaaaagggtg tggatgcggg atcacttttt 720aacgcgaaag gacaaggact taatcttaga gatggacaag gaatttgggt atcttatgca 780gatgcaacat attctaccaa taaagtagga gtaaatgctt ttgatccaaa tttacagcaa 840aatcaaactg ctgctttttg gggaacagct aatcaaaaag tgaatttaga tataacttta 900aatggggtta gaattcaaaa tgctgatatt caaagtattg atgatgctat tgcttatatc 960aataccttta ctgcaccaac ggatacaagg gatggaacag gtgtaaaagc ggttaaaaat 1020aaggatggta gtggaattga ttttgtcaat gataatgccg atggtactac agataatatg 1080aaaaatatca atcttgtggt tgccaatacc aatacagcag gtgagctttg gaatgctgta 1140tggaataaca acaatcaaac atttacattt aataataatg gtaatggaca ggctggaaca 1200ccgactatta ataaaaatgg ttcttctttg tggacagcta caaatattac atttacacca 1260caacctcctc aagcagctac gaatgttcag cttactggtg gactaaatgc acaaataata 1320acagcacata aatatattta tagttcaaac cctgtggata taggtcctat gtataatcct 1380gacggtggac cagcattcca gcctggtgct aatgcaacta caagaccaac tgaaccaggt 1440tcagcagctt attgggatgc tgttaatggt ggacttttaa atactaatgt aagaactttt 1500agaaccacag aagatttaag agaactttta caaagggatg ctagatatgg ggttgattat 1560gatggaagtg gaacttttgc tgcagctgat attaatcaaa atataaaagt agtagtaacg 1620gcagatggac attttgctat ttccaatgct aatgaacaat caactgttcc accaaatgct 1680attaatggtg taggaaatgc cactacaaca gatccaaaaa atatgagttt taatataaca 1740gcttatagta acaaacaagg aactgtaagt actaatgatg ctttcactgc tatttttaaa 1800gctttcgatg gtcctttggt tataggaaat cagatcaaag aaagcgaaca acttaagctt 1860tctgcttttt cggcggggct tgaaatttat gattctttag gttcaaaaca cactttagaa 1920gtgcagtttg ttaagcaaag taccactcaa gatgggggta atgaatggca aatgatcatc 1980cgtgtacctg aacctgcaga gattaacact acaggcgaag gaccaaacaa tatcatcgta 2040ggaacagcta gatttaacaa tgacggctct ttagctagtt atacaccaag aacgataaat 2100ttctcaccaa acaatggtgc cgcaccaaat caacaaatca aactttcctt tggaacaagt 2160ggaagcaatg acggccttgt aagctcaaat tctgcttcaa ctctaacagg acaggcaact 2220gatggttata cttcaggtaa cttaaaacct gatgctatcc gtgtggatga taaaggtaat 2280atcttaggtg aatttactaa tggcaaaacc tttgctgtag caaaaatcgc aatggcttca 2340gtggcaaata actcaggtct tgaggaaatt ggtggaaatc tttttaaagt tactgcaaat 2400agtggtaata tcgtggtagg tgaagcagga acaggaggtc gtggtgagat gaaaacctca 2460gctcttgaaa tgtcaaatgt ggatttaagt cgttctttaa cagagcttat tatcattcaa 2520agaggttatc aagcaaactc aaaaaccatt tcaacgagtg atcaaatgct ccaaactcta 2580atccagctta aacaataa 2598512616DNACampylobacter jejuni 51atggcaaaga ttagaattca tgaaatcgca aaagaattag gttatgatag taaggaaatt 60attgaaaagg caaatgaatt aggacttgga attaaaacag catcaaatgc tgtagaacct 120gagattgcgg cagctattta tgagtatata caaacaagag aaattccaga agcttttaag 180aaaaatatca aaactcctac agcaaaaaag cctaaaaaag aaaatataaa agaacaagaa 240aagctaaatg aatctgaaaa aaaagaacct aaaaaagaag aaaagcttaa acaagaagtt 300aaaaaagaag aattaaaaat tgaaaaagaa aatgcaaaag aggaagaaaa acaagaaatt 360attgatgctc ataagccaca aagccttgct agtgcaactt tagccaaaag acgcggactt 420gttattgtta aaaagaaaaa agacgaagaa gaaattcaag ttaaaaaaga agaagtaaaa 480aattcaaatg atatatctat caataatgaa gagcgcttaa gtttaaaaac tatgttttca 540aatgctgatg agagtttaaa gaaaaagaaa aaagaaaaaa aatcttttgt tgcgagtaaa 600aaagaaagta ccgaaaaaat gaatttttta gatgaacatg attttggtga tatttcttta 660gatgatgaag atgaggtagt attacctgat tttagtgtaa aagaacaaga aaaaccacaa 720aatatcaata aaaaacaacc taattttata agacaagctg ttggaaattc tgcgggtttt 780gggtttgaag gtggaattca aagaagaagt cgtaaaaaac catctaaaaa gattgaaaaa 840aaggaagtag aagaagtagg tagcgttgct atttctaaag aaattcgtgt gtatgaattc 900gctgataaga taggaaaaag cactagtgaa gtgatttcaa aacttttcat gcttggaatg 960atgacaacaa aaaatgattt cttagatgaa gatgcgattg aaattttggc tgctgaattt 1020ggtatagaga tcaatatcat taacgaggct gatgagtttg attatgtaaa agactatgaa 1080gaagagactg atgaaaaaga tttagtgact agagcacctg tgattaccat catggggcat 1140gttgatcatg gtaaaacttc tttgttagat tatattagaa aatcacgcgt tgcaagtggt 1200gaagcagggg gtattactca gcacgtgggt gcttatatgg tagaaaaaaa cgggcgtaaa 1260attactttta tcgatactcc aggtcacgaa gcttttactg ctatgcgtgc aaggggtgca 1320agtatcactg atattgtaat catcgttgta gccgcagatg atggggtaaa accacaaacc 1380aaagaagcga taaatcatgc taaagcagca ggtgtgccta ttattattgc tattaataaa 1440atggataaag aagcagcaaa tcccgatatg gtaaaaactc aactcgcaga aatggaaatc 1500atgccagtag aatggggcgg atcttatgaa tttgtaggag tttcggctaa aacaggaatg 1560gggattgaag atttgcttga aatcgtgctt ttacaagctg atattttaga acttaaagcc 1620aatccaaaaa gttttgctaa agcaagcatt atagaaagtt ctgtgcaaaa agggcgtggt 1680gcggtggcta ctgtcatcgt gcaaaatgga acacttactg taggaagtac cgtggttgca 1740ggcgaggctt atggaaaagt gcgtgcgatg agcgatgatc aaggtaaagc cttaaaagaa 1800attaaaccag gcgaatgtgg ggttatcgta gggcttagtg aagtagcaga tgcaggtgaa 1860attttaatcg cagtaaaaac cgataaagaa gcaagagaat atgctaataa acgccacgaa 1920tacaatcgcc aaaaagaact tagcaaatcc actaaagtta gcattgatga gcttggagct 1980aagatcaaag aaggtaatct aaaagccttg cctgttattt taaaagctga tgtgcaagga 2040tctttagaag ccttaaaggc aagtttagaa aaacttagaa atgatgagat taaagtgaat 2100atcattcata gtggagtagg aggaatcacg caaagtgata tagagcttgc aagtgcgagt 2160gaaaactcta tagtactagg ttttaacata cgcccaacag gggaagttaa agagcgtgct 2220aaggataaag gcgtagaaat taaaacttat aatgtaattt ataatctttt agacgatgta 2280aaagccttac ttggtggtat gatgagcccg attatttctg aagagcaatt aggacaagca 2340gagattagac aagtgatcaa tgtgccaaaa atcggacaaa tcgcaggttg tatggtaact 2400gaaggggtga ttaatcgtgg agccaaaatt cgccttatcc gtgatggagt tgtggtttat 2460gaaggaaatg taagttcgct taaacgcttt aaagatgatg ctaaagaagt ggcaaaaggc 2520tatgagtgtg gcgtaggtat agaagggtgc gatgatatga gagtgggtga ttatatagaa 2580agctataaag aagtagagga acaagcaagt ctatga 2616522841DNACampylobacter jejuni 52atgctagcac ctggcatggg agaatgggtt tacaaggcta atttattttt atttggagaa 60tttgcgtatt attatccttt tttcttattt attttaaatt atgtttatta taaaagaaat 120tacaaattag ctaattttac aagaagagag ctttttggta taggatttgc ctttttctcg 180agtttgcttt tatttgcagt tttttatcct aattcaggct atatactaga gcttgcttat 240gcgatttttt ctactatttt ggggcatact gggagcggaa ttttcgctct tttacttcta 300ctattttctt tggttttatt gtttccaaaa tttgcaaaag aaattttaaa aatagaatta 360gattttactt atttattaaa agtagagcaa gcttttaaat ctttacttat gcgtgtattt 420ggtggagaaa acgagaaaga agatgtaggt aaatcagaac ctatagttcc aaaattaaat 480attttgcaag atagtattta tggaaattta caaataaaca aaaaagggga aaccaataac 540ttagaacaga taattaaaga tagcaatatc aatgcaagta aaaattcaat taccacggcc 600aaggaaaatt ttgaaaaact aaaaaatcaa attttagatg aaaccataga gattgataaa 660caaagtttaa aagaatcaag aagttttgtt catgagcatt ctcaacaagt gcgaaatttc 720gcacaaaagg ctagtaaaat gagcattagt cttgatgaag attttaattt tatttcagaa 780gaagaggtag atatgattcc tgaacgtttt ttaaaaccta aaaaacttga agatataaag 840caaatagata caaataaaaa tttagatgag ccaagttata aacgtaaaaa tattgaaatt 900ccagtttcta atcaagaagt taaaccaaaa atttttacaa aagagcttga acttagagag 960aatttgataa aaaaagaaaa actagaacaa gaatacaaag cctatcaaaa tgaaatttta 1020gaaaataaag taaaacaaga aattaaaaaa ttagaagaat atgatgcgat aaattcaagc 1080gatattatag aagggaataa atatagtttt aatagcccaa aaacaattaa aacagaaaca 1140gaagaatcag acaaaataaa tgaaaataaa aatctagata aagcagacaa tatctttgaa 1200tttgctccca ttgtagaaga gttaaatcat ccttatatag aacctactcc tataaaaaat 1260ataaatgaaa tagttataga agaaaaaaat acactcgatt ttatccaaaa tacagaaact 1320aaaatcgata atgaaaaaac aaatgatcaa gaaattaaac ttcaaaaagc agttttagcc 1380aaagaaattg ctattaacca agctttattg cgtgaaatag agcagggcga aatagaaaaa 1440ccaaaagatt tcaccttgcc gccattagat tttttagcta atccaaaaga acacaaacaa 1500gaaatcaatg aaagtgaaat agataaaaaa atttataatc ttcttgaaaa attgcgtcgt 1560tttaaaatag gcggcgatgt tataagcact tatgttggtc ctgtggtaac tacttttgaa 1620tttcgtccta gtgcagatgt gaaagtaagt cgtattttaa atttacaaga tgatttaact 1680atggctttaa tggcaaaatc aatccgtatt caagctccaa taccaggaaa agatgttgta 1740ggtatagaag ttccaaatga tgaaattcaa accatttatt taagagaaat tttacaaagt 1800gaagttttta aaaacgctaa aagtccttta accatagctt taggtaaaga tatagtaggc 1860aatgcttttg taaccgatct taaaaaactt ccgcatttac tcatcgcagg aacgacaggt 1920agtggtaaaa gtgtggggat aaattctatg cttttaagtc ttttatatcg caactctcca 1980aaaaccttgc gtttgatgat gatagatcct aagatgcttg aatttagcat ttataatgac 2040attcctcatc ttttaactcc tgttatcaca gatccaaaaa aagcagtcaa tgcgctttca 2100aatatggtag ctgaaatgga aagacgctat cgcttaatgg ctgatgcaaa aaccaaaaat 2160atagaaaatt acaatgaaaa aatgaaagaa ttaggcggag aaaaacttcc ttttattgta 2220gtaattatcg atgaacttgc tgatttgatg atgactgcgg gtaaagatgt agaattttat 2280ataggaagac ttgcgcaaat ggcaagagca agtggaatcc acttgattgt agctacacaa 2340cgaccttctg ttgatgttgt aacaggacta attaaagcga atttaccaag tagaatttct 2400tataaagtag ggcaaaaaat tgactctaaa gttattttag atgctatggg tgctgaaagt 2460ttacttggaa gaggggattg tttatttact cctcctggaa caagctctat agtgcgtttg 2520catgcgcctt ttgcaagcga atttgaaata gaaaaaatcg tggattttct aaaggatcaa 2580caaagcgtag aatatgatga aagcttttta aaggatcagc aaagcgtagg tgttacaaca 2640aatgaaagct ttgatgggga agcagatgag ctttatgaag aagctaaaag agtaatctta 2700gaagatggaa aaacaagcat ttcttattta caacgccgtt taaaaatcgg ctataaccgc 2760tctgcaaata ttattgaaca acttacgcaa aacgggattt taagcgaacc tgatgccaaa 2820ggacaaaggg aaatcttgta a 2841533126DNACampylobacter jejuni 53atgaaaaaat ttttttgttt aactttagtt tgtaaacttt ttgctttaag cgaatttgaa 60cttcatcata ttgataaagt acataagcta gggtatagcg gagatactat tataataggt 120gtagccgatg atgcttttaa tcaagatcat attagtttaa aggataagat tttaaagtct 180acttatccta ctgatacagc tgggaaacag cttatacctg atttgaaaaa atcaacacac 240ggaagtcatg tagcaggtat agctgttgga gcaaagatag gcgatagcaa accttatgga 300gtggcttatg gggcaaaatt ttatggagct ggggtgtttc caaatggctc ttacactcaa 360attcctgata tttataattt tttcaaagat gtgagtatta ttaataatag ctggggtatt 420aatttttatc cttattttaa tcttaaggct tcaaattctg gattagtaga ttgtactcaa 480actaatcaag ggacaagcta taatatctgt aatactcctt tggaatatgt tatgaaagca 540gataaggttg ctaatgatat gatgaggctt agcaaggaca agggagtatt aaatgtattt 600gctgctggta atgaaggaat tcttagccct gctttgcatg cgattttacc aagttatgat 660gaatctttaa gagcttggtt ggctgttgga gctttggatg caaatgagat tactttagaa 720tcagatggga ctttaataat taaaagtcaa ggtttggctg attttagtaa tggttttaag 780ggagctacga atttttcttt agttgctgct

ggagtaaata ttaataatgt tgattcaagc 840actaatgata agtttacaaa aaaaagtgga acttctatgg cagcacctat ggtaagtgga 900acagcggcac tggtcaagca aaatttcccc tttttggatg gtaagcaaat tgctgatata 960ctattaagta cagcaaataa aaattataag gctccaaaat ttactgttaa acaagtaacc 1020gatggaacaa atcaacctaa atttcttatt gtgtatattt cgcaagatcc acctgggata 1080gaagatgaaa taaaacggga tttaaaacag ctttacaatg gaatacaagt tcaagttaat 1140ggacaatgga ttgattatag tgattatatt tgggataata gagatagtgc gcagtcacaa 1200aaacttaata cttccactat tagttctatt aatggagtag ttagagttga gaaagaagaa 1260ttatttggac aaggaatttt agatgcacaa aaggcgttaa aaggactgag tattttagat 1320gcaaacagac tcagtgatca ggatgtatta aaatatgagc aagaacctaa tacagcttat 1380tatactataa acactgcagg ttatgatgct gaattttcta atgatattag tcaaagaaaa 1440tgggatgaaa gtactcattt atcaagtgct attaataaac ctacacattt agctaatctt 1500aacatagggt tatctaaaga aggtgaaggt attttgatta tcagtggtca aaatacttat 1560gagggcgcaa ctttaatcaa acaaggagaa ttaaagctta aaggaaaagt taaaaataat 1620gcttatgtag aacaaaaagc aatattaagc ggtaatggta ttgtagggca aaatttaaac 1680aataaaggca tagttagacc tggaaatgaa gatttgaatg atttaaccgt gcaaggaact 1740tatactcaag aaggagttga ttctaaattg caacttgatt ttggtaatta taaaaattct 1800aaactgattg caaaaactta tgatattaag agcgggaatt tagaatatat tcctttacct 1860aaatactata tcttaaataa gccagtgaaa attaatttgg gagatttgga aaaaagttta 1920tcatctttta atcatgtttt gatacaaaat acctatgctt taaattttga ttttgtttta 1980agtgatgatt tagtgagtat taataaaacc ttaataaaac ctaatttaaa gccaaatgct 2040tacgaaattc ctaatacaag cttgggaaat gctttaagac aattgcgatc tagggcagac 2100ttgagtcaga cttatcagga attttttgct tctttagata atggaataga tgtaaagact 2160aaattaaata gaatagaagg ttcagggtat ttaagcactt ttagtaatca taatcaatct 2220aatttaatgc aaaataatat gttatttacc cttcatcctc ttaatattaa taattttgca 2280caaaacaata atatcttact tgctagtact tatttaccta gaatttttag caatgaagaa 2340tatttttggc atcttactcc aagttataaa tactataaag ataaagattt ttcaggtcaa 2400aaaacaggtg ctaatatctc tttaggagaa aatttctcat caggcttttt agcttatgct 2460ttatctcttt ctagcgctaa atttaatttt aataatggta gtgatttgaa gagttataac 2520atggatttat tgcttaatta taaccatgat ttagatttta taaaaatatt aagtggatta 2580ggtataggtg taggatttaa tactcttaat cgttttgtag tagagcagcc aattgaaggc 2640aaatataaaa cattgcaaac ttcagcccag cttggtgtaa ctaaagatat tattttaggt 2700caagatttta tttttaatcc tttaatgtat tttacacata gtttttttta tcaagaagat 2760tttaaagaaa ataaaagtcc ttttgctaaa aattatgaaa gtttaaaaca tcatagcata 2820aatgcaaatt taggttttaa tcttgctaaa aatatagagc aagatgatta tcaagcttct 2880ttttctactt ttgtaatttt tgaaaaaaga atttatggaa gaactttaga aaataaggct 2940agttttgttg attttcctat tgcttttatt caaaaatata aattaaaaga taatatttta 3000agtcaaggtt ttaattcaga atttttatat aaaaacaatg tattttggca gtttatgtta 3060atgaatagat tttctcataa tgcctatgaa ttgcatttaa tgagttcagt aggaaaacgt 3120ttttga 3126543270DNACampylobacter jejuni 54atgccaaaac gaacagatat taaaagcatt ttacttatag gaagtggtcc tattgtgata 60ggacaagctt gtgaatttga ttattctgga actcaagccg caaagacttt aaaagaatta 120ggatatcgtg tagtattaat caactcaaat cctgcaacca tcatgacaga tcccgaattt 180gcagatgcga cttatataga acccataaca aaagaaagta ttttaagtat tattaaaaaa 240gaaaaaattg atgcaatttt gccaactatg ggtggacaag tagcgttaaa tgttgctatg 300gaagtttatg aaagcggact tttaggagat gtgaaatttt taggcgcaaa tcctgaggcg 360attaaaaaag gcgaagatcg tcaggttttt aaagaatgta tgaaaaaaat tggcatggat 420ttgccaaaat cgatgtatgc gtataattat gacgaagctt taaaagccgt agatgaaatc 480gactttcctt tgatgatccg tgcttcttat actttagggg gtgctggaag tggtgtggtt 540tacaatatgg acgaatttaa agaacttacc aatactgctt tagctttatc acctattcat 600gaaattttga ttgaagaaag tttgttaggt tggaaagaat atgaaatgga agttatacgc 660gatagagcgg ataattgtat catagtttgt agcatagaaa atatcgatcc tatgggagtt 720catacaggag atagtattac aatagctcca gcattaactt tgacagataa agaatatcaa 780gttatgcgta atgcttcttt tgctattttg cgtgaaattg gtgtagatac aggcggaagt 840aatgtgcaat ttgctatcaa cccaaaaaat ggaagaatga tagttataga aatgaatcca 900agagtttcaa gatcaagtgc tttagcttct aaggcaacgg gttatcctat agcaaaggtt 960gcgacacttt tggcagtagg ttttagctta gatgagatta aaaatgatat tacaggaact 1020cctgcatctt tcgagcctgt gattgattat attgtaacaa aaattcctcg ctttaccttt 1080gaaaaatttc caggagcaaa tacaacttta ggtacagcta tgaaaagtgt gggtgaggta 1140atggctatag gacgcacttt taaagaaagt atacaaaaag cactttgttc gcttgagcgt 1200tctttaagtg gttttgatag ggtaaaattt gaagatagaa atgatcttgt ttttaaaatt 1260cgcaatgcca atgaaaagcg tttactttat gttgctcaag cttttaggga aggttttagc 1320gtagaagaac tttatgagct ttgtaaaata gatccttggt ttttaacaca gattaaagaa 1380attgtagatt ttgaagaaca aattgatatg gatattttaa acaataaggc tcttttgaga 1440aaagcaaaaa ctatgggctt ttcagataaa atgatagcct tgcttgtaaa tttgaaagat 1500aatttagaat taagccaaaa tgatatttat tatgtaagaa tgaagcaaaa aatcatcgca 1560gaatttagtg aagtggatac ttgtgcgggt gaatttgaag ccttaactcc ttatctttat 1620tcaagtatca atgtaagcga actcactcaa agtaaaaacg atgctaagga taaaaaagaa 1680aaaaaagtga tgattatagg tggggggcca aaccgtatag gacaaggtat agaatttgac 1740tatgcttgcg tacatgcttc ttttgcgctt aaagatatgg gtattaaaac tattatgtat 1800aattgtaatc ctgaaaccgt ttcgactgac tatgatacaa gtgatatttt gtatttcgag 1860cctattgatt tcgaacattt aagagcggtg attgagcgtg aaaaacctga tggagtgatt 1920gtgcattttg gtggacaaac tcctttgaaa tttgctaagc gtttaagtgc ttttggagct 1980aagattatag gtactagcgc aagagtaatt gatatggcag aagatagaaa gaaatttgcc 2040gaatttatta caaagctagg tatcaatcag ccaaaaaatt ctactgcaac aagcgtagaa 2100gaagcggttc ttaaggctag tgatataggg tatcctgtgc ttgtaagacc aagttatgtt 2160ttaggtgggc gtgcgatgcg cgtggtaaat gatgaggctg aacttagact ctatatgcaa 2220gaagctgtgg atgtaagcga taaaagccct gttttgatcg atcagttttt agacaatgct 2280acagaaattg atgttgatgc gatttgtgat ggcaaagatg tttatgttgc aggaattatg 2340gagcacatag aagaagcagg aattcattcg ggtgacagtg cttgttcttt gccgccttgc 2400aatatcgatg aaaaaatgca agaatttatt gcacaaaaaa ccgcagatat tgctttaaat 2460ttgggagttg taggactttt aaatatacaa tttgctttac ataataatga gctttatatg 2520atagaggtaa atcctagagc tagtcgtacc ataccttttg ttagtaaagc tacgggtatt 2580cctttagcaa aagtggcaac gcgtgtgatg tggcaaggaa atttaaaaga agctttaaaa 2640ttttatgata cttttaaagt ggttaatttt gatactaaaa ttttacgccc taaaactcca 2700aaatatatga gcgtgaaaga agcagtattt ccatttgcaa aacttagtgg aagtgattta 2760gaattaggtc ctgaaatgcg ttcaacgggt gaagttatgg gtataagcaa ggattttgca 2820aattcttatg cgaaaagtca aattgcatcg tttaatcatc ttccagagca aggcgtggta 2880tttatctcct taaaagataa ggataaaaaa tataccaaaa aaatcgctgc agaatatgta 2940aagcttggct ttaagcttat ggcaacaggg ggaacttgca aggaaatttt agaaagtggt 3000tttgagtgcg aacttgtaca taaaatttca gaaggacgcc ccaatgttga agataaattg 3060aaaaatggag aaattcactt agttatcaat acaagcgata gtcacagttt taaaggcgat 3120acgaaaaaaa ttcgtgaaaa tattattcgt tttaaaatac cttattttac aaatttacga 3180tcagctttag caggtgcaaa atcgattaaa gctatacaga gtaaatcttg cctagatgta 3240aagagtttgc aagagtggct taaatcttga 3270553365DNACampylobacter jejuni 55atgaaaaata tcacattaac taaaatacct ataggagagg gcaaagaacc ctgtttaaat 60tctaaaaaga tagttttatc tttagctact atttcttttt tggcaagttg tgctaatgct 120aaattaaatt ctgaaataaa aacttatgat gaagttaata aaaatgttaa aactagatca 180gcaagtgttt atagccctca agctaagatc aatacgacta taaattcttt acacaatcaa 240caagtaacta ttactggaaa tggaacatca aattctttaa caatcggatc aagtggaact 300ctaggtagca taggcaatac aggtaaaatc atctatgccc atgctaatgg tagcaacact 360cttactcttg caaatcttac taataataga actattaatg gtaagattgg tatagaaaac 420aatggtaatt ttacaggaac tattgctgtc aacacctttg aaaatacagg tcaaattaat 480ggacaaattt acatgggaat ttggggtaac aactcaggaa ctcttaatat agataaattt 540gacaatagtg gaaccataat tgacaacaat aaaggagttt ttttgaagga aagaatacca 600acatacaaac ctttaataac agtggtttta ttagtgcaaa taagggtgta gatataggca 660acataggaac cataaaaaat tttaataaca acggaactat acaaggctca gaagtgggag 720tggctataaa tacaaaaata gatactttta ctaataatgg ttttattaat tcccctggta 780gtggacaatg gaataatggt atatggataa gtagcaatgc taccatagaa aagcttgtta 840acaatggcac aataaaagga ggacattctg ctataatggt aacatctcag catataaaaa 900ctgttgaaaa tacaggaatt atacatgctg aaggagaatg gggttctagt atattattag 960aatatggtgg ttttatagag catataatca atactggaac cataagtaat aataatgttg 1020gtataggttc agcttatgga gtatttggaa cacttaccat aaaagatgga ggtatggttt 1080atggaaaata ctcggcaata ggagtgggtc gatcgcaaac tctaggagat ttatatatag 1140atggacgttc aaataatggc acagtaagtg gaatttatag tgaagaacat ggaattttat 1200tagagaataa ctcacgaact caaaaaatag aacttaaaaa tggcggcatt ataaaaggta 1260atatcgatgg tataagattg ataaactcgg cctctttaag tggagaaatg attttatctg 1320gcgaaggttc tagggtagaa ggtggaagag gtgttggtat attgaatcga agtggaaaaa 1380tagaaggctc tataaaagta gaagatggag caactgttac ggctacttcg aatcgagcca 1440tagctaactc tggctcagga agtataacag gtggtattac tgttagtggg aaaaacacta 1500aacttgaagg aaatataatc aatacaggta atgcttctat aggtagtgat atcaagatag 1560aaggtggagc taaggtagaa ggtggtcttg ttaatcaagg taatggaagt atctcaggaa 1620gtgttcaagt aagtggtggt agtagtattg attccattac caatgagggt aatggagcta 1680tttctggttc aattactgta tataaagata gtaaacttga ttctatcact aacacttcta 1740catcatctac aggtataagt ggttctatta ctaacaatag tgataataaa cttgaaattt 1800ctaattcagg taatatcggt ggtaagattg aaagtacagg tagtgctgat atggtgatta 1860gcaatagtaa tggtggaact attagtggcg gtattagttc ttcaggaagt ggaagcacta 1920gtatttccaa ttcacaaggc tcaaccataa ataacggcat cactgtttca ggatcagcac 1980aagttgaaat ctccaatcaa ggctcagtag gtaaagatga aaatggtaat acagtaacta 2040acaatggtag tggtagtgtt ggaatcaaag attggcttgt ttctacagat aaaaacacag 2100gtaaattaaa cactgtggtt ataggtggaa gtagagcttt taatgtaaaa gtagaaaaca 2160tcaccgtaga tcaaagcaat gttgatcttg aagagctaaa cgatataaac aacatcatct 2220caggtgttaa tcaaaacaat attggcaata taggaaccaa tggaagtgga gaaatatctt 2280taagctttga tccaataaca ggaaagctta ctacagattt taatcttaat gcttccatat 2340caggtgcaac ctttagatct ttaatctcta ctacttcaag aagatcaacc tttatagata 2400atgttatggg taattctatg caaagctttg ctttagcttc ttcaagtaaa tctcaaagca 2460tcgctatgtc tgaaaagggt aatttatatg cagatgcaag tgattatata aagagtgatt 2520taaataatgg aagctatggt tctaataaag aacattcttt attcatcctt ccttatactt 2580cttcacagaa tgttgaactt tctttaaatg aagaaagtaa aggacacact aaaggaacca 2640ttataggtta ttctacttta aaagacagtg gaatatatgg tgtgtatgca ggttatgaag 2700atacaaaaat gggttcaact tattttgata ttaataatag aacctattat gcaggtttaa 2760aatactttaa taccttattt actacagaaa aaggtcaaga agtttatatc aaagctcaag 2820gtaaagctgc tttgattaaa aatgatttaa ctgaaaaaat aggaaataat gaagctaaag 2880ctgaacctaa ttcttatgct tatggagtca atacagcctt aggtatgaat tttatttcta 2940ataaagatat attctctcct gaaataggtc ttgcttatga aggaggttat actgaagctt 3000tttctatgaa agacaccata ggacaagcaa cagttaaagg tggagaaaga acctatgcaa 3060actatttaaa tcttttctct actaaaacaa gtcttacttg gtttagagat tggttgccta 3120atttaaaaac ttcagtagaa cttggagcta agtttaatat caatcctaaa gtagaagctg 3180aggctagatt tggtaatata aaagtaagtg atgagtttga tttaccaaga gtacaaaaat 3240ttgtaagcac ttcttttatc gttcctgtta atgaagcttt ctattttagt ttaaactata 3300atggaatgtt tgataaagat ggcaataccc atacaggatt tgctcagttt aattatcttt 3360ggtaa 3365563436DNACampylobacter jejuni 56atgaataaaa ctgcattaac taaaacatac acaaaagata tacaaaattc ctgtttaaat 60tctaaaaaga tagttttatc tttagctact atttcttttt tggcaagttg tactcatgct 120acacttactc ctgaaataaa aacttacgaa gagacaaata gacatgctaa agctaggtca 180ggtcttcaat ctagaaattc gaataatgag actataaata atttacaaac tttaactaaa 240actataagtg acaccggcaa tactctagtt atagaaagta gtggaactat tactatttct 300aatgatgggc aacaagcagt aaactttcaa ccaaattctt caacttctac ctttttaaat 360aaaggaactc ttataggtgg aaataatact gctagtgttc aactaggagc agcaaatgga 420aataacggtg ttagcataga aacctttaat aatcaaggta tcataggtaa tggttcttct 480aaatttggag taacagtttt tggggggggg gagtaaagat aaccctaaat ctataatcaa 540taattttagt aatagtggaa ctattcactc taatactggt gaaagtattt attttggtaa 600cgccaaaata tcaagttttg ttaatagtgg gactattaag agtaaacaag gtgcaggagt 660aaatatatct caaggaacaa gtatagagaa ttttaacaat accggaaccg gaattattga 720aggcaagaga atgggtgtaa atgttcgttc aacaataaat accttcgtca atgacggttt 780aattgctgca acgaacgatg gaatacagat aaatgctaat gtaaaaacat taataaataa 840gggaaccata aaaggagatg ctatatctat aagatcatta ggtggaacta tagaaacatt 900gaccaatgaa ggcattatgt atggtaaaag tgctggtatt tacatgaaca gaagtcttgt 960taaaactctt acaaatagcg gtaccattaa tcaaaacaat tcggcaactt ggtctgctgg 1020tataaaactc gaaaatggta gtatcataga aaatatcatc aacacaggat ctatccgttc 1080taatgctttt ggaatatctg taactggtgg taaatttgga acacttacca taaaagatgg 1140aggtatggtt tatggaaaat actcggcaat aggagtgggt cgatcgcaaa ctctaggaga 1200tttatatata gatggacgtt caaataatgg cacagtaagt ggaatttata gtgaagaaca 1260tggaatttta ttagagaata actcacgaac tcaaaaaata gaacttaaaa atggcggcat 1320tataaaaggt aatatcgatg gtataagatt gataaactcg gcctctttaa gtggagaaat 1380gattttatct ggcgaaggtt ctagggtaga aggtggaaga ggtgttggta tattgaatcg 1440aagtggaaaa atagaaggct ctataaaagt agaagatgga gcaactgtta cggctacttc 1500gaatcgagcc atagctaact ctggctcagg aagtataaca ggtggtatta ctgttagtgg 1560gaaaaacact aaacttgaag gaaatataat caatacaggt aatgcttcta taggtagtga 1620tatcaagata gaaggtggag ctaaggtaga aggtggtctt gttaatcaag gtaatggaag 1680tatctcagga agtgttcaag taagtggtgg tagtagtatt gattccatta ccaatgaggg 1740taatggagct atttctggtt caattactgt atataaagat agtaaacttg attctatcac 1800taacacttct acatcatcta caggtataag tggttctatt actaacaata gtgataataa 1860acttgaaatt tctaattcag gtaatatcgg tggtaagatt gaaagtacag gtagtgctga 1920tatggtgatt agcaatagta atggtggaac tattagtggc ggtattagtt cttcaggaag 1980tggaagcact agtatttcca attcacaagg ctcaaccata aataacggca tcactgtttc 2040aggatcagca caagttgaaa tctccaatca aggctcagta ggtaaagatg aaaatggtaa 2100tacagtaact aacaatggta gtggtagtgt tggaatcaaa gattggcttg tttctacaga 2160taaaaacaca ggtaaattaa acactgtggt tataggtgga agtagagctt ttaatgtaaa 2220agtagaaaac atcaccgtag atcaaagcaa tgttgatctt gaagagctaa acgatataaa 2280caacatcatc tcaggtgtta atcaaaacaa tattggcaat ataggaacca atggaagtgg 2340agaaatatct ttaagctttg atccaataac aggaaagctt actacagatt ttaatcttaa 2400tgcttccata tcaggtgcaa cctttagatc tttaatctct actacttcaa gaagatcaac 2460ctttatagat aatgttatgg gtaattctat gcaaagcttt gctttagctt cttcaagtaa 2520atctcaaagc atcgctatgt ctgaaaaggg taatttatat gcagatgcaa gtgattatat 2580aaagagtgat ttaaataatg gaagctatgg ttctaataaa gaacattctt tattcatcct 2640tccttatact tcttcacaga atgttgaact ttctttaaat gaagaaagta aaggacacac 2700taaaggaacc attataggtt attctacttt aaaagacagt ggaatatatg gtgtgtatgc 2760aggttatgaa gatacaaaaa tgggttcaac ttattttgat attaataata gaacctatta 2820tgcaggttta aaatacttta ataccttatt tactacagaa aaaggtcaag aagtttatat 2880caaagctcaa ggtaaagctg ctttgattaa aaatgattta actgaaaaaa taggaaataa 2940tgaagctaaa gctgaaccta attcttatgc ttatggagtc aatacagcct taggtatgaa 3000ttttatttct aataaagata tattctctcc tgaaataggt cttgcttatg aaggaggtta 3060tactgaagct ttttctatga aagacaccat aggacaagca acagttaaag gtggagaaag 3120aacctatgca aactatttaa atcttttctc tactaaaaca agtcttactt ggtttagaga 3180ttggttgcct aatttaaaaa cttcagtaga acttggagct aagtttaata tcaatcctaa 3240agtagaagct gaggctagat ttggtaatat aaaagtaagt gatgagtttg atttaccaag 3300agtacaaaaa tttgtaagca cttcttttat cgttcctgtt aatgaagctt tctattttag 3360tttaaactat aatggaatgt ttgataaaga tggcaatacc catacaggat ttgctcagtt 3420taattatctt tggtaa 3436573561DNACampylobacter jejuni 57atgggtaaaa ttatgaaaac tatggacgga aatgaggctg ctgcatacgc tgcgtatgct 60tttactgaag ttgctggaat ttatcctatt acacctagtt ctcctatggc tgattatacc 120gatatgtggg cagctgcagg aaaaaaaaat ctttttggag ttcctgtaaa aatcgtagaa 180atgcaaagtg aagcaggagc tgcaggtagt gtgcatggat ctttacaagc tggggctttg 240actacaactt atacggcttc tcaaggatta ctccttaaaa ttccaaatat gtataaaata 300gcaggtcaat tactcccctg tgtaatccat gtagcagcgc gttctttggc tgctcaagct 360ttgtctatct ttggtgatca tcaagatatt tatgcagcaa gacaaattgg ttttgctatg 420ctttgttcgc attctgtgca agaaaccatg gacttagctg gtgtagcaca tttagctgca 480attaagggaa gagtgccatt tttacatttt tttgatggtt ttagaacaag ccatgaaatt 540caaaaagttg aagtaatgga ttatgcgcat tttgatagat tattagatag agaagctttg 600cttgaattta gaaataatgc tttaaatcca gaaaatccaa aaacacgtgg aacagcacaa 660aatgatgata tttattttca aactagagaa gtaagcaatc gtttttacga tgctttacct 720gatgttgtta atgaatatat gcaagaaatt tcaaaaatta caggtagaga atacaaacca 780tttacttatt atggtcacaa agagccagag tgtgtgattg ttgctatggg ttctgtaact 840caagcacttg aagaagtggt ggactatctt aatgccaagg gtgaaaaggt agggatttta 900aaagtttatc tttatcgccc atttagttta aaatatttct ttgatgttat gccaaaatca 960gtgaaaaaaa tcgcggtttt agatagaacc aaagaaccag gaagtctcgg agaaccactt 1020tatcttgatg taaaatcagc tttctatgga agagaaaatg ctcctgttat agtgggtgga 1080agatacggac tttcttcaaa ggatgttgat cctgctcaaa tgatagcagt atttgaaaat 1140cttaaacttg ataatccaaa agatggcttt actgtaggta taattgatga tgtaactcat 1200acttcactga gtactggaga gaaaatttca cttggagatg aaagtacgat cgaatgttta 1260ttttacggac ttggtgctga tggaactgtg ggtgcaaata aaaactcgat taaaatcatc 1320ggagataaaa cggattttta cgctcaagct tattttgctt atgattctaa aaaatcaggg 1380ggttatacaa gaagccattt aagattttct aaaaaaccta tccgttcaac ttatcttgtt 1440tcaactccgc attttatcgc ttgttcggta gcggcttatt tggaaattta tgatgtttta 1500gcaggaattc gcaaaggagg aactttcctt ttaaatagta tttggaatgc tgaagaaacc 1560ataagacaac ttccagatgc agtaaagaaa actttagctg aaaaagaagt aaatttttat 1620atcatcaatg caaccaaact agctcgtgat ataggtttgg gaaatcgtac aaataccatt 1680atgcaatcag cctttttcaa acttgcaaaa atcattcctt atgaagacgc acaaaaatac 1740atgaaagagc ttgcgtataa atcttatagt aaaaaaggcg atgctattgt agaaatgaat 1800tacaaggcta ttgatgtggg tgctgatgga cttgtaaaag ttgaagtgga tccaaattgg 1860aaaaatttag agcttaaaga aaaagaacaa accaatgcct ataaaggtac tgaatttgtt 1920gaaaaaatcg taaaacctat gaatgcggct aagggtgatg atttacctgt ttcagccttt 1980ttaggttatg aagatggaag ttttgaacac ggcacaaccg aatacgaaaa acgcggtgtt 2040ggggttatgg taccaagatg gatagaggca aattgtattc aatgcaatca atgtgcttca 2100gtttgtccgc atgctgttat caggccattt ttgattaatg atgaagaaat ggcaaatgca 2160cctcgcggtg taaaagatca tgctttagaa gctaaaggaa ccaaaggaga aaaattaagc 2220tttaaaattc aagtttctcc acttgattgt acaggctgtg agctttgtgt tcatgagtgt 2280cctactaaag aaaaatcttt ggttatggta ccacttcaag aagagatgga ttttggtgag 2340caagaaaatg cggattattt atttaaagaa

attacttata aagatgatat tttaaataaa 2400gaaaccacaa aaggagcgca atttgcccaa cctttatttg aattccatgg ggcatgtcct 2460ggatgtgggg aaactcctta tattacttta attacaagat tgttcggtga aagaatgatt 2520gtggctaatg ctacaggttg tagttctatt tatgggggtt cagctccatc aactccttat 2580agaaaaagtg tgaaaaatgg acacggtcct gcttggggaa attcactttt tgaagacaat 2640gctgagtttg gtttgggtat gaaaattgca actgaaaata caagacaccg cattgaacat 2700atcatgaatg aaagtatgca agaagttcca aatgctttat cagctctttt taaagattgg 2760attgcaaata aagacaatgg tgctatgtct gtggaaatta aagataaaat gatccctatt 2820ttagagcaaa ataaaaatat taaagctgta caagatatat tagagcttaa acagtattta 2880agtaaaaaat ctcactggat ttttggtggt gatggttggg cttatgatat aggctatggc 2940ggacttgatc atgttttagc aagtggagaa aatgtaaata ttttagtgct tgatacagaa 3000gtttattcta atacaggcgg tcaaagttca aaatcttcta gaacaggagc tgtagcacag 3060tttgcagcag caggcaaacc tatacagaaa aaagatctag gtcaaattgc tatgacttat 3120ggttatattt ttgtagcaca agtaaattca acggcaaatt atactcatct tatcaaagct 3180atcactgcag ctgaggccta tgatggacca tctttggtga tttgttattc tccttgtata 3240gctcatggta ttaaaggtgg gctgggttac tcaggagagc aaggtgagct tgctacaaaa 3300tgtggttatt ggccacttta tacctttgat cctcgtttag aagagcaagg aaaaaatcct 3360ttaactctaa caggaaaaga acctgattgg gatttatatg agcaattttt gatgaatgaa 3420gtgcgttata attcacttaa aaaagcaaat cctgaacacg ctgctgagct ttttgaacgc 3480aataaaaaag acgctcaacg tcgctataga cagcttaagc gtattgctat ggctgattat 3540agcaatgagg tcgaaagctg a 3561584137DNACampylobacter jejuni 58atgtgcgata tgttagataa taaattagga aatcgtttaa gagtagactt ctcaaacatt 60tcaaaacaaa tagaaatccc aaatcttcta caattacaaa aaaagagttt tgattatttt 120ttaaatcttg ataatggtga aagtggtata gaaaaagttt ttaaatcaat ttttcctatt 180catgatccgc aaaatagatt gagtcttgaa tatgttagta gtgaaatagg caagccaaaa 240tataccattc gcgaatgcat ggaaagaggt ttgacttatt ctgtaaattt aaaaatgaaa 300atccgtctta ctctgcatga aaaagatgaa aaaacagggg aaaaagttgg cgtaaaagat 360attaaagaac aagaaattta tatccgcgaa attcctttaa tgacagatcg tgtatctttt 420atcattaacg gggttgagag agtggttgta aatcaattac atagaagccc tggtgttatt 480tttaaagaag aagaaagttc aacggttgca aataagcttg tttatacagc acaaattatt 540cctgatcgtg gttcgtggct ttattttgaa tacgatgcca aagatgtttt gtatgtaaga 600atcaataagc gtagaaaagt tcctgtaact atgcttttta gagctttagg gtataaaaaa 660caagatatta ttaagttgtt ttatcctatt cagactatac atgtgaaaaa agataaattt 720ttaacagaat ttaatccaaa tgattttatg gatagaatag aatatgatat taaagatgaa 780aaaggaaaaa tcgttcatca agctggaaaa agacttacaa agaaaaaagc agaacagctt 840attaaagacg gtttaaaatg gatagaatat cctgtagaaa ttttacttaa tcgttattta 900gcaaatccta ttattgataa agaaagtgga gaggttttat ttgattcttt aactttgtta 960gatgagagta agcttgctaa gattaaagag caaaaaagtt ttgatatagc aaatgacttg 1020gctaatggcg ttgatgcagc gattattaac tcctttgccc aagatggaga aactctaaaa 1080cttcttaaac aaagtgaaaa tatcgatgat gaaaatgatt tagctgcgat tagaatttac 1140aaagttatgc gcccaggtga acctgtggta aaagatgcag cgaaggcttt tgtaaatgat 1200ttattcttca atcctgaaag atacgatctt accaaggtag gtcgtatgaa aatgaaccat 1260aaattaggtc ttgaagtacc tgagtatgtt actgttttga ctaatgaaga tattattaaa 1320actgcaaaat atttaattaa agtaaaaaat ggtaaaggac atattgatga tagagatcat 1380ttaggaaatc gtcgtatccg ttctataggt gaacttttag ccaatgaact tcatttaggt 1440cttgcaaaaa tgcaaaaggc gatcagagat aaatttactt ctttaaatgc ggatcttgat 1500aaagtaatgc cttatgattt aatcaatcct aaaatgatta ctacaactat cattgaattt 1560tttacaggag gtcagctttc gcaatttatg gatcaaacca accctttaag cgaggttact 1620cataagcgtc gtttgtcagc gcttggtgaa ggtggacttg taaaagaaag agcaggtttt 1680gaagtgcgtg atgttcacgc gacacattat ggtagaattt gtccagttga aacacctgaa 1740ggtcaaaata ttggtttgat taacactctt tctacttatg caaaagtaaa tgaacttggc 1800tttgttgaag cgccatatag aaaagttgta aatggtaaag tgactaatga agttgtttat 1860cttacagcga cacaagaaga aggcttgttt atcgcaccag cttcaactaa ggttgatgct 1920aaaggcaata tagtagaaga atttgttgag gctaggcaag atggtgaaac tatacttgca 1980agacgcgaag aagtgcaatt aatcgatctt tgctcaggta tggttgttgg agttgcagct 2040tctttgattc cgtttttaga gcacgatgat gcaaacagag cgctaatggg ttcaaacatg 2100caacgtcaag ctgtgccact tcttactgct tcagctccga tagtaggaac aggtatggaa 2160caaattattg cgcgtgatgc ttgggaagct gttaaagcaa agcgtggcgg tgtggttgag 2220aaagtggata ataaaagcat tttcatttta ggtgaagatg ataaaggtcc atttattgac 2280cattacacta tggagaaaaa tttaagaacc aatcaaaata caaattatat tcaacaccct 2340attgttaaaa aaggtgatat agtaaaagca ggacaaatta tcgcagatgg tccttctatg 2400gatcaaggcg aacttgctat aggtaaaaat gctttaatcg cttttatgcc ttggaatggt 2460tataactatg aggatgctat agttgtaagt gagagaatta ttcgtgaaga tacttttaca 2520agcgtgcaca tttatgaaaa agaaattgaa gcaagagaac taaaagacgg tatagaagaa 2580attaccaaag atattccaaa tgtaaaagaa gaagatgttg cgcatcttga tgagagcggt 2640attgcaaaaa ttggtaccca tatcaaacca ggtatgattt tggtgggtaa ggtttctcca 2700aaaggtgagg ttaaaccaac tcctgaagaa agacttttaa gagcgatttt tggagaaaaa 2760gcaggacatg ttgtgaataa atccctttat gcaaccgctt ctttagaggg tgttgttgtg 2820gatgttaaaa ttttcactaa aaaaggctat gaaaaagatg atcgcgcaat aaaatcttat 2880gataaagaaa aaatggcttt agaaaaagag catcatgata gacttttgat gatggataga 2940gaagaaatgc ttcgtgtttg tgctcttctt tccaaagcct ctttaaatag cgatcaaaaa 3000attggagata aaaattataa aaaaggacaa actgcagata ttagcgaact tgaaaaaatc 3060aatcgtttta ctttaacaac tttgattaaa gcttattcta aagagattca aaaagaatac 3120gatgatttaa aaaatcattt ccaaaatgag aagaaaaaat taaaagcaga acacgatgaa 3180aagcttgaaa ttttagaaaa agatgatatt ttaccaagtg gggtaattaa gcttgttaaa 3240gtttatattg ctacaaaaag aaagcttaaa gtcggtgata aaatggcagg acgtcatgga 3300aataaaggta tagtttcaac tatagttcct gaagtagata tgccttattt gccaaatggt 3360aagagcgtgg atattgcgct taatccactt ggcgttccaa gtcgtatgaa tataggtcaa 3420attttagaaa gtcatttagg tttagttgga cttagacttg gggatcaaat tcaagaaatt 3480tttgatagaa agcaaaaaga ttttcttaaa gaattaagag cgaaaatact tgaaatttgt 3540tctattccaa gacttgcaaa cgaaaaagaa tttattaaaa gcttaagcga tgaagagctt 3600ttaaactatg ctagagactg gagtaaagga gttaaatttt ctactcctgt ttttgaaggt 3660gtaaatatag aagaatttag caagcttttt aaaatggcta agatagatat ggatggcaaa 3720acagaacttt atgatggacg cacgggggaa aaaattgcag agcgtgttca tgtaggatgt 3780atgtatatgc taaaactcca tcacttggtt gatgaaaaag ttcatgcaag aagtacagga 3840ccttatagct tggttaccca acaacctgtg ggtggtaaag cactctttgg gggacaaaga 3900tttggagaaa tggaagtttg ggcacttgaa gcttatggag cggctcacac tttaagagaa 3960atgttaacca taaaatcaga tgatgtagaa ggtagattta gtgcctataa agcattgaca 4020aaaggtgaaa atgttccagc aacaggaatt cctgaaacat tttttgtatt aaccaatgag 4080cttaaatctc ttgctttaga tgttgagatt tttgataagg atgaagataa tgagtaa 4137594491DNACampylobacter jejuni 59atggatttag aaaatatcct agaaaataat caaagcatag gtttatatca cccaaagaac 60gaacacgatg cctgtggtat cgctgcagtt gctaatatac gcggtattgc ttcttataag 120gttatttgtg atgctttaga aattttgatg aatcttgaac accgaggtgg tacaggagct 180gaagaaaatt caggtgatgg ggcggggatt ttaatccaaa ttccacatga tttttttaaa 240actcaagaat tgggttttga acttcctaaa aagggtgatt atgctgtagc acagatgttt 300ttatcaccca atactgatgc aaaagaagaa gcaaaagaaa tatttttaca aggtttaaag 360gataaaaaac ttgaattttt aggttttaga gaagtgcctt ttaatcctag cgatataggt 420gcaagtgctt taaaagctat gccttatttt ttacaagcct ttgtaaaaaa accaagtaaa 480ataagtgcag gacttgagtt tgaaagagtg ctttatagta cgcgtcgact tatagaaaaa 540agagctatta atgtgccaaa attttatttt tcaagttttt cttcacgcac catagtttat 600aaaggaatgc ttctttcaac tcaattgagc gatttttatc ttgattttaa agatgtcaat 660atgaaatcag ccatcgcttt ggtgcattct cgcttttcga ctaatacctt cccaagttgg 720gaaagagccc atccaaaccg ttatatggtg cataatggag agattaatac catacgcgga 780aatgttgata gcataagagc tagagaaggc ttgatgcaaa gtgagtattt tgaaaattta 840gatgaaattt ttcctatcat agctaagctt agcagtgatt ctgcaatgtt tgataatact 900ttagaatttt tagctctaaa tggtcgtact ttagaagaag cttttatgat gatggtgcca 960gaaccttggc ataaaaatga aaatatggaa agcaaaaagc gtgcttttta tgaatatcat 1020tctttattga tggagccttg ggatggacct gctgctatag tttttactga tggagtgatt 1080atgggggcga gtttggatag aaatggtttt cgtccttcaa ggtattatct tacaaaagat 1140gatatgctca tactttcaag tgaaacaggg gctttaaaac ttgatgaaaa aaatatcaaa 1200gctaaaaaac gcttagaacc tggaaaactt ttactcgttg atacagcaag aggtagggtt 1260atagctgata atgaaatcaa agagcattat gctaatgcta agccttataa aaaatggctt 1320aaaaatttag ttgaacttga aaaacaaaaa agcggagttt ataaacatca gtttttaaaa 1380gaagatgagg ttttaaaact tcaaaaagct tttggttgga gttatgatga gcttaaaatg 1440agcgtggctg ctatggctca aaatggtaaa gaagctatag cagctatggg tgtagatact 1500cctttggcta tactttctaa aacttatcaa cctttgtata attattttaa acaacttttt 1560gcacaagtaa ctaatcctcc tcttgatgcc ataagagaag agattgttac ttctacaagg 1620atttatctag gaagcgaagg caatttatta aaacccgatg aaaacaatgc aaaacgcgta 1680aaaatagcct tgcctgtgat aagcaatgaa gaactttttg aagttaaggc tttaaataaa 1740tttcaagtta aagaattttc tatactttat gattattcta aaaaaacttt agaaaaggct 1800ttagatgaac tttgcgttaa gatagaagat gaggttaaaa aaggtgtttc tattatcatt 1860ttaagcgata aaggagtgga tgaaaaaaac gcttatatcc ctgctttgct tgctgtttct 1920ggagtgcata atcatctagt aagaaaaaat ttaagaacac atacaagtct tatcatcgaa 1980agtggtgaac ctagagaaat tcatcatttt gcatgtcttt taggttatgg tgcgactgtt 2040attaatcctt atttggttta tgagagtata caaaaactca ttgccaataa agatttaaat 2100ttaagttatg aaaaggcggt agaaaatttc atcaaggcaa gttcaagtgg tatagtcaaa 2160attgcttcta aaatgggggt ttctaccttg caaagttata atggctctgc actttttgaa 2220tgtctgggct taagctctaa ggtgattgat aaatacttca cttctacaac ttcacgcatt 2280gaaggtatgg atttagaaga ttttgaaaaa gaactcattg ctttacacaa acatgctttt 2340aacgatacac ataaggcttt agattctaaa ggaattcatg gttttagaag tgctaaagaa 2400gaacatttaa tcgatccgct tgtgattttt aatcttcagc aagcctgtcg caacaaagac 2460tataaaagct ttaaaaaata ctcggcttta gtagatgaaa aacaagttaa tttgcgttct 2520ttgatggaat ttgattttag tgaagctatc agtatagata aggttgaaag tgtagaaagt 2580atagttaaac gctttagaac aggggcgatg agttatggtt ctatttctaa agaagcacac 2640gagtgtttag cacaggctat gaataaaata ggtgctaaat caaattcagg tgaaggtggt 2700gaggatgaag aacgctatga aatcaaagag ggtgtggata aaaactcagc cattaagcaa 2760gtagcaagtg ggcgttttgg cgtggattta aactacttaa gtcatgcaaa agaaattcaa 2820atcaaagtcg ctcaaggtgc aaaaccaggt gagggcggac aattaatggg ctttaaagtc 2880tatccttgga tagctaaggc tagacattct actgcaggtg tgacgcttat ttccccacct 2940cctcatcatg atatttattc tattgaggat ttggctcaac tcatttatga tttaaaacat 3000gcgaacaaag acgctaaaat ttcagtaaaa cttgtaagcg aaaatggcat aggaacggtt 3060gctgcaggtg tggctaaggc aggcgcgaat ttaatccttg tttcaggtta tgatggaggt 3120acgggtgcaa gtcctagaac ttctataccg catgctggaa ttccttggga gttaggctta 3180gctgaaacgc atcaaacttt gatcttaaat aagcttagag atagggtaag attagaaact 3240gatggaaagc ttatgaatgg gcgtgattta gccatagcag cacttttagg agctgaagaa 3300tttggttttg caaccgctcc tttgattgtt ttaggttgta caatgatgag agtttgtcat 3360ctaaatacct gtccttttgg tatagccact caagatacag aacttagaga tcgtttcaaa 3420ggcaaagtag atgatgtgat taatttcatg tattttatag ctgaggagct tagagaatac 3480atggcaaggc ttggttttga acgcctagat gatatgatag gtcgcgtgga taaactccgc 3540caaaaaagtg tgcaaggtaa agcaggaaag ctaaatttag ataaaatttt aaaatccttg 3600cctacttata atagaaccgc tgtgcatttt aaagattata aagacaataa acttgaaaaa 3660acgattgatt atagaatttt actaccactt tgtaaaaatg ctgtggagaa aaaagagcct 3720atcaaacttt ctttagaagt aggaaatcaa agtcgtactt ttgcaactat gctttcaagt 3780gaaattttaa aaacttatgg aaaagatgct ttagatgaag atagtatcca tatcaaagct 3840ataggcaatg caggcaatag ctttggagcg tttttgttaa agggtattaa acttgagatt 3900ataggcgata gcaatgatta tttaggcaag ggtttaagtg gtggtaaaat catagcaaaa 3960atttcaaatg aagccacttt ttcacctgaa gaaaatatca tcgcaggaaa tgcttgttta 4020tacggagcta caaaaggtga agtgtattta gatggtatag caggggaaag attttgtgta 4080agaaattcag gggctttggc tgtggtttta ggaacaggcg tgcatggttg tgaatatatg 4140acaggtggac aagttgtagt tcttggagat gtgggtgcga atttcgctgc tggtatgagt 4200gggggcgttg tttatatctt tggaagacac aatgaagctc atgtaaatac cgagcttgtg 4260gatattaaag atcttaatgc taaggatgaa aaagaattaa aagctgtgat agaaaaacat 4320atcacttata cagattctaa aaaggctaaa gatattttag aaaaattcga taaaaaagac 4380ttttttaaag tcatgccaag agattatgaa aagatgttaa aaatgcttga tctttgtaaa 4440aatgaaaaag atccaaattt agcagcattt ttgaaaatca cacaaaaata a 4491604554DNACampylobacter jejuni 60atgagtaaat ttaaagtaat agaaattaaa gaagatgcaa gacctagaga ttttgaagca 60tttcaactaa gacttgcaag tcctgaaaaa atcaaatcat ggtcttatgg agaagtaaaa 120aaaccagaaa ctattaatta tagaacctta aagcctgaaa gagatgggct tttttgtgca 180aagatttttg gacctataag agattatgag tgtctttgtg gtaaatacaa aaaaatgcgt 240tttaaaggcg ttaagtgtga aaaatgtggt gttgaagtag caaattcaaa agtgcgtcgt 300tctagaatgg ggcatatcga gcttgtaact cctgtggctc atatttggta tgttaattct 360cttccaagcc gtataggaac gcttttgggt gttaagatga aagatcttga gcgcgtgctt 420tattatgaag cttatattgt tgaaaaccca ggtgatgctt tctatgataa tgaaagtact 480aaaaaagtgg aatattgcga tgttttgaac gaagagcaat atcaaaattt aatgcaacgc 540tatgaaaata gcggctttaa agcaagaatg ggtggagaag ttgttcgtga tttacttgca 600aatttagatc ttgtagcgct tttaaatcag cttaaagaag aaatgggggc tacaaattca 660gaggctaaga aaaaaactat cattaaacgc ttaaaagttg tagaaaattt cttaaattca 720aatttaaacg ccaataccga tagcgacgaa gctgtaccaa atcgtcctga atggatgatg 780attacaaatc ttccagtttt accgccagat ttgcgtcctt tagtggcttt agatggtggg 840aaatttgcag tttctgatgt gaatgactta tatcgtcgtg ttatcaatag aaatacacgt 900cttaaaaaac ttatggaact tgatgcacct gaaatcatta tcagaaatga aaaaagaatg 960cttcaagagg ctgttgatgc gctttttgac aacggtcgtc gtgctaatgc tgtaaaagga 1020gcaaataaac gcccattgaa atctttaagt gaaatcatca aagggaaaca aggacgtttt 1080agacaaaatc tactaggtaa aagggtggat ttctcaggtc gtagcgttat tgttgtaggt 1140ccaaaactta gaatggatca atgcggttta cctaaaaaaa tggctttaga gctttttaag 1200ccacatcttt tagctaagct tgaagaaaaa ggttatgcaa ccacagtaaa acaagctaaa 1260aaaatgatag aaaataaaac caatgaagtt tgggaatgtt tagaagaggt agtaaaggga 1320catcctgtta tgctaaaccg tgcacctact ttgcataagc tttctatcca agcttttcat 1380cctgttttag tggaaggtaa ggctatacaa cttcatcctt tggtttgtgc agcatttaac 1440gcagactttg atggggatca aatggcagtg catgtaccgc tttctcaaga ggctattgca 1500gaatgtaaag tgcttatgct ttcatcaatg aatattcttt taccagcaag cggtaagtct 1560gtaaccgttc catcgcaaga tatggtttta ggaatttatt atctttcgtt ggaaaaagca 1620ggtgctaaag gttcgcataa aatttgtaca ggcattgatg aagtgatgat ggcacttgaa 1680agcaagtgtt tggatattca tgcgagcata caaactatgg tagatggtag aaagattacc 1740actacagcag gaagattgat tgttaaatcc atcttgcctg attttgtgcc tgaaaatagt 1800tggaataaag tcttaaagaa aaaagacatt gctgcgcttg tagattatgt ttataaacaa 1860ggtggtttag agattacagc aagtttctta gatagactta aaaatttagg ttttgaatat 1920gcaactaaag caggtatttc aatttcgatt gcagatatta ttgttcctaa tgataaacaa 1980aaagctatcg atgaagcaaa aaaacaagta agagaaattc aaaattctta taatctcggt 2040ttgattactt caggggaaag atacaataaa atcattgata tttggaaaag tacaaacaat 2100gttctttcaa aagaaatgat gaagcttgta gaaaaagata aagaaggttt taactctatt 2160tatatgatgg cagattctgg tgctaggggt agtgcagctc aaatttctca gcttgctgcg 2220atgagaggac ttatgaccaa acctgatggt tctattatcg aaacgcctat tatttcaaat 2280ttccgtgaag ggctaaatgt tcttgaatac tttatttcaa ctcacggtgc tagaaaaggt 2340cttgcagata ccgctcttaa aacagcaaat gcgggttatt tgacaagaaa actcatcgat 2400gttgcacaaa atgtaaaaat taccattgaa gattgtggaa cacatgaggg tgttgaaatc 2460aatgaaatta ccgcagatag ttctattata gaaactttag aagaaagaat tttaggcagg 2520gttttagctg aggatgtgat tgatcctatt acaaattctg tgctttttgc ggaaggtact 2580ttaatggatg aggaaaaagc aaaaattctt ggcgaaagcg gtataaaaag tgtcaatatc 2640cgcactccta ttacctgcaa agctaaaaaa ggaatttgtg caaaatgtta tggtatcaat 2700cttggtgaag gtaaattagt aaaaccaggc gaagcagtgg gaattatttc cgctcaatct 2760atcggtgaac caggaacgca gctaactcta agaactttcc atagcggggg aactgcaagt 2820acggatttac aagatagaca agtaagcgca caaaaagaag gttttataag attttataat 2880cttaaaactt ataaaaacaa agaaggtaaa aatatcgtag caaatcgtag aaatgcggcg 2940gttttacttg tggagccaaa aatcaaaact ccatttaaag gtgtgattaa tatagaaaat 3000attcatgaag atgtgattgt ttctattaaa gataaaaaac aagaagtaaa atacatatta 3060agaaaatacg atcttgctaa accaaatgaa ttagcaggtg taagtggcag tatagatgga 3120aaactttatt tgccatatca aagcggcatg caagtagaag aaaatgaaag tatcgtagaa 3180gtgattaaag agggttggaa tgtaccaaat cgtattcctt ttgcgagtga aattttagta 3240gaagatggcg agcctgtagt tcaaaatatc aaagcaggcg aaaaaggaac actcaaattt 3300tacatcctta aaggcgatgg tttagataga gtaaaaaatg ttaaaaaagg tgatattgtt 3360aaagaaaaag gattctttgt agtgattgct gatgaaaatg atagagaagc aaaaagacac 3420tatatcccaa gagaatctaa gatagaattt aacgatagtg aaaaaatcga tgacgcaaat 3480actatcattg caagtgctcc taaaaaagaa agaaaagtga ttgcagaatg ggatgcttat 3540aataatacta tcattgcaga aattgatggt gttgtaagct ttgaggatat tgaagcaggt 3600tatagtgccg atgagcaaat tgatgaagct acaggtaagc gttctttagt aattaatgag 3660tatttaccta gcggagttag accaactttg gtaattgcag gaaaaggtga taaagctgtg 3720cgttatcacc ttgaaccaaa aaccgttatt tttgttcatg atggcgataa aattgctcaa 3780gcagatattt tagcaaaaac tccaaaagca gcagctaaat caaaggatat tacaggaggt 3840cttccaagag tttctgaact ttttgaagca agaaaaccaa aaaatgcggc tgtgattgca 3900gaaattgatg gtgttgttcg ttttgataag cctttgcgtt ctaaagaaag aattattatc 3960caagcagaag atggaacaag tgctgagtat ttaatcgaca aatcaaaaca tattcaagta 4020agagatggag agtttattca tgcaggtgaa aaacttacag atggagttgt ttcgagtcat 4080gatgtgctta aaattttagg tgaaaaagcc ttgcattatt atttgatttc tgaaattcag 4140caagtttatc gcggacaagg tgttgtgatt tctgataaac atatagaagt tatcgtttct 4200caaatgctaa gacaagtaaa agttgtagat agtggacata cgaaatttat tgaaggtgat 4260ttggtttcaa gacgtaaatt ccgtgaagaa aatgaaagaa tcattagaat gggtggagaa 4320ccagctattg ccgagcctgt gcttttaggt gtaacaagag cagcgattgg aagtgatagt 4380gtgatttctg cggcttcatt ccaagaaact accaaagttt taactgaagc aagtatagca 4440ggtaaatttg actacttaga agatttaaaa gaaaatgtta ttctaggtag aatgattcct 4500gttggaacag ggctttatgg cgaacaaaat ttaaaactta aagaacaaga ataa 455461156RNACampylobacter jejuni 61auggcuuaug aagaugaaga agauuuaaau uacgaugauu augaaaacga agaugaagaa 60uauccacaaa aucaccauaa aaauuauaau uacgaugaug augauuauga auacgaugau 120gauaacaaug augaugauuu uuaugagaug gauuaa 15662198RNACampylobacter jejuni 62augaucaauc cuauacaaca aaguuaugug gcaaauaccg cauuaaauac aaauagaaua 60gauaaagaaa cuaaaacaaa cgauacucaa aaaacggaaa augauaaagc gaguaaaauc 120gcagagcaga uuaaaaacgg uacuuauaaa aucgauacaa aagcuacagc ugcugcgauu 180gcugacucuu uaaucuaa 19863351RNACampylobacter jejuni 63augaaaaaaa uacuuauucu acuuacacua

ugugcuuuug cuuuuggugc aagugaaugu 60gauagaaaaa ucgaucguau caauaaagaa aucaguuuuu cuaaagcgca uaaugauaca 120gcuagaacuu uaagcuuaga gcuugcuuua aaacaaguac aaaaugauug ugcuaaagau 180ccuauguuuu augauaaaaa guuagaagcu aaaaaacuua aagaacaaga aguggaaaaa 240aucgaaaaag aacuugaugc uuuaaaagaa caaaaagauu auaugagcaa ggcugaguau 300aaagcuaaaa aagaagcuuu aaaagaacaa aaagagaaaa ucaaaaaaua a 35164417RNACampylobacter jejuni 64augaguuuug gugaaauuau aguuauuuua guuguagcga uuuuagucuu aggaccugau 60aaacuuccag aagcuauagu acaaauagca aaaauucuaa aggcuguaaa acgcaacaua 120gaugaugcaa aaucaagcau agaaaaagaa auacgcauca augacuuaaa agaagaagcu 180aagaaauaca aagaugaauu uucaagcacu aaugaaaaua uacgcaaaaa acucagcuuu 240gaagaauuug augaccuuaa gagagauauu uuagauaaaa caaagguaga uuuaaccuuu 300gauagcagag augauaaagu aaaaaauaac cuuagcggac aaaauuuaaa uacagaagaa 360aaaccaaauc uuagcaaauu agaaacacaa gauaaaaacg gaaaaauaaa uguuuga 41765426RNACampylobacter jejuni 65augcaaaaag cuaaaauuuu aauugccuua aguuuuuuuu uauuaguuuu aucugccugu 60ucuaaugaug aaaaaaauau uuccaagacu caaaauacag aucaagaagu aguccaaaua 120gaacaaaacg augaaaaaac agaauuaagu gacuccaacc ugccuuuacc uguagaugau 180gaagcacaaa guucaaauga ugaacaugaa gucaauccua guauuaucaa cucuuuauau 240aaacaaaaau gcgccacuug ucauggagaa aaaggggaau uaaaaccuaa aaacagcacg 300gccauuaaaa ccuugagcaa uaaaauuuuu auacaaaaaa uaaaaacgau aaaagauaaa 360aaccauaguu uuuuaaguga ugaacaaauu caaaauuuag cugauuuuau aaacaaagga 420aaauaa 42666435RNACampylobacter jejuni 66augcgaagac uaaguauuuu acuugcaauu uuaauaguua uuaauauaac agcuugugau 60aguaaaacag aaaauuacua caaaaaucuu ccuagcgaag caaaagaaaa agcgaaagaa 120ugcaaagaaa gcggaacucu uagcgaagau uguauuaaug cauuaaaagu ugguguuaaa 180ccaacaaaug aagaggguaa auacagucca aacacaccga aaaaaucuga uaaucaaaua 240uuagaagcuu uaaaacaaaa ugauuuaaaa aaagaaaaaa ccacaaaaga uauuaaccaa 300aguucagaaa auaaugaaag uauuauaaua ccaccuauag cagaaacacc uucugaaauu 360uauccuucca aaacaacaga aaacaaucaa aguucuaucu uuagcgauga uguuaauaug 420acacaggaaa aauga 43567525RNACampylobacter jejuni 67augaugaaga agaaauuggu uuuauuagga agugcugcag ugguauuuuu ugccgcuugu 60gcaaugaaua gugggguaag uucagaacaa auuggacuua gaaaagcaag uuuagaaaau 120gaaaauaaag uaaauuuagu ggaggcaaau uucacaacuu uacagccugg ggaaucuacu 180cguuuugagc guucuuauga aaaugcacca ccauuaauuc cgcaugcuau ugaagauuug 240uuaccuauaa cuaaagauaa caauaugugc uuaagcugcc augauaaggc uauagcagca 300gaugcuggug caacuccacu uccugcuagu cauuauuaug auuuuagaca caauaaaacc 360acaggagaua ugauuagcga uagucguuuu aauugcacuc agugucaugu uccacaaagu 420gaugcaaaac cuuuaguggg aaauagcuuu aaaccugaau uuaaaaauga acaauuaaaa 480agucguucaa auuuaauuga ugugauuaau gaggguguaa aguaa 52568606RNACampylobacter jejuni 68augaaaaaaa ucaaaaaaau cauucaaauu gguaugauag gugguuuagc agcuguugcu 60ggaggugcuu uagcagguug uggaaguaau aaugacaaug cagauacuuu aaaucaagcg 120gcuaaugcuc aaggagcuuu uguaauuauc gaagaaacag cuccagggca guauaaaauc 180aaagaucaau auccaaguga ugaaacaagg guaguuuuaa aagaucuuaa ugguacagaa 240agaauuuuau ccaaagaaga aauggaugcu uugauuaaag aagaagcagc uaaaauugau 300aauggaacuu caaauuuaac uaaagacaau ggacaaauca guaguggggg auugaguuua 360ggggaaacuu uacucgcaag ugcugcaggu gcuauuuuag gaaguuggau agguucaaaa 420cuuuucaaua aucaaaauuu ugccaaccaa caacgcggug cuuuuucaaa ucaaagugcu 480uaucaaagga guguuaauag uuuuaauaaa gcaggcacaa caagcucugc uucaagugcu 540aaaaaaucag guuuuuuugg uggaggcucu aaagccacaa guucuaguuc uucuuuuggc 600ucuuaa 60669633RNACampylobacter jejuni 69augacaaaau uuuuaagcau uuguaguuua auugcgaugu uguuaagugg uuguggaagu 60gauuuuccug gacaaccuag cgauguggcu agaguucagc aaaacaaaua uccaaaugga 120aauuuaaaaa aagaaauucc cuauaauaaa gauucaagaa uacauggguu aaaaagagcu 180uuuuaugaca auggucagcu aagagcugaa gaaaauuaua aaaauggaaa aaaagaugga 240auuagcaggg aauauucuag aaaugggcaa uuacuugagg aggugcauuu uaaagauaau 300cgcggauaug gugauuuugc aagcuauuau gagaauggaa auaugagagc aaagggaaaa 360cuacuuggcu auaaugaaga ugguaugcca gaauuugaag guaauuacaa ggaauauuau 420gaaaauggaa cuuuaaugug ugauuauaau uuugauaaua aagguaaauu ugauggagua 480caaaagcguu augaugaaaa uggcgccuua gaagacgaag aaaauuauaa aaauggacuu 540aaaaauggag ucuuuagaga auauaaaaaa ggggagauug uaagagaaga agaauauaaa 600aaugguauuu uaguagcaaa accuaaaaau uag 63370735RNACampylobacter jejuni 70augaaaaaaa uauuuuuaag uguuuuuuug guuuugaguu uaaaugcuca aaaucuugaa 60auagauaaaa uaagaacaga uuuguauucu aaaaguggag caaauguucu uaaaaaaguu 120gaaauuucuu uggaauuuga ugggaauaau uuaaaagaaa augaaaauaa guuaauugau 180gcuguaaaua caguaauuuc aggguuuuuu uaugaagaua uuuuuacaga aauuggaaaa 240aauaauuuua aaaaaacuuu agaaaaauuu uuagauaaga aauauaagau uaaacuagau 300gauauauaua ucauaucuuu aaguggagug gaaaaauuug auuuagagga guuuaaacgc 360uuuuuagaaa guacugaggc uaaagagaag gguaugggua gcgagguaaa aaaagcacuu 420gaaaacuuag aaguuccuaa aacucaaguu ccuaguguug aaaagauccc aacuccuagu 480guuccaaauu uagaagucaa gcaaguugaa cagcuuuuca aagauccaga ugaagaaaau 540aaaaaugaca auggagaaau caauauagau aauuuaaaua caccuaaaau gacuccagau 600auagaagaaa aaauuaaaag agauuuaauc gccaauccuc cacaaauauu caaagaaaau 660aacgcaagca agccuuauca uuugccacaa acaggcuaug auauaaagcu ugaugagaau 720ucaacgcaaa auuag 73571780RNACampylobacter jejuni 71augaaaaauu augguuugag uaauuuaaau ucguuuuuac uugcuuuagc aauauauauu 60aguauaguaa uucuuguuuu uuuuagacuu guaagcgagg uugaaccugc uauacaauau 120acugauauaa aagauaguuu uguagauauu gaacuugcug aaccaucaaa acaaguuauu 180acucaaagca acacuccuaa agaaauacaa aaaccaacag agcaaauuga uauagaaaag 240cuuuuugcuc agacuacaaa uaaaacaguu aaaacugaag auauugacca aaaggcaagu 300aauuuuaaug agcuuuuugg aaauauuaaa gaaauacaag aagaaaagac uacaaaaauu 360caaucaagug cuaaaucagg aauuucuagu gccccaaaac cucaagcuuc ugaacuugua 420aaacaacuua augauaguuu acuucaagaa gaaaguucaa cgcaaggcga aagcacaaag 480gcgcaaaaga uuggaauuua ugaugaauuu uuagggaaag uugugcguau uaucacucaa 540agauggacuc aguauuaucc aaauagugaa aaaauuucug uuaagguaaa aauuuuuauu 600gaugaaaaug gaaaauuugg cuauacuuca guugaaaaaa gugggaaucc uuuauaugau 660gcuaaagugg cugaauuuuu agaaagucaa aaagguaaau uuauuacuua uccuccgcaa 720aauaaaaaua uaagcauuac caugaauuua agagaugaag uaaaaguuaa aaaugauuag 78072822RNACampylobacter jejuni 72augaaaaaau uuucuuuagu cgcagcaacu uugauugcag guguaguuuu aaauguaaau 60gcagcuacag uagcuacugu uaauggcaag agcauuagcg auacagaagu aagugaauuu 120uuugccccua ugcuuagagg acaggauuuu aaaacuuugc cagauaauca aaaaaaagcu 180cuuauucagc aauauauuau gcaagauuua auuuugcaag augcuaaaaa acaaaauuua 240gaaaaagacc cuuuauacac aaaagaacuu gaucgugcaa aagaugcaau acuuguuaau 300guuuaucaag agaaaauuuu aaauacuauu aaaauugaug cggcuaaagu uaaagcuuuu 360uaugaucaaa auaaagacaa auauguaaaa ccugcaagag ugcaagcaaa acauaucuua 420guagcgacag aaaaagaagc uaaggauauu auuaacgaac uuaaagguuu aaaagguaaa 480gaacuagaug cuaaauuuag cgagcuugcu aaagagaaau caauugaucc agguucaaaa 540aaccaaggug gugagcuugg uugguuugau caaucaacua ugguaaagcc uuuuacagau 600gcugcuuucg cgcuuaaaaa ugguacuauu acuacaacuc cgguaaaaac gaauuuuggu 660uaucauguaa ucuuaaaaga aaauucgcaa gcuaaagguc aaaucaaauu ugaugaagua 720aaacaaggua uugaaaacgg acuuaaauuu gaagaauuua aaaaaguuau caaucaaaaa 780ggccaagauc ucuuaaauag ugcuaaagug gaauauaaau aa 82273837RNACampylobacter jejuni 73auggaaaauc aaaaaaauga auuugaugau auuauuuuag aaaaaaguaa uaaaagugaa 60aaaguaaaaa aaauucuuuu acgaguuauu gcuuuaguua uuuuguuuuu agcuaucaug 120auaguuauga agcuuauuaa ugguaguggu gaugaaaaua cgcaaaauca aaguguauug 180ccaagugaac cuauagcaac ucaagacaau aacaaugaua cuucuuuuga aaguaugcca 240auuacagaua auacuucagc agaagaucaa uuugaggcau uaagaaaaca auuucaagau 300gaacaaaaua caacucaaaa uacaacaacc ucuaguucaa auaacaauga uacuacaaau 360uuugcuaugc cugaucaaga aguuccagca gaaccaacag caacuacuuc agcaaauacc 420acuccacaag caaguacucc uaaacaagaa guaacacaaa cugcaaaauc uaaagaagaa 480gcaaaaaaac aaacagcugu aaaaaaagaa aaagaaagug caaaacaaac cccuaaaaaa 540gaacaaaaug caaaugauuu auuuaaaaau guugaugcua aaccuguaca uccaaguggu 600uuagcaucgg guauuuaugu gcaaauuuuc ucaguaagua auuuggauca aaaaucaaaa 660gaacuugcuu cuguaaagca aaaagguuau gauuauaaac uuuauaaaac uacaguugga 720aguaaagaaa uuaccaaggu uuuaauagga ccauuugaaa aggcagauau ugcagcagaa 780cuugcuaaaa uccguaagga uauugcaaaa gaugcuuuuu cuuuuacuuu aaaauga 837741173RNACampylobacter jejuni 74augaaaaaga agauuguuuu aaucauuuua auugcaauac uuggaagugu uggggcuuau 60uuuauuuuuu uuaauaauga ugaaaaaauc agcuauuuaa cucaaaaaau acaaaaaaaa 120gauauaucuc aaaccauaga ggcaguagga aagguauaug ccaaagauca agucgaugug 180ggugcucaag uuaguggaca aauuauaaaa cuuuauguug augugggaac ucauguaaag 240caaggugauu ugaucgcuca aauugauaaa gauaaacaac aaaacgauuu agauauuaca 300aaagcucagc uugaaagugc uaaggcuaau uuagagagua aaaaaguugc ccuugagauu 360gcgaauaagc aauaucaaag agagcaaaaa cuuuaugcag cuaaagcaag uucucuugaa 420aauuuagaaa cucaaaaaaa uaauuauuau acuuuaaaag ccaauguugc agagcuuaau 480gcucaaguag uucagcuuga aaucacucuu aaaaaugcac aaaaagauuu agguuauaca 540accauuacug cuccuaugga ugguguugug auuaauguag cuguagauga aggacaaaca 600guuaaugcua aucaaaacac uccuacuaua guccguauag cuaauuuaga cgaaauggaa 660guaagaaugg aaauagcaga ggcugaugug aguaagauaa aaguaggaac agagcuugau 720uuuucuuugc uuaaugaucc ucaaaaaacu uaucaugcua agauugcaag uauagaucca 780gcugauacug aagugaguga uucuaguaca agcucaagcu caucaaguuc gaguucuuca 840agcucaagcu caucaaaugc uauuuauuau uacgcaaaau uuuauguagc caauaaagau 900gauuuuuugc guauugguau gaguauacaa aaugaaauug ucguagcaag ugcaaaggcu 960guuuuagcag ugccaacuua ugcaauuaaa agcgauccaa aaggcuauua uguugaaauu 1020uuggaaaauc aaaaagcugu uaaaaaauau gucaaacuug gcauuaaaga uucuaucaau 1080acucaaauuu uagaaggugu aaaugaagau gaagaauuga uaguaagcuc aagugcugau 1140gguuuagcuc cuaaaaugaa guugagauuu uaa 1173751629RNACampylobacter jejuni 75augaaaauuu uacuuuuaaa ugaaaacccu guaguuucaa gacuuguaag ccuuagugcu 60aaaaaaaugu cuuaugauuu ugaagaacuu aaugcuuaua gugaaaauuu ggguaauuau 120gaugugauug uuguagauag ugauacucca gcaccuuuaa aaauucuuaa agaaaaaugc 180gauagguuga uuuuuuuagc cccgcgaaau caaaauguag aagauauaga ugcgcaaauu 240uuacaaaaac cuuuuuuacc uacagauuuu uuaaauuuac uuaauaauaa agaugcgaac 300aagcauacau cuauugauuu gccaauguua agcaaugaug aaaauccuua ugcugauaua 360agcuuggauu uagauaauuu aaauuuagau gauuugccug augaaaauuc uuuagauaua 420aauucagagg gaauggaaga uuugaguuuu gaugaugaug cucaagauga uaaugcaaac 480aaaacuuuag aaacucaaaa uuuagaacau gaaacaauua aagaacagac ucaagaagac 540acucaaauug auuuagauuu aacuuuagaa gauggcgaaa gugaaaaaga agacuuaagc 600caagaacaua cagcuuugga uacugagccu aguuuagaug agcuagauga uaaaaaugau 660gaagauuuag aaaucaaaga agaugauaaa aaugaagaaa uagaaaagca agaauuauua 720gacgauucua aaacaaauac auuagaaaug caagaagagc uuagcgaauc ucaagaugau 780aauucaaaca aaacuuuaga aacucaaaau uuagaacaug acaauuuaga acaagaaaca 840auuaaagaac agacucaaga agacacucaa auugauuuag auuuaacuuu agaagauggc 900gaaagugaaa aagaagacuu aagccaagaa cauacagcuu uggauacuga gccuaguuua 960gaugagcuag augauaaaaa ugaugaagau uuagaagaua auaaagaauu acaagcuaau 1020auaagcgauu uugaugaucu uccugagguu gaagagcaag aaaaagaaau ggauuuugau 1080gaucuuccug aggaugcuga auuuuuaggu caagcaaaau auaaugaaga aucagaggaa 1140aauuuagagg aguuugcucc uguuguggaa gaagauauuc aagaugaaau agaugauuuu 1200gcuucaaauu ugaguacuca agaucaaauc aaagaagaac uagcucaacu ugaugagcuu 1260gauuauggua uugauaguga caauaguagc aaggucuuag aagauuuuaa agaugaacca 1320auuuuagacg auaaagaauu aggaacaaau gaagaggaag ugguugugcc aaauuuaaau 1380auaagugauu uugauacauu gaaagaaagu gauauacaag aagcucuugg agaggaaauc 1440uuagaaaaaa augaagagcc uauaguaagu gauguaacua aagaugauaa uagcgaagag 1500auaguuaaug agcuuagcca aagcauagca ggagcgauca cuucaaguau uaaagaugau 1560accuuaaaag cugcucuuaa ggguaugaau augaauauaa auauaaacau uaguuuuaaa 1620gaggauuga 1629761833RNACampylobacter jejuni 76augaaaaaaa auauuuuacg cuuagguauu gucguuuugg uuuuacuuau agcgggaguu 60uuauggcuaa auaaugauau caaucaaaaa aaagaagaug aagcaaauaa aaaugccauu 120gcagcaaaug cugauuuuuc uuugcuuagc gaugaugauc caaauuuuga aaaauggggu 180aagguuuuuc cagagcaacu aaaaauguau uuaacgguug aaaaagaaga gccuaaggcu 240acugaauuug gugguaauuu agcuuauuca aaauuaauuc gcuuuccuca auuaaccaua 300cuuugggcag gauauccuuu uagucuugau uucaaugaag aaagagggca uuuuuggguu 360caaguagauc aaaugaaaac agcaagaaac aacaaagauu uucuuaaugc ccauggacuu 420gcugcuuuua aaggucaacc ugcagcuugu augaauuguc auaguggaug gacuccaugg 480cuuauaaaaa auguugcuaa aggagauuuu acugcuuuua acucuacaaa uuauuggacu 540augauuaaaa auaucccagc uguugauggu auaguagaaa auucaccuga acaugcaggc 600ccacauggug guaaaagaau ggguguaacu ugugcagauu gucacaaucc aaaugauaug 660aguuuaagac uuacucgucc agcagcuauu aaugcuuuag uuucuagagg auaugaaaaa 720gauccaguac aaggcguaaa agcuacaaga gaagaaauga gaacuuuagu uugcucucaa 780ugucauguug aauacuauuu uaaaccaaca ggggaaaaag uaaaaguaau gggugaaacu 840auuguagaug auaguucuaa aaaauggugg aauggaacuc agaaaaauua ugaugaguau 900gaguuuugga gagauggcaa uaaaguuaaa gagauugaaa ccgaugguau aguuuuaacu 960uuuccuugga gugaguggaa aaaaggacaa ccauuuagaa uugaaaugcu agaugauuau 1020uaugauaaag uucguggagu auuuggagcu gauuuuacuc auaaauuaac aggagcgcaa 1080auuauuaaaa uucaacaucc agaaagugaa cuuuauagug gcggugugca ugcugcaaau 1140ggaguaaguu gcguggauug ucauaugccu uauguuagag aaggagcuaa aaagguuacu 1200caacacaaua ucacuucucc uuuaagagau auuaacucug cuuguaaguc uugucauaaa 1260caaagugaag auuauuuaaa agcucaagug cuugacauac aaaacagcgu ugcacaugau 1320caaagaacug cagaguaugc aauuguuagu uugauuaugg auacuaaaaa auuacgcgau 1380gaacuaggca auauggaaaa auuccaaagc gauggaaaag cugaugcgaa aaaaauuagc 1440gaagagcuaa aagaaguuuu agaacuucau cguaaagcuc aaaugagagc ggauuuuguu 1500aaugcugaaa acucaacugg uuuccauaau ccucgcgaag cuucaagaau guuauugcaa 1560gcuguugaua uggcaagaau gggacaaacu aaacuuguag aaauugcagc ggcaaaugga 1620auuaaagauu uuaaaacuuc aaauuuaggu uuugaagaua uucaaaaauu uaauccagga 1680gagcuuuauu auaaaguaga uguuaauaau cauaaagcug gagagcguua cuaugcagau 1740gaaaaagaug uuaauggcaa uccuccaaaa gaacuuuuag agcaugauaa agagcuugcu 1800ccuuauaauu aucaagugau ugauaaaaaa uaa 1833771980RNACampylobacter jejuni 77augaaaagcg uaaaauugaa gguuucgcug auugcaaauu uaaucgcagu aguguguuug 60auaauuuuag guguuguaac auuuauauuu guaaagcaag caauuuuuca ugaaguugug 120aaugcugaaa uaaauuaugu uaaaacggcu aaaaauucua uagagucuuu uaaggcaaga 180aauucuuuag cucuugaaag uuuagcuaaa aguauuuuaa agcauccuau agaacaguua 240gauagucaag augcuuuaau gcauuauguu ggaaaagauu uaaagaauuu uagagaugcu 300ggaagauucu uagcaguuua uauugcucaa ccaaauggcg aacuuguugu aagcgaucca 360gacucugaug cuaaaaauuu agauuuugga acuuauggaa aagcugauaa uuaugaugcu 420agaacaagag aguauuauau agaagcaguu aaaacaaaua aacuuuauau uaccccaucu 480uauauugaug uaacuacaaa uuuaccuugc uuuacauauu cuauuccgcu uuauaaagau 540gguaaauuua uagggguuuu ggcuguagau auucuugcgg cagauuugca agcugaauuu 600gaaaauuuac cagguagaac uuuuguauuu gaugaagaaa auaaaguauu uguuucuaca 660gacaaagcuc uuuuacaaaa agguuaugau auuagugcaa uugcaaaucu ugcuaaaacu 720aaagaggauc uugaaccuuu ugaguauacu agaccaaaag augguaauga aagauuugcu 780guaugcacaa agguuucugg aauuuauacu gcuugcguug gagagccaau agaacaaaua 840gaagcuccag uuuauaaaau ugcauuuaua caaacugcga uuguuauuuu uacaaguauu 900auuagcguca uccuccuuua uuucaucgua ucaaaauacc ucuccccacu ugcagcuauc 960caaacagguu uaacuucauu cuuugauuuu aucaacuaua aaacaaaaaa uguuuccacu 1020auagaaguaa aaagcaauga ugaauuugga caaaucucaa augcuaucaa ugaaaacauu 1080cuugcuacua aaagaggcuu agaacaagac aaucaagccg uuaaagaauc aguucaaacc 1140guaucaguug uagaaggugg uaauuuaaca gcaagaauua cugcuaaucc aagaaaccca 1200cagcuuauug aacuuaaaaa uguucuaaau aaacuucuug auguuuuaca agcuagagua 1260gguucugaua ugaaugcuau ucauaaaauu uuugaagaau acaaaagcuu agacuuuaga 1320aauaaauuag aaaaugcuag cgguagugua gaauuaacua cuaaugcuuu aggugaugaa 1380auaguuaaaa ugcuaaaaca aaguucagac uuugcuaaug cuuuagcuaa ugaaagugga 1440aaauuacaaa cugcuguuca aagcuuaacc acuucuucaa auucucaagc ucaaucuuua 1500gaagaaacug cagcagcuuu agaagagauc acuucuucua ugcaaaaugu uucaguuaaa 1560acuagugaug uuaucacuca aucugaagag auuaaaaaug uuacagguau uauaggugau 1620auugcagauc aaaucaaucu uuuagcuuua aaugcagcua uugaagcagc ucgugcugga 1680gaacauggua gaggcuuugc agugguagcu gaugaaguua gaaaguuagc ugaaagaacu 1740caaaagucuu uaucagaaau ugaagcuaau acuaauuuac uuguucaauc uaucaaugau 1800auggcagaaa guauuaaaga acaaacugca gguaucacuc aaaucaauga uagcguagcu 1860caaauugauc aaacuacuaa agauaauguu gaaauugcua augaaucagc uauuauuucu 1920aguacaguaa gugauauagc uaauaauauc uuagaagaug uuaagaagaa gagguuuuaa 1980781998RNACampylobacter jejuni 78augcaaucaa uaaauucagg caaauccguu ggaauuucag cuaagcuuac gcuauggguu 60ggaauuuuag uuguauuaau uuuagcaauc acaagugcua uuaguuacuu ugauucgaga 120aacaauacau augaauugcu aaaagacacu caguuaaaaa cuaugcaaga uguggaugcu 180uucuuuaaaa gcuaugcuau gucaaaaaga aaugguauuc aaauacuagc caaugagcua 240acaaaucguc cugauaugag cgaugaagag cuaaucaauc uuaucaaagu aauuaaaaaa 300guuaaugacu acgaucuagu uuauguagga uuugauaaua caggaaaaaa uuaucaaucu 360gaugaucaaa uuuuagaucu aucaaaaggu uaugauacua aaaaucgucc uugguauaaa 420gcugccaaag aagcaaaaaa gcuuauagua acagaaccuu auaaauccgc cgcuagcgga 480gagguugguu uaacuuacgc ugcuccauuu uaugauagaa auggaaauuu uagagguguu 540guagguggag auuaugaucu agcaaauuuu ucaaccaaug uuuuaacugu aggaaaauca 600gacaauaccu uuacugaagu acuugauuca gaaggaacaa uacuuuuuaa ugaugaaguu 660gcuaaaauac uaacaaaaac agaauuaagu aucaauaucg ccaaugcaau caaagcaaau 720ccugcucuua uugauccaag aaaccaagau acuuuauuua ccgcuaaaga ucaccaaggc 780guagauuaug cgauuaugug uaauucugcu uuuaauccuu uauuuagaau uuguacaaua 840acagaaaaca aaguuuauac cgaagcuguu aauucuauuu uaaugaaaca aguuauaguu 900gguauuauag cuauaaucau agcuuuaauc uugauuagau uuuuaaucag cagaagucuc 960uccccacuug cagcuaucca aacagguuua acuucauucu uugauuuuau caacuauaaa 1020acaaaaaaug uuuccacuau agaaguaaaa agcaaugaug aauuuggaca aaucucaaau

1080gcuaucaaug aaaacauucu ugcuacuaaa agaggcuuag aacaagacaa ucaagccguu 1140aaagaaucag uucaaaccgu aucaguugua gaagguggua auuuaacagc aagaauuacu 1200gcuaauccaa gaaacccaca gcuuauugaa cuuaaaaaug uucuaaauaa acuucuugau 1260guuuuacaag cuagaguagg uucugauaug aaugcuauuc auaaaauuuu ugaagaauac 1320aaaagcuuag acuuuagaaa uaaauuagaa aaugcuagcg guaguguaga auuaacuacu 1380aaugcuuuag gugaugaaau aguuaaaaug cuaaaacaaa guucagacuu ugcuaaugcu 1440uuagcuaaug aaaguggaaa auuacaaacu gcuguucaaa gcuuaaccac uucuucaaau 1500ucucaagcuc aaucuuuaga agaaacugca gcagcuuuag aagagaucac uucuucuaug 1560caaaauguuu caguuaaaac uagugauguu aucacucaau cugaagagau uaaaaauguu 1620acagguauua uaggugauau ugcagaucaa aucaaucuuu uagcuuuaaa ugcagcuauu 1680gaagcagcuc gugcuggaga acaugguaga ggcuuugcag ugguagcuga ugaaguuaga 1740aaguuagcug aaagaacuca aaagucuuua ucagaaauug aagcuaauac uaauuuacuu 1800guucaaucua ucaaugauau ggcagaaagu auuaaagaac aaacugcagg uaucacucaa 1860aucaaugaua gcguagcuca aauugaucaa acuacuaaag auaauguuga aauugcuaau 1920gaaucagcua uuauuucuag uacaguaagu gauauagcua auaauaucuu agaagauguu 1980aagaagaaga gguuuuaa 1998792253RNACampylobacter jejuni 79augagaauua caaauaaacu uaacuucaca aauaguguga auaauucuau gggcggucaa 60agugcuuuau aucagauauc ucaacaacuu gcuucagguu ugaaaauaca aaauucauau 120gaagaugcaa gcacuuauau agauaauacg cgucuugaau augaaauuaa aacguuagaa 180caaguaaaag aaucaacaag uagagcucaa gaaaugacuc aaaauaguau gaaagcuuua 240caagauaugg uuaaacuucu ugaagauuuu aaaguuaaag uaacccaagc ugcaagcgau 300agcaauucuc aaaccucaag agaagcuaua gcaaaagaac uagaacguau aaaagaaagc 360auaguucagc uugcaaauac caguguuaau ggucaguauc uuuuugcggg uucucaaguu 420gcaaacaaac cuuuugauuc uaauggaaau uauuauggag auaaaaauaa uauuaaugua 480guaacuggag cuggaacuga aagcccauac aauauaccag guugggauuu auuuuuuaaa 540gcagauggag acuauaaaaa acaaauaagc acuaauguua guuuuacaga uaaucguugg 600gauuuaaaua aagacccuga uaaaacuaaa uaucucacag gagauucuaa auggcaacaa 660cuuaucggac aaaguuaugu aaaagauaau agcuuagaug cugacaaaga cuuugaguau 720gaugauagca aacuagauuu uccuccaaca acucuuuaug uucaagguac aagacccgau 780ggaacaaguu uuaaaagugc uguacucguc aaacccgaag auacuuuaga agauguaaug 840gaaaauauug gagcucuuua ugguaauacu ccaaauaaua aaguaguaga aguaaguaug 900aaugauagug gucaaauuca aauuacagau cuaaagcaag guaauaauaa acucgauuuu 960caugcuguag cuuucacacc acaagcugau gauaaaacug aauuaaauaa uauuauccaa 1020gcagcacagg augaaggcau uacaauggaa gauguuacaa acaggguuau gacugcugca 1080cuaggaaauc ccaauaaugg agauauuaca aauuuaaaua auccuguaac cauucaaauu 1140aacggacaaa acuuugaaau ugauuuaaaa caaacugauu uuaucaaaag uaaaaugaca 1200gauacagaug gaaaugcugc uaauggagcu gauuacgaua auguguauuu ugaaaaaaau 1260ggcaauacug uuuaugguaa uguuucucaa guuaucaaag gaagcaaugc uuaugccacu 1320gauucaacca aacuuagcga gguaauggca ggagauagcc uaaaugguac uacuuuaaau 1380uuaaaaguca auuccaaagg uggaaauucu uacgauguua cuauaaauuu acaaacuuca 1440acuguaagcu auccugaucc uaauaaucca ggucaaacca uaagcuuucc uauuaugcau 1500acuaauccug caacuggaaa uagugggguu guuacaggau caaaugauau uacuuauggu 1560caaauuaaug auauuauagg uauguuugcu gcagauaaaa uuccuacaac aaccauacaa 1620gccaauaaug gucaaauuaa uaaugcagau uauacccaaa uacaacaacu caugaaagau 1680ucacaagcua cuguugaugu aaguauggau uauaaagguc guauuagugu uacugauaaa 1740cuuucaucag gaaccaauau agaaauuucu cuuagugauu cucaaagugg ccaauuucca 1800gcaccuccuu uuaccacaac uucuacugua caaaaugguc caaauuuuag uuuuagcgcg 1860aauaauucuu uaacuauaga ugagccaaau guggauauua uuaaagauuu agauucaaug 1920auugaugcug uuuuaaaagg caauaugaga gcagacuccg aaagugaaaa cccuagaaau 1980acagguaugc aaggagcuuu agaaagacuu gaucauuuag cagaucaugu uagcaagcuu 2040aauacaacua ugggagcaua ucauaauacu aucgaaggug uuaauacacg cacaucauuu 2100uuaagcguua auguccaaag uauaaaauca aaugugauug auguagauua uggugaggca 2160augaugaauu uaaugcaagu ucaacuugca uaucaagcuu cucuuaaagc uaguacaaca 2220auuucucaac uuagcuuauu aaauuauaug uaa 2253802598RNACampylobacter jejuni 80augaugagau cacuuugguc uggcguaagc ggacuacaag cacaucaagu ugcgauggau 60guugaaggua auaacauuuc aaauguuaau accacugguu uuaaauauuc ucgugcagau 120uuugggacua uguuuagcca aacugugaaa aucgcuacag cuccaacuga uggaagaggc 180ggaucuaauc cacuucaaau cggucuuggc guuucaguaa guucuacaac uagaauucau 240ucucaagguu caguucaaac cacagauaaa aacacugacg uugcuauaaa uggcgauggu 300uuuuuuaugg uaagcgauga ugguggucuu acaaacuauc uuacaaggag cggggauuuu 360aaacuagaug cuuauggaaa uuuuguuaau aaugcagguu uuguugucca aggguggaau 420aucaacuggg augaucaaac uauagauagu ucaagaacuc cacaaaauau uuuuaucgau 480ccagguaugc auaucccugc agcaaaaucu acugaaguug cuaucaaagc gaauuuaaau 540agugguuuaa auauaggaac uucaaguaga aaucuuuaug cacuugauuc uguucaugga 600uggaauacua aaacccaaag agcagaagau gaaaaugaua caggaacuac ucaguuuuau 660acgacuucua agaauucugu agaagugaca gaaaagggug uggaugcggg aucacuuuuu 720aacgcgaaag gacaaggacu uaaucuuaga gauggacaag gaauuugggu aucuuaugca 780gaugcaacau auucuaccaa uaaaguagga guaaaugcuu uugauccaaa uuuacagcaa 840aaucaaacug cugcuuuuug gggaacagcu aaucaaaaag ugaauuuaga uauaacuuua 900aaugggguua gaauucaaaa ugcugauauu caaaguauug augaugcuau ugcuuauauc 960aauaccuuua cugcaccaac ggauacaagg gauggaacag guguaaaagc gguuaaaaau 1020aaggauggua guggaauuga uuuugucaau gauaaugccg augguacuac agauaauaug 1080aaaaauauca aucuuguggu ugccaauacc aauacagcag gugagcuuug gaaugcugua 1140uggaauaaca acaaucaaac auuuacauuu aauaauaaug guaauggaca ggcuggaaca 1200ccgacuauua auaaaaaugg uucuucuuug uggacagcua caaauauuac auuuacacca 1260caaccuccuc aagcagcuac gaauguucag cuuacuggug gacuaaaugc acaaauaaua 1320acagcacaua aauauauuua uaguucaaac ccuguggaua uagguccuau guauaauccu 1380gacgguggac cagcauucca gccuggugcu aaugcaacua caagaccaac ugaaccaggu 1440ucagcagcuu auugggaugc uguuaauggu ggacuuuuaa auacuaaugu aagaacuuuu 1500agaaccacag aagauuuaag agaacuuuua caaagggaug cuagauaugg gguugauuau 1560gauggaagug gaacuuuugc ugcagcugau auuaaucaaa auauaaaagu aguaguaacg 1620gcagauggac auuuugcuau uuccaaugcu aaugaacaau caacuguucc accaaaugcu 1680auuaauggug uaggaaaugc cacuacaaca gauccaaaaa auaugaguuu uaauauaaca 1740gcuuauagua acaaacaagg aacuguaagu acuaaugaug cuuucacugc uauuuuuaaa 1800gcuuucgaug guccuuuggu uauaggaaau cagaucaaag aaagcgaaca acuuaagcuu 1860ucugcuuuuu cggcggggcu ugaaauuuau gauucuuuag guucaaaaca cacuuuagaa 1920gugcaguuug uuaagcaaag uaccacucaa gaugggggua augaauggca aaugaucauc 1980cguguaccug aaccugcaga gauuaacacu acaggcgaag gaccaaacaa uaucaucgua 2040ggaacagcua gauuuaacaa ugacggcucu uuagcuaguu auacaccaag aacgauaaau 2100uucucaccaa acaauggugc cgcaccaaau caacaaauca aacuuuccuu uggaacaagu 2160ggaagcaaug acggccuugu aagcucaaau ucugcuucaa cucuaacagg acaggcaacu 2220gaugguuaua cuucagguaa cuuaaaaccu gaugcuaucc guguggauga uaaagguaau 2280aucuuaggug aauuuacuaa uggcaaaacc uuugcuguag caaaaaucgc aauggcuuca 2340guggcaaaua acucaggucu ugaggaaauu gguggaaauc uuuuuaaagu uacugcaaau 2400agugguaaua ucgugguagg ugaagcagga acaggagguc guggugagau gaaaaccuca 2460gcucuugaaa ugucaaaugu ggauuuaagu cguucuuuaa cagagcuuau uaucauucaa 2520agagguuauc aagcaaacuc aaaaaccauu ucaacgagug aucaaaugcu ccaaacucua 2580auccagcuua aacaauaa 2598812616RNACampylobacter jejuni 81auggcaaaga uuagaauuca ugaaaucgca aaagaauuag guuaugauag uaaggaaauu 60auugaaaagg caaaugaauu aggacuugga auuaaaacag caucaaaugc uguagaaccu 120gagauugcgg cagcuauuua ugaguauaua caaacaagag aaauuccaga agcuuuuaag 180aaaaauauca aaacuccuac agcaaaaaag ccuaaaaaag aaaauauaaa agaacaagaa 240aagcuaaaug aaucugaaaa aaaagaaccu aaaaaagaag aaaagcuuaa acaagaaguu 300aaaaaagaag aauuaaaaau ugaaaaagaa aaugcaaaag aggaagaaaa acaagaaauu 360auugaugcuc auaagccaca aagccuugcu agugcaacuu uagccaaaag acgcggacuu 420guuauuguua aaaagaaaaa agacgaagaa gaaauucaag uuaaaaaaga agaaguaaaa 480aauucaaaug auauaucuau caauaaugaa gagcgcuuaa guuuaaaaac uauguuuuca 540aaugcugaug agaguuuaaa gaaaaagaaa aaagaaaaaa aaucuuuugu ugcgaguaaa 600aaagaaagua ccgaaaaaau gaauuuuuua gaugaacaug auuuugguga uauuucuuua 660gaugaugaag augagguagu auuaccugau uuuaguguaa aagaacaaga aaaaccacaa 720aauaucaaua aaaaacaacc uaauuuuaua agacaagcug uuggaaauuc ugcggguuuu 780ggguuugaag guggaauuca aagaagaagu cguaaaaaac caucuaaaaa gauugaaaaa 840aaggaaguag aagaaguagg uagcguugcu auuucuaaag aaauucgugu guaugaauuc 900gcugauaaga uaggaaaaag cacuagugaa gugauuucaa aacuuuucau gcuuggaaug 960augacaacaa aaaaugauuu cuuagaugaa gaugcgauug aaauuuuggc ugcugaauuu 1020gguauagaga ucaauaucau uaacgaggcu gaugaguuug auuauguaaa agacuaugaa 1080gaagagacug augaaaaaga uuuagugacu agagcaccug ugauuaccau cauggggcau 1140guugaucaug guaaaacuuc uuuguuagau uauauuagaa aaucacgcgu ugcaaguggu 1200gaagcagggg guauuacuca gcacgugggu gcuuauaugg uagaaaaaaa cgggcguaaa 1260auuacuuuua ucgauacucc aggucacgaa gcuuuuacug cuaugcgugc aaggggugca 1320aguaucacug auauuguaau caucguugua gccgcagaug augggguaaa accacaaacc 1380aaagaagcga uaaaucaugc uaaagcagca ggugugccua uuauuauugc uauuaauaaa 1440auggauaaag aagcagcaaa ucccgauaug guaaaaacuc aacucgcaga aauggaaauc 1500augccaguag aauggggcgg aucuuaugaa uuuguaggag uuucggcuaa aacaggaaug 1560gggauugaag auuugcuuga aaucgugcuu uuacaagcug auauuuuaga acuuaaagcc 1620aauccaaaaa guuuugcuaa agcaagcauu auagaaaguu cugugcaaaa agggcguggu 1680gcgguggcua cugucaucgu gcaaaaugga acacuuacug uaggaaguac cgugguugca 1740ggcgaggcuu auggaaaagu gcgugcgaug agcgaugauc aagguaaagc cuuaaaagaa 1800auuaaaccag gcgaaugugg gguuaucgua gggcuuagug aaguagcaga ugcaggugaa 1860auuuuaaucg caguaaaaac cgauaaagaa gcaagagaau augcuaauaa acgccacgaa 1920uacaaucgcc aaaaagaacu uagcaaaucc acuaaaguua gcauugauga gcuuggagcu 1980aagaucaaag aagguaaucu aaaagccuug ccuguuauuu uaaaagcuga ugugcaagga 2040ucuuuagaag ccuuaaaggc aaguuuagaa aaacuuagaa augaugagau uaaagugaau 2100aucauucaua guggaguagg aggaaucacg caaagugaua uagagcuugc aagugcgagu 2160gaaaacucua uaguacuagg uuuuaacaua cgcccaacag gggaaguuaa agagcgugcu 2220aaggauaaag gcguagaaau uaaaacuuau aauguaauuu auaaucuuuu agacgaugua 2280aaagccuuac uuggugguau gaugagcccg auuauuucug aagagcaauu aggacaagca 2340gagauuagac aagugaucaa ugugccaaaa aucggacaaa ucgcagguug uaugguaacu 2400gaagggguga uuaaucgugg agccaaaauu cgccuuaucc gugauggagu ugugguuuau 2460gaaggaaaug uaaguucgcu uaaacgcuuu aaagaugaug cuaaagaagu ggcaaaaggc 2520uaugagugug gcguagguau agaagggugc gaugauauga gaguggguga uuauauagaa 2580agcuauaaag aaguagagga acaagcaagu cuauga 2616822841RNACampylobacter jejuni 82augcuagcac cuggcauggg agaauggguu uacaaggcua auuuauuuuu auuuggagaa 60uuugcguauu auuauccuuu uuucuuauuu auuuuaaauu auguuuauua uaaaagaaau 120uacaaauuag cuaauuuuac aagaagagag cuuuuuggua uaggauuugc cuuuuucucg 180aguuugcuuu uauuugcagu uuuuuauccu aauucaggcu auauacuaga gcuugcuuau 240gcgauuuuuu cuacuauuuu ggggcauacu gggagcggaa uuuucgcucu uuuacuucua 300cuauuuucuu ugguuuuauu guuuccaaaa uuugcaaaag aaauuuuaaa aauagaauua 360gauuuuacuu auuuauuaaa aguagagcaa gcuuuuaaau cuuuacuuau gcguguauuu 420gguggagaaa acgagaaaga agauguaggu aaaucagaac cuauaguucc aaaauuaaau 480auuuugcaag auaguauuua uggaaauuua caaauaaaca aaaaagggga aaccaauaac 540uuagaacaga uaauuaaaga uagcaauauc aaugcaagua aaaauucaau uaccacggcc 600aaggaaaauu uugaaaaacu aaaaaaucaa auuuuagaug aaaccauaga gauugauaaa 660caaaguuuaa aagaaucaag aaguuuuguu caugagcauu cucaacaagu gcgaaauuuc 720gcacaaaagg cuaguaaaau gagcauuagu cuugaugaag auuuuaauuu uauuucagaa 780gaagagguag auaugauucc ugaacguuuu uuaaaaccua aaaaacuuga agauauaaag 840caaauagaua caaauaaaaa uuuagaugag ccaaguuaua aacguaaaaa uauugaaauu 900ccaguuucua aucaagaagu uaaaccaaaa auuuuuacaa aagagcuuga acuuagagag 960aauuugauaa aaaaagaaaa acuagaacaa gaauacaaag ccuaucaaaa ugaaauuuua 1020gaaaauaaag uaaaacaaga aauuaaaaaa uuagaagaau augaugcgau aaauucaagc 1080gauauuauag aagggaauaa auauaguuuu aauagcccaa aaacaauuaa aacagaaaca 1140gaagaaucag acaaaauaaa ugaaaauaaa aaucuagaua aagcagacaa uaucuuugaa 1200uuugcuccca uuguagaaga guuaaaucau ccuuauauag aaccuacucc uauaaaaaau 1260auaaaugaaa uaguuauaga agaaaaaaau acacucgauu uuauccaaaa uacagaaacu 1320aaaaucgaua augaaaaaac aaaugaucaa gaaauuaaac uucaaaaagc aguuuuagcc 1380aaagaaauug cuauuaacca agcuuuauug cgugaaauag agcagggcga aauagaaaaa 1440ccaaaagauu ucaccuugcc gccauuagau uuuuuagcua auccaaaaga acacaaacaa 1500gaaaucaaug aaagugaaau agauaaaaaa auuuauaauc uucuugaaaa auugcgucgu 1560uuuaaaauag gcggcgaugu uauaagcacu uauguugguc cugugguaac uacuuuugaa 1620uuucguccua gugcagaugu gaaaguaagu cguauuuuaa auuuacaaga ugauuuaacu 1680auggcuuuaa uggcaaaauc aauccguauu caagcuccaa uaccaggaaa agauguugua 1740gguauagaag uuccaaauga ugaaauucaa accauuuauu uaagagaaau uuuacaaagu 1800gaaguuuuua aaaacgcuaa aaguccuuua accauagcuu uagguaaaga uauaguaggc 1860aaugcuuuug uaaccgaucu uaaaaaacuu ccgcauuuac ucaucgcagg aacgacaggu 1920agugguaaaa guguggggau aaauucuaug cuuuuaaguc uuuuauaucg caacucucca 1980aaaaccuugc guuugaugau gauagauccu aagaugcuug aauuuagcau uuauaaugac 2040auuccucauc uuuuaacucc uguuaucaca gauccaaaaa aagcagucaa ugcgcuuuca 2100aauaugguag cugaaaugga aagacgcuau cgcuuaaugg cugaugcaaa aaccaaaaau 2160auagaaaauu acaaugaaaa aaugaaagaa uuaggcggag aaaaacuucc uuuuauugua 2220guaauuaucg augaacuugc ugauuugaug augacugcgg guaaagaugu agaauuuuau 2280auaggaagac uugcgcaaau ggcaagagca aguggaaucc acuugauugu agcuacacaa 2340cgaccuucug uugauguugu aacaggacua auuaaagcga auuuaccaag uagaauuucu 2400uauaaaguag ggcaaaaaau ugacucuaaa guuauuuuag augcuauggg ugcugaaagu 2460uuacuuggaa gaggggauug uuuauuuacu ccuccuggaa caagcucuau agugcguuug 2520caugcgccuu uugcaagcga auuugaaaua gaaaaaaucg uggauuuucu aaaggaucaa 2580caaagcguag aauaugauga aagcuuuuua aaggaucagc aaagcguagg uguuacaaca 2640aaugaaagcu uugaugggga agcagaugag cuuuaugaag aagcuaaaag aguaaucuua 2700gaagauggaa aaacaagcau uucuuauuua caacgccguu uaaaaaucgg cuauaaccgc 2760ucugcaaaua uuauugaaca acuuacgcaa aacgggauuu uaagcgaacc ugaugccaaa 2820ggacaaaggg aaaucuugua a 2841833126RNACampylobacter jejuni 83augaaaaaau uuuuuuguuu aacuuuaguu uguaaacuuu uugcuuuaag cgaauuugaa 60cuucaucaua uugauaaagu acauaagcua ggguauagcg gagauacuau uauaauaggu 120guagccgaug augcuuuuaa ucaagaucau auuaguuuaa aggauaagau uuuaaagucu 180acuuauccua cugauacagc ugggaaacag cuuauaccug auuugaaaaa aucaacacac 240ggaagucaug uagcagguau agcuguugga gcaaagauag gcgauagcaa accuuaugga 300guggcuuaug gggcaaaauu uuauggagcu gggguguuuc caaauggcuc uuacacucaa 360auuccugaua uuuauaauuu uuucaaagau gugaguauua uuaauaauag cugggguauu 420aauuuuuauc cuuauuuuaa ucuuaaggcu ucaaauucug gauuaguaga uuguacucaa 480acuaaucaag ggacaagcua uaauaucugu aauacuccuu uggaauaugu uaugaaagca 540gauaagguug cuaaugauau gaugaggcuu agcaaggaca agggaguauu aaauguauuu 600gcugcuggua augaaggaau ucuuagcccu gcuuugcaug cgauuuuacc aaguuaugau 660gaaucuuuaa gagcuugguu ggcuguugga gcuuuggaug caaaugagau uacuuuagaa 720ucagauggga cuuuaauaau uaaaagucaa gguuuggcug auuuuaguaa ugguuuuaag 780ggagcuacga auuuuucuuu aguugcugcu ggaguaaaua uuaauaaugu ugauucaagc 840acuaaugaua aguuuacaaa aaaaagugga acuucuaugg cagcaccuau gguaagugga 900acagcggcac uggucaagca aaauuucccc uuuuuggaug guaagcaaau ugcugauaua 960cuauuaagua cagcaaauaa aaauuauaag gcuccaaaau uuacuguuaa acaaguaacc 1020gauggaacaa aucaaccuaa auuucuuauu guguauauuu cgcaagaucc accugggaua 1080gaagaugaaa uaaaacggga uuuaaaacag cuuuacaaug gaauacaagu ucaaguuaau 1140ggacaaugga uugauuauag ugauuauauu ugggauaaua gagauagugc gcagucacaa 1200aaacuuaaua cuuccacuau uaguucuauu aauggaguag uuagaguuga gaaagaagaa 1260uuauuuggac aaggaauuuu agaugcacaa aaggcguuaa aaggacugag uauuuuagau 1320gcaaacagac ucagugauca ggauguauua aaauaugagc aagaaccuaa uacagcuuau 1380uauacuauaa acacugcagg uuaugaugcu gaauuuucua augauauuag ucaaagaaaa 1440ugggaugaaa guacucauuu aucaagugcu auuaauaaac cuacacauuu agcuaaucuu 1500aacauagggu uaucuaaaga aggugaaggu auuuugauua ucagugguca aaauacuuau 1560gagggcgcaa cuuuaaucaa acaaggagaa uuaaagcuua aaggaaaagu uaaaaauaau 1620gcuuauguag aacaaaaagc aauauuaagc gguaauggua uuguagggca aaauuuaaac 1680aauaaaggca uaguuagacc uggaaaugaa gauuugaaug auuuaaccgu gcaaggaacu 1740uauacucaag aaggaguuga uucuaaauug caacuugauu uugguaauua uaaaaauucu 1800aaacugauug caaaaacuua ugauauuaag agcgggaauu uagaauauau uccuuuaccu 1860aaauacuaua ucuuaaauaa gccagugaaa auuaauuugg gagauuugga aaaaaguuua 1920ucaucuuuua aucauguuuu gauacaaaau accuaugcuu uaaauuuuga uuuuguuuua 1980agugaugauu uagugaguau uaauaaaacc uuaauaaaac cuaauuuaaa gccaaaugcu 2040uacgaaauuc cuaauacaag cuugggaaau gcuuuaagac aauugcgauc uagggcagac 2100uugagucaga cuuaucagga auuuuuugcu ucuuuagaua auggaauaga uguaaagacu 2160aaauuaaaua gaauagaagg uucaggguau uuaagcacuu uuaguaauca uaaucaaucu 2220aauuuaaugc aaaauaauau guuauuuacc cuucauccuc uuaauauuaa uaauuuugca 2280caaaacaaua auaucuuacu ugcuaguacu uauuuaccua gaauuuuuag caaugaagaa 2340uauuuuuggc aucuuacucc aaguuauaaa uacuauaaag auaaagauuu uucaggucaa 2400aaaacaggug cuaauaucuc uuuaggagaa aauuucucau caggcuuuuu agcuuaugcu 2460uuaucucuuu cuagcgcuaa auuuaauuuu aauaauggua gugauuugaa gaguuauaac 2520auggauuuau ugcuuaauua uaaccaugau uuagauuuua uaaaaauauu aaguggauua 2580gguauaggug uaggauuuaa uacucuuaau cguuuuguag uagagcagcc aauugaaggc 2640aaauauaaaa cauugcaaac uucagcccag cuugguguaa cuaaagauau uauuuuaggu 2700caagauuuua uuuuuaaucc uuuaauguau uuuacacaua guuuuuuuua ucaagaagau 2760uuuaaagaaa auaaaagucc uuuugcuaaa aauuaugaaa guuuaaaaca ucauagcaua 2820aaugcaaauu uagguuuuaa ucuugcuaaa aauauagagc aagaugauua ucaagcuucu 2880uuuucuacuu uuguaauuuu ugaaaaaaga auuuauggaa gaacuuuaga aaauaaggcu 2940aguuuuguug auuuuccuau ugcuuuuauu caaaaauaua aauuaaaaga uaauauuuua 3000agucaagguu uuaauucaga auuuuuauau aaaaacaaug uauuuuggca guuuauguua 3060augaauagau uuucucauaa ugccuaugaa uugcauuuaa ugaguucagu aggaaaacgu 3120uuuuga 3126843270RNACampylobacter jejuni 84augccaaaac gaacagauau uaaaagcauu uuacuuauag gaaguggucc uauugugaua 60ggacaagcuu gugaauuuga uuauucugga acucaagccg caaagacuuu aaaagaauua 120ggauaucgug uaguauuaau caacucaaau ccugcaacca ucaugacaga ucccgaauuu 180gcagaugcga cuuauauaga acccauaaca aaagaaagua uuuuaaguau uauuaaaaaa 240gaaaaaauug augcaauuuu gccaacuaug gguggacaag uagcguuaaa uguugcuaug

300gaaguuuaug aaagcggacu uuuaggagau gugaaauuuu uaggcgcaaa uccugaggcg 360auuaaaaaag gcgaagaucg ucagguuuuu aaagaaugua ugaaaaaaau uggcauggau 420uugccaaaau cgauguaugc guauaauuau gacgaagcuu uaaaagccgu agaugaaauc 480gacuuuccuu ugaugauccg ugcuucuuau acuuuagggg gugcuggaag uggugugguu 540uacaauaugg acgaauuuaa agaacuuacc aauacugcuu uagcuuuauc accuauucau 600gaaauuuuga uugaagaaag uuuguuaggu uggaaagaau augaaaugga aguuauacgc 660gauagagcgg auaauuguau cauaguuugu agcauagaaa auaucgaucc uaugggaguu 720cauacaggag auaguauuac aauagcucca gcauuaacuu ugacagauaa agaauaucaa 780guuaugcgua augcuucuuu ugcuauuuug cgugaaauug guguagauac aggcggaagu 840aaugugcaau uugcuaucaa cccaaaaaau ggaagaauga uaguuauaga aaugaaucca 900agaguuucaa gaucaagugc uuuagcuucu aaggcaacgg guuauccuau agcaaagguu 960gcgacacuuu uggcaguagg uuuuagcuua gaugagauua aaaaugauau uacaggaacu 1020ccugcaucuu ucgagccugu gauugauuau auuguaacaa aaauuccucg cuuuaccuuu 1080gaaaaauuuc caggagcaaa uacaacuuua gguacagcua ugaaaagugu gggugaggua 1140auggcuauag gacgcacuuu uaaagaaagu auacaaaaag cacuuuguuc gcuugagcgu 1200ucuuuaagug guuuugauag gguaaaauuu gaagauagaa augaucuugu uuuuaaaauu 1260cgcaaugcca augaaaagcg uuuacuuuau guugcucaag cuuuuaggga agguuuuagc 1320guagaagaac uuuaugagcu uuguaaaaua gauccuuggu uuuuaacaca gauuaaagaa 1380auuguagauu uugaagaaca aauugauaug gauauuuuaa acaauaaggc ucuuuugaga 1440aaagcaaaaa cuaugggcuu uucagauaaa augauagccu ugcuuguaaa uuugaaagau 1500aauuuagaau uaagccaaaa ugauauuuau uauguaagaa ugaagcaaaa aaucaucgca 1560gaauuuagug aaguggauac uugugcgggu gaauuugaag ccuuaacucc uuaucuuuau 1620ucaaguauca auguaagcga acucacucaa aguaaaaacg augcuaagga uaaaaaagaa 1680aaaaaaguga ugauuauagg uggggggcca aaccguauag gacaagguau agaauuugac 1740uaugcuugcg uacaugcuuc uuuugcgcuu aaagauaugg guauuaaaac uauuauguau 1800aauuguaauc cugaaaccgu uucgacugac uaugauacaa gugauauuuu guauuucgag 1860ccuauugauu ucgaacauuu aagagcggug auugagcgug aaaaaccuga uggagugauu 1920gugcauuuug guggacaaac uccuuugaaa uuugcuaagc guuuaagugc uuuuggagcu 1980aagauuauag guacuagcgc aagaguaauu gauauggcag aagauagaaa gaaauuugcc 2040gaauuuauua caaagcuagg uaucaaucag ccaaaaaauu cuacugcaac aagcguagaa 2100gaagcgguuc uuaaggcuag ugauauaggg uauccugugc uuguaagacc aaguuauguu 2160uuaggugggc gugcgaugcg cgugguaaau gaugaggcug aacuuagacu cuauaugcaa 2220gaagcugugg auguaagcga uaaaagcccu guuuugaucg aucaguuuuu agacaaugcu 2280acagaaauug auguugaugc gauuugugau ggcaaagaug uuuauguugc aggaauuaug 2340gagcacauag aagaagcagg aauucauucg ggugacagug cuuguucuuu gccgccuugc 2400aauaucgaug aaaaaaugca agaauuuauu gcacaaaaaa ccgcagauau ugcuuuaaau 2460uugggaguug uaggacuuuu aaauauacaa uuugcuuuac auaauaauga gcuuuauaug 2520auagagguaa auccuagagc uagucguacc auaccuuuug uuaguaaagc uacggguauu 2580ccuuuagcaa aaguggcaac gcgugugaug uggcaaggaa auuuaaaaga agcuuuaaaa 2640uuuuaugaua cuuuuaaagu gguuaauuuu gauacuaaaa uuuuacgccc uaaaacucca 2700aaauauauga gcgugaaaga agcaguauuu ccauuugcaa aacuuagugg aagugauuua 2760gaauuagguc cugaaaugcg uucaacgggu gaaguuaugg guauaagcaa ggauuuugca 2820aauucuuaug cgaaaaguca aauugcaucg uuuaaucauc uuccagagca aggcguggua 2880uuuaucuccu uaaaagauaa ggauaaaaaa uauaccaaaa aaaucgcugc agaauaugua 2940aagcuuggcu uuaagcuuau ggcaacaggg ggaacuugca aggaaauuuu agaaaguggu 3000uuugagugcg aacuuguaca uaaaauuuca gaaggacgcc ccaauguuga agauaaauug 3060aaaaauggag aaauucacuu aguuaucaau acaagcgaua gucacaguuu uaaaggcgau 3120acgaaaaaaa uucgugaaaa uauuauucgu uuuaaaauac cuuauuuuac aaauuuacga 3180ucagcuuuag caggugcaaa aucgauuaaa gcuauacaga guaaaucuug ccuagaugua 3240aagaguuugc aagaguggcu uaaaucuuga 3270853365RNACampylobacter jejuni 85augaaaaaua ucacauuaac uaaaauaccu auaggagagg gcaaagaacc cuguuuaaau 60ucuaaaaaga uaguuuuauc uuuagcuacu auuucuuuuu uggcaaguug ugcuaaugcu 120aaauuaaauu cugaaauaaa aacuuaugau gaaguuaaua aaaauguuaa aacuagauca 180gcaaguguuu auagcccuca agcuaagauc aauacgacua uaaauucuuu acacaaucaa 240caaguaacua uuacuggaaa uggaacauca aauucuuuaa caaucggauc aaguggaacu 300cuagguagca uaggcaauac agguaaaauc aucuaugccc augcuaaugg uagcaacacu 360cuuacucuug caaaucuuac uaauaauaga acuauuaaug guaagauugg uauagaaaac 420aaugguaauu uuacaggaac uauugcuguc aacaccuuug aaaauacagg ucaaauuaau 480ggacaaauuu acaugggaau uugggguaac aacucaggaa cucuuaauau agauaaauuu 540gacaauagug gaaccauaau ugacaacaau aaaggaguuu uuuugaagga aagaauacca 600acauacaaac cuuuaauaac agugguuuua uuagugcaaa uaagggugua gauauaggca 660acauaggaac cauaaaaaau uuuaauaaca acggaacuau acaaggcuca gaagugggag 720uggcuauaaa uacaaaaaua gauacuuuua cuaauaaugg uuuuauuaau uccccuggua 780guggacaaug gaauaauggu auauggauaa guagcaaugc uaccauagaa aagcuuguua 840acaauggcac aauaaaagga ggacauucug cuauaauggu aacaucucag cauauaaaaa 900cuguugaaaa uacaggaauu auacaugcug aaggagaaug ggguucuagu auauuauuag 960aauauggugg uuuuauagag cauauaauca auacuggaac cauaaguaau aauaauguug 1020guauagguuc agcuuaugga guauuuggaa cacuuaccau aaaagaugga gguaugguuu 1080auggaaaaua cucggcaaua ggaguggguc gaucgcaaac ucuaggagau uuauauauag 1140auggacguuc aaauaauggc acaguaagug gaauuuauag ugaagaacau ggaauuuuau 1200uagagaauaa cucacgaacu caaaaaauag aacuuaaaaa uggcggcauu auaaaaggua 1260auaucgaugg uauaagauug auaaacucgg ccucuuuaag uggagaaaug auuuuaucug 1320gcgaagguuc uaggguagaa gguggaagag guguugguau auugaaucga aguggaaaaa 1380uagaaggcuc uauaaaagua gaagauggag caacuguuac ggcuacuucg aaucgagcca 1440uagcuaacuc uggcucagga aguauaacag gugguauuac uguuaguggg aaaaacacua 1500aacuugaagg aaauauaauc aauacaggua augcuucuau agguagugau aucaagauag 1560aagguggagc uaagguagaa gguggucuug uuaaucaagg uaauggaagu aucucaggaa 1620guguucaagu aagugguggu aguaguauug auuccauuac caaugagggu aauggagcua 1680uuucugguuc aauuacugua uauaaagaua guaaacuuga uucuaucacu aacacuucua 1740caucaucuac agguauaagu gguucuauua cuaacaauag ugauaauaaa cuugaaauuu 1800cuaauucagg uaauaucggu gguaagauug aaaguacagg uagugcugau auggugauua 1860gcaauaguaa ugguggaacu auuaguggcg guauuaguuc uucaggaagu ggaagcacua 1920guauuuccaa uucacaaggc ucaaccauaa auaacggcau cacuguuuca ggaucagcac 1980aaguugaaau cuccaaucaa ggcucaguag guaaagauga aaaugguaau acaguaacua 2040acaaugguag ugguaguguu ggaaucaaag auuggcuugu uucuacagau aaaaacacag 2100guaaauuaaa cacugugguu auagguggaa guagagcuuu uaauguaaaa guagaaaaca 2160ucaccguaga ucaaagcaau guugaucuug aagagcuaaa cgauauaaac aacaucaucu 2220cagguguuaa ucaaaacaau auuggcaaua uaggaaccaa uggaagugga gaaauaucuu 2280uaagcuuuga uccaauaaca ggaaagcuua cuacagauuu uaaucuuaau gcuuccauau 2340caggugcaac cuuuagaucu uuaaucucua cuacuucaag aagaucaacc uuuauagaua 2400auguuauggg uaauucuaug caaagcuuug cuuuagcuuc uucaaguaaa ucucaaagca 2460ucgcuauguc ugaaaagggu aauuuauaug cagaugcaag ugauuauaua aagagugauu 2520uaaauaaugg aagcuauggu ucuaauaaag aacauucuuu auucauccuu ccuuauacuu 2580cuucacagaa uguugaacuu ucuuuaaaug aagaaaguaa aggacacacu aaaggaacca 2640uuauagguua uucuacuuua aaagacagug gaauauaugg uguguaugca gguuaugaag 2700auacaaaaau ggguucaacu uauuuugaua uuaauaauag aaccuauuau gcagguuuaa 2760aauacuuuaa uaccuuauuu acuacagaaa aaggucaaga aguuuauauc aaagcucaag 2820guaaagcugc uuugauuaaa aaugauuuaa cugaaaaaau aggaaauaau gaagcuaaag 2880cugaaccuaa uucuuaugcu uauggaguca auacagccuu agguaugaau uuuauuucua 2940auaaagauau auucucuccu gaaauagguc uugcuuauga aggagguuau acugaagcuu 3000uuucuaugaa agacaccaua ggacaagcaa caguuaaagg uggagaaaga accuaugcaa 3060acuauuuaaa ucuuuucucu acuaaaacaa gucuuacuug guuuagagau ugguugccua 3120auuuaaaaac uucaguagaa cuuggagcua aguuuaauau caauccuaaa guagaagcug 3180aggcuagauu ugguaauaua aaaguaagug augaguuuga uuuaccaaga guacaaaaau 3240uuguaagcac uucuuuuauc guuccuguua augaagcuuu cuauuuuagu uuaaacuaua 3300auggaauguu ugauaaagau ggcaauaccc auacaggauu ugcucaguuu aauuaucuuu 3360gguaa 3365863436RNACampylobacter jejuni 86augaauaaaa cugcauuaac uaaaacauac acaaaagaua uacaaaauuc cuguuuaaau 60ucuaaaaaga uaguuuuauc uuuagcuacu auuucuuuuu uggcaaguug uacucaugcu 120acacuuacuc cugaaauaaa aacuuacgaa gagacaaaua gacaugcuaa agcuagguca 180ggucuucaau cuagaaauuc gaauaaugag acuauaaaua auuuacaaac uuuaacuaaa 240acuauaagug acaccggcaa uacucuaguu auagaaagua guggaacuau uacuauuucu 300aaugaugggc aacaagcagu aaacuuucaa ccaaauucuu caacuucuac cuuuuuaaau 360aaaggaacuc uuauaggugg aaauaauacu gcuaguguuc aacuaggagc agcaaaugga 420aauaacggug uuagcauaga aaccuuuaau aaucaaggua ucauagguaa ugguucuucu 480aaauuuggag uaacaguuuu uggggggggg gaguaaagau aacccuaaau cuauaaucaa 540uaauuuuagu aauaguggaa cuauucacuc uaauacuggu gaaaguauuu auuuugguaa 600cgccaaaaua ucaaguuuug uuaauagugg gacuauuaag aguaaacaag gugcaggagu 660aaauauaucu caaggaacaa guauagagaa uuuuaacaau accggaaccg gaauuauuga 720aggcaagaga auggguguaa auguucguuc aacaauaaau accuucguca augacgguuu 780aauugcugca acgaacgaug gaauacagau aaaugcuaau guaaaaacau uaauaaauaa 840gggaaccaua aaaggagaug cuauaucuau aagaucauua gguggaacua uagaaacauu 900gaccaaugaa ggcauuaugu augguaaaag ugcugguauu uacaugaaca gaagucuugu 960uaaaacucuu acaaauagcg guaccauuaa ucaaaacaau ucggcaacuu ggucugcugg 1020uauaaaacuc gaaaauggua guaucauaga aaauaucauc aacacaggau cuauccguuc 1080uaaugcuuuu ggaauaucug uaacuggugg uaaauuugga acacuuacca uaaaagaugg 1140agguaugguu uauggaaaau acucggcaau aggagugggu cgaucgcaaa cucuaggaga 1200uuuauauaua gauggacguu caaauaaugg cacaguaagu ggaauuuaua gugaagaaca 1260uggaauuuua uuagagaaua acucacgaac ucaaaaaaua gaacuuaaaa auggcggcau 1320uauaaaaggu aauaucgaug guauaagauu gauaaacucg gccucuuuaa guggagaaau 1380gauuuuaucu ggcgaagguu cuaggguaga agguggaaga gguguuggua uauugaaucg 1440aaguggaaaa auagaaggcu cuauaaaagu agaagaugga gcaacuguua cggcuacuuc 1500gaaucgagcc auagcuaacu cuggcucagg aaguauaaca ggugguauua cuguuagugg 1560gaaaaacacu aaacuugaag gaaauauaau caauacaggu aaugcuucua uagguaguga 1620uaucaagaua gaagguggag cuaagguaga agguggucuu guuaaucaag guaauggaag 1680uaucucagga aguguucaag uaaguggugg uaguaguauu gauuccauua ccaaugaggg 1740uaauggagcu auuucugguu caauuacugu auauaaagau aguaaacuug auucuaucac 1800uaacacuucu acaucaucua cagguauaag ugguucuauu acuaacaaua gugauaauaa 1860acuugaaauu ucuaauucag guaauaucgg ugguaagauu gaaaguacag guagugcuga 1920uauggugauu agcaauagua augguggaac uauuaguggc gguauuaguu cuucaggaag 1980uggaagcacu aguauuucca auucacaagg cucaaccaua aauaacggca ucacuguuuc 2040aggaucagca caaguugaaa ucuccaauca aggcucagua gguaaagaug aaaaugguaa 2100uacaguaacu aacaauggua gugguagugu uggaaucaaa gauuggcuug uuucuacaga 2160uaaaaacaca gguaaauuaa acacuguggu uauaggugga aguagagcuu uuaauguaaa 2220aguagaaaac aucaccguag aucaaagcaa uguugaucuu gaagagcuaa acgauauaaa 2280caacaucauc ucagguguua aucaaaacaa uauuggcaau auaggaacca auggaagugg 2340agaaauaucu uuaagcuuug auccaauaac aggaaagcuu acuacagauu uuaaucuuaa 2400ugcuuccaua ucaggugcaa ccuuuagauc uuuaaucucu acuacuucaa gaagaucaac 2460cuuuauagau aauguuaugg guaauucuau gcaaagcuuu gcuuuagcuu cuucaaguaa 2520aucucaaagc aucgcuaugu cugaaaaggg uaauuuauau gcagaugcaa gugauuauau 2580aaagagugau uuaaauaaug gaagcuaugg uucuaauaaa gaacauucuu uauucauccu 2640uccuuauacu ucuucacaga auguugaacu uucuuuaaau gaagaaagua aaggacacac 2700uaaaggaacc auuauagguu auucuacuuu aaaagacagu ggaauauaug guguguaugc 2760agguuaugaa gauacaaaaa uggguucaac uuauuuugau auuaauaaua gaaccuauua 2820ugcagguuua aaauacuuua auaccuuauu uacuacagaa aaaggucaag aaguuuauau 2880caaagcucaa gguaaagcug cuuugauuaa aaaugauuua acugaaaaaa uaggaaauaa 2940ugaagcuaaa gcugaaccua auucuuaugc uuauggaguc aauacagccu uagguaugaa 3000uuuuauuucu aauaaagaua uauucucucc ugaaauaggu cuugcuuaug aaggagguua 3060uacugaagcu uuuucuauga aagacaccau aggacaagca acaguuaaag guggagaaag 3120aaccuaugca aacuauuuaa aucuuuucuc uacuaaaaca agucuuacuu gguuuagaga 3180uugguugccu aauuuaaaaa cuucaguaga acuuggagcu aaguuuaaua ucaauccuaa 3240aguagaagcu gaggcuagau uugguaauau aaaaguaagu gaugaguuug auuuaccaag 3300aguacaaaaa uuuguaagca cuucuuuuau cguuccuguu aaugaagcuu ucuauuuuag 3360uuuaaacuau aauggaaugu uugauaaaga uggcaauacc cauacaggau uugcucaguu 3420uaauuaucuu ugguaa 3436873561RNACampylobacter jejuni 87auggguaaaa uuaugaaaac uauggacgga aaugaggcug cugcauacgc ugcguaugcu 60uuuacugaag uugcuggaau uuauccuauu acaccuaguu cuccuauggc ugauuauacc 120gauauguggg cagcugcagg aaaaaaaaau cuuuuuggag uuccuguaaa aaucguagaa 180augcaaagug aagcaggagc ugcagguagu gugcauggau cuuuacaagc uggggcuuug 240acuacaacuu auacggcuuc ucaaggauua cuccuuaaaa uuccaaauau guauaaaaua 300gcaggucaau uacuccccug uguaauccau guagcagcgc guucuuuggc ugcucaagcu 360uugucuaucu uuggugauca ucaagauauu uaugcagcaa gacaaauugg uuuugcuaug 420cuuuguucgc auucugugca agaaaccaug gacuuagcug guguagcaca uuuagcugca 480auuaagggaa gagugccauu uuuacauuuu uuugaugguu uuagaacaag ccaugaaauu 540caaaaaguug aaguaaugga uuaugcgcau uuugauagau uauuagauag agaagcuuug 600cuugaauuua gaaauaaugc uuuaaaucca gaaaauccaa aaacacgugg aacagcacaa 660aaugaugaua uuuauuuuca aacuagagaa guaagcaauc guuuuuacga ugcuuuaccu 720gauguuguua augaauauau gcaagaaauu ucaaaaauua cagguagaga auacaaacca 780uuuacuuauu auggucacaa agagccagag ugugugauug uugcuauggg uucuguaacu 840caagcacuug aagaaguggu ggacuaucuu aaugccaagg gugaaaaggu agggauuuua 900aaaguuuauc uuuaucgccc auuuaguuua aaauauuucu uugauguuau gccaaaauca 960gugaaaaaaa ucgcgguuuu agauagaacc aaagaaccag gaagucucgg agaaccacuu 1020uaucuugaug uaaaaucagc uuucuaugga agagaaaaug cuccuguuau agugggugga 1080agauacggac uuucuucaaa ggauguugau ccugcucaaa ugauagcagu auuugaaaau 1140cuuaaacuug auaauccaaa agauggcuuu acuguaggua uaauugauga uguaacucau 1200acuucacuga guacuggaga gaaaauuuca cuuggagaug aaaguacgau cgaauguuua 1260uuuuacggac uuggugcuga uggaacugug ggugcaaaua aaaacucgau uaaaaucauc 1320ggagauaaaa cggauuuuua cgcucaagcu uauuuugcuu augauucuaa aaaaucaggg 1380gguuauacaa gaagccauuu aagauuuucu aaaaaaccua uccguucaac uuaucuuguu 1440ucaacuccgc auuuuaucgc uuguucggua gcggcuuauu uggaaauuua ugauguuuua 1500gcaggaauuc gcaaaggagg aacuuuccuu uuaaauagua uuuggaaugc ugaagaaacc 1560auaagacaac uuccagaugc aguaaagaaa acuuuagcug aaaaagaagu aaauuuuuau 1620aucaucaaug caaccaaacu agcucgugau auagguuugg gaaaucguac aaauaccauu 1680augcaaucag ccuuuuucaa acuugcaaaa aucauuccuu augaagacgc acaaaaauac 1740augaaagagc uugcguauaa aucuuauagu aaaaaaggcg augcuauugu agaaaugaau 1800uacaaggcua uugauguggg ugcugaugga cuuguaaaag uugaagugga uccaaauugg 1860aaaaauuuag agcuuaaaga aaaagaacaa accaaugccu auaaagguac ugaauuuguu 1920gaaaaaaucg uaaaaccuau gaaugcggcu aagggugaug auuuaccugu uucagccuuu 1980uuagguuaug aagauggaag uuuugaacac ggcacaaccg aauacgaaaa acgcgguguu 2040gggguuaugg uaccaagaug gauagaggca aauuguauuc aaugcaauca augugcuuca 2100guuuguccgc augcuguuau caggccauuu uugauuaaug augaagaaau ggcaaaugca 2160ccucgcggug uaaaagauca ugcuuuagaa gcuaaaggaa ccaaaggaga aaaauuaagc 2220uuuaaaauuc aaguuucucc acuugauugu acaggcugug agcuuugugu ucaugagugu 2280ccuacuaaag aaaaaucuuu gguuauggua ccacuucaag aagagaugga uuuuggugag 2340caagaaaaug cggauuauuu auuuaaagaa auuacuuaua aagaugauau uuuaaauaaa 2400gaaaccacaa aaggagcgca auuugcccaa ccuuuauuug aauuccaugg ggcauguccu 2460ggaugugggg aaacuccuua uauuacuuua auuacaagau uguucgguga aagaaugauu 2520guggcuaaug cuacagguug uaguucuauu uauggggguu cagcuccauc aacuccuuau 2580agaaaaagug ugaaaaaugg acacgguccu gcuuggggaa auucacuuuu ugaagacaau 2640gcugaguuug guuuggguau gaaaauugca acugaaaaua caagacaccg cauugaacau 2700aucaugaaug aaaguaugca agaaguucca aaugcuuuau cagcucuuuu uaaagauugg 2760auugcaaaua aagacaaugg ugcuaugucu guggaaauua aagauaaaau gaucccuauu 2820uuagagcaaa auaaaaauau uaaagcugua caagauauau uagagcuuaa acaguauuua 2880aguaaaaaau cucacuggau uuuugguggu gaugguuggg cuuaugauau aggcuauggc 2940ggacuugauc auguuuuagc aaguggagaa aauguaaaua uuuuagugcu ugauacagaa 3000guuuauucua auacaggcgg ucaaaguuca aaaucuucua gaacaggagc uguagcacag 3060uuugcagcag caggcaaacc uauacagaaa aaagaucuag gucaaauugc uaugacuuau 3120gguuauauuu uuguagcaca aguaaauuca acggcaaauu auacucaucu uaucaaagcu 3180aucacugcag cugaggccua ugauggacca ucuuugguga uuuguuauuc uccuuguaua 3240gcucauggua uuaaaggugg gcuggguuac ucaggagagc aaggugagcu ugcuacaaaa 3300ugugguuauu ggccacuuua uaccuuugau ccucguuuag aagagcaagg aaaaaauccu 3360uuaacucuaa caggaaaaga accugauugg gauuuauaug agcaauuuuu gaugaaugaa 3420gugcguuaua auucacuuaa aaaagcaaau ccugaacacg cugcugagcu uuuugaacgc 3480aauaaaaaag acgcucaacg ucgcuauaga cagcuuaagc guauugcuau ggcugauuau 3540agcaaugagg ucgaaagcug a 3561884137RNACampylobacter jejuni 88augugcgaua uguuagauaa uaaauuagga aaucguuuaa gaguagacuu cucaaacauu 60ucaaaacaaa uagaaauccc aaaucuucua caauuacaaa aaaagaguuu ugauuauuuu 120uuaaaucuug auaaugguga aagugguaua gaaaaaguuu uuaaaucaau uuuuccuauu 180caugauccgc aaaauagauu gagucuugaa uauguuagua gugaaauagg caagccaaaa 240uauaccauuc gcgaaugcau ggaaagaggu uugacuuauu cuguaaauuu aaaaaugaaa 300auccgucuua cucugcauga aaaagaugaa aaaacagggg aaaaaguugg cguaaaagau 360auuaaagaac aagaaauuua uauccgcgaa auuccuuuaa ugacagaucg uguaucuuuu 420aucauuaacg ggguugagag agugguugua aaucaauuac auagaagccc ugguguuauu 480uuuaaagaag aagaaaguuc aacgguugca aauaagcuug uuuauacagc acaaauuauu 540ccugaucgug guucguggcu uuauuuugaa uacgaugcca aagauguuuu guauguaaga 600aucaauaagc guagaaaagu uccuguaacu augcuuuuua gagcuuuagg guauaaaaaa 660caagauauua uuaaguuguu uuauccuauu cagacuauac augugaaaaa agauaaauuu 720uuaacagaau uuaauccaaa ugauuuuaug gauagaauag aauaugauau uaaagaugaa 780aaaggaaaaa ucguucauca agcuggaaaa agacuuacaa agaaaaaagc agaacagcuu 840auuaaagacg guuuaaaaug gauagaauau ccuguagaaa uuuuacuuaa ucguuauuua 900gcaaauccua uuauugauaa agaaagugga gagguuuuau uugauucuuu aacuuuguua 960gaugagagua agcuugcuaa gauuaaagag caaaaaaguu uugauauagc aaaugacuug 1020gcuaauggcg uugaugcagc gauuauuaac uccuuugccc aagauggaga aacucuaaaa 1080cuucuuaaac aaagugaaaa uaucgaugau gaaaaugauu uagcugcgau uagaauuuac 1140aaaguuaugc gcccagguga accuguggua aaagaugcag cgaaggcuuu uguaaaugau 1200uuauucuuca auccugaaag auacgaucuu accaagguag gucguaugaa aaugaaccau 1260aaauuagguc uugaaguacc ugaguauguu acuguuuuga cuaaugaaga uauuauuaaa 1320acugcaaaau auuuaauuaa aguaaaaaau gguaaaggac auauugauga uagagaucau 1380uuaggaaauc gucguauccg uucuauaggu gaacuuuuag ccaaugaacu ucauuuaggu

1440cuugcaaaaa ugcaaaaggc gaucagagau aaauuuacuu cuuuaaaugc ggaucuugau 1500aaaguaaugc cuuaugauuu aaucaauccu aaaaugauua cuacaacuau cauugaauuu 1560uuuacaggag gucagcuuuc gcaauuuaug gaucaaacca acccuuuaag cgagguuacu 1620cauaagcguc guuugucagc gcuuggugaa gguggacuug uaaaagaaag agcagguuuu 1680gaagugcgug auguucacgc gacacauuau gguagaauuu guccaguuga aacaccugaa 1740ggucaaaaua uugguuugau uaacacucuu ucuacuuaug caaaaguaaa ugaacuuggc 1800uuuguugaag cgccauauag aaaaguugua aaugguaaag ugacuaauga aguuguuuau 1860cuuacagcga cacaagaaga aggcuuguuu aucgcaccag cuucaacuaa gguugaugcu 1920aaaggcaaua uaguagaaga auuuguugag gcuaggcaag auggugaaac uauacuugca 1980agacgcgaag aagugcaauu aaucgaucuu ugcucaggua ugguuguugg aguugcagcu 2040ucuuugauuc cguuuuuaga gcacgaugau gcaaacagag cgcuaauggg uucaaacaug 2100caacgucaag cugugccacu ucuuacugcu ucagcuccga uaguaggaac agguauggaa 2160caaauuauug cgcgugaugc uugggaagcu guuaaagcaa agcguggcgg ugugguugag 2220aaaguggaua auaaaagcau uuucauuuua ggugaagaug auaaaggucc auuuauugac 2280cauuacacua uggagaaaaa uuuaagaacc aaucaaaaua caaauuauau ucaacacccu 2340auuguuaaaa aaggugauau aguaaaagca ggacaaauua ucgcagaugg uccuucuaug 2400gaucaaggcg aacuugcuau agguaaaaau gcuuuaaucg cuuuuaugcc uuggaauggu 2460uauaacuaug aggaugcuau aguuguaagu gagagaauua uucgugaaga uacuuuuaca 2520agcgugcaca uuuaugaaaa agaaauugaa gcaagagaac uaaaagacgg uauagaagaa 2580auuaccaaag auauuccaaa uguaaaagaa gaagauguug cgcaucuuga ugagagcggu 2640auugcaaaaa uugguaccca uaucaaacca gguaugauuu ugguggguaa gguuucucca 2700aaaggugagg uuaaaccaac uccugaagaa agacuuuuaa gagcgauuuu uggagaaaaa 2760gcaggacaug uugugaauaa aucccuuuau gcaaccgcuu cuuuagaggg uguuguugug 2820gauguuaaaa uuuucacuaa aaaaggcuau gaaaaagaug aucgcgcaau aaaaucuuau 2880gauaaagaaa aaauggcuuu agaaaaagag caucaugaua gacuuuugau gauggauaga 2940gaagaaaugc uucguguuug ugcucuucuu uccaaagccu cuuuaaauag cgaucaaaaa 3000auuggagaua aaaauuauaa aaaaggacaa acugcagaua uuagcgaacu ugaaaaaauc 3060aaucguuuua cuuuaacaac uuugauuaaa gcuuauucua aagagauuca aaaagaauac 3120gaugauuuaa aaaaucauuu ccaaaaugag aagaaaaaau uaaaagcaga acacgaugaa 3180aagcuugaaa uuuuagaaaa agaugauauu uuaccaagug ggguaauuaa gcuuguuaaa 3240guuuauauug cuacaaaaag aaagcuuaaa gucggugaua aaauggcagg acgucaugga 3300aauaaaggua uaguuucaac uauaguuccu gaaguagaua ugccuuauuu gccaaauggu 3360aagagcgugg auauugcgcu uaauccacuu ggcguuccaa gucguaugaa uauaggucaa 3420auuuuagaaa gucauuuagg uuuaguugga cuuagacuug gggaucaaau ucaagaaauu 3480uuugauagaa agcaaaaaga uuuucuuaaa gaauuaagag cgaaaauacu ugaaauuugu 3540ucuauuccaa gacuugcaaa cgaaaaagaa uuuauuaaaa gcuuaagcga ugaagagcuu 3600uuaaacuaug cuagagacug gaguaaagga guuaaauuuu cuacuccugu uuuugaaggu 3660guaaauauag aagaauuuag caagcuuuuu aaaauggcua agauagauau ggauggcaaa 3720acagaacuuu augauggacg cacgggggaa aaaauugcag agcguguuca uguaggaugu 3780auguauaugc uaaaacucca ucacuugguu gaugaaaaag uucaugcaag aaguacagga 3840ccuuauagcu ugguuaccca acaaccugug ggugguaaag cacucuuugg gggacaaaga 3900uuuggagaaa uggaaguuug ggcacuugaa gcuuauggag cggcucacac uuuaagagaa 3960auguuaacca uaaaaucaga ugauguagaa gguagauuua gugccuauaa agcauugaca 4020aaaggugaaa auguuccagc aacaggaauu ccugaaacau uuuuuguauu aaccaaugag 4080cuuaaaucuc uugcuuuaga uguugagauu uuugauaagg augaagauaa ugaguaa 4137894491RNACampylobacter jejuni 89auggauuuag aaaauauccu agaaaauaau caaagcauag guuuauauca cccaaagaac 60gaacacgaug ccugugguau cgcugcaguu gcuaauauac gcgguauugc uucuuauaag 120guuauuugug augcuuuaga aauuuugaug aaucuugaac accgaggugg uacaggagcu 180gaagaaaauu caggugaugg ggcggggauu uuaauccaaa uuccacauga uuuuuuuaaa 240acucaagaau uggguuuuga acuuccuaaa aagggugauu augcuguagc acagauguuu 300uuaucaccca auacugaugc aaaagaagaa gcaaaagaaa uauuuuuaca agguuuaaag 360gauaaaaaac uugaauuuuu agguuuuaga gaagugccuu uuaauccuag cgauauaggu 420gcaagugcuu uaaaagcuau gccuuauuuu uuacaagccu uuguaaaaaa accaaguaaa 480auaagugcag gacuugaguu ugaaagagug cuuuauagua cgcgucgacu uauagaaaaa 540agagcuauua augugccaaa auuuuauuuu ucaaguuuuu cuucacgcac cauaguuuau 600aaaggaaugc uucuuucaac ucaauugagc gauuuuuauc uugauuuuaa agaugucaau 660augaaaucag ccaucgcuuu ggugcauucu cgcuuuucga cuaauaccuu cccaaguugg 720gaaagagccc auccaaaccg uuauauggug cauaauggag agauuaauac cauacgcgga 780aauguugaua gcauaagagc uagagaaggc uugaugcaaa gugaguauuu ugaaaauuua 840gaugaaauuu uuccuaucau agcuaagcuu agcagugauu cugcaauguu ugauaauacu 900uuagaauuuu uagcucuaaa uggucguacu uuagaagaag cuuuuaugau gauggugcca 960gaaccuuggc auaaaaauga aaauauggaa agcaaaaagc gugcuuuuua ugaauaucau 1020ucuuuauuga uggagccuug ggauggaccu gcugcuauag uuuuuacuga uggagugauu 1080augggggcga guuuggauag aaaugguuuu cguccuucaa gguauuaucu uacaaaagau 1140gauaugcuca uacuuucaag ugaaacaggg gcuuuaaaac uugaugaaaa aaauaucaaa 1200gcuaaaaaac gcuuagaacc uggaaaacuu uuacucguug auacagcaag agguaggguu 1260auagcugaua augaaaucaa agagcauuau gcuaaugcua agccuuauaa aaaauggcuu 1320aaaaauuuag uugaacuuga aaaacaaaaa agcggaguuu auaaacauca guuuuuaaaa 1380gaagaugagg uuuuaaaacu ucaaaaagcu uuugguugga guuaugauga gcuuaaaaug 1440agcguggcug cuauggcuca aaaugguaaa gaagcuauag cagcuauggg uguagauacu 1500ccuuuggcua uacuuucuaa aacuuaucaa ccuuuguaua auuauuuuaa acaacuuuuu 1560gcacaaguaa cuaauccucc ucuugaugcc auaagagaag agauuguuac uucuacaagg 1620auuuaucuag gaagcgaagg caauuuauua aaacccgaug aaaacaaugc aaaacgcgua 1680aaaauagccu ugccugugau aagcaaugaa gaacuuuuug aaguuaaggc uuuaaauaaa 1740uuucaaguua aagaauuuuc uauacuuuau gauuauucua aaaaaacuuu agaaaaggcu 1800uuagaugaac uuugcguuaa gauagaagau gagguuaaaa aagguguuuc uauuaucauu 1860uuaagcgaua aaggagugga ugaaaaaaac gcuuauaucc cugcuuugcu ugcuguuucu 1920ggagugcaua aucaucuagu aagaaaaaau uuaagaacac auacaagucu uaucaucgaa 1980aguggugaac cuagagaaau ucaucauuuu gcaugucuuu uagguuaugg ugcgacuguu 2040auuaauccuu auuugguuua ugagaguaua caaaaacuca uugccaauaa agauuuaaau 2100uuaaguuaug aaaaggcggu agaaaauuuc aucaaggcaa guucaagugg uauagucaaa 2160auugcuucua aaaugggggu uucuaccuug caaaguuaua auggcucugc acuuuuugaa 2220ugucugggcu uaagcucuaa ggugauugau aaauacuuca cuucuacaac uucacgcauu 2280gaagguaugg auuuagaaga uuuugaaaaa gaacucauug cuuuacacaa acaugcuuuu 2340aacgauacac auaaggcuuu agauucuaaa ggaauucaug guuuuagaag ugcuaaagaa 2400gaacauuuaa ucgauccgcu ugugauuuuu aaucuucagc aagccugucg caacaaagac 2460uauaaaagcu uuaaaaaaua cucggcuuua guagaugaaa aacaaguuaa uuugcguucu 2520uugauggaau uugauuuuag ugaagcuauc aguauagaua agguugaaag uguagaaagu 2580auaguuaaac gcuuuagaac aggggcgaug aguuaugguu cuauuucuaa agaagcacac 2640gaguguuuag cacaggcuau gaauaaaaua ggugcuaaau caaauucagg ugaagguggu 2700gaggaugaag aacgcuauga aaucaaagag gguguggaua aaaacucagc cauuaagcaa 2760guagcaagug ggcguuuugg cguggauuua aacuacuuaa gucaugcaaa agaaauucaa 2820aucaaagucg cucaaggugc aaaaccaggu gagggcggac aauuaauggg cuuuaaaguc 2880uauccuugga uagcuaaggc uagacauucu acugcaggug ugacgcuuau uuccccaccu 2940ccucaucaug auauuuauuc uauugaggau uuggcucaac ucauuuauga uuuaaaacau 3000gcgaacaaag acgcuaaaau uucaguaaaa cuuguaagcg aaaauggcau aggaacgguu 3060gcugcaggug uggcuaaggc aggcgcgaau uuaauccuug uuucagguua ugauggaggu 3120acgggugcaa guccuagaac uucuauaccg caugcuggaa uuccuuggga guuaggcuua 3180gcugaaacgc aucaaacuuu gaucuuaaau aagcuuagag auaggguaag auuagaaacu 3240gauggaaagc uuaugaaugg gcgugauuua gccauagcag cacuuuuagg agcugaagaa 3300uuugguuuug caaccgcucc uuugauuguu uuagguugua caaugaugag aguuugucau 3360cuaaauaccu guccuuuugg uauagccacu caagauacag aacuuagaga ucguuucaaa 3420ggcaaaguag augaugugau uaauuucaug uauuuuauag cugaggagcu uagagaauac 3480auggcaaggc uugguuuuga acgccuagau gauaugauag gucgcgugga uaaacuccgc 3540caaaaaagug ugcaagguaa agcaggaaag cuaaauuuag auaaaauuuu aaaauccuug 3600ccuacuuaua auagaaccgc ugugcauuuu aaagauuaua aagacaauaa acuugaaaaa 3660acgauugauu auagaauuuu acuaccacuu uguaaaaaug cuguggagaa aaaagagccu 3720aucaaacuuu cuuuagaagu aggaaaucaa agucguacuu uugcaacuau gcuuucaagu 3780gaaauuuuaa aaacuuaugg aaaagaugcu uuagaugaag auaguaucca uaucaaagcu 3840auaggcaaug caggcaauag cuuuggagcg uuuuuguuaa aggguauuaa acuugagauu 3900auaggcgaua gcaaugauua uuuaggcaag gguuuaagug gugguaaaau cauagcaaaa 3960auuucaaaug aagccacuuu uucaccugaa gaaaauauca ucgcaggaaa ugcuuguuua 4020uacggagcua caaaagguga aguguauuua gaugguauag caggggaaag auuuugugua 4080agaaauucag gggcuuuggc ugugguuuua ggaacaggcg ugcaugguug ugaauauaug 4140acagguggac aaguuguagu ucuuggagau gugggugcga auuucgcugc ugguaugagu 4200gggggcguug uuuauaucuu uggaagacac aaugaagcuc auguaaauac cgagcuugug 4260gauauuaaag aucuuaaugc uaaggaugaa aaagaauuaa aagcugugau agaaaaacau 4320aucacuuaua cagauucuaa aaaggcuaaa gauauuuuag aaaaauucga uaaaaaagac 4380uuuuuuaaag ucaugccaag agauuaugaa aagauguuaa aaaugcuuga ucuuuguaaa 4440aaugaaaaag auccaaauuu agcagcauuu uugaaaauca cacaaaaaua a 4491904554RNACampylobacter jejuni 90augaguaaau uuaaaguaau agaaauuaaa gaagaugcaa gaccuagaga uuuugaagca 60uuucaacuaa gacuugcaag uccugaaaaa aucaaaucau ggucuuaugg agaaguaaaa 120aaaccagaaa cuauuaauua uagaaccuua aagccugaaa gagaugggcu uuuuugugca 180aagauuuuug gaccuauaag agauuaugag ugucuuugug guaaauacaa aaaaaugcgu 240uuuaaaggcg uuaaguguga aaaauguggu guugaaguag caaauucaaa agugcgucgu 300ucuagaaugg ggcauaucga gcuuguaacu ccuguggcuc auauuuggua uguuaauucu 360cuuccaagcc guauaggaac gcuuuugggu guuaagauga aagaucuuga gcgcgugcuu 420uauuaugaag cuuauauugu ugaaaaccca ggugaugcuu ucuaugauaa ugaaaguacu 480aaaaaagugg aauauugcga uguuuugaac gaagagcaau aucaaaauuu aaugcaacgc 540uaugaaaaua gcggcuuuaa agcaagaaug gguggagaag uuguucguga uuuacuugca 600aauuuagauc uuguagcgcu uuuaaaucag cuuaaagaag aaaugggggc uacaaauuca 660gaggcuaaga aaaaaacuau cauuaaacgc uuaaaaguug uagaaaauuu cuuaaauuca 720aauuuaaacg ccaauaccga uagcgacgaa gcuguaccaa aucguccuga auggaugaug 780auuacaaauc uuccaguuuu accgccagau uugcguccuu uaguggcuuu agaugguggg 840aaauuugcag uuucugaugu gaaugacuua uaucgucgug uuaucaauag aaauacacgu 900cuuaaaaaac uuauggaacu ugaugcaccu gaaaucauua ucagaaauga aaaaagaaug 960cuucaagagg cuguugaugc gcuuuuugac aacggucguc gugcuaaugc uguaaaagga 1020gcaaauaaac gcccauugaa aucuuuaagu gaaaucauca aagggaaaca aggacguuuu 1080agacaaaauc uacuagguaa aaggguggau uucucagguc guagcguuau uguuguaggu 1140ccaaaacuua gaauggauca augcgguuua ccuaaaaaaa uggcuuuaga gcuuuuuaag 1200ccacaucuuu uagcuaagcu ugaagaaaaa gguuaugcaa ccacaguaaa acaagcuaaa 1260aaaaugauag aaaauaaaac caaugaaguu ugggaauguu uagaagaggu aguaaaggga 1320cauccuguua ugcuaaaccg ugcaccuacu uugcauaagc uuucuaucca agcuuuucau 1380ccuguuuuag uggaagguaa ggcuauacaa cuucauccuu ugguuugugc agcauuuaac 1440gcagacuuug auggggauca aauggcagug cauguaccgc uuucucaaga ggcuauugca 1500gaauguaaag ugcuuaugcu uucaucaaug aauauucuuu uaccagcaag cgguaagucu 1560guaaccguuc caucgcaaga uaugguuuua ggaauuuauu aucuuucguu ggaaaaagca 1620ggugcuaaag guucgcauaa aauuuguaca ggcauugaug aagugaugau ggcacuugaa 1680agcaaguguu uggauauuca ugcgagcaua caaacuaugg uagaugguag aaagauuacc 1740acuacagcag gaagauugau uguuaaaucc aucuugccug auuuugugcc ugaaaauagu 1800uggaauaaag ucuuaaagaa aaaagacauu gcugcgcuug uagauuaugu uuauaaacaa 1860ggugguuuag agauuacagc aaguuucuua gauagacuua aaaauuuagg uuuugaauau 1920gcaacuaaag cagguauuuc aauuucgauu gcagauauua uuguuccuaa ugauaaacaa 1980aaagcuaucg augaagcaaa aaaacaagua agagaaauuc aaaauucuua uaaucucggu 2040uugauuacuu caggggaaag auacaauaaa aucauugaua uuuggaaaag uacaaacaau 2100guucuuucaa aagaaaugau gaagcuugua gaaaaagaua aagaagguuu uaacucuauu 2160uauaugaugg cagauucugg ugcuaggggu agugcagcuc aaauuucuca gcuugcugcg 2220augagaggac uuaugaccaa accugauggu ucuauuaucg aaacgccuau uauuucaaau 2280uuccgugaag ggcuaaaugu ucuugaauac uuuauuucaa cucacggugc uagaaaaggu 2340cuugcagaua ccgcucuuaa aacagcaaau gcggguuauu ugacaagaaa acucaucgau 2400guugcacaaa auguaaaaau uaccauugaa gauuguggaa cacaugaggg uguugaaauc 2460aaugaaauua ccgcagauag uucuauuaua gaaacuuuag aagaaagaau uuuaggcagg 2520guuuuagcug aggaugugau ugauccuauu acaaauucug ugcuuuuugc ggaagguacu 2580uuaauggaug aggaaaaagc aaaaauucuu ggcgaaagcg guauaaaaag ugucaauauc 2640cgcacuccua uuaccugcaa agcuaaaaaa ggaauuugug caaaauguua ugguaucaau 2700cuuggugaag guaaauuagu aaaaccaggc gaagcagugg gaauuauuuc cgcucaaucu 2760aucggugaac caggaacgca gcuaacucua agaacuuucc auagcggggg aacugcaagu 2820acggauuuac aagauagaca aguaagcgca caaaaagaag guuuuauaag auuuuauaau 2880cuuaaaacuu auaaaaacaa agaagguaaa aauaucguag caaaucguag aaaugcggcg 2940guuuuacuug uggagccaaa aaucaaaacu ccauuuaaag gugugauuaa uauagaaaau 3000auucaugaag augugauugu uucuauuaaa gauaaaaaac aagaaguaaa auacauauua 3060agaaaauacg aucuugcuaa accaaaugaa uuagcaggug uaaguggcag uauagaugga 3120aaacuuuauu ugccauauca aagcggcaug caaguagaag aaaaugaaag uaucguagaa 3180gugauuaaag aggguuggaa uguaccaaau cguauuccuu uugcgaguga aauuuuagua 3240gaagauggcg agccuguagu ucaaaauauc aaagcaggcg aaaaaggaac acucaaauuu 3300uacauccuua aaggcgaugg uuuagauaga guaaaaaaug uuaaaaaagg ugauauuguu 3360aaagaaaaag gauucuuugu agugauugcu gaugaaaaug auagagaagc aaaaagacac 3420uauaucccaa gagaaucuaa gauagaauuu aacgauagug aaaaaaucga ugacgcaaau 3480acuaucauug caagugcucc uaaaaaagaa agaaaaguga uugcagaaug ggaugcuuau 3540aauaauacua ucauugcaga aauugauggu guuguaagcu uugaggauau ugaagcaggu 3600uauagugccg augagcaaau ugaugaagcu acagguaagc guucuuuagu aauuaaugag 3660uauuuaccua gcggaguuag accaacuuug guaauugcag gaaaagguga uaaagcugug 3720cguuaucacc uugaaccaaa aaccguuauu uuuguucaug auggcgauaa aauugcucaa 3780gcagauauuu uagcaaaaac uccaaaagca gcagcuaaau caaaggauau uacaggaggu 3840cuuccaagag uuucugaacu uuuugaagca agaaaaccaa aaaaugcggc ugugauugca 3900gaaauugaug guguuguucg uuuugauaag ccuuugcguu cuaaagaaag aauuauuauc 3960caagcagaag auggaacaag ugcugaguau uuaaucgaca aaucaaaaca uauucaagua 4020agagauggag aguuuauuca ugcaggugaa aaacuuacag auggaguugu uucgagucau 4080gaugugcuua aaauuuuagg ugaaaaagcc uugcauuauu auuugauuuc ugaaauucag 4140caaguuuauc gcggacaagg uguugugauu ucugauaaac auauagaagu uaucguuucu 4200caaaugcuaa gacaaguaaa aguuguagau aguggacaua cgaaauuuau ugaaggugau 4260uugguuucaa gacguaaauu ccgugaagaa aaugaaagaa ucauuagaau ggguggagaa 4320ccagcuauug ccgagccugu gcuuuuaggu guaacaagag cagcgauugg aagugauagu 4380gugauuucug cggcuucauu ccaagaaacu accaaaguuu uaacugaagc aaguauagca 4440gguaaauuug acuacuuaga agauuuaaaa gaaaauguua uucuagguag aaugauuccu 4500guuggaacag ggcuuuaugg cgaacaaaau uuaaaacuua aagaacaaga auaa 45549120DNAArtificial sequenceSynthetic PCR primer 91gctatcccac aaattgataa 20

Claims

1. A polypeptide comprising a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, or b) an amino acid sequence consisting of at least 20 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, or c) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a), or d) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of b), said polypeptide being antigenic in a mammal.

2. The polypeptide according to claim 1, wherein the at least 20 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47 in any one of SEQ ID NOs: 1-30.

3. The polypeptide according to claim 1, wherein the at least 20 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, and 258 in any one of SEQ ID NOs: 13-30.

4. The polypeptide according to claim 1, which is fused or conjugated to an immunogenic carrier molecule.

5. The polypeptide according to claim 4, wherein the immunogenic carrier molecule is a polypeptide that induces T-helper lymphocyte responses in a majority of humans.

6. A pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable carrier, vehicle or diluent, and which further comprises an immunological adjuvant, said polypeptide comprising: a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, or b) an amino acid sequence consisting of at least 20 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, or c) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a), or d) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of b).

7. The pharmaceutical composition according to claim 6, wherein the adjuvant is an aluminium based adjuvant.

8. A method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a polypeptide, said polypeptide comprising: a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, or b) an amino acid sequence consisting of at least 20 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, or c) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a), or d) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of b), or a pharmaceutical composition comprising said polypeptide so as to induce adaptive immunity against C. jejuni in the animal.

9. The method according to claim 8, wherein the animal receives between 0.5 and 5,000 .mu.g of the polypeptide according to claim 1 per administration.

10. The method according to claim 8, wherein the animal is a human being.

11. The method according to claim 8, wherein the immunity is effective in reducing the risk of attracting infection with C. jejuni or is effective in treating or ameliorating infection with C. jejuni.

12. An isolated nucleic acid fragment, which comprises i) a nucleotide sequence encoding a polypeptide, said polypeptide comprising: a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, or b) an amino acid sequence consisting of at least 20 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, or c) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a), or d) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of b) or ii) a nucleotide sequence consisting of the amino acid encoding part of any one of SEQ ID NOs: 30-90, iii) a nucleotide sequence consisting of at least 15 consecutive nucleotides in the amino acid encoding part of any one of SEQ ID NOs: 30-90, iv) a nucleotide sequence having a sequence identity of at least 80% with the nucleotide sequence in ii), v) a nucleotide sequence having a sequence identity of at least 80% with the nucleotide sequence in iii), vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

13. The nucleic acid fragment according to claim 12, which is a DNA fragment or an RNA fragment.

14. The nucleic acid fragment according to claim 12, wherein the sequence identity with the nucleotide sequence in ii) or iii) is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

15. A vector comprising a nucleic acid fragment, said nucleic acid fragment comprising: i) a nucleotide sequence encoding a polypeptide, said polypeptide comprising: a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, or b) an amino acid sequence consisting of at least 20 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, or c) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a), or d) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of b) or ii) a nucleotide sequence consisting of the amino acid encoding part of any one of SEQ ID NOs: 30-90, iii) a nucleotide sequence consisting of at least 15 consecutive nucleotides in the amino acid encoding part of any one of SEQ ID NOs: 30-90, iv) a nucleotide sequence having a sequence identity of at least 80% with the nucleotide sequence in ii), v) a nucleotide sequence having a sequence identity of at least 80% with the nucleotide sequence in iii), vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

16. The vector according to claim 15, which is a cloning vector or an expression vector.

17. The vector according to claim 16, which comprises in operable linkage and in the 5'-3' direction, an expression control region comprising an enhancer/promoter for driving expression of the nucleic acid fragment defined in claim 13-i), optionally a signal peptide coding sequence, a nucleotide sequence defined in claim 13-i), and optionally a terminator.

18. The vector according to claim 13, which is selected from the group consisting of a virus, a bacteriophage, a plasmid, a minichromosome, and a cosmid.

19. A method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a nucleic acid, said nucleic acid comprising: i) a nucleotide sequence encoding a polypeptide, said polypeptide comprising: a) an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1-30, or b) an amino acid sequence consisting of at least 20 contiguous amino acid residues from any one of SEQ ID NOs: 1-30, or c) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of a), or d) an amino acid sequence having a sequence identity of at least 80% with the amino acid sequence of b) or ii) a nucleotide sequence consisting of the amino acid encoding part of any one of SEQ ID NOs: 30-90, iii) a nucleotide sequence consisting of at least 15 consecutive nucleotides in the amino acid encoding part of any one of SEQ ID NOs: 30-90, iv) a nucleotide sequence having a sequence identity of at least 80% with the nucleotide sequence in ii), v) a nucleotide sequence having a sequence identity of at least 80% with the nucleotide sequence in iii), vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi) or an expression vector comprising said nucleic acid so as to induce adaptive immunity against C. jejuni in the animal.

20. The method according to claim 19, wherein the animal is a human being.

21. The method according to claim 19, wherein the immunity is effective in reducing the risk of attracting infection with C. jejuni or is effective in treating or ameliorating infection with C. jejuni.